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Cardiovascular diseases and atherogenesis have been and still are an important topic many
scientists are working on.
In the 16th century, Leonardo da Vinci had described “The narrowing of the passage of
blood vessels, thickening of the coats of these vessels and hardening of arteries”. This is the
first documentation of atherosclerosis, but today our understanding of atherogenesis as a
process of a chronic inflammatory disease has been updated by many mechanisms such as
hypercholesterolemia, dysfunction of endothelial cells, oxidation of lipoproteins and espe‐
cially oxidative stress. In particular, the endothelium is responsible for the regulation of vas‐
cular tone, the exchange of plasma and cell biomolecules, inflammation, lipid metabolism
and modulation of fibrinolysis and coagulation. Endothelial cell disruption, morphological
abnormalities in size and shape, susceptibility to apoptosis and abnormal release of endo‐
thelial cell-derived factors are strictly implicated in the pathogenetic mechanisms of cardio‐
vascular diseases. Growing evidence indicates that chronic and acute overproduction of
oxidative stress alters endothelial cells as pivotal early event in atherogenesis.
It is important to remember that drugs intake, such as statins, life style control for regulating
fat intake and exercise activity must be monitored for improving cardiovascular disease in‐
cidence. In recent years a novel topic regarding antioxidant properties of some natural sub‐
stances seems to be very important for decreasing certain problems related to cardiovascular
diseases and atherogenesis.
This book presents the state of the art of the antioxidants in the clinical and experimental
approaches in order to bring better understanding of the mechanisms and useful therapies
for these diseases. We hope that it can indicate new “current trends” for identifying new
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1. Introduction
Cardiovascular diseases (CVDs) remain the leading cause of death in modern societies. The
primary cause of dramatic clinical events of CVDs, such as unstable angina, myocardial in‐
farction and stroke, is the atherosclerotic process [1,2,3].
The pathophysiological mechanisms of atherosclerosis are complicated and the integrated
picture of the disease process is not yet complete, so currently is largely investigated. It is
widely recognized that oxidative stress,  lipid deposition, inflammation, Vascular smooth
muscle cells (VSMCs) differentiation and endothelial dysfunction play a critical role in the
formation, progression and eventually rupture of the atherosclerotic plaque [4]. Multiple risk
factors have been associated with the development of atherosclerotic lesions; these include
diabetes mellitus, hypertension, obesity and tobacco smoking. The risk factors are influenced
by genetic predisposition, but also by environmental factors, particularly diet. Moreover, ag‐
ing promotes physiological changes, such as oxidative stress, inflammation and endothelial
dysfunction strictly associated with the pathophysiology of atherosclerosis [5].
The common belief that signs of atherosclerosis and CVDs are clinically relevant only dur‐
ing adult and elderly age is gradually changing, increasing evidence supports that athero‐
genesis is initiated in childhood [6].
Low-density lipoproteins (LDL) are crucial to the development of atherosclerotic lesions,
whereas high-density lipoproteins (HDL) are inhibitors of the process, primarily through
the process of reverse cholesterol transport [4,7]. Dysfunctional lipid homeostasis plays a
central role in the initiation and progression of atherosclerotic lesions. Oxidized-LDL (ox-
LDL) induces endothelial dysfunction with focal inflammation which causes increased ex‐
pression of atherogenic signaling molecules that promote the adhesion of monocytes and T
© 2013 Fabrizio Rodella and Favero; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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lymphocytes to the arterial endothelium and their penetration into the intima. Early stages
of plaque development involve endothelial activation induced by inflammatory cytokines,
ox-LDL and/or changes in endothelial shear stress [8,9]. The monocyte-derived macrophag‐
es, by taking up ox-LDL, become foam cells, which are typical cellular elements of the fatty
streak, the earliest detectable atherosclerotic lesion [10].
After initial injury, different cell types, including endothelial cells, platelets and inflammato‐
ry cells release growth factors and cytokines that induce multiple effects: oxidative stress,
inflammation, VSMCs differentiation from the contractile state to the active synthetic state
and then proliferate and migrate in the subendothelial space [11,12]. Inflammatory cell accu‐
mulation, migration and proliferation of VSMCs, as well as the formation of fibrous tissue,
lead to the enlargement and restructuring of the lesion, with the formation of an evident fi‐
brous cap and other vascular morphological changes [2,13]. Atherosclerotic plaques result
from the progressive accumulation of cholesterol and lipids in oxidized forms, extracellular
matrix material and inflammatory cells [14]. In fact, atherosclerosis manifests itself histologi‐
cally as an arterial lesions known as plaques, which have been extensively characterized:
plaques contain a central lipid core that is most often hypocellular and may include crystals
of cholesterol that have formed in the foam cells. The lipid core is separated from the arterial
lumen by a fibrous cap and myeloproliferative tissue that consists of extracellular matrix
and VSMCs. Advanced lesions can grow sufficiently large to block blood flow and so devel‐
op an acute occlusion due to the formation of thrombus or blood clot resulting in the impor‐
tant and severe cardiovascular clinical events [2,10].
Figure 1. Main vascular alterations observed during atherogenesis. LDL: low density lipoprotein; HDL: high density lip‐
oprotein.
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2. Atherosclerosis and oxidative stress
Oxidative stress is defined as an imbalance between pro-oxidant and anti-oxidant factors in
favour of pro-oxidants and is central to the pathophysiology of atherosclerosis. The analysis
of plaque composition has revealed products of protein and lipid oxidation, such as chlori‐
nated, nitrated amino acids, lipid hydroperoxides, short-chain aldehydes, oxidized phos‐
pholipids, F2α-isoprostanes and oxysterols [15].
Excessive production of reactive oxygen species (ROS) during oxidative stress, out stripping
endogenous anti-oxidant defence mechanisms, has been implicated in processes in which
they oxidize and damage DNA, protein, carbohydrates and lipids. There are multiple poten‐
tial enzymatic sources of ROS, including mitochondrial respiratory cycle, heme, arachidonic
acid enzyme, xanthine oxidase, nitric oxide synthese and others. However, the predominant
ROS-producing enzyme in the VSMCs and in the myocardium is NADPH oxidase, that
plays a pivotal role in the atherogenesis [16].
Figure 2. Generation and main damages induced by ROS. Modified from [17]. O2-: superoxide; HO`: hydroxyl; H2O2:
hydrogen peroxide..
ROS may contribute to LDL oxidation, inflammation, local monocyte chemoattractant pro‐
tein production, upregulation of adhesion molecules and macrophages recruitment, endo‐
thelial dysfunction, platelet aggregation, extracellular matrix remodelling through collagen
degradation, thus playing a central role in the development and progression of atheroscle‐
rosis  and  eventually  in  plaque  rupture  [17,18,19].  Several  oxidative  systems  potentially
contribute to LDL oxidation in vivo, included NADPH oxidases, xanthine oxidase, myelo‐
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peroxidase,  uncoupled  nitric  oxide  synthase,  lipoxygenases  and  mitochondrial  electron
transport chain [20,21,22]. Ox-LDL particles exhibit multiple atherogenic properties, which
include uptake and accumulation of macrophages, as well as pro-inflammatory, immuno‐
genic, apoptotic and cytotoxic activities, induction of the expression of adhesion molecules
on endothelial cells, promotion of monocyte differentiation into macrophages, production
and release of pro-inflammatory cytokines and chemokines from macrophages [14].
In particular, at endothelial level, ROS regulates numerous signaling pathways including
those regulating growth, proliferation, inflammatory responses of endothelial cells, barrier
function and vascular remodeling; while at VSMC level, ROS mediates growth, migration,
matrix regulation, inflammation and contraction [23,24,25], all are critical factors in the pro‐
gression and complication of atherosclerosis.
A vicious cycle between oxidative stress and oxidative stress-induced atherosclerosis leads
to the development and progression of atherosclerosis.
Figure 3. Role of ROS and oxidative stress in the atherosclerosis. Modified from [24]. O2: oxygen; O2-: superoxide; H2O2:
hydrogen peroxide; VSMC: vascular smooth muscle cell.
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3. Atheroprotective strategies
Recently, various pharmacological therapies have been designed to reduce the development
and progression of the atherosclerotic plaque and remarkable therapeutic advances in the
treatment of CVDs have been made with insulin sensitizers, statins, inhibitors of the renin-
angiotensin system and anti-platelet agents [19,26]. However, strictly control of cardiovascu‐
lar risk factors are often difficult to obtain and the progression of atherosclerosis has not
been completely prevented with current pharmacological therapeutic options. Moreover,
the modern evolution of Western societies seemingly steers populations towards a profound
sedentary lifestyle and incorrect diet is becoming difficult to reverse. Understanding of the
mechanisms that explain the fatal effects of physical inactivity and incorrect diet, the benefi‐
cial effects of an healthy lifestyle remains largely unexplored [3].
Concerning atherosclerosis prevention by foods, dietary supplements and healthy life style
may provide prevention and/or treatment to the onset and development of atherosclerosis.
Development of an atheroprotective strategy acting on oxidative stress involved in the
pathogenesis of atherosclerosis and with little toxicity or adverse effects may provide an ide‐
al therapeutic treatment for atherosclerosis. Actually, numerous studies have investigated
the prevention and treatment of atherosclerosis using naturally-occurring anti-oxidants.
In this review we summarize the many pieces of the puzzle to identified molecular targets
for prevention and therapy against atherosclerosis and present that a healthy life style has
natural anti-atherogenic activity which has been forgotten by modern societies.
Figure 4. Potential atheroprotective role of anti-oxidants in the atherogenic process. Modified from [27]. ox-LDL: oxi‐
dized-low density lipoprotein; ROS: reactive oxygen species.
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Physical activity is currently recognized as a potent tool for the prevention of chronic degen‐
erative diseases, including CVDs and common tumors, such as those affecting the colon,
breast, prostate and endometrium [28].
There is a body of clinical and experimental evidence showing that voluntary and imposed
physical exercise prevents the progression of CVDs and reduces cardiovascular morbidity
and mortality. Therefore a physically active state is an appropriate and natural biological
condition for human and most animal species [3].
It has been demonstrated that exercise slows the progression of atherosclerosis, promoting
its stabilization and preventing plaque rupture in a variety of hypercholesterolaemic animal
models, such as apolipoproteinE-deficient mice and LDL receptor-deficient mice, whereas
physical inactivity accelerates it [3,29].
Exercise  increases  blood  anti-oxidant  capacity  through  elevating  hydrophilic  anti-oxi‐
dants  (uric  acid,  bilirubin and vitamin C) and decreases lipophilic  anti-oxidants (carote‐
noids  and  vitamin  E)  [28].  It  is  noteworthy  that  exercise  prevents  plaque  vulnerability
and atherosclerosis progression without necessarily correcting classic risk factors, such as
hypercholesterolaemia,  endothelial  dysfunction and high blood pressure,  suggesting that
exercise  can  directly  affect  plaque  composition  and phenotype,  thus  preventing  the  ap‐
pearance of fatal lesions. Besides the effect of diet and drugs, the protective role of regu‐
lar  exercise  against  atherosclerosis  is  well  established and its  beneficial  atheroprotective
effects are not limited to one particular cell, but to a variety of cells and tissues involved
in the pathogenesis of atherosclerosis and metabolic disorders, such as macrophages and
adipose tissue [3].
Regular exercise and a correct diet would be natural atheroprotective approaches which has
been forgotten by modern societies.
5. Diet
Several epidemiological studies suggest that a correct diet is significantly associated with
reduced risks of CVDs. Phytochemicals including polyphenols like flavonoids, resveratrol
and ellagitannins have been shown to be associated with lower risks of CVDs [30,31]. In
fact,  they  are  potent  anti-oxidants  and  anti-inflammatory  agents,  thereby  counteracting
oxidative  damage  and inflammation.  Actually,  dietary  anti-oxidants  have  attracted  con‐
siderable  attention  as  preventive  and  therapeutic  agents.  There  is  adequate  evidence
from observational in vitro,  ex vivo  and in vivo  studies that consumption of certain foods
results  to  a  reduction  in  oxidative  stress  [27].  Evidence  linking  dietary  anti-oxidants  to
atherosclerosis in humans is still circumstantial and although in some studies the associa‐
tion of  anti-oxidant  intake  and low risk  for  atherosclerosis  is  perceptible,  in  others  this
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association cannot be established. The inconsistency of the results reflects the limitations
of human studies, the diet differences, the pre-existing total anti-oxidant status, the stage
of  disease,  the interaction between dietary modulation and genetic  composition of  indi‐
viduals,  the dosage and duration of supplementation, the age and the sex. On the other
hand, studies in animal models of atherosclerosis clearly show an atheroprotective effect
of  dietary anti-oxidants,  however,  they focus mainly on early atherosclerotic  events and
not in advanced atherosclerosis as in humans [27].
Cardiovascular prevention and treatment strategies should consider the simple, direct and
inexpensive dietary approach as a first-line strategy to the burgeoning burden of CVDs,
alone or in combination with pharmalogic treatments [10].
In this review we focus our attention on the main natural anti-oxidants contained in food
and on their primary diet source.
6. Polyphenol
Polyphenols are the most abundant anti-oxidants in human diet and are common constitu‐
ents of foods of plant origin and are widespread constituents of fruits, vegetables, cereals,
olive, legumes, chocolate and beverages, such as tea, coffee and wine [32,33].
They are defined according to the nature of their backbone structures: phenolic acids, flavo‐
noids and the less common stilbenes and lignans. Among these, flavonoids are the most
abundant polyphenols in the diet [34]. Despite their wide distribution, the health effects of
dietary polyphenols have been attentively studied only in recent years [32] and several stud‐
ies, although not all, have found an inverse association between polyphenol consumption
and CVDs motality [35].
Polyphenols  exert  anti-atherosclerotic  effects  in the early stages of  atherosclerosis  devel‐
opment, they decrease LDL oxidation, improve endothelial function, increase vasorelaxa‐
tion,  modulate  inflammation  and  lipid  metabolism,  improve  anti-oxidant  status  and
protect  against  atherothrombotic  events  including  myocardial  ischemia  and  platelet  ag‐
gregation [35].
Many  polyphenols  have  direct  anti-oxidant  properties,  acting  as  reducing  agents,  and
may react  with  reactive  chemical  species  forming products  with  much lower  reactivity.
Polyphenols may also affect indirectly the redox status by increasing the capacity of en‐
dogenous  anti-oxidants  or  by  inhibiting  enzymatic  systems  involved  in  ROS  formation
[36].  The  free-radical  scavenging  activity  of  many polyphenols  has  been  reported  to  be
much stronger than that of vitamin C, vitamin E or glutathione, the major anti-oxidants
present in the body.
In spite of their potent protective effects in the development of atherosclerosis, little is
known about aortic distribution of polyphenols [34].
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Figure 5. Main atheroprotective mechanisms exert by polyphenols. VSMC: vascular smooth muscle cell; LDL: low den‐
sity lipoprotein; ROS: reactive oxygen species.
6.1. Resveratrol
Resveratrol naturally occurs as a polyphenol found in grapes and grape products, including
wine, as well as other sources, like nuts [37]. In grapes, resveratrol is present in the skin as
both free resveratrol and piceid.
Initially characterized as a phytoalexin, a toxic compound produced by higher plants in re‐
sponse to infection or other stresses, such as nutrient deprivation, resveratrol attracted little
interest until 1992 when it was postulated to explain some of the cardioprotective effects of
red wine [36].
Treatment with resveratrol has been found to reduce oxidative stress and increase the activi‐
ties of several anti-oxidant enzymes including superoxide dismutase, catalase, glutathione,
glutathione reductase, glutathione peroxidase and glutathione-5-transferase [38]. Resvera‐
trol also prevents the oxidation of polyunsaturated fatty acids found in LDL and inhibits the
ox-LDL uptake in the vascular wall in a concentration-dependent manner, as well as pre‐
vents damage caused to lipids through peroxidation [38]. These effects were found to be
stronger respect the well known anti-oxidant vitamin E. Moreover, resveratrol has been pro‐
posed to influence and maintain a balance between production of vasodilatators and vaso‐
costrictors respectively [38,39], thereby preventing platelet aggregation and oxidative stress,
which leads to reduction in CVD risk [40].
Current Trends in Atherogenesis8
Resveratrol so has been demonstrated to exert a variety of health benefits including anti-
atherogenic, anti-inflammatory and anti-tumor effects. These positive effects are attributed
mainly to its anti-oxidant and anti-coagulative properties.
Figure 6. Main atheroprotective mechanisms exert by resveratrol. LDL: low density lipoprotein; HDL: high density lipo‐
protein; ROS: reactive oxygen species.
Resveratrol reduced not only vascular lipid levels, including LDL and triglycerides, but also
the myocardial complications by influencing infarct size, apoptosis and angiogenesis. In ad‐
dition, resveratrol feeding prevented steatohepatitis induced by atherogenic diets through
modulation of expression of genes involved in lipogenesis and lipolysis, reduced total and
LDL levels, while increasing HDL levels in plasma.
Several investigations with human and various animal model have demonstrated an ab‐
sence of toxic effects after supplementation with resveratrol across a wide range of dos‐
ages [38].
Promising findings by several groups have demonstrated the potential cardioprotection of
resveratrol by reducing atherosclerotic plaque onset and formation.
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Flavonoids, many of which are polyphenolic compounds, are believed to be beneficial for
the prevention and treatment of atherosclerosis and CVDs mainly by decreasing oxidative
stress and increasing vasorelaxation [32,40,41]. More than 8.000 different flavonoids have
been described and since they are prerogative of the kingdom of plants, they are part of
human diet  with  a  daily  total  intake  amounting  to  1  g,  which  is  higher  than  all  other
classes of phytochemicals and known dietary anti-oxidants. In fact, the daily intake of vita‐
min C, vitamin E and β-carotene from food is estimated minor of 100 mg. A number of dif‐
ferent  factors,  such  as  harvesting,  environmental  factors  and  storage,  may  affect  the
polyphenol content of plants. Additional variability in flavonoid content could be expected
in finished food products because its availability is largely dependent on the cultivar type,
geographical origin, agricultural practices, post-harvest handling and processing of the fla‐
vonoid containing ingredients [32].
Flavonoids are widely distributed in the plant and are categorized as flavonol, flavanol, fla‐
vanone, flavone, anthocyanidin and isoflavone. Quercetin is one of the most widely distrib‐
uted flavonoids, which are abundant in red wine, tea and onions. Quercetin intake is
therefore suggested to be beneficial for human health and its anti-oxidant activity should
yield a variety of biological effects.
The major flavanols in the diet are catechins. They are abundant in green tea (about 150mg/
100ml) and lesser extent in black tea (13.9 mg/100 ml) where parent catechins are oxidized
into complex polyphenols during fermentation. Red wine (270 mg/L) and chocolate (black
chocolate: 53.5 mg/100 g; milk chocolate: 15.9 mg/100 g) are also sources of catechins [34].
Polyphenols and/or flavonoids exhibit a variety of beneficial biological effects, including an‐
ti-oxidant, anti-hypertensive, anti-viral, anti-inflammatory and anti-tumor activities; more‐
over some flavonoids have also been reported to modulate insulin resistance, endothelial
function and apoptosis [32,41].
Many studies have shown that flavonoids demonstrate protective effects against the initia‐
tion and progression of atherosclerosis. The bioactivity of flavonoids and related polyphe‐
nols appears to be mediated through a variety of mechanisms, though particular attention
has been focused on their direct and indirect anti-oxidant actions. In particular, it has been
shown that the consumption of flavinoids limits the development of atheromatous lesions,
inhibiting the oxidation of LDL, which is considered a key mechanism in the endothelial le‐
sions occurring in atherosclerosis.
Mechanisms of anti-oxidant effects include also: suppression of ROS formation either by in‐
hibition of enzymes or chelating trace elements involved in free radical production, scaveng
ROS and upregulation or protection of anti-oxidant defences [32]. The phenolic hydroxyl
groups of flavonoids, which act as electron donors, are responsible for free radical scaveng‐
ing activity [27,40].
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Since the evidence of therapeutic effects of dietary flavinoids continues to accumulate, flavi‐
noids could be considered as anti-oxidant nutrients available in everyday life as a protective
tool for prevention of atherosclerosis.
Figure 7. Main atheroprotective mechanisms exert by flavinoids. LDL: low density lipoprotein.
7. Green tea
Tea, a beverage consumed worldwide, is a source of both pleasure and healthful benefits.
Originally recommended in traditional Chinese medicine, green tea (Camellia sinensis) has
gained considerable attention due to its anti-oxidant, anti-inflammatory, anti-hypertensive,
anti-diabetic and anti-mutagenic properties [42].
Green tea constitutes 20%-22% of tea production and is principally consumed in China, Ja‐
pan, Korea and Morocco. Green tea, or non-fermented tea, contains the highest amount of
flavonoids, in comparison to its partially fermented (oolong tea) and fermented (black tea)
counterparts and, due to its high content of polyphenolic flavonoids, has shown unique car‐
diovascular health benefits. In green tea, catechins comprise 80% to 90% of total flavonoids,
with epigallocatechin gallate, being the most abundant catechin (48–55%), followed by epi‐
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gallocatechin (9–12%), epicatechin gallate (9–12%) and epicatechin (5–7%) [42]. The catechin
content of green tea depends on several factors including how the leaves are processed be‐
fore drying, preparation of the infusion and decaffeination, as well as the form in which it is
distributed in the market (instant preparations, iced and ready-to-drink teas have been
shown to contain fewer catechins) [43]. When tea leaves are rolled or broken during indus‐
try manufacture, catechins come in contact with polyphenol oxidase, resulting in their oxi‐
dation and the formation of flavanol dimers and polymers known as theaflavins and
thearubigins [44].
Tea leaves destined to become black tea are rolled and allowed to ferment, resulting in rela‐
tively high concentrations of theaflavins and thearubigins and relatively low concentrations
of catechins. Consequently, green tea contains relatively high concentrations of catechins
and low concentrations of theaflavins and thearubigins. It is important to underline that
black tea administration to LDL receptor-deficient mice did not affect aortic fatty streak le‐
sion area, although fatty streak lesion areas in the same animal model supplemented with
anti-oxidants, such as vitamin C, vitamin E and β-carotene, were 60% smaller than those of
control animals [44,45]. On the other hand, green tea catechins have been shown to inhibit
formation of ox-LDL, may decrease linoleic acid and arachidonic acid concentrations [46],
elevate serum anti-oxidative activity and prevent or attenuate decreases in anti-oxidant en‐
zyme activities [44]. In addition to having anti-oxidant properties, green tea catechins have
also been shown to reduce VSMCs proliferation [42].
In particular, Erba et al. (2005) showed a significant decrease in plasma peroxide levels,
DNA oxidative damage and LDL oxidation, as well as a significant increase in total anti-oxi‐
dant activity in the plasma of healthy volunteers who consumed two cups of green tea per
day in addition to a balanced and controlled diet demonstrating that green tea may act syn‐
ergistically with a correct diet in affecting the biomarkers of oxidative stress [47]. Much of
the evidence supporting anti-oxidant functions of tea polyphenols is derived from assays of
their anti-oxidant activity in vitro. However, evidence that tea polyphenols are acting direct‐
ly or indirectly as anti-oxidants in vivo is more limited [44].
It is very important to underline also that while green tea beverage consumption is con‐
sidered part  of  a  healthy  lifestyle,  green  tea  extracts  supplements  should  be  used with
caution. Very high doses of green tea extracts (6 g–240 g) have been associated with hepa‐
totoxicity in patients who used them for a duration of 5 to 120 days, changing in blood bi‐
ochemical parameters included an elevation of serum levels of aspartate aminotransferase,
alanine  aminotransferase,  alkaline  phosphatase,  total  bilirubin  and  albumin  levels.  Al‐
though, it was observed a reversal of symptoms when subjects stopped taking the green
tea supplement [42].
In addition, in a number of countries, tea is commonly consumed with milk. Interactions be‐
tween tea polyphenols and proteins found in milk have been found to diminish total anti-
oxidant capacity in vitro, but it is presently unclear whether consuming tea with milk
substantially alters the biological activities of tea flavonoids in vivo. The addition of milk to
tea did not significantly alter areas under the curve for plasma catechins or flavonols in hu‐
man volunteers, suggesting that adding milk to tea does not substantially affect the bioavail‐
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ability of tea catechins or flavonols. Two studies in humans found that the addition of milk
decreased or eliminated increase in plasma anti-oxidant capacity induced by tea consump‐
tion, whereas another found no effect [44].
Nevertheless, a diet rich in foods containing anti-oxidant polyphenols, like green tea bever‐
ages, combined with physical activity and a correct diet may offer primary prevention
against CVDs. While future clinical trials could further elucidate the cardioprotective bene‐
fits of green tea beverages, on the basis of existing reports, freshly prepared green tea ap‐
pears to be a healthy dietary choice to consider as an atheroprotective strategy.
8. Herbal
Studies of the herbal medicines for the prevention and treatment of atherosclerosis have re‐
ceived much attention in recent years. Single compounds isolated from some herbal materi‐
als have been shown to reduce the production or remove the build up of cholesterol in vitro
or in vivo studies. Glabrol from Glycyrrhiza glabra has been found to be an acyl-coenzyme
A: a cholesterol acyltransferase inhibitor that blocks the esterification and intestinal absorp‐
tion of free cholesterol. Curcumin from Curcuma longa inhibited cholesterol accumulation.
Puerarin from Pueraria lobata can promote cholesterol excretion into bile by upregulating
the rate-limiting enzyme in the synthesis of bile acid from cholesterol. Moreover, these ex‐
tracts have anti-oxidative effects and may reduce the levels of ox-LDL and increased the lev‐
els of HDL [48].
9. Pomegranate juice
Pomegranate juice consumption slowed atherosclerosis progression through the potent anti-
oxidant properties of pomegranate polyphenols [35].
Pomegranate fruit (Punica granatum L.) has been rated to contain the highest anti-oxidant ca‐
pacity in its juice, when compared to other commonly consumed polyphenol rich beverages.
The anti-oxidant capacity of pomegranate juice was shown to be three times higher than that
of red wine and green tea, based on the evaluation of the free-radical scavenging and iron
reducing capacity [30]. It was also shown to have significantly higher levels of anti-oxidants
in comparison to commonly consumed fruit juices, such as grape, cranberry, grapefruit or
orange juice. The principal anti-oxidant polyphenols in pomegranate juice are ellagitannins
and anthocyanins. Ellagitannins account for 92% of the anti-oxidant activity of pomegranate
juice and are concentrated in peel, membranes and piths of the fruit. The bioavailability of
pomegranate polyphenols is affected by several factors, including: interindividual variabili‐
ty, differential processing of pomegranate juice, as well as the use of analytical techniques
sensitive enough to detect low postprandial concentrations of these metabolites [30].
One pomegranate fruit contains about 40% of an adult’s recommended daily requirement of
vitamin C and is high in polyphenol compounds. The pomegranate plant contains alkaloids,
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mannite, ellagic acid and gallic acid and the bark and rind contain various tannins. The pol‐
yphenols in pomegranate are believed to provide the anti-oxidant activity and protect LDL
against cell-mediated oxidation directly by interaction with the LDL [49]. In fact, the supple‐
mentation of pomegranate juice revealed a significant reduction in the atherosclerotic lesion
area compared to the water-treated group reporting significant anti-oxidant capacities of all
pomegranate extracts.
The principal mechanisms of action of pomegranate juice may include: increased serum an‐
ti-oxidant capacity, decreased plasma lipids and lipid peroxidation, decreased ox-LDL up‐
take by macrophages, decreased intima-media thickness, decreased atherosclerotic lesion
areas, decreased inflammation and decreased systolic blood pressure, thereby reducing/
inhibiting the progression of atherosclerosis and the subsequent potential development of
CVDs [30,50].
On the basis of limited safety data, high doses of pomegranate polyphenol extracts may
have some deleterious effects: gastric irritation, allergic reactions, including pruritus, urtica‐
ria, angioedema, rhinorrhea, bronchospasm, dyspnea and red itchy eyes. Moreover, dried
pomegranate peel may contain aflatoxin, a potent hepatocarcinogen; thus, it should be used
cautiously by patients who have hepatic dysfunction or who are taking other hepatotoxic
agents. Pomegranate may also increase the risk for rhabdomyolysis during statin therapy, as
a result of intestinal CYP3A4 inhibition and increased absorption of active drugs [49].
10. Wine
The last two decades have seen renewed interest in the health benefits of wine, as documented
by increasing research and several epidemiologic observations showing that moderate wine
drinkers have lower cardiovascular mortality rates than heavy drinkers or teetotalers. Most of
the beneficial effects of wine against CVDs have been attributed to the presence in red wine of
resveratrol and other polyphenols. Wines contain polyphenolic compounds that can be rough‐
ly classified in flavonoid and non flavonoid compounds; both classes of compounds have been
implicated in the protective effects of wine on the cardiovascular system. Resveratrol is one of
the most biologically active polyphenols contained in wine.
Moderate wine intake reduces cardiovascular risk [51]. In addition, it is known that alcohol
favourably modifies the lipid pattern by decreasing total plasma cholesterol, in particular
LDL, and by increasing HDL. Cardiovascular risk reduction seems to be linked largely to
the effect of non-alcoholic components, mainly resveratrol and other polyphenols, on the
vascular wall and blood cells and a great part of the beneficial effects of resveratrol on vas‐
cular function are due to its anti-oxidant effects.
The effect of resveratrol and other wine polyphenols on oxidative stress has been scarcely
explored in humans and only a few studies have analyzed the effects of wine supplementa‐
tion on indexes of oxidation in vivo [36].
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Figure 8. Main polyphenols in wine. * Polyphenols contained only in white wine. Modified from [36].
11. Olive oil
A high intake of some unsaturated fatty acid and/or anti-oxidant compounds can both re‐
duce pro-atherogenic risk factors and the susceptibility of the vascular wall to pro-inflam‐
matory and pro-atherogenic triggers.
Many Authors started to recognize olive oil as one of the key elements in the cardioprotec‐
tion and longevity of inhabitants of Mediterranean regions. The healthful properties of olive
oil have been often attributed to its high content of monounsaturated fatty acids, namely
oleic acid [7]. However, it should be underlined that olive oil, unlike other vegetable oils,
contains high amounts of several micronutrient constituents, including polyphenolic com‐
pounds (100– 1000 mg/kg) [10].
The major phenolic compounds in olive oil are: simple phenols (i.e., hydroxytyrosol, tyro‐
sol); polyphenols (oleuropein glucoside); secoiridoids, dialdehydic form of oleuropein and
ligstroside lacking a carboxymethyl group and the aglycone form of oleuropein glucoside
and ligstroside and lignans. Around 80% or more of the olive oil phenolic compounds are
lost in the refination process, thus, their content is higher in virgin olive oil (around 230 mg/
kg) than in other olive oils.
Olive oil supplementation (50 mg/day) to the diet enriched LDL with oleic acid and signifi‐
cantly reduced human LDL susceptibility to in vitro oxidation, thus making them signifi‐
cantly less atherogenic. In part, this reflects the lesser susceptibility of monounsaturated
fatty acids to lipid peroxidation compared with that of polyunsaturated fatty acids, which
are particularly prone to peroxidation due to the greater number of double bonds [10,52].
Olive oil consumption could reduce oxidative damage, on one hand, due to its richness in
oleic acid and, on the other hand, due to its minor components of the olive oil particularly
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the phenolic compounds. The phenolic content in virgin olive oil could reduce the lipid oxi‐
dation and inhibit platelet-induced aggregation [53].
Moreover, olive oil minor components have also been involved in the anti-oxidant activity
of olive oil. Some components of the unsaponifiable fraction, such as squalene, β-sitosterol
or triterpenes, have been shown to display anti-oxidant and chemopreventive activities and
capacity to improve endothelial function decreasing the expression of cell adhesion mole‐
cules and increasing vasorelaxation [54].
Olive oil phenolic compounds are able to bind the LDL lipoprotein and to protect other phe‐
nolic compounds bound to LDL from oxidation. The role of phenolic compounds from olive
oil on DNA oxidative damage remains controversial and perhaps more sensitive methods
would be required to detect differences among the types of olive oil consumed. Further
studies are required to establish the potential benefits of olive oil and those of its minor com‐
ponents on DNA oxidative damage.
One of the most well known and important characteristic of the Mediterranean diet is the
presence of virgin olive oil as the principal source of energy from fat. In contrast to other
edible oils with a similar fatty composition, like sunflower, soybean and rapeseed canola
oils, virgin olive oil is a natural juice, while the seed oils must be refined before consump‐
tion, thus changing its original composition during this process. Virgin olive oils are those
obtained from the olives solely by mechanical or other physical means under conditions that
do not lead alteration in the oil. The olives have not undergone any treatment other than
washing, decantation, centrifugation or filtration [53].
Virgin olive oil is a source of healthy unsaturated fatty acids and hundreds of micronu‐
trients, especially anti-oxidants, as phenol compounds, vitamin E and carotenes.
Results of the randomized cross-over clinical trials performed in humans on the anti-oxidant
effects of olive oil phenolic compounds are controversial. The protective effects on lipid oxi‐
dation in these trials have been better displayed in oxidative stress conditions, i.e. males,
submitted to a very strict anti-oxidant diet, hyperlipidaemic or peripheral vascular disease
patients. Carefully controlled studies in appropriate populations, or with a large sample
size, are urgently required to definitively establish the in vivo anti-oxidant properties of the
active components of virgin olive oil [55].
12. Oligoelements in water
Epidemiological studies have revealed both a higher incidence of CVDs and cerebrovascular
mortality in soft water areas and a negative correlation between water hardness and cardio‐
vascular mortality [56,57]. Actually, there is not enough evidence to determine whether hard
water contains protective substances not present in soft water or if there are detrimental
substances in soft water.
Water contains oligominerals, such as calcium, magnesium, cobalt, lithium, vanadium, sili‐
con, copper, iron, zinc and manganese, that are some important factors in reducing the risk
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of CVD onset. On the other hand, elements like cadmium, lead, silver, mercury and thallium
are considered to be harmful [58].
Magnesium deficiency is considered to be a risk factor of CVDs, in fact its supplementation
delays the onset of atherosclerosis or hinders its development. On the other hand, silicon is a
major trace element in animal diets and humans ingest between 20-50 mg/day of silicon
with the Western diet [59]. Main dietary sources are whole grain cereals and their products
(including beer), rice, some fruits and vegetables and drinking water, especially bottled min‐
eral waters with geothermal and volcanic origin [60]. Numerous studies showed that silicon
has a role in maintaining the integrity, the stability and the elastic properties of arterial walls
[61,62] and postulated silicon as a protective factor against the development of age-linked
vascular diseases, such as atherosclerosis and hypertension [62,63].
In addition, vanadium is considered to have anti-atherosclerotic properties; lithium can also
inhibit the synthesis of cholesterol, but has an atherogenous activity that can be inhibited by
supplementation with appropriate quantities of calcium. A copper-deficient diet can induce
hypercholesterolemia and hypertriglyceridemia that is, in turn, intensified by high levels of
dietary zinc [58,64].
On the basis of these limited data, intakes of silicon, magnesium and vanadium in water and
avoiding exposure to cadmium and lead are important elements of the prophylaxis of
CVDs, so hard water has positive health effects and should not be replaced by drinking wa‐
ter with insufficient amounts of beneficial elements [58]. It is important to remember also
that water has small contribution of mineral trace respect to total dietary intake (7% from
liquid vs 93% from solid food) [58,65].
13. Melatonin supplementation
Melatonin, an endogenously produced indoleamine, is a remarkably functionally pleiotropic
molecule [66] which functions as a highly effective anti-oxidant and free radical scavenger
[67,68]. Endogenously produced and exogenously administered melatonin has beneficial ac‐
tions on the cardiovascular system [69,70,71].
Exogenously administered melatonin is quickly distributed throughout the organism; it may
cross all morphophysiological barriers and it enters cardiac and vascular cells easily. High‐
est intracellular concentration of melatonin seem to be in the mitochondria; this is especially
important as the mitochondria are a major site of free radicals and oxidative stress genera‐
tion. Moreover, melatonin administration in a broad range of concentration, both by the oral
and intravenous routes, has proven to be safe for human studies [72,73].
Melatonin itself appears to have an atheroprotective activity during LDL oxidation and also
melatonin’s precursors and breakdown products inhibit LDL oxidation, comparable to vita‐
min E. Because of its lipophilic and nonionized nature, melatonin should enter the lipid
phase of the LDL particles and prevent lipid peroxidation [9] and may also augments en‐
dogenous cholesterol clearance.
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Melatonin also counteracts the cell oxidative burden indirectly by stimulating the produc‐
tion of cell ROS detoxifying enzymes, specially glutathione peroxidase, glutathione reduc‐
tase and superoxide desmutase. Melatonin besides being a more effective anti-oxidant than
resveratrol can reverse the pro-oxidant DNA damage induced in low concentration of re‐
sveratrol, when added in combination [74].
Moreover, 6-hydroxymelatonin, the main in vivo metabolite of melatonin, and its precursor,
N-acetyl-5-hydroxytryptamine, were potent in reducing in vitro LDL peroxidation. The abili‐
ty of the parent molecule melatonin as well as its metabolites to function in radical detoxifi‐
cation greatly increases its ability to limit oxidative abuse at many levels within cells [9].
Therefore it can be suggested that although melatonin per se would have physiologically or
pharmacologically effects to inhibit in vivo LDL oxidation, its action sinergically with its
main catabolite would be more active [75]. Melatonin may exert protective and benefical ef‐
fects against CVDs reducing the risk of atherosclerosis and hypertension [9].
It is important to underline that the recent discovery of melatonin in grapes [74] opens new
pespectives in the field of natural anti-oxidative atheroprotective strategies.
14. Vitamins
Vitamin C is a water-soluble vitamin and is believed to regenerate vitamin E from its oxi‐
dized state back to its activated state. The principal sources of vitamin C are citrus fruits,
tomatoes and potatoes. Natural vitamin E is a mixture of tocopherols and tocotrienols syn‐
thesized only by plants and the natural sources are vegetal oils. In fact, olive oil contains vi‐
tamin E and many of its beneficial effects are attributed to this constituent.
Vitamin E acts as a chain-breaking anti-oxidant for LDL lipids [27]. In vitro enrichment of
LDL in vitamin E drastically increases their resistance to oxidative stress and it has also been
reported to inhibit the cytotoxicity of ox-LDL toward cultured endothelial cells. Vitamin E
has been reported to retard atherosclerosis progression in certain arteries of primates fed an
atherosclerosis diet. In humans, both women and men, exhibited reduced vascular disease
parameters [75], beneficial effects in the reduction of risk of onset and progression of athero‐
sclerosis, due to its inhibition of LDL oxidation and association with molecular modulation
of the interaction of immune and endothelial cells. A long term supplementation with vita‐
min E in hypercholesterolemic patients and/or chronic smokers increase levels of autoanti‐
bodies against ox-LDL. There is also a quite convincing evidence from in vitro studies that
vitamin C strongly inhibits LDL oxidation [27].
It is important to underline that there are no definite recommendations on the dose and du‐
ration of supplementation with vitamins in human. Although, high dietary intake of fruit
and vegetables is associated with a reduction in the incidence of atherosclerosis, stroke and
cardiovascular mortality in general [27]. Moreover, epidemiologic studies have reported
that high dietary intake of foods rich in vitamin E, vitamin C and β-carotene have been in‐
versely associated with the incidence of CVDs [35].
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Actually, it is difficult to conclude that a clinical benefit of anti-oxidants in CVD is estab‐
lished. Thus, it is necessary to clarify why anti-oxidants showed their beneficial effects in
vitro,  whereas  less  satisfactory  results  were  observed in  some,  although not  all,  clinical
conditions [40].
15. HDL-based diet
It is well known that LDL are crucial to the development of atherosclerotic lesions, whereas
HDL are inhibitors of the process, so the primary focus of pharmaceutical lipid modulation
is reduced LDL; this strategy has reduced cardiovascular morbidity and mortality by up to
25% [76].
Recent studies also suggest that HDL inhibits oxidation, prevents the expression of inflam‐
matory mediators and the expansion of pro-atherogenic myeloid cells and reduces the ex‐
pression of pro-coagulant enzymes, each of which may contribute in smaller ways to
atheroprotective effects [77].
The synthesis and release of HDL into the peripheral vasculature is the first step in reverse
cholesterol transport that is proposed to be a major mechanism by which HDL mediates its
atheroprotective effects [78]. However, HDL possesses multiple anti-atherosclerotic proper‐
ties in addition to reverse cholesterol transport. HDL acts as a transporter of a variety of fat-
soluble vitamins, including vitamin E, and also as a natural anti-oxidant protecting for LDL
in a multifactorial manner. Moreover, HDL are associated with enzymes with anti-oxidant
capacity, like paraoxonase that is a major contributor to the anti-oxidant activity of HDL
[78]. Paraoxonase is synthesized in the liver and released into the circulation, where it be‐
comes closely associated with HDL.
HDL has also been demonstrated to improve endothelial function, maintain the integrity of
vascular endothelium and may induce the production of vasodilators, such as prostacyclin,
by the endothelium. HDL has also been demonstrated to exhibit anti-thrombotic and anti-
inflammatory activities.
The combination of a low saturated fat diet and increased exercise raises HDL levels by 5–
14% and lowers triglyceride, LDL and total cholesterol levels by 4–18%, 7–15% and 7-18%,
respectively. Thus, simple lifestyle measures including a correct diet and increased activity
represent a cost-effective and low-risk intervention that is associated with a range of health
benefits [76].
There is considerable interest at present in the possible therapeutic effects of elevating HDL
levels to capitalize on their vasculoprotective effects. Although, clinical evidence to date has
provided inconsistent results and suggests that raising HDL levels may not be the straight‐
forward answer to atheroprotection [79,80]; HDL-based therapies, also combined with other
atheroprotective strategies, may be a valide future atheroprotective approach.
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in a multifactorial manner. Moreover, HDL are associated with enzymes with anti-oxidant
capacity, like paraoxonase that is a major contributor to the anti-oxidant activity of HDL
[78]. Paraoxonase is synthesized in the liver and released into the circulation, where it be‐
comes closely associated with HDL.
HDL has also been demonstrated to improve endothelial function, maintain the integrity of
vascular endothelium and may induce the production of vasodilators, such as prostacyclin,
by the endothelium. HDL has also been demonstrated to exhibit anti-thrombotic and anti-
inflammatory activities.
The combination of a low saturated fat diet and increased exercise raises HDL levels by 5–
14% and lowers triglyceride, LDL and total cholesterol levels by 4–18%, 7–15% and 7-18%,
respectively. Thus, simple lifestyle measures including a correct diet and increased activity
represent a cost-effective and low-risk intervention that is associated with a range of health
benefits [76].
There is considerable interest at present in the possible therapeutic effects of elevating HDL
levels to capitalize on their vasculoprotective effects. Although, clinical evidence to date has
provided inconsistent results and suggests that raising HDL levels may not be the straight‐
forward answer to atheroprotection [79,80]; HDL-based therapies, also combined with other
atheroprotective strategies, may be a valide future atheroprotective approach.




As a result of increased understanding of the characteristics and production of ROS and
oxidative stress and demonstrated a link either directly or indirectly to atherosclerosis, the
reduction of ROS or decreasing their rate of production may delay the onset and progres‐
sion of atherosclerosis. Aging promotes physiological changes, such as oxidative stress, in‐
flammation  and endothelial  dysfunction  strictly  associated  with  the  pathophysiology  of
atherosclerosis.  Actually,  compelling  evidence  indicates  that  increased  consumption  of
correct  diet  containing nutritive and non-nutritive compounds with anti-oxidant proper‐
ties may contribute to the improvement of the quality of life by delaying onset and reduc‐
ing the risk of CVDs and, in particular, the development of an atheroprotective strategies
acting on oxidative stress involved in the pathogenesis  of  atherosclerosis  and with little
toxicity or adverse effects may provide an ideal simil-therapeutic treatment against athero‐
sclerosis. Actually, cardiovascular prevention and treatment strategies should consider the
simple, direct and inexpensive dietary approach as a first line approach to the burgeoning
burden of  CVDs,  alone or in combination with pharmacological  treatments.  In this  con‐
text,  wine, tea,  fruit  and olive oil  received much attention, because they are particularly
rich in natural anti-oxidants.
However, a better understanding of the oxidative stress-dependent signal transduction
mechanisms, their localization, and the integration of both ROS-dependent transcriptional
and signaling pathways in vascular pathophysiology is anyway a prerequisite for effective
pharmacological and non pharmacological interventions for cardiovascular protection from
oxidative stress.
In conclusion, the proposal that anti-oxidants may retard the progression of atherosclerosis
is very interesting and promising, but further studies are needed to better understand the
mechanisms that underline the biological effect of healthy life style.
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1. Introduction
Currently the onset and progression of atherosclerosis have been established as the result of
different cellular and molecular alterations that are not inevitable but rather predictable and
so modifiable, if recognized on time [1,2].
From a morphologic point of view the vascular wall (common to each artery, vein or capilla‐
ry of blood and lymphatic circulation) is made by three layers or tunicae: the tunica intima-
starting from the inner and containing the endothelium, directly facing blood; the tunica
media-with longitudinally oriented layers of smooth muscle cells connected by elastic and
collagen fibers, that change the thickness according to the vascular type and function; and
the tunica adventitia- the most external layer, containing vasa vasorum, necessary to maintain
high metabolic requirements in larger vessels and the source of endothelial progenitors in
neovasculogenesis [3-5].
However in this complex and specialized architecture, the endothelium layer certainly rep‐
resents the first sensor of hemodynamic stress [6] and the favorite target for atherogenic fac‐
tors, like circulating inflammatory molecules, macrophages, lipoproteins (LDLs) and many
drugs [7].
Therefore in this scenario it is necessary to update the knowledge on the endothelium,
which is the main player in the initial step of atherogenesis, and its involvement in a pivotal
biological mechanism, called endoplasmic reticulum (ER) stress, associated to cardiovascu‐
lar damage and invalidating pathologies such as stroke, cardiac ischemia, chronic renal fail‐
ure, macular degeneration and obesity [8-11].
In particular we elucidate here the importance of the ER stress in the artery wall, because it
very recently has emerged as a novel event able to promote athero-susceptibility and hyper‐
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tension both in animal models and in clinical patients [11,12]. Remarkably this event is early
detectable in the endothelial cells [13], sometimes concurrent with other well-known athero‐
genic processes, like inflammation, oxidative damage and endothelial cell death.
Nevertheless considering the focal distribution of plaques and their cumulative progression
during the whole lifespan [14], it is mandatory to consider the role of ER stress signaling in
the circulatory bed, in order to maintain the proper ER function, so preventing or reducing
the progression into irreversible cardiovascular dysfunctions, such as atherosclerosis, hyper‐
tension and ischemic heart disease [15-17].
We firmly believe that focusing integrated basic and applied research on ER stress in the ar‐
tery tree and in the heart might open new avenues in the treatment and management of in‐
validating cardiovascular complications [18,19].
2. The endothelium and the endoplasmic reticulum homeostasis
According to the most accredited theory that indicates inflammation as the first pathogenic
mechanism of atherosclerosis, the endothelium is really the crucial target of circulating mol‐
ecules or cells and constitutes the main entrance for LDL during the initial step of asympto‐
matic artery wall changes that end into plaques or atheromata and their dramatic clinical
evolution [20-23].
Recent studies have outlined that in atherosusceptible sites in the artery tree, endothelial
cells acquire a proinflammatory phenotype which is permissive in the plaque development
by expressing pro-inflammatory sensors such as Toll-like receptors (TLRs), that in turn at‐
tract leukocytes adhesion in the intima layer. Mainly TLR 2 and TLR4 are active in mouse in
the progression of atherosclerosis and their signals stimulate a downstream adaptor mole‐
cule, called Toll/IL-1 receptor domain-related adaptor protein that induces interferon or
TRIF. Indeed also in human vascular tree, by immunostaining and mRNA survey TLR2 and
TLR4 have been well characterized in selected sites, including the aorta, subclavia, carotid,
mesenteric, iliac and temporal arteries [24].
Nevertheless an important concept to remind here is that the relationship between the vas‐
cular endothelium and the blood is not only “passive” in receiving inflammatory or meta‐
bolic stimuli, but instead “active”, with pleiotropic activities like the secretion of regulatory
factors for cholesterol and lipid homeostasis, platelets recruitment, and the adaptation to lo‐
cal changes of blood flow and pressure [25,26].
Moreover the artery wall, in particular in healthy resistance arteries, is not a static but a dy‐
namic and plastic structure, able to remodel its diameter and structure, adapting to rapid
changes in the systemic pressure [27].
Indeed also artery geometry directly influences the athero-susceptibility and the distribution
of mechanical forces associated to blood flux, that impair the endothelium [25,28,29].
In particular during unstable hemodynamic flux and changes in blood direction, mainly in
arterial branches and bifurcations, it is particularly evident the heterogeneity of endothelial
Current Trends in Atherogenesis28
phenotypes that change their common flat shape and assume a polygonal morphology to‐
gether with a different turnover. These events are linked to the susceptibility of a specific
vessel to develop atherosclerosis and to the onset of valve calcification in the heart [30-32].
So endothelial dysfunctions may have serious consequences and a direct impact on the en‐
dothelial cells’ role and activities, mainly on the resistance to dangerous stimuli that pro‐
mote the onset of pro-atherogenic vascular damage recently reviewed by [33].
Indeed they involve different structural and functional aspects of the endothelium, that is
classified as a monocellular squamous type of epithelium [34], lining human vascular and
lymphatic tree, poorly detectable by traditional light microscopy but well characterized by
electron microscopy and related techniques [35-37].
Nevertheless the real consideration of the endothelium by physicians has begun about 50
years ago, but only in the last decade, it has obtained more importance in the cardiovascular
community, with the rediscovery of Weibel-Palade bodies and caveole signals, the role of
transcytosis mechanism, and the active participation into vascular permeability [38-40].
Among most critical structural changes linked to endothelial dysfunctions, there are the reduc‐
tion of glycocalix, which is the external component necessary to react against toxic apoB LDL,
and the over-development of fundamental organelles like Golgi complex and the ER [41,42].
Remarkably the ER signaling in the vascular wall is the main topic of this chapter, because
much more attention must be given to ER homeostasis in atheroprone sites in the artery tree,
resulting from a chronic adaptive reaction to flow disturbance, concurrent with oxidative
damage and inflammation [43,44].
Abnormal ER activity has been recently reported in coronary arteries during altered he‐
modynamic changes, diagnosed by genetic techniques as an abnormal transcription of se‐
lected  genes;  while,  in  contrast,  the  transcriptional  activity  is  lacking  in  more  resistant
arterial beds [45,46].
Remarkably it must be pointed out that, in mammalian epithelial cells, the ER is commonly
depicted by ultrastructural analysis as a perinuclear network of tubules and membranes,
and by tomography as a dynamic assembly of tridimensional stacks associated to mitochon‐
dria [47-49].
Moreover it is well-known that the ER has different specialization and structure, called
rough or smooth, if associated or not to ribosomes in the same cell, but in specialized cardiac
and smooth muscle cells in the vascular wall it is called the sarcoplasmic reticulum [50,51].
Anyway, this dynamic organelle represents the elective site where nascent polypeptide
chains are gradually converted in a stable tertiary structure, that is associated to a specific
protein [52].
Among the main ER functions have been comprised the folding of neo-synthesized secreto‐
ry and trans-membrane proteins, the regulation of calcium balance and the synthesis of lip‐
ids, like steroids and cholesterol [53].
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If one of these activities fails, the ER efficiency is lost and aberrant unfolded proteins accu‐
mulate within the ER membranes, causing the “ER stress”. This condition has been defined
as “ any perturbation that compromises the protein folding functionality” in the organelle
and implies an adaptive response to restore correct ER homeostasis [54,55].
So it has become clear that each perturbation in the ER balance interferes with folding process
of different proteins, that are devoid of their intrinsic function, so unable to properly work in
the cells and often degraded by a process called ER associated degradation (ERAD) [56-58].
In mammalian cells, disrupted ER homeostasis can be restored within short or long time ac‐
cording to the type of stimulus, if acute and transient or chronic and prolonged.
It is accepted that endothelial cells may tolerate acute stressors that last short time, such as
circulatory ischemia or hypoxia, calcium and nutrient deprivation, adapting themselves to
clear dysfunctional proteins. In doing this activity, they use a rapid process that involves a
transient intracellular signaling from the ER to the nuclear transcription mechanism of
genes, called “unfolded protein response” or UPR [59-62]. Indeed UPR is able to rectify and
limit the cellular damage induced by metabolic, genetic, environmental factors, enhancing
cell survival, but strictly related to the duration of the stress. On the contrary, if the stressful
stimuli are severe or last for a long time, like the majority of chronic inflammatory and he‐
modynamic factors in atherogenesis, UPR is unable to resolve persistent ER stress so leading
to endothelial cell death, generally by apoptosis (Figure 1).
Figure 1. ER stress balance – Schematic representation of ER homeostasis: on the left, adaptive responses to acute
stress that lead to recovery and on the right, reactions to chronic vascular stress that lead to apoptosis. NF-kB-Nuclear
Factor k-B; ERAD-ER-associated degradation; CHOP- C/EBP homologous protein; JNK- c JUN NH2-terminal kinase.
Adapted by [63].
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3. ER stress and UPR pathways in cardiovascular diseases
Given the vital role of fundamental UPR to augment the protein folding in the ER and to
reduce the pool of misfolded products, it is clear that this organelle represents an efficient
checkpoint for quality control of secretory proteins that may migrate to other organelles
and/or to the plasma membrane to be secreted. Indeed UPR works also in collaboration with
the Golgi apparatus and plasma membrane, and only correctly-assembled molecules are
driven to their final destination. Therefore the kinetic and the amplitude of UPR are emerg‐
ing as key events for combine a stress response in specific cell types to their final fate and
eventually death [64].
In the heart, for example, the UPR pathway produces several proteins, that ameliorate the
ER ability to cope with stress, by three separate mechanisms: 1) translational attenuation,
that avoids further deposition of abnormal proteins in the ER; 2) transcriptional activation of
genes for chaperones and related proteins [65]; 3) activation of a process to hamper the fur‐
ther deposition of dysfunctional proteins called ERAD [11].
Indeed to start the quality control work in the ER factory, it is crucial that about one-third of
novel proteins are translocated there, because they acquire the specific configuration and as‐
sembling with the assistance of ER chaperones, then further change by post-translational
modifications, like disulphide bonds or glycosylation performed by specialized enzymes
[66,67].
Remarkably unlike the cytosol, where the abnormal accumulation of proteins is handled by
different families of chaperones, belonging to heat shock protein (HSP) 20 and HSP70 fami‐
lies, called HSP25/27 and HSP70 [68,69], in the ER environment the UPR mechanism is sus‐
tained by specific resident chaperones, glucose-regulated protein (GRP) GRP78 /Bip, GRP94
and by lectin chaperones calnexin, calreticulin and calmegin [70,71].
In eukaryotic cells GRP78, a trans-membrane protein, is called “the master regulator” of ER
stress response and usually works by binding to nascent polypeptides to ensure their proper
secondary structure. In unstressed conditions, GRP78 is usually associated to three different
UPR-sensors and renders them inactive through the direct interaction with their N-terminus
[72]. In contrast, when unfolded proteins accumulate in the ER, GRP78 dissociates from
three UPR-sensing elements, and allows their oligomerization and activation, so ensuring
the start of the UPR cascade.
Currently, it is established that GRP78 is induced by chemical and inflammatory atherogen‐
ic factors, further associated to ER stress signaling, such as excess cholesterol, oxidized phos‐
pholipids, peroxynitrite, homocysteine [73,74]. In a recent in vitro model, that simulates
human arterial shear stress waveforms, GRP78 was over-expressed in the endothelial cells
as a compensatory effect before lesion development [75]. The mechanisms by which GRP78
increased were dependent on upstream alpha 2-beta1integrin linked to p38 activity localized
to focal adhesion in the endothelial cells upon long-term shear stress [76].
Remarkably in the above study it was further demonstrated that inflammatory cytokines as‐
sociated to atheroprone environment, had no effect on GRP78 expression in the endothelial
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If one of these activities fails, the ER efficiency is lost and aberrant unfolded proteins accu‐
mulate within the ER membranes, causing the “ER stress”. This condition has been defined
as “ any perturbation that compromises the protein folding functionality” in the organelle
and implies an adaptive response to restore correct ER homeostasis [54,55].
So it has become clear that each perturbation in the ER balance interferes with folding process
of different proteins, that are devoid of their intrinsic function, so unable to properly work in
the cells and often degraded by a process called ER associated degradation (ERAD) [56-58].
In mammalian cells, disrupted ER homeostasis can be restored within short or long time ac‐
cording to the type of stimulus, if acute and transient or chronic and prolonged.
It is accepted that endothelial cells may tolerate acute stressors that last short time, such as
circulatory ischemia or hypoxia, calcium and nutrient deprivation, adapting themselves to
clear dysfunctional proteins. In doing this activity, they use a rapid process that involves a
transient intracellular signaling from the ER to the nuclear transcription mechanism of
genes, called “unfolded protein response” or UPR [59-62]. Indeed UPR is able to rectify and
limit the cellular damage induced by metabolic, genetic, environmental factors, enhancing
cell survival, but strictly related to the duration of the stress. On the contrary, if the stressful
stimuli are severe or last for a long time, like the majority of chronic inflammatory and he‐
modynamic factors in atherogenesis, UPR is unable to resolve persistent ER stress so leading
to endothelial cell death, generally by apoptosis (Figure 1).
Figure 1. ER stress balance – Schematic representation of ER homeostasis: on the left, adaptive responses to acute
stress that lead to recovery and on the right, reactions to chronic vascular stress that lead to apoptosis. NF-kB-Nuclear
Factor k-B; ERAD-ER-associated degradation; CHOP- C/EBP homologous protein; JNK- c JUN NH2-terminal kinase.
Adapted by [63].
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3. ER stress and UPR pathways in cardiovascular diseases
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three UPR-sensing elements, and allows their oligomerization and activation, so ensuring
the start of the UPR cascade.
Currently, it is established that GRP78 is induced by chemical and inflammatory atherogen‐
ic factors, further associated to ER stress signaling, such as excess cholesterol, oxidized phos‐
pholipids, peroxynitrite, homocysteine [73,74]. In a recent in vitro model, that simulates
human arterial shear stress waveforms, GRP78 was over-expressed in the endothelial cells
as a compensatory effect before lesion development [75]. The mechanisms by which GRP78
increased were dependent on upstream alpha 2-beta1integrin linked to p38 activity localized
to focal adhesion in the endothelial cells upon long-term shear stress [76].
Remarkably in the above study it was further demonstrated that inflammatory cytokines as‐
sociated to atheroprone environment, had no effect on GRP78 expression in the endothelial
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cells. So it is plausible that hemodynamic flow might be the earliest ER stressor and GRP78
inducer in an atheroprone environment.
Moreover the conservative pro-survival role of GRP78 is outlined also in vivo, considering
that GRP78-deficient mice are embryonic lethal and present increased apoptosis [77].
The canonical UPR starting signals include three distinct pathways: the inositol-requiring
kinase 1 (IRE1), the transcriptional factor activating transcription factor 6 (ATF6) and the
protein kinase-like ER kinase (PERK) [15] (Figure 2).
Figure 2. Canonical UPR pathways. IRE1- inositol-requiring kinase 1; ATF6- ATF4- activating transcription factors 6 or
4; XBP1- x-box binding protein 1; eIF2alpha- initiation factor 2 alpha; ERAD- ER-associated protein degradation path‐
way; GRP78- glucose-regulated protein; PERK- protein kinase-like ER kinase; CHOP- C/EBP homologous protein. Modi‐
fied from [15,78].
This last enzyme is able to phosphorylate the translation initiation factor 2 alpha (eIF2alpha)
after ER stress then reduces the further protein load on the ER by blocking mRNA transla‐
tion. In contrast, there are some mRNAs that require eIF2 alpha autophosphorylation for
their translation, including the transcriptional factor ATF4, that is directly involved in the
nuclear activation of UPR-related genes. Furthermore eIF2 alpha influences, by endonu‐
clease activity, the splicing of another transcriptional factor, called X-box binding protein 1
(XBP1), that regulates the transcription of UPR-related genes, although in the heart its func‐
tion is largely unknown [79].
ATF6 is another crucial transcriptional factor that, moving from the Golgi complex, becomes
activated and able to interact with XBP1 target genes for the synthesis of molecular chaper‐
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ones and also for enzymes involved in the ER-associated protein degradation pathway
(ERAD). The ERAD mechanism mediates the translocation of unfolded proteins from the ER
into the cytosol where they are degraded by the ubiquitin-proteasome system and so allevi‐
ates the ER over-crowding [58].
Interestingly, a novel gene, called derlin-3, as a component of the ERAD induced by ATF6,
was recently discovered in the mouse heart, and derlin-3 over-expression was able to protect
cardiomyocytes from ischemia-induced apoptosis in vitro [80].
Besides ER chaperones involvement, dysfunctional proteins may be degraded directly in the
ER in a chaperone-independent manner, by a specialized protease system called the ubiqui‐
tin-proteasome, that works independently or in synergy with the UPR. According to recent
clinical and experimental studies, atherosclerosis may be considered also as a “protein-qual‐
ity disease” and the proteasome works at early phases of the disease, especially in both the
coronary and carotid arteries, as a compensatory reaction to prevent complete protein dys‐
function [81].
It is currently accepted that in mammalians the necessity to remove aberrant proteins that
engulfed the ER environment is based upon three main ER activities: 1) the transient UPR
associated to resident chaperones, 2) the ubiquitin-proteasome system and 3) the prolonged
UPR linked to autophagy [82].
In particular through this last process, properly called macro-autophagy, abnormal cyto‐
plasmic contents or organelles engulfed in autophagosomes, upon fusion with lysosomes,
are degraded.
Evidence is emerging that the ER provides membrane for autophagosome formation and
that autophagy is crucial for ER homeostasis due to its ability to remove unwanted or dam‐
aged organelles like abnormal mitochondria by mitophagy [83]. Moreover the ER contrib‐
utes also lipids and specific proteins, such as beclin-1, to initiate autophagosome formation
very close to itself. This physical proximity probably reflects a functional dependence be‐
tween ER and autophagy process, that in the endothelial cells often occurs in response to
reactive oxygen species (ROS) by circuits localized to the ER surface [84]. However in divid‐
ing cells with high turnover, autophagy may not be so relevant, but in long-lived cells like
smooth muscle cells and cardiomyocytes, it is critical to maintain optimal cellular function.
Remarkably autophagy is a suitable mechanism to eliminate abnormal proteins and organ‐
elles, during fast and relatively mild ER stress conditions, but if the ER stress is severe, this
mechanism is overwhelmed.
Anyway, many studies suggest that autophagy is activated in the heart and vascular tree as
a defensive mechanism for survival during myocardial ischemia/reperfusion and in athero‐
sclerosis [85,86].
If autophagy may be considered as a safeguard that protects vascular wall from rupture-prone
lesions, autophagy up-regulation by recent pharmacologic modulators has been proven to be
effective in short-term experimental studies on knockout atherosclerotic mice [87]. Moreover
autophagy is directly involved in the acute setting of cardiac diseases by providing metabolic
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cells. So it is plausible that hemodynamic flow might be the earliest ER stressor and GRP78
inducer in an atheroprone environment.
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that GRP78-deficient mice are embryonic lethal and present increased apoptosis [77].
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kinase 1 (IRE1), the transcriptional factor activating transcription factor 6 (ATF6) and the
protein kinase-like ER kinase (PERK) [15] (Figure 2).
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fied from [15,78].
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after ER stress then reduces the further protein load on the ER by blocking mRNA transla‐
tion. In contrast, there are some mRNAs that require eIF2 alpha autophosphorylation for
their translation, including the transcriptional factor ATF4, that is directly involved in the
nuclear activation of UPR-related genes. Furthermore eIF2 alpha influences, by endonu‐
clease activity, the splicing of another transcriptional factor, called X-box binding protein 1
(XBP1), that regulates the transcription of UPR-related genes, although in the heart its func‐
tion is largely unknown [79].
ATF6 is another crucial transcriptional factor that, moving from the Golgi complex, becomes
activated and able to interact with XBP1 target genes for the synthesis of molecular chaper‐
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ones and also for enzymes involved in the ER-associated protein degradation pathway
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into the cytosol where they are degraded by the ubiquitin-proteasome system and so allevi‐
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Besides ER chaperones involvement, dysfunctional proteins may be degraded directly in the
ER in a chaperone-independent manner, by a specialized protease system called the ubiqui‐
tin-proteasome, that works independently or in synergy with the UPR. According to recent
clinical and experimental studies, atherosclerosis may be considered also as a “protein-qual‐
ity disease” and the proteasome works at early phases of the disease, especially in both the
coronary and carotid arteries, as a compensatory reaction to prevent complete protein dys‐
function [81].
It is currently accepted that in mammalians the necessity to remove aberrant proteins that
engulfed the ER environment is based upon three main ER activities: 1) the transient UPR
associated to resident chaperones, 2) the ubiquitin-proteasome system and 3) the prolonged
UPR linked to autophagy [82].
In particular through this last process, properly called macro-autophagy, abnormal cyto‐
plasmic contents or organelles engulfed in autophagosomes, upon fusion with lysosomes,
are degraded.
Evidence is emerging that the ER provides membrane for autophagosome formation and
that autophagy is crucial for ER homeostasis due to its ability to remove unwanted or dam‐
aged organelles like abnormal mitochondria by mitophagy [83]. Moreover the ER contrib‐
utes also lipids and specific proteins, such as beclin-1, to initiate autophagosome formation
very close to itself. This physical proximity probably reflects a functional dependence be‐
tween ER and autophagy process, that in the endothelial cells often occurs in response to
reactive oxygen species (ROS) by circuits localized to the ER surface [84]. However in divid‐
ing cells with high turnover, autophagy may not be so relevant, but in long-lived cells like
smooth muscle cells and cardiomyocytes, it is critical to maintain optimal cellular function.
Remarkably autophagy is a suitable mechanism to eliminate abnormal proteins and organ‐
elles, during fast and relatively mild ER stress conditions, but if the ER stress is severe, this
mechanism is overwhelmed.
Anyway, many studies suggest that autophagy is activated in the heart and vascular tree as
a defensive mechanism for survival during myocardial ischemia/reperfusion and in athero‐
sclerosis [85,86].
If autophagy may be considered as a safeguard that protects vascular wall from rupture-prone
lesions, autophagy up-regulation by recent pharmacologic modulators has been proven to be
effective in short-term experimental studies on knockout atherosclerotic mice [87]. Moreover
autophagy is directly involved in the acute setting of cardiac diseases by providing metabolic
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substrates for producing energy and thiol repairing, so the regulation of the autophagic machi‐
nery may offer promising therapeutic opportunities to treat ischemia/reperfusion damage and
heart hypertrophy [88,89]. Recently this interesting eventuality has been also demonstrated in
experimental studies in genetic murine models, notably beclin 1(+/-) and Atg5 deficient mice,
even if its application in clinical trials is still an hypothesis [90].
In this scenario it is intriguing the proposed role of macrophages, able to remove apoptotic
cell debris in the advanced atherosclerotic plaque by a mechanism called efferocytosis. It is
well-known the active role of these cells in the inflammatory cascade inside the vascular
wall, where they enter as adherent monocytes then become macrophages and foam cells, ac‐
cording to the progression of atherosclerosis [91]. The efferocytosis process seems necessary
to limit atherosclerosis, because only a selective fully-operative efferocytosis retards the pro‐
gression of this inflammatory disease [92-94].
The apolipoprotein E (ApoE) family comprises crucial lipoproteins present in the blood to
transport the cholesterol and also to modulate several metabolic diseases like atherosclerosis
and Alzheimer’s [95]. The human ApoE gene is composed by different isoforms with different
metabolic properties and the most studied are apoE3 that is protective and apoE4 that, in con‐
trast, accelerates atherosclerosis and coronary damage. A recent study demonstrated that peri‐
toneal macrophages isolated from ApoE4 mice were defective in the efferocytosis mechanism
and if stimulated by inflammatory molecules, such as oxidized lipoproteins (ox-LDLs), were
sensitive to apoptosis throughout the abnormal intensification of ER stress pathway [96]. How‐
ever the above condition was greatly ameliorated by chemical stimulation of ER signaling, that
reduced inflammation linked to apoE4, and balanced ER stress response.
Anyway if the UPR involvement in pathological complications has been largely outlined, it
is important to remind that this signaling is commonly evoked during the heart morphogen‐
esis and in healthy physiological conditions [97].
Really the strict association between the UPR signaling and pathology has been reported
since about 20 years ago, in different pioneering papers [98,99] that discussed the relation‐
ship between dysfunctional ER and proteotoxicity, and its direct role in neurodegenerative
conditions characterized by abnormal protein deposition, like Parkinson’s and Alzheimer’s
diseases.
Seminal studies have then elucidated the crucial role of the disruption of the regular ER ac‐
tivity in several metabolic disorders like obesity, diabetes insipidus up to neurodegenerative
diseases like Creuzfeld-Jacob, Hungtington’s, Parkinson’s [9,100]. Moreover this mechanism
has been actually involved in the pathogenesis of chronic disorders, including cancer, liver
diseases, heart failure and in particular atherosclerosis [101,102].
Interestingly ER sensing may contribute to atherogenic damage by four ways: 1) by connect‐
ing lipid metabolism and UPR; 2) by promoting abnormal glucose metabolism and insulin
activation that serve as a bridge-mechanism between metabolic dysfunctions and atheroscle‐
rosis; 3) by driving macrophages cell death after cholesterol loading; 4) by controlling auto‐
immunity based on the processing and presentation of MHC-1 associated peptides.
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Currently there is ample evidence of the involvement of the immune system in the patho‐
genesis of atherosclerosis and ER stress-driven autoimmunity may represent a novel contri‐
buting factor in the progression of the disease [103,104].
4. ER stress induced-cell death in the vascular wall
A growing body of evidence indicates that prolonged ER stress, due to the persistent accu‐
mulation in the ER of misfolded proteins beyond the ability of transient UPR, causes cell
death in the vascular wall and may contribute to the pathogenesis of atherosclerosis and
other cardiovascular disorders, such as cardiac hypertrophy, and acute coronary syndrome
[78,105-107].
Intriguingly, the three arms of UPR act together to resolve the prolonged ER stress but if
they fail to reduce the amount of unfolded or misfolded proteins, an ER-driven pro-apoptot‐
ic signal starts.
The most common apoptosis-triggering molecule associated to UPR signaling is called
C/EBP homologous protein, or CHOP, known also as GADD153 [108].
In the endothelial cells, different atherosclerotic-relevant UPR inducers have been identified
in many in vitro and in vivo studies. In particular, the strict association between ER stress
marker GRP78 and CHOP has been reported in patients and in coronary artery samples,
mainly in thin-wall or ruptured plaques associated with unstable angina respect to stable
plaques. Evident localization of two ER-stress signals was further correlated to mRNA ex‐
pression by in situ hybridization in thin-walled plaques and results indicated a positive rela‐
tionship between these markers and plaque vulnerability in human coronary arteries [109].
Among murine models, many studies have been performed in apolipoprotein E deficient mice
(ApoE-/-), fed a standard chow diet that developed atherosclerosis during the life-span up to ne‐
crotic plaques [110]. In this murine model, ER stress markers such as GRP78 and CHOP are up-
regulated in macrophages at all stages of lesion development in the aortic root [111]. However
it is important to remark that in the aorta of ApoE-/- mice at 9 weeks of age, corresponding to
early atherosclerotic phase, no apoptosis was detected, but this event occurred in macrophages
and foam cells in advanced lesions at 23 weeks of age. Remarkably strong GRP78-immunos‐
taining was also localized in the fibrous cap surface in hyperhomocysteinemic ApoE-/- [112].
Furthermore in transgenic CHOP-deficient mice less macrophages have been found in ad‐
vanced atherogenic lesions, such as instable plaques, respect to wild-type mice.
Intriguingly in double knockout mice (CHOP and ApoE-deficient) the rupture of athero‐
sclerotic plaques was significantly reduced despite their high-cholesterol diet [113]. Indeed
also in primary cultured macrophages free cholesterol accumulated in the ER and stimulat‐
ed apoptosis in a CHOP-dependent pathway, so CHOP probably contributed in vivo and in
vitro to instability of plaques due to macrophage cell death.
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The most common apoptosis-triggering molecule associated to UPR signaling is called
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taining was also localized in the fibrous cap surface in hyperhomocysteinemic ApoE-/- [112].
Furthermore in transgenic CHOP-deficient mice less macrophages have been found in ad‐
vanced atherogenic lesions, such as instable plaques, respect to wild-type mice.
Intriguingly in double knockout mice (CHOP and ApoE-deficient) the rupture of athero‐
sclerotic plaques was significantly reduced despite their high-cholesterol diet [113]. Indeed
also in primary cultured macrophages free cholesterol accumulated in the ER and stimulat‐
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It is emerging that, in crucial artery wall sites, the IRE1 branch of the canonical UPR mecha‐
nism and its downstream CHOP signaling are activated also by various factors like distur‐
bed blood flow and hypertension [19,114,115] and modified LDL.
High level of XBP1 splicing was detected in atherosclerosis prone areas, and in a mouse iso‐
graft model mimicking XBP1 overexpression, peculiar signs of atherogenic damage have
been detected, like neointima formation and monocytes infiltration [116].
In particular in the endothelium multiple UPR pathways are activated by phospholipolized
LDL that stimulate ER stress associated to cytoskeleton stress fibers formation, inflammation
and dysregulation of calcium homeostasis, even if strictly related to the intensity and dura‐
tion of the lipidic stress [117] (Figure 3)
Figure 3. Multiple signaling triggered by lipoproteins in endothelial cells. ATF- activating transcription factors 2, 3, 4,
6; LDL- low density lipoproteins; CHOP- C/EBP homologous protein; XBP1- x-box binding protein 1; eIF2alpha- initia‐
tion factor 2 alpha; MAPK- mitogen activated protein kinase. Adapted by [117].
However not only in the initial pro-atherogenic phase but also in advanced phase, associat‐
ed to the plaque rupture, it is crucial that the endothelium maintains its integrity, so ham‐
pering the diffusion in the blood of the circulating plaque.
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In particular during this advanced step, it has been reported that increased apoptotic endo‐
thelial cells may act as a pro-coagulant and favor the increase of platelet adhesion during the
plaque erosion [118].
In human coronary arteries plaque vulnerability is associated to the expression of ER stress
proteins like CHOP and macrophage apoptosis [119,120].
Unlike clinical patients, murine animal model of atherosclerosis are unsuited for studying
plaque disruption or acute thrombosis, so they are currently studied to characterize early
atherosclerotic phases up to necrotic plaque [121].
Recently in CHOP-deficient mice mated with ApoE-/- atherosclerotic mice, it has been dem‐
onstrated a direct causal link between reduced CHOP-induced apoptosis and plaque ne‐
crosis [122]. In this double transgenic model, ER stress has different impacts on the vascular
damage, according to the lesion stage of the artery. Indeed it is possible that in an early athe‐
rogenic phase, the UPR mechanism may be protective in macrophages and smooth muscle
cells, but after persistent damage, the UPR-induced apoptosis is associated to plaque vulner‐
ability and rupture.
Besides the endothelium, also smooth muscle cells in artery wall can be susceptible to ER
stress-UPR and compromise plaque integrity by reducing the protective fibrous cap in ad‐
vanced atherosclerosis [123].
Moreover atherogenic stressors like cholesterol and homocysteine are able to up-regulate
CHOP and apoptosis in smooth muscle cells in vitro [124]. Indeed in human aortic cells the
delivery of 7-ketocholesterol, an oxysterol linked in patients to high cardiovascular risk and
atherosclerosis, activated UPR pathway up to apoptosis [125].
However unfortunately clear molecular evidences of pathways linking UPR to smooth mus‐
cle cells in atherosclerosis are still lacking. This is not true for macrophages, and the role of
UPR in macrophages apoptosis is an emerging field of investigation [91].
Remarkably in atherosclerosis dual impact of macrophages resistance to apoptosis has been
related to different stages of the disease: it may be beneficial in early lesions, where they hin‐
der inflammation, but is detrimental in advanced phases, where they contribute to a signifi‐
cant increase in the lesion size associated to elevated chemokines expression and monocytes
recruitment [126].
Furthermore it is important to point out that if inflammatory foam cells in the sub-endotheli‐
um space are cleared by active macrophages to prevent further secondary necrosis, in paral‐
lel many inflammatory pathways are activate to potentiate atherogenic damage, including
nuclear factor k-B (NFkB) and mitogen-activated protein kinase (MAPK), in particular p38-
MAPK cascade [127].
As commonly accepted, the chronic activation of the three canonical UPR pathways in the
ER, triggers different pro-apoptotic mechanisms in the vascular wall, that may be mitochon‐
dria-dependent or independent, but largely complementary and integrated [128].
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It is emerging that, in crucial artery wall sites, the IRE1 branch of the canonical UPR mecha‐
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High level of XBP1 splicing was detected in atherosclerosis prone areas, and in a mouse iso‐
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been detected, like neointima formation and monocytes infiltration [116].
In particular in the endothelium multiple UPR pathways are activated by phospholipolized
LDL that stimulate ER stress associated to cytoskeleton stress fibers formation, inflammation
and dysregulation of calcium homeostasis, even if strictly related to the intensity and dura‐
tion of the lipidic stress [117] (Figure 3)
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6; LDL- low density lipoproteins; CHOP- C/EBP homologous protein; XBP1- x-box binding protein 1; eIF2alpha- initia‐
tion factor 2 alpha; MAPK- mitogen activated protein kinase. Adapted by [117].
However not only in the initial pro-atherogenic phase but also in advanced phase, associat‐
ed to the plaque rupture, it is crucial that the endothelium maintains its integrity, so ham‐
pering the diffusion in the blood of the circulating plaque.
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thelial cells may act as a pro-coagulant and favor the increase of platelet adhesion during the
plaque erosion [118].
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proteins like CHOP and macrophage apoptosis [119,120].
Unlike clinical patients, murine animal model of atherosclerosis are unsuited for studying
plaque disruption or acute thrombosis, so they are currently studied to characterize early
atherosclerotic phases up to necrotic plaque [121].
Recently in CHOP-deficient mice mated with ApoE-/- atherosclerotic mice, it has been dem‐
onstrated a direct causal link between reduced CHOP-induced apoptosis and plaque ne‐
crosis [122]. In this double transgenic model, ER stress has different impacts on the vascular
damage, according to the lesion stage of the artery. Indeed it is possible that in an early athe‐
rogenic phase, the UPR mechanism may be protective in macrophages and smooth muscle
cells, but after persistent damage, the UPR-induced apoptosis is associated to plaque vulner‐
ability and rupture.
Besides the endothelium, also smooth muscle cells in artery wall can be susceptible to ER
stress-UPR and compromise plaque integrity by reducing the protective fibrous cap in ad‐
vanced atherosclerosis [123].
Moreover atherogenic stressors like cholesterol and homocysteine are able to up-regulate
CHOP and apoptosis in smooth muscle cells in vitro [124]. Indeed in human aortic cells the
delivery of 7-ketocholesterol, an oxysterol linked in patients to high cardiovascular risk and
atherosclerosis, activated UPR pathway up to apoptosis [125].
However unfortunately clear molecular evidences of pathways linking UPR to smooth mus‐
cle cells in atherosclerosis are still lacking. This is not true for macrophages, and the role of
UPR in macrophages apoptosis is an emerging field of investigation [91].
Remarkably in atherosclerosis dual impact of macrophages resistance to apoptosis has been
related to different stages of the disease: it may be beneficial in early lesions, where they hin‐
der inflammation, but is detrimental in advanced phases, where they contribute to a signifi‐
cant increase in the lesion size associated to elevated chemokines expression and monocytes
recruitment [126].
Furthermore it is important to point out that if inflammatory foam cells in the sub-endotheli‐
um space are cleared by active macrophages to prevent further secondary necrosis, in paral‐
lel many inflammatory pathways are activate to potentiate atherogenic damage, including
nuclear factor k-B (NFkB) and mitogen-activated protein kinase (MAPK), in particular p38-
MAPK cascade [127].
As commonly accepted, the chronic activation of the three canonical UPR pathways in the
ER, triggers different pro-apoptotic mechanisms in the vascular wall, that may be mitochon‐
dria-dependent or independent, but largely complementary and integrated [128].
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The most common death-sensors activated in the mitochondria are: 1) the stimulation of ino‐
sitol requiring protein-1 (IRE1) that can further regulate B-cell lymphoma-2 (BCL-2) family
of proteins and 2) PERK and ATF6 signals that directly induce CHOP/GADD153 protein.
Remarkably, CHOP is also involved in the activation of a mitochondria-independent mecha‐
nism of apoptosis that relies on inositol-1,4,5-triphosphate receptor (IP3R), able to trigger ab‐
normal calcium (Ca2+) flux from the ER and the death receptor Fas [129].
Although three branches may be activated by any prolonged stressful event, the timing of
each pathway can differ and persistent ER stress leads to sequential progression of IRE1,
then ATF6, finally PERK respectively. Moreover it is important to outline that each pro-
apoptotic mechanism is strictly cell-type and stimulus-specific.
IRE 1 isoforms are activated by auto-phosphorylation and trigger the splicing and transla‐
tion of mRNA transcript for a specific transcription factor, called XBP1s, that induces chap‐
erones and other molecules able to limit ER stress.
However in mammalian cells, IRE1 stimulates also another mechanism known as regulated
IRE1 dependent decay (RIDD) [130], that may directly lead to apoptosis even if this branch
is still controversial in cardiovascular diseases.
Nevertheless the major downstream effector of IRE1 signaling is the BCL-2 family of pro‐
teins, that includes both anti-apoptotic and pro-apoptotic members able to regulate the ac‐
tivity of ER and mitochondria [131].
In human and mice anti-apoptotic domains are called Bcl-2 and Bcl-XL, while the most well
characterized pro-apoptotic are Bcl2-associated x protein (BAX) and Bcl2-homologous an‐
tagonist (BAK) proteins. When these last two members become activated in the mitochon‐
dria, release cytochrome c and other death factors that may amplify the caspases cascade up
to overt cell death. Despite in vitro observations on IRE1 signaling, actually there is not yet in
vivo evidence for apoptosis along this pathway [132].
Remarkably CHOP signaling is common also to PERK and ATF6 pathways in the ER stress
response, where it may act like in the IRE1, even if there is the possibility to by-pass the mi‐
tochondria and to stimulate calcium flux, working on the ER calcium channel called inosi‐
tol-1, 4, 5-triphosphate or IP3R [133].
Many recent studies point to the apoptotic mechanism driven by calcium release from the
ER lumen, able to stimulate the calcium-sensing enzyme called calcium/calmodulin-depend‐
ent protein kinase, CaMK II, which in turn regulates other apoptotic pathways, like FAS ac‐
tivation but also caspase 12 [134,135].
In advanced atherosclerosis, the level of ER stress-CHOP expression in macrophages is very
high despite the presence of TRLs ligands and the activation of TRIF-signaling. A crucial
concept in the regulation of macrophage apoptosis in atherosclerosis is called “the two-hit
concept”, that consists in the eventuality of a milder ER stress in vivo respect to in vitro. So
different cumulative sub-apoptotic stimuli may lead to a synergic more effective response in
the artery vessel, and in particular because generally TLRs act as a second pro-apoptotic
stimuli. If this eventuality is lost as evident in advanced ruptured plaque and related throm‐
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bosis, it may be due to an inability to resist to PERK and eIF2alpha signaling and to reduce
downstream ATF4-CHOP associated apoptosis in vivo as recently hypothesized [136].
In Figure 4 we resumed complex relationships between ER signaling and apoptosis in athe‐
rogenesis.
Figure 4. Different ER signals leading to successful apoptosis. IP3R- inositol -1,4, 5,-triphosphate receptor; PERK- pro‐
tein kinase-like ER kinase; ATF6- activating transcription factor 6; IRE1- inositol requiring protein1; BCL2- B cell lympho‐
ma/leukemia 2; Bak- Bcl2-homologous antagonist; Bax- Bcl2-associated x protein; RIDD- regulated IRE1-dependent
decay; CaMK II- calcium/calmodulin-dependent protein kinase; FAS- tumor necrosis factor receptor superfamily mem‐
ber 6; CHOP- C/EBP homologous protein; BH3- homology domain. Adapted by [107].
5. ER stress as a therapeutic target in atherosclerosis and metabolic
diseases
In metabolic diseases such as atherosclerosis, hypertension, diabetes and related cardiovas‐
cular complications, improved understanding of ER stress pathways and their relationship
with inflammation and apoptosis represents the basis on which to try novel drugs, to test
therapeutic interventions and to identify targets for different therapeutic options.
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The most common death-sensors activated in the mitochondria are: 1) the stimulation of ino‐
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of proteins and 2) PERK and ATF6 signals that directly induce CHOP/GADD153 protein.
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then ATF6, finally PERK respectively. Moreover it is important to outline that each pro-
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ER lumen, able to stimulate the calcium-sensing enzyme called calcium/calmodulin-depend‐
ent protein kinase, CaMK II, which in turn regulates other apoptotic pathways, like FAS ac‐
tivation but also caspase 12 [134,135].
In advanced atherosclerosis, the level of ER stress-CHOP expression in macrophages is very
high despite the presence of TRLs ligands and the activation of TRIF-signaling. A crucial
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cular complications, improved understanding of ER stress pathways and their relationship
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therapeutic interventions and to identify targets for different therapeutic options.
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In cardiovascular diseases but also in the endothelial cells and cardiomyocytes in vitro, the
regulation of the UPR arms can lead to an adaptation phase and survival or to a detrimental
phase that ends into cell death.
These opposite effects, considered as “the double-edged sword”, are an important issue for
vascular biology, even if the molecular mechanisms that differentially regulate survival or
cell death are yet to be clarified [137,138].
Anyway, it is possible to resume ER-regulatory interventions into two types: 1) one directly
targeting ER stress-UPR by interfering with UPR branches with the use of chemical chaper‐
ones or inhibitors; 2) others indirectly targeting ER stress-UPR by regulation of related
apoptosis, autophagy, oxidative or inflammatory signaling.
It is established that diabetic retinopathy is a major complication of diabetes, associated to
inflammation and leukocyte adhesion in the endothelium of retinal vasculature, that impairs
the inner blood-retinal barrier necessary to normal visual activity [139].
Recently ER stress has been involved in the pathogenesis of this invalidating disease [140].
However when used as a preconditioning tool, it may provide therapeutic benefits.
In particular the activation of XBP1s in endothelial cells, negatively regulates IRE1-alpha
phosphorylation and suppresses inflammation. So, improving this branch of ER stress path‐
way may be useful to prevent or limit retinopathy in diabetes [141].
Furthermore emerging data on angiotensin II-induced cardiac hypertrophy in mice, have
demonstrated a direct involvement of ER stress and related markers, GRP78 and CHOP, in
cardiac remodeling and fibrosis [18].
ER chaperones represent a group of low-molecular compounds able to increase ER folding
capacity and alleviate the accumulation of dysfunctional proteins, so maintaining ER ho‐
meostasis [142]. Different chaperones like 4-phenyl butyrate (PBA) and taurine-conjugated
deoxycholic acid (TUDCA) have been successfully tested in vivo in different murine models
of atherosclerosis, diabetes and leptin resistance where ER stress was attenuated [143].
Moreover PBA and TUDCA, have been successfully tested against endothelium-dependent
relaxation and oxidative damage in the aorta and mesenteric artery in hypertensive mice
[19]. Indeed ER signaling might represent a potential target to reverse hypertension-induced
vascular and cardiac dysfunctions.
In particular ER stress was linked also to oxidative damage, due to abnormal calcium flux
from the ER driven by protein misfolding and its uptake into the mitochondria where calci‐
um disrupted the electron transport chain [144]. Nevertheless further studies are required to
elucidate how these two mechanisms can activate each other [145].
In a mouse model of type 2 diabetes chemical chaperones increased insulin sensitivity acting
by antioxidant properties, this finding is particularly interesting because ER stress may also
induce insulin-resistance [146,147].
A recent study performed in transgenic ApoE-/- mice, fed a Western diet, has supported the
protective role of hydrogen sulfide, a product generated from L-cysteine catalyzed by cysta‐
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thionine-L-lyase in the cardiovascular system, as an effective anti-atherosclerotic compound.
Indeed it reduces oxidative damage in the aorta but also potentiates the adaptive beneficial
role of ER signaling by increasing GRP78 expression in the intima layer. This effect might be
related to the reduction of plasma level of LDL and lipids deposition in the aorta [148].
Furthermore up-regulation of T-cadherin has emerged as an effective tool that limits the
progression of atherosclerotic lesions in endothelial cells in vitro. This molecule is a glycosyl‐
phosphatidylinositol-anchored element belonging to the cadherin family, that colocalizes
with GRP78 on the plasma membrane [149]. Its over-expression or silencing by genetic ma‐
nipulations selectively attenuates or amplifies the PERK branch of the UPR cascade obtained
by ER stressors like homocysteine, thapsigargin and brefeldin A, so influencing apoptosis
[150]. Indeed T-cadherin up-regulation is able to directly limit the phosphorylation of the
eukaryotic translation initiation factor 2 alpha (phospho-eIF2alpha) and CHOP-driven cell
death, even if how it communicates with ER-stress machinery in vitro is not yet known.
Salubrinal is another chemical chaperone that modulates the dephosphorylation of eIF2alpha,
so reducing abnormal protein load on the ER and prolonged UPR, and it has been demonstrat‐
ed to limit ischemia-reperfusion damage in the mice brain [151]. Despite some promising re‐
ports, it is important to consider that there are different commercial preparations of the drug
providing different level of protection, so the real efficacy is currently debated.
Finally among ER-resident chemical chaperones oxygen-regulated protein150 (ORP150), a
150 kDa oxygen-regulated protein, has been implicated not only in reducing apoptosis dur‐
ing oxidative damage but also in preventing ox-LDLs induced ER stress in transfected vas‐
cular endothelial cells. In particular, by immune-precipitation assay it has been
demonstrated that ORP150 is bound to three ER stress sensors IRE1alpha, PERK and ATF6
so maintaining them in an inactive status and contributing to delay UPR activation. Further‐
more ORP150 and IRE1alpha were also linked in situ in atherosclerotic lesions from human
carotid plaque, but no ORP150-IRE1 alpha association was detected in normal human mam‐
mary artery [152].
A growing body of evidence indicates that LDLs, modified by oxidation, enzymatic attack,
glycation and aggregation in ox-LDL, trigger local vascular inflammation and toxic events
implicated in atherosclerosis, but in contrast high density lipoproteins (HDLs) have anti-
atherogenic properties that have been linked to reduced ER stress and autophagy [153].
In endothelial cells in vitro HDLs pretreatment was able to prevent detrimental UPR path‐
ways inhibiting IRE1 alpha activation and phosphorylation in the PERK arm and the nucle‐
ar translocation of ATF6 that triggered the pro-apoptotic CHOP signaling. All these
mechanisms were stimulated by prolonged ER stress induced by ox-LDLs that in parallel ac‐
tivated also autophagy then overwhelmed by apoptosis if the vascular stress lasted too
much. However, calcium deregulation was a common upstream signal for two parallel path‐
ways in this in vitro model, where ER stress-UPR but also autophagy are involved. Indeed
HDLs were able to prevent the increase in autophagic markers like LC3-II and beclin-1 in
the endothelial cells that, silenced for beclin 1 and then stimulated by toxic ox-LDLs, dis‐
played less ability to be recognized by macrophages.
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apoptosis, autophagy, oxidative or inflammatory signaling.
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phosphorylation and suppresses inflammation. So, improving this branch of ER stress path‐
way may be useful to prevent or limit retinopathy in diabetes [141].
Furthermore emerging data on angiotensin II-induced cardiac hypertrophy in mice, have
demonstrated a direct involvement of ER stress and related markers, GRP78 and CHOP, in
cardiac remodeling and fibrosis [18].
ER chaperones represent a group of low-molecular compounds able to increase ER folding
capacity and alleviate the accumulation of dysfunctional proteins, so maintaining ER ho‐
meostasis [142]. Different chaperones like 4-phenyl butyrate (PBA) and taurine-conjugated
deoxycholic acid (TUDCA) have been successfully tested in vivo in different murine models
of atherosclerosis, diabetes and leptin resistance where ER stress was attenuated [143].
Moreover PBA and TUDCA, have been successfully tested against endothelium-dependent
relaxation and oxidative damage in the aorta and mesenteric artery in hypertensive mice
[19]. Indeed ER signaling might represent a potential target to reverse hypertension-induced
vascular and cardiac dysfunctions.
In particular ER stress was linked also to oxidative damage, due to abnormal calcium flux
from the ER driven by protein misfolding and its uptake into the mitochondria where calci‐
um disrupted the electron transport chain [144]. Nevertheless further studies are required to
elucidate how these two mechanisms can activate each other [145].
In a mouse model of type 2 diabetes chemical chaperones increased insulin sensitivity acting
by antioxidant properties, this finding is particularly interesting because ER stress may also
induce insulin-resistance [146,147].
A recent study performed in transgenic ApoE-/- mice, fed a Western diet, has supported the
protective role of hydrogen sulfide, a product generated from L-cysteine catalyzed by cysta‐
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Indeed it reduces oxidative damage in the aorta but also potentiates the adaptive beneficial
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related to the reduction of plasma level of LDL and lipids deposition in the aorta [148].
Furthermore up-regulation of T-cadherin has emerged as an effective tool that limits the
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with GRP78 on the plasma membrane [149]. Its over-expression or silencing by genetic ma‐
nipulations selectively attenuates or amplifies the PERK branch of the UPR cascade obtained
by ER stressors like homocysteine, thapsigargin and brefeldin A, so influencing apoptosis
[150]. Indeed T-cadherin up-regulation is able to directly limit the phosphorylation of the
eukaryotic translation initiation factor 2 alpha (phospho-eIF2alpha) and CHOP-driven cell
death, even if how it communicates with ER-stress machinery in vitro is not yet known.
Salubrinal is another chemical chaperone that modulates the dephosphorylation of eIF2alpha,
so reducing abnormal protein load on the ER and prolonged UPR, and it has been demonstrat‐
ed to limit ischemia-reperfusion damage in the mice brain [151]. Despite some promising re‐
ports, it is important to consider that there are different commercial preparations of the drug
providing different level of protection, so the real efficacy is currently debated.
Finally among ER-resident chemical chaperones oxygen-regulated protein150 (ORP150), a
150 kDa oxygen-regulated protein, has been implicated not only in reducing apoptosis dur‐
ing oxidative damage but also in preventing ox-LDLs induced ER stress in transfected vas‐
cular endothelial cells. In particular, by immune-precipitation assay it has been
demonstrated that ORP150 is bound to three ER stress sensors IRE1alpha, PERK and ATF6
so maintaining them in an inactive status and contributing to delay UPR activation. Further‐
more ORP150 and IRE1alpha were also linked in situ in atherosclerotic lesions from human
carotid plaque, but no ORP150-IRE1 alpha association was detected in normal human mam‐
mary artery [152].
A growing body of evidence indicates that LDLs, modified by oxidation, enzymatic attack,
glycation and aggregation in ox-LDL, trigger local vascular inflammation and toxic events
implicated in atherosclerosis, but in contrast high density lipoproteins (HDLs) have anti-
atherogenic properties that have been linked to reduced ER stress and autophagy [153].
In endothelial cells in vitro HDLs pretreatment was able to prevent detrimental UPR path‐
ways inhibiting IRE1 alpha activation and phosphorylation in the PERK arm and the nucle‐
ar translocation of ATF6 that triggered the pro-apoptotic CHOP signaling. All these
mechanisms were stimulated by prolonged ER stress induced by ox-LDLs that in parallel ac‐
tivated also autophagy then overwhelmed by apoptosis if the vascular stress lasted too
much. However, calcium deregulation was a common upstream signal for two parallel path‐
ways in this in vitro model, where ER stress-UPR but also autophagy are involved. Indeed
HDLs were able to prevent the increase in autophagic markers like LC3-II and beclin-1 in
the endothelial cells that, silenced for beclin 1 and then stimulated by toxic ox-LDLs, dis‐
played less ability to be recognized by macrophages.
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Remarkably, even if autophagy is not involved in apoptosis, probably contributes like a ben‐
eficial “eat-me” signal on the cell surface by exposing phosphatydylserine, necessary to the
clearance by efferocytosis of apoptotic cells [154] (Figure 5). All these important findings
suggest a potential efficacy for HDLs-based therapeutic opportunities in atherosclerosis.
Figure 5. Beneficial role of high density lipoproteins upstream ER stress and autophagy in endothelial cells. HDL- high
density lipoprotein; LDL: low density lipoprotein; ox-LDL- oxidized lipoproteins; LC3-II- microtubule-associated pro‐
tein1 light chain 3; CHOP- C/EBP homologous protein; JNK- c-Jun N-terminal kinase. Adapted from [154].
Recently an interesting study reported the peculiar expression on endothelial cells and macro‐
phages of a novel GRP78-interacting protein induced by ER stress, called Gipie [155]. Gipie be‐
longs to the Girdin family protein and is localized in the ER and Golgi apparatus in the
endothelial cell lines (human umbilical vein endothelial cell-HUVEC and human coronary ar‐
tery endothelial cells-HCAEC), but not in epithelial or mesenchymal cells in vitro. The transfec‐
tion of Gipie into HUVEC cells exposed to ER inducer thapsigargin, a specific blocker of ER
calcium ATP-ase pumps, was able to decrease CHOP expression and apoptosis.
Moreover the same protection was demonstrated by Gipie’s over-expression in rat carotid
artery endothelial cells after baloon injury, a well-known in vivo model of endothelial dam‐
age and restenosis. Finally also in adult P65 mice aorta, Gipie was superimposed with
GRP78 in atheroprone sites like the inner curvature of the aortic arch, but not in the outer
curvature or in the ascending aorta, less sensitive to hemodynamic stress. By interaction
with GRP78, Gipie modulates IRE1/JNK signaling and CHOP expression, so reducing apop‐
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tosis, even if the detailed mechanism by which it regulates GRP78/IRE1 activation is still un‐
known. Anyway even if more studies on transgenic Gipie-deficient animals will improve
the understanding of the proper function in circulatory system, Gipie may be considered a
reliable therapeutic target in atherosclerosis yet.
6. Conclusions
Actually the pivotal role of ER stress response in atherosclerosis and cardiovascular diseases
is widely accepted. Nevertheless it remains much work to do in particular to discover the
multiple relationship between different integrated pathways associated to ER signaling and
to maintain the best ER stress modulation in the endothelium and vascular wall. Indeed it is
important to point out that in biology the UPR is considered a surviving mechanism, so its
complete deregulation may not be useful but dangerous. However additional experimental
studies are required to help identify novel therapies to restore proper ER homeostasis but in
particular, those to stabilize the minority of dangerous plaques associated with acute cardio‐
vascular damage.
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1. Introduction
Atherosclerosis has been formerly considered as a lipid-mediated disease. It has long been
assumed that atherogenesis could be simply explained by lipid accumulation in the vessel
wall leading to endothelial dysfunction with adverse vascular wall remodelling. However,
over the last decade, a number of studies have clearly demonstrated that lipids are not the
whole story in the pathogenesis of atherosclerosis. Accumulating evidence has shown that
inflammation and the immune system play a major role in the initiation, progression and
destabilization of atheromata [1,2,3,4]. Mainly innate immunity pathways have long been
believed to contribute to atherogenesis, and special attention has been given to macrophag‐
es, because these effector cells are important for intracellular lipid accumulation and foam
cell formation [5]. Yet, although macrophages constitute the largest cell population, other
immune cell subsets, namely dendritic cells (DCs) and T cells, can also be found within athe‐
rosclerotic plaques and seem to participate in immune responses during atherogenesis.
DCs are the pacemakers of the immune system. These professional antigen-presenting cells
play a key role in inducing adaptive immune responses on the one hand, and are critically
involved in promoting and maintaining immune tolerance on the other [6]. They originate
from hematopoietic stem cells in the bone marrow and circulate as precursors in the blood
stream, taking residence in target tissues at sites of potential antigen entry. Within blood
vessels [7] and other tissues, they give rise to immature interstitial DCs that act as sentinels,
which continuously and efficiently sample the antigenic content of their microenvironment.
In the steady state, immature DCs capture harmless self-antigens in the absence of inflam‐
matory signals. They might enter the regional lymph nodes to present the self-antigen to na‐
ïve or resting T cells, which will be deleted by apoptosis, silenced by the induction of anergy
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1. Introduction
Atherosclerosis has been formerly considered as a lipid-mediated disease. It has long been
assumed that atherogenesis could be simply explained by lipid accumulation in the vessel
wall leading to endothelial dysfunction with adverse vascular wall remodelling. However,
over the last decade, a number of studies have clearly demonstrated that lipids are not the
whole story in the pathogenesis of atherosclerosis. Accumulating evidence has shown that
inflammation and the immune system play a major role in the initiation, progression and
destabilization of atheromata [1,2,3,4]. Mainly innate immunity pathways have long been
believed to contribute to atherogenesis, and special attention has been given to macrophag‐
es, because these effector cells are important for intracellular lipid accumulation and foam
cell formation [5]. Yet, although macrophages constitute the largest cell population, other
immune cell subsets, namely dendritic cells (DCs) and T cells, can also be found within athe‐
rosclerotic plaques and seem to participate in immune responses during atherogenesis.
DCs are the pacemakers of the immune system. These professional antigen-presenting cells
play a key role in inducing adaptive immune responses on the one hand, and are critically
involved in promoting and maintaining immune tolerance on the other [6]. They originate
from hematopoietic stem cells in the bone marrow and circulate as precursors in the blood
stream, taking residence in target tissues at sites of potential antigen entry. Within blood
vessels [7] and other tissues, they give rise to immature interstitial DCs that act as sentinels,
which continuously and efficiently sample the antigenic content of their microenvironment.
In the steady state, immature DCs capture harmless self-antigens in the absence of inflam‐
matory signals. They might enter the regional lymph nodes to present the self-antigen to na‐
ïve or resting T cells, which will be deleted by apoptosis, silenced by the induction of anergy
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or primed to become regulatory T cells [8]. In contrast, when infection and tissue damage
occur, immature DCs take up antigens in the presence of inflammatory signals, which
evokes activation and functional transformation into mature DCs. Meanwhile, they exit the
non-lymphoid tissues to migrate via afferent lymph vessels to lymphoid tissues, where they
completely mature. Mature DCs present short peptide fragments, which are bound to the
surface molecules CD1 or major histocompatibility complex (MHC)-I or MHC-II. Conse‐
quently, they activate (naïve) T and B lymphocytes that recognize the presented antigen [9].
Morphological changes occur as well during the DC life cycle: DC precursors are often
small, round-shaped cells that turn into larger cells with an irregular (star-like) shape and
cytoplasmic protrusions (dendrites) as the cell matures, while migrating DCs are also called
veiled cells, as they possess large cytoplasmic 'veils' rather than dendrites [10].
Following the first observation of DCs in human arteries in 1995 [11], numerous studies sug‐
gest that these cells presumably play a crucial role in directing innate or adaptive immunity
against altered self-antigens present in atherosclerosis. Localization of DCs nearby vasa
vasorum allows monitoring of the major access pathways to the vessel wall and screening of
the tissue environment for the appearance of exogenous and endogenous stressors [12].
Once sufficiently activated, DCs in the arterial wall might present the (modified auto-) anti‐
gens, such as oxidized epitopes on apoptotic cells, oxidized low density lipoproteins
(oxLDL) or heat shock proteins (Hsp) to T cells and initiate inflammatory responses.
2. (Auto-)antigens implicated in atherogenesis and their effects on DCs
Many (auto-)antigens are involved in atherogenesis, both endogenous and exogenous. Here,
we summarize some of the best-studied endogenous self-antigens in relation to DC function.
2.1. Oxidized low density lipoprotein (oxLDL)
OxLDL is one of the best-studied antigens in atherogenesis. It is considered as a ‘neoanti‐
gen’, i.e. a self-antigen that has the potential to provoke an auto-immune response upon
modification, but that is tolerated by the immune system in its normal (unmodified) form
[13]. It has already been shown that oxLDL can induce differentiation of monocytes into
phenotypically abnormal cells, when it is added to monocytes during the early stages of dif‐
ferentiation [14]. These cells have functional characteristics of DCs, such as decreased endo‐
cytosis capacity, increased ability to stimulate T cell proliferation and secretion of IL-12, but
not IL-10. These findings were consistent with our own study (unpublished data), which
showed that monocytes differentiated (at least partly) into DCs, when they were incubated
with oxLDL. This was evidenced by a pronounced decrease in the expression of CD14, a
typical monocyte/macrophage marker, and increased expression of CD1a, which is mainly
expressed on cortical thymocytes and DCs, and CCR-6, a receptor for CCL20 that is ex‐
pressed by resting T cells and DCs (figure 1).
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Figure 1. Effects of oxLDL on monocyte differentiation. Expression of CD14, CCR-6 and CD1a after 24h incubation of
monocytes with 10 µg/mL oxLDL or 50 µg/mL oxLDL points to differentiation to a phenotype with characteristics of
DCs (N=3). ***P<0.001, *P<0.05 versus control, Repeated Measures ANOVA and Dunnett’s post-hoc test.
Apart from the induction of monocyte differentiation into DCs, oxLDL can also activate
DCs, as demonstrated by several in vitro studies. After 24h incubation with high concentra‐
tions of oxLDL (50 µg/mL), expression of activation markers CD40, CD80 and CD83 was sig‐
nificantly upregulated (figure 2), and endocytotic capacity was significantly reduced (figure
3; own unpublished data).
Figure 2. Effects of oxLDL on maturation of monocyte-derived DCs. Expression of maturation markers CD40, CD80 and
CD83 after 24h incubation of immature monocyte-derived DCs with 10 µg/mL or 50 µg/mL oxLDL (N=4). Black bars
represent the positive control for DC maturation, monocyte-derived DCs stimulated with lipopolysaccharide (LPS; 0.1
µg/mL). ***P<0.001, **P<0.01, *P<0.05 versus control, Repeated Measures ANOVA and Dunnett’s post-hoc test.
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completely mature. Mature DCs present short peptide fragments, which are bound to the
surface molecules CD1 or major histocompatibility complex (MHC)-I or MHC-II. Conse‐
quently, they activate (naïve) T and B lymphocytes that recognize the presented antigen [9].
Morphological changes occur as well during the DC life cycle: DC precursors are often
small, round-shaped cells that turn into larger cells with an irregular (star-like) shape and
cytoplasmic protrusions (dendrites) as the cell matures, while migrating DCs are also called
veiled cells, as they possess large cytoplasmic 'veils' rather than dendrites [10].
Following the first observation of DCs in human arteries in 1995 [11], numerous studies sug‐
gest that these cells presumably play a crucial role in directing innate or adaptive immunity
against altered self-antigens present in atherosclerosis. Localization of DCs nearby vasa
vasorum allows monitoring of the major access pathways to the vessel wall and screening of
the tissue environment for the appearance of exogenous and endogenous stressors [12].
Once sufficiently activated, DCs in the arterial wall might present the (modified auto-) anti‐
gens, such as oxidized epitopes on apoptotic cells, oxidized low density lipoproteins
(oxLDL) or heat shock proteins (Hsp) to T cells and initiate inflammatory responses.
2. (Auto-)antigens implicated in atherogenesis and their effects on DCs
Many (auto-)antigens are involved in atherogenesis, both endogenous and exogenous. Here,
we summarize some of the best-studied endogenous self-antigens in relation to DC function.
2.1. Oxidized low density lipoprotein (oxLDL)
OxLDL is one of the best-studied antigens in atherogenesis. It is considered as a ‘neoanti‐
gen’, i.e. a self-antigen that has the potential to provoke an auto-immune response upon
modification, but that is tolerated by the immune system in its normal (unmodified) form
[13]. It has already been shown that oxLDL can induce differentiation of monocytes into
phenotypically abnormal cells, when it is added to monocytes during the early stages of dif‐
ferentiation [14]. These cells have functional characteristics of DCs, such as decreased endo‐
cytosis capacity, increased ability to stimulate T cell proliferation and secretion of IL-12, but
not IL-10. These findings were consistent with our own study (unpublished data), which
showed that monocytes differentiated (at least partly) into DCs, when they were incubated
with oxLDL. This was evidenced by a pronounced decrease in the expression of CD14, a
typical monocyte/macrophage marker, and increased expression of CD1a, which is mainly
expressed on cortical thymocytes and DCs, and CCR-6, a receptor for CCL20 that is ex‐
pressed by resting T cells and DCs (figure 1).
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Figure 1. Effects of oxLDL on monocyte differentiation. Expression of CD14, CCR-6 and CD1a after 24h incubation of
monocytes with 10 µg/mL oxLDL or 50 µg/mL oxLDL points to differentiation to a phenotype with characteristics of
DCs (N=3). ***P<0.001, *P<0.05 versus control, Repeated Measures ANOVA and Dunnett’s post-hoc test.
Apart from the induction of monocyte differentiation into DCs, oxLDL can also activate
DCs, as demonstrated by several in vitro studies. After 24h incubation with high concentra‐
tions of oxLDL (50 µg/mL), expression of activation markers CD40, CD80 and CD83 was sig‐
nificantly upregulated (figure 2), and endocytotic capacity was significantly reduced (figure
3; own unpublished data).
Figure 2. Effects of oxLDL on maturation of monocyte-derived DCs. Expression of maturation markers CD40, CD80 and
CD83 after 24h incubation of immature monocyte-derived DCs with 10 µg/mL or 50 µg/mL oxLDL (N=4). Black bars
represent the positive control for DC maturation, monocyte-derived DCs stimulated with lipopolysaccharide (LPS; 0.1
µg/mL). ***P<0.001, **P<0.01, *P<0.05 versus control, Repeated Measures ANOVA and Dunnett’s post-hoc test.
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Figure 3. Effects of oxLDL on endocytotic capacity of monocyte-derived DCs. Decreased endocytotic capacity of mono‐
cyte-derived DCs 24h after stimulation with oxLDL (10 µg/mL or 50 µg/mL) or the positive control LPS (0.1 µg/mL)
provides functional evidence of DC maturation (N=5). *P<0.05, Repeated Measures ANOVA, Dunnett’s post-hoc test.
Cell morphology pointed to DC maturation as well: oxLDL-stimulated monocyte-derived
DCs became more elongated and were arranged in clusters, when compared to unstimulat‐
ed monocyte-derived DCs. The arrangement in clusters was also more pronounced when
cells were stimulated with 50 µg/mL oxLDL as compared to cells stimulated with the lower
concentration of oxLDL (10 µg/mL) (figure 4; own unpublished data). Alderman et al. [15]
compared the effects of mildly, moderately and highly oxidized LDL and reported a signifi‐
cant upregulation of DC activation markers, including HLA-DR, CD40 and CD86 when cells
were incubated with highly oxidized LDL. Furthermore, highly oxidized LDL increased DC-
induced T cell proliferation. However, high concentrations of highly oxidized LDL (100
µg/mL) inhibited DC function through increased DC apoptosis [15]. In contrast, another
study demonstrated that oxLDL did not trigger maturation of immature DCs [14]. This
seems to be a discrepancy, but can easily be explained by a concentration-dependent effect
of oxLDL. Perrin-Cocon and colleagues [14] varied the oxLDL concentrations between
2.5-10.0 µg/mL, which could have been insufficient to obtain monocyte-derived DC matura‐
tion. Also Zaguri et al. [16] observed no effect of 10 µg/mL oxLDL on CD86, CD83, and
CCR-7 expression on DCs, whereas all those activation markers were upregulated with
higher concentrations of oxLDL (50-100 µg/mL). Finally, Nickel et al. [17] reported matura‐
tion and differentiation of DCs by 10 µg/mL, but he investigated other phenotypic out‐
comes, such as the expression of scavenger receptors LOX1 and CD36, the mannose receptor
CD205 and the activation of the nuclear factor kappa B (NF-κB) pathway.
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Figure 4. Effects of oxLDL on morphology of monocyte-derived DCs. Representative micrographs of immature, mono‐
cyte-derived DC cultures after 24h incubation with medium (A), 0.1 µg/mL lipopolysaccharide (LPS; positive control for
DC maturation; B), 10 µg/mL oxLDL (C), or 50 µg/mL oxLDL (D). Phase contrast light microscopy, magnification: 10x
(A, D), 20x (B, C).
2.2. Beta2-Glycoprotein I
Beta2-glycoprotein I (β2-GPI) is a plasma protein involved in the haemostatic system that
has been detected in carotid atherosclerotic lesions [18]. A previous study in mice showed
that the transfer of lymphocytes obtained from β2-GPI-immunized LDLr-/- mice into synge‐
neic mice resulted in larger fatty streaks within the recipients compared with mice that re‐
ceived lymphocytes from control mice [19]. From that study, it appeared that T cells specific
for β2-GPI are able to increase atherosclerosis, suggesting that β2-GPI is a target auto-anti‐
gen in atherosclerosis [19].
In vitro studies have demonstrated that oxidative modification of β2-GPI, either spontane‐
ously or induced by treatment with hydrogen peroxide, rendered the self-antigen able to in‐
duce an autoimmune response. Oxidized β2-GPI caused DC maturation, indicated by
increased expression of CD80, CD86, CD83 and HLA-DR [20]. In addition, the interaction
between oxidized β2-GPI and DCs led to enhanced secretion of IL-12, IL-1β, IL-6, IL-8,
TNFα and IL-10. DCs stimulated with oxidized β2-GPI showed increased allostimulatory
ability and induced T-helper (Th)1 polarization [20]. Also, glucose-modified β2-GPI caused
phenotypic and functional maturation of iDCs, by activation of the p38 MAPK, ERK and
NF-κB pathways. However, DCs stimulated with glucose-modified β2-GPI primed naïve T
cells toward a Th2 polarization [21].
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provides functional evidence of DC maturation (N=5). *P<0.05, Repeated Measures ANOVA, Dunnett’s post-hoc test.
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ed monocyte-derived DCs. The arrangement in clusters was also more pronounced when
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concentration of oxLDL (10 µg/mL) (figure 4; own unpublished data). Alderman et al. [15]
compared the effects of mildly, moderately and highly oxidized LDL and reported a signifi‐
cant upregulation of DC activation markers, including HLA-DR, CD40 and CD86 when cells
were incubated with highly oxidized LDL. Furthermore, highly oxidized LDL increased DC-
induced T cell proliferation. However, high concentrations of highly oxidized LDL (100
µg/mL) inhibited DC function through increased DC apoptosis [15]. In contrast, another
study demonstrated that oxLDL did not trigger maturation of immature DCs [14]. This
seems to be a discrepancy, but can easily be explained by a concentration-dependent effect
of oxLDL. Perrin-Cocon and colleagues [14] varied the oxLDL concentrations between
2.5-10.0 µg/mL, which could have been insufficient to obtain monocyte-derived DC matura‐
tion. Also Zaguri et al. [16] observed no effect of 10 µg/mL oxLDL on CD86, CD83, and
CCR-7 expression on DCs, whereas all those activation markers were upregulated with
higher concentrations of oxLDL (50-100 µg/mL). Finally, Nickel et al. [17] reported matura‐
tion and differentiation of DCs by 10 µg/mL, but he investigated other phenotypic out‐
comes, such as the expression of scavenger receptors LOX1 and CD36, the mannose receptor
CD205 and the activation of the nuclear factor kappa B (NF-κB) pathway.
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DC maturation; B), 10 µg/mL oxLDL (C), or 50 µg/mL oxLDL (D). Phase contrast light microscopy, magnification: 10x
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2.2. Beta2-Glycoprotein I
Beta2-glycoprotein I (β2-GPI) is a plasma protein involved in the haemostatic system that
has been detected in carotid atherosclerotic lesions [18]. A previous study in mice showed
that the transfer of lymphocytes obtained from β2-GPI-immunized LDLr-/- mice into synge‐
neic mice resulted in larger fatty streaks within the recipients compared with mice that re‐
ceived lymphocytes from control mice [19]. From that study, it appeared that T cells specific
for β2-GPI are able to increase atherosclerosis, suggesting that β2-GPI is a target auto-anti‐
gen in atherosclerosis [19].
In vitro studies have demonstrated that oxidative modification of β2-GPI, either spontane‐
ously or induced by treatment with hydrogen peroxide, rendered the self-antigen able to in‐
duce an autoimmune response. Oxidized β2-GPI caused DC maturation, indicated by
increased expression of CD80, CD86, CD83 and HLA-DR [20]. In addition, the interaction
between oxidized β2-GPI and DCs led to enhanced secretion of IL-12, IL-1β, IL-6, IL-8,
TNFα and IL-10. DCs stimulated with oxidized β2-GPI showed increased allostimulatory
ability and induced T-helper (Th)1 polarization [20]. Also, glucose-modified β2-GPI caused
phenotypic and functional maturation of iDCs, by activation of the p38 MAPK, ERK and
NF-κB pathways. However, DCs stimulated with glucose-modified β2-GPI primed naïve T
cells toward a Th2 polarization [21].
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2.3. Heat shock proteins
Another category of auto-antigens that have been implicated in atherosclerosis are the
stress-induced heat shock proteins (HSPs) [22]. HSPs are responsible for the repair or degra‐
dation of denatured proteins and, by maintaining protein conformation, they enhance the
cell’s ability to survive under conditions of metabolic or oxidative stress [23]. The mRNA ex‐
pression level of several HSPs, including HSP40 and HSP70, has been shown to be signifi‐
cantly increased in carotid endarterectomy specimens as compared to healthy arteries [24].
HSP70 seems to be homogenously distributed throughout the intima and media in healthy
aortas, and a strong increase in its immunostaining intensity is observed in aortic athero‐
sclerotic plaques [25]. They appear to stimulate an immune response leading to the develop‐
ment and progression of atherosclerosis [26]. A number of studies indicate that HSPs are
associated with DC function and might trigger DC activation and maturation. DCs seem to
overexpress HSP70 in atherosclerotic plaques and the latter protein is presumably an impor‐
tant trigger for DC activation [27]. Gp96 (of the HSP90 family) and HSP70 have indeed been
shown to stimulate bone marrow-derived DCs in vitro to secrete cytokines [28] and to ex‐
press antigen-presenting (MHC II) and costimulatory molecules (B7.2) [29]. However, To‐
dryk and colleagues [30] reported that HSP70 targets immature DCs to make them
significantly more able to capture antigens. The presence of HSP70 inhibited DC maturation
induced by tumour cell lysates from parental B16 cells and maintained the DC precursor
population in a more poorly differentiated phenotype. Thus, there is still controversy on
whether HSPs activate DCs or keep them in an immature state, and data are lacking to ro‐
bustly support a conclusion.
3. Survival of DCs in oxidative stress environments
Atherosclerosis is a disease that is associated with strong oxidative stress, and the creation
of neo-epitopes is one of the consequences of this situation. As mentioned in section 2, the
presence of reactive oxygen species (ROS) in atherosclerotic plaques may lead to the forma‐
tion of oxLDL and oxidized β2-GPI, which might affect DC phenotype and function. Indeed,
oxidative stress has been shown to alter the capacity of antigen-presenting cells to process
antigens and to initiate a primary T-cell response. In this respect, it is interesting to unravel
whether DCs show phenotypic adaptations in order to function under oxidative stress situa‐
tions. In a recent study, we demonstrated that DCs appear to be resistant to the detrimental
effects of oxidative stress. We showed by confocal live cell imaging that monocyte-derived
DCs, which were generated as described earlier [31], were better capable of neutralizing
ROS induced by tertiary-butylhydroperoxide (tert-BHP) in comparison to their precursor
monocytes [31]. Tert-BHP was selected to induce ROS because it acutely evokes oxidative
stress, resulting in cell toxicity [32]. Decomposition of tert-BHP to alkoxyl or peroxyl radicals
accelerates lipid peroxidation chain reactions [33]. By means of a neutral red viability assay,
we observed that tert-BHP induced significant and rapid cell death in both monocytes and
DCs. Yet, monocyte-derived DCs were more resistant to tert-BHP-induced cell death than
their precursor cells [31]. A PCR profiler array specific for oxidative stress and antioxidant-
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related pathways revealed an upregulation of several important antioxidant genes during
differentiation of monocytes into DCs, including catalase, peroxiredoxin 2 (PRDX2) and glu‐
tathione peroxidase 3 (GPX3). Catalase encodes the enzyme that catalyses the decomposi‐
tion of hydrogen peroxide to water and oxygen. GPX3 and PRDX2 are genes encoding
enzymes that can detoxify hydrogen peroxide and lipid hydroperoxides [34,35]. However,
PRDX2 is more efficient in neutralizing hydrogen peroxide than catalase or GPXs [36,37].
Immunoblotting or immunohistochemistry showed that the upregulated transcription of
PRDX2 and GPX3 was translated in a significant increase at the protein level. Especially
PRDX2 appears to be an important factor in the neutralization of ROS induced by tert-BHP
[31]. Previously, and in accordance with our recent findings, two studies that used different
detection methods reported high expression of antioxidant enzymes in monocyte-derived
DCs. A functional study indicated indirectly that monocyte-derived DCs might show en‐
hanced activity of catalase [38]. A proteomic analysis showed higher expression of superox‐
ide dismutase (SOD)2, PRDX1 and PRDX2 in monocyte-derived DCs when compared to
precursor monocytes [39]. The latter study also stated that DCs were more resistant than
monocytes to apoptosis induced by high amounts of oxLDL [39]. It is conceivable that the
good survival skills of monocyte-derived DCs in oxidative stress environments are crucial in
atherosclerotic plaques, enabling these professional antigen-presenting cells to exert their
function(s).
4. DC subtypes in mice and men
As discussed above, DCs process and present self and foreign antigens to T cells and are
therefore important inducers of adaptive immune responses. However, ‘the’ DC does not
exist, as DCs comprise a network of subsets that are phenotypically, functionally, and de‐
velopmentally distinct [40,41]. It is essential to understand the diversity in DC subtypes to
target DCs for immunomodulating therapies. Most studies on DC subsets have been per‐
formed in mice, because lymphoid tissue is easier to obtain from mice than from humans.
Mature mouse DCs are identified based on their expression of the integrin alpha X chain
CD11c, the costimulatory molecules CD40, CD80 and CD86, and high surface levels of the
antigen-presenting molecule MHC II [42,43,40]. The T cell markers CD4 and CD8 (in the
form of a αα-homodimer) are also expressed on mouse DCs, and can be used to distin‐
guish different subtypes [44]. In general, three DC subsets can be characterized in mouse
lymphoid tissue (table 1):  1)  CD8α+  CD4-  DCs;  2)  CD8α-  CD4+  DCs;  and 3)  CD8α-  CD4-
DCs [44].  The CD8α+  CD4-  DCs are mainly localized in the T cell  areas of lymphoid or‐
gans,  whereas  the  CD8α-  CD4+  DCs  are  found  in  the  marginal  zones.  Yet,  upon
stimulation by microbial products, such as lipopolysaccharide, the latter can also migrate
to the T cell zones [45,46]. Other markers that can be used to further subdivide mouse DC
subsets  include the  integrin  alpha M chain  CD11b and the  endocytosis  receptor  CD205
(DEC205). The CD8α+  CD4- DCs are also CD205+ CD11b- and they are mainly present in
the thymus, and at moderate levels in lymph nodes [40]. Lymph nodes further contain, in
contrast to spleen, CD8α- CD4- CD11b+ CD205mid DCs which are considered as the mature
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2.3. Heat shock proteins
Another category of auto-antigens that have been implicated in atherosclerosis are the
stress-induced heat shock proteins (HSPs) [22]. HSPs are responsible for the repair or degra‐
dation of denatured proteins and, by maintaining protein conformation, they enhance the
cell’s ability to survive under conditions of metabolic or oxidative stress [23]. The mRNA ex‐
pression level of several HSPs, including HSP40 and HSP70, has been shown to be signifi‐
cantly increased in carotid endarterectomy specimens as compared to healthy arteries [24].
HSP70 seems to be homogenously distributed throughout the intima and media in healthy
aortas, and a strong increase in its immunostaining intensity is observed in aortic athero‐
sclerotic plaques [25]. They appear to stimulate an immune response leading to the develop‐
ment and progression of atherosclerosis [26]. A number of studies indicate that HSPs are
associated with DC function and might trigger DC activation and maturation. DCs seem to
overexpress HSP70 in atherosclerotic plaques and the latter protein is presumably an impor‐
tant trigger for DC activation [27]. Gp96 (of the HSP90 family) and HSP70 have indeed been
shown to stimulate bone marrow-derived DCs in vitro to secrete cytokines [28] and to ex‐
press antigen-presenting (MHC II) and costimulatory molecules (B7.2) [29]. However, To‐
dryk and colleagues [30] reported that HSP70 targets immature DCs to make them
significantly more able to capture antigens. The presence of HSP70 inhibited DC maturation
induced by tumour cell lysates from parental B16 cells and maintained the DC precursor
population in a more poorly differentiated phenotype. Thus, there is still controversy on
whether HSPs activate DCs or keep them in an immature state, and data are lacking to ro‐
bustly support a conclusion.
3. Survival of DCs in oxidative stress environments
Atherosclerosis is a disease that is associated with strong oxidative stress, and the creation
of neo-epitopes is one of the consequences of this situation. As mentioned in section 2, the
presence of reactive oxygen species (ROS) in atherosclerotic plaques may lead to the forma‐
tion of oxLDL and oxidized β2-GPI, which might affect DC phenotype and function. Indeed,
oxidative stress has been shown to alter the capacity of antigen-presenting cells to process
antigens and to initiate a primary T-cell response. In this respect, it is interesting to unravel
whether DCs show phenotypic adaptations in order to function under oxidative stress situa‐
tions. In a recent study, we demonstrated that DCs appear to be resistant to the detrimental
effects of oxidative stress. We showed by confocal live cell imaging that monocyte-derived
DCs, which were generated as described earlier [31], were better capable of neutralizing
ROS induced by tertiary-butylhydroperoxide (tert-BHP) in comparison to their precursor
monocytes [31]. Tert-BHP was selected to induce ROS because it acutely evokes oxidative
stress, resulting in cell toxicity [32]. Decomposition of tert-BHP to alkoxyl or peroxyl radicals
accelerates lipid peroxidation chain reactions [33]. By means of a neutral red viability assay,
we observed that tert-BHP induced significant and rapid cell death in both monocytes and
DCs. Yet, monocyte-derived DCs were more resistant to tert-BHP-induced cell death than
their precursor cells [31]. A PCR profiler array specific for oxidative stress and antioxidant-
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related pathways revealed an upregulation of several important antioxidant genes during
differentiation of monocytes into DCs, including catalase, peroxiredoxin 2 (PRDX2) and glu‐
tathione peroxidase 3 (GPX3). Catalase encodes the enzyme that catalyses the decomposi‐
tion of hydrogen peroxide to water and oxygen. GPX3 and PRDX2 are genes encoding
enzymes that can detoxify hydrogen peroxide and lipid hydroperoxides [34,35]. However,
PRDX2 is more efficient in neutralizing hydrogen peroxide than catalase or GPXs [36,37].
Immunoblotting or immunohistochemistry showed that the upregulated transcription of
PRDX2 and GPX3 was translated in a significant increase at the protein level. Especially
PRDX2 appears to be an important factor in the neutralization of ROS induced by tert-BHP
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ide dismutase (SOD)2, PRDX1 and PRDX2 in monocyte-derived DCs when compared to
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good survival skills of monocyte-derived DCs in oxidative stress environments are crucial in
atherosclerotic plaques, enabling these professional antigen-presenting cells to exert their
function(s).
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exist, as DCs comprise a network of subsets that are phenotypically, functionally, and de‐
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target DCs for immunomodulating therapies. Most studies on DC subsets have been per‐
formed in mice, because lymphoid tissue is easier to obtain from mice than from humans.
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CD11c, the costimulatory molecules CD40, CD80 and CD86, and high surface levels of the
antigen-presenting molecule MHC II [42,43,40]. The T cell markers CD4 and CD8 (in the
form of a αα-homodimer) are also expressed on mouse DCs, and can be used to distin‐
guish different subtypes [44]. In general, three DC subsets can be characterized in mouse
lymphoid tissue (table 1):  1)  CD8α+  CD4-  DCs;  2)  CD8α-  CD4+  DCs;  and 3)  CD8α-  CD4-
DCs [44].  The CD8α+  CD4-  DCs are mainly localized in the T cell  areas of lymphoid or‐
gans,  whereas  the  CD8α-  CD4+  DCs  are  found  in  the  marginal  zones.  Yet,  upon
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to the T cell zones [45,46]. Other markers that can be used to further subdivide mouse DC
subsets  include the  integrin  alpha M chain  CD11b and the  endocytosis  receptor  CD205
(DEC205). The CD8α+  CD4- DCs are also CD205+ CD11b- and they are mainly present in
the thymus, and at moderate levels in lymph nodes [40]. Lymph nodes further contain, in
contrast to spleen, CD8α- CD4- CD11b+ CD205mid DCs which are considered as the mature
Dendritic Cells in Atherogenesis: From Immune Shapers to Therapeutic Targets
http://dx.doi.org/10.5772/52900
61
form of tissue interstitial  DCs [40,42,43] (table 1).  Another DC subtype, which is langer‐
inhigh CD11b+ CD8αlow CD205high, is only found in skin-draining lymph nodes and consid‐
ered as the mature form of epidermal Langerhans cells.  These cells are also positive for
MHC II and CD40, CD80 and CD86, suggesting that they are fully activated [42].
The numerous DC subtypes in mouse lymphoid organs are all able to present antigens to T
cells, however, they differ in other aspects of DC-T cell communication [40]. CD8α+ DCs
mainly induce Th1/Th17-polarizing cytokine responses in CD4+ effector T cells, whereas
CD8α- DCs are able to induce Th2-biased cytokine responses [47,48,49,50]. CD8α+ DCs also
seem to be specialized for the uptake and cross-presentation of exogenous antigens on MHC
I and consequently stimulate CD8+ cytotoxic T cells, whereas CD8α- DCs mainly stimulate





to localization MOUSE HUMAN
cDCs lymphoid organ-
resident cDC
CD8α+ CD4- CD205+ CD11b- lineage- HLA-DR+ CD11c+ CD1b/c+
CD8α- CD4+ lineage- HLA-DR+ CD11c+ CD141+
CD8α- CD4- CD205mid CD11b+ lineage- HLA-DR+ CD11c+ CD16+
circulating cDC CD8α- CD11b+ CD11chigh CD1c+ CD11c+
















cDC = conventional dendritic cell, pDC = plasmacytoid dendritic cell
lineage = cocktail of CD3, CD14, CD16, CD19, CD20, CD56; CD1c = BDCA-1; CD303 = BDCA-2; CD141 = BDCA-3; CD304
= BDCA-4
BDCA = blood dendritic cell antigen
Table 1. Markers used for characterization of DC subtypes in mice and men
It has to be noticed that the association between mouse and human DC subsets remains elu‐
sive, making translation of the above-mentioned findings difficult. One of the major barriers
in comparing mouse and human DC subsets is the lack of CD8α expression on human DCs
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[53]. As a result, it remains unclear which subtype represents the human equivalent of ma‐
ture mouse CD8α+ DCs. Another important barrier is that most human studies are per‐
formed on blood, due to the limited availability of human spleen tissue. Moreover, human
blood DCs are mainly immature and heterogeneous in their expression of a range of mark‐
ers. It might be that part of the heterogeneity reflects differences in the maturation or activa‐
tion state of DCs, rather than that they all represent separate sub-lineages. Yet, one subtype
that is similar to its mouse counterpart is the human Langerhans cell, which expresses CD1a
and langerin and is characterized by the presence of Birbeck granules [40].
In human blood, the first made classification is often the distinction between plasmacytoid
(p)DCs, and myeloid or conventional DCs (cDCs) (table 1). Freshly isolated pDCs resemble
plasma cells and have a morphology typical of that of large, round cells with a diffuse nucleus
and few dendrites. These type I IFN-producing cells (IPCs) are specialized in innate antiviral
immune responses by producing copious amounts of type I interferons. pDCs express CD303
(blood dendritic cell antigen (BDCA) 2), CD304 (BDCA 4) and CD123 (IL 3Rα), whereas cDCs
are characterized by their expression of CD1c (BDCA 1) and CD11c [54] (table 1). In addition,
pDCs and cDCs also express different sets of Toll-like receptors (TLRs). In brief, pDCs express
mainly TLR7 and TLR9, whereas cDCs exhibit strong expression of TLR1, TLR2, TLR3, TLR4,
and TLR8. Accordingly, pDCs mainly recognize viral components with subsequent produc‐
tion of a large amount of IFN-α. In contrast cDCs recognize bacterial components and produce
pro-inflammatory cytokines such as IL-12p70, TNF-α, and IL-6 [54,7].
Furthermore, cDCs and pDCs also differ in migration behaviour. Generally it is assumed
that myeloid (m)DCs are the conventional DCs that infiltrate peripheral tissues, while pDCs
migrate directly from the blood into lymphoid organs [54]. Finally, a small third population
of blood DCs expressing CD11c and BDCA-3 (CD141) but not BDCA-1, CD123 or BDCA-2
can be distinguished (table 1). Of particular importance is their superior antigen cross-pre‐
sentation capacity and expression of the XC chemokine receptor 1 (XCR1), suggesting that
they represent the human counterpart of mouse CD8α+ DCs. They emerge as a distinctive
myeloid DC subset that is characterized by high expression of TLR3, production of IL-12
and IFN-β, and a superior capacity to induce T helper-1 cell responses, when compared to
BDCA-1+ mDCs [54,7].
Only in a few recent studies, human DCs have been isolated from lymphoid tissues, which
allow direct comparison with mouse DC subtypes. Mittag and colleagues [41] identified
four DC subsets in human spleen that resemble DCs found in human blood. These include
three cDC subtypes and one pDC subtype (table 1). The cDCs are all negative for lineage
markers and positive for HLA-DR and CD11c, and they differ in their expression of CD1b/c
(= BDCA-1), CD141 (= BDCA-3) and CD16. The pDCs express high levels of CD304 (=
BDCA-4), but not CD11c [41]. Moreover, the hallmark functions of mouse CD8α+ DC sub‐
sets, which include IL-12p70 secretion and cross-presentation, appeared to be not restricted
to the equivalent human CD141+ cDCs as thought earlier, but shared by CD1b/c+ and CD16+
DC subsets [41].
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form of tissue interstitial  DCs [40,42,43] (table 1).  Another DC subtype, which is langer‐
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blood DCs are mainly immature and heterogeneous in their expression of a range of mark‐
ers. It might be that part of the heterogeneity reflects differences in the maturation or activa‐
tion state of DCs, rather than that they all represent separate sub-lineages. Yet, one subtype
that is similar to its mouse counterpart is the human Langerhans cell, which expresses CD1a
and langerin and is characterized by the presence of Birbeck granules [40].
In human blood, the first made classification is often the distinction between plasmacytoid
(p)DCs, and myeloid or conventional DCs (cDCs) (table 1). Freshly isolated pDCs resemble
plasma cells and have a morphology typical of that of large, round cells with a diffuse nucleus
and few dendrites. These type I IFN-producing cells (IPCs) are specialized in innate antiviral
immune responses by producing copious amounts of type I interferons. pDCs express CD303
(blood dendritic cell antigen (BDCA) 2), CD304 (BDCA 4) and CD123 (IL 3Rα), whereas cDCs
are characterized by their expression of CD1c (BDCA 1) and CD11c [54] (table 1). In addition,
pDCs and cDCs also express different sets of Toll-like receptors (TLRs). In brief, pDCs express
mainly TLR7 and TLR9, whereas cDCs exhibit strong expression of TLR1, TLR2, TLR3, TLR4,
and TLR8. Accordingly, pDCs mainly recognize viral components with subsequent produc‐
tion of a large amount of IFN-α. In contrast cDCs recognize bacterial components and produce
pro-inflammatory cytokines such as IL-12p70, TNF-α, and IL-6 [54,7].
Furthermore, cDCs and pDCs also differ in migration behaviour. Generally it is assumed
that myeloid (m)DCs are the conventional DCs that infiltrate peripheral tissues, while pDCs
migrate directly from the blood into lymphoid organs [54]. Finally, a small third population
of blood DCs expressing CD11c and BDCA-3 (CD141) but not BDCA-1, CD123 or BDCA-2
can be distinguished (table 1). Of particular importance is their superior antigen cross-pre‐
sentation capacity and expression of the XC chemokine receptor 1 (XCR1), suggesting that
they represent the human counterpart of mouse CD8α+ DCs. They emerge as a distinctive
myeloid DC subset that is characterized by high expression of TLR3, production of IL-12
and IFN-β, and a superior capacity to induce T helper-1 cell responses, when compared to
BDCA-1+ mDCs [54,7].
Only in a few recent studies, human DCs have been isolated from lymphoid tissues, which
allow direct comparison with mouse DC subtypes. Mittag and colleagues [41] identified
four DC subsets in human spleen that resemble DCs found in human blood. These include
three cDC subtypes and one pDC subtype (table 1). The cDCs are all negative for lineage
markers and positive for HLA-DR and CD11c, and they differ in their expression of CD1b/c
(= BDCA-1), CD141 (= BDCA-3) and CD16. The pDCs express high levels of CD304 (=
BDCA-4), but not CD11c [41]. Moreover, the hallmark functions of mouse CD8α+ DC sub‐
sets, which include IL-12p70 secretion and cross-presentation, appeared to be not restricted
to the equivalent human CD141+ cDCs as thought earlier, but shared by CD1b/c+ and CD16+
DC subsets [41].
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5. Discriminating between DCs and macrophages
It has become clear that DCs, especially DCs from myeloid origin, are very heterogeneous,
representing several subtypes with a common origin, but different anatomical locations
(lymphoid organs vs. non-lymphoid organs), function and phenotype. Moreover, there is al‐
so a very close relationship between myeloid DCs and macrophages (figure 5).
The distinction of the differences between macrophages and the heterogeneous family of
DCs is notoriously difficult and complicated by the plasticity of both cell types [55]. Mono‐
cytes that exit the blood and enter tissues under inflammatory conditions can differentiate to
macrophages, but also to DCs that share several phenotypic features and functions, making
it difficult to unambiguously define macrophages and DCs as individual entities [56]. In ad‐
dition, resting peripheral monocytes, obtained from mouse peritoneal cavity lavage, repre‐
sent an immature population, capable of further differentiation along either the dendritic or
the macrophage pathway, depending on the type of stimuli (cytokines, growth factors) they
receive [10]. Furthermore, many DC subsets are not clearly defined and it is absolutely nec‐
essary to bear in mind that different groups use different methods to identify and character‐
ize DCs [57]. Often, the starting populations are preselected based on randomly defined
expression levels of markers that were believed to be specific for either DCs or macrophag‐
es, but are in fact expressed by both [58] (figure 5).
Figure 5. Functional characteristics and surface markers of DCs and macrophages. Increasing evidence demonstrates an
enormous overlap between what is considered a 'macrophage' and a ‘DC'. Abbreviations: MHC II, major histocompatibil‐
ity complex class II; BDCA-1, blood dendritic-cell antigen-1; DC-SIGN, dendritic cell-specific ICAM-3-grabbing non-integrin.
Consequently, confusion in distinguishing between macrophages and DCs has been – at
least in part – caused by the use of nonspecific cell surface markers, such as CD11c. In addi‐
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tion, the number of DC and macrophage subpopulations that can be defined is an exponen‐
tial function of the number of markers that has been examined [59]. Moreover, since each
gene/protein has its own intrinsic expression level, the heterogeneity is really unlimited [60].
CD11c, a commonly used DC marker, was already known to be expressed by most tissue
macrophages before the use of CD11c-reporter transgenes as markers of DCs, and of CD11c-
DTR mice to ‘selectively’ deplete them [59,61]. Other markers that have been used to track
macrophages and DCs in mice include F4/80, CD11b and MHC II, but they have also turned
out to be nonspecific [57]. Too little attention has been paid to the expression of antimicrobi‐
al effector molecules, such as lysozyme, which is highly secreted by monocytes and macro‐
phages, but only weakly expressed, if at all, by DCs [62]. Part of the confusion may also
result from the flexibility and plasticity of macrophages and from the presence of resident
and migratory activated DCs in the same organ [63].
The confusion could be possibly resolved if the appropriate reflections are considered [57].
For example, the correctness of CD11c to identify DCs depends on the anatomical site in
question. In the spleen and lymph nodes, mononuclear phagocytes with high expression
levels of CD11c – though not those with low or intermediate CD11c – appear to be DCs rath‐
er than macrophages. Accumulating evidence confirms that spleen and lymph node DCs are
functionally different from macrophages, do not originate from differentiating monocytes,
and share fewer characteristics with monocytes than macrophages [64,65,66]. However, in
the lung, high levels of CD11c are expressed on macrophages [67,68], and there are many
other anatomical locations apart from the lymphoid organs where macrophages are CD11c-
positive. It has been proposed many times that the same set of markers that allows us to dis‐
criminate between DCs and macrophages in lymphoid organs, can also be used in non-
lymphoid organs, but it has become clear that this assumption is not correct.
Recent in vivo experiments in mice have increased our understanding of the development
and functions of DC and macrophage subsets [69,70,71]. However, despite this progress in
mice, corresponding human subsets are yet to be characterized. Until now, there is no mor‐
phologic or protein marker of macrophages or DCs which is unambiguous. Moreover, a sin‐
gle set of markers cannot be assumed to apply to all stages of cell differentiation and
activation. In conclusion, there is insufficient knowledge to make definitive claims about
any marker combination, particularly in non-lymphoid compartments.
If the distinction between DCs and macrophages cannot be made based on morphological
features, can it be based on function? Several criteria to define DCs include the property of
DCs to localize in the T cell zone of lymphoid organs where they can stimulate T cells, as
well as their ability to migrate and carry antigen [72,73]. In contrast, macrophages are best
defined by their phagocytic activity and are generally considered as tissue-resident cells.
However, recent studies show that macrophages can also migrate and that Langerhans cells
(i.e. DCs from the skin and mucosa that carry large Birbeck granules) are not important for T
cell priming [74]. In addition, some macrophage subtypes, such as microglia, show only
poor phagocytic capacity [57]. Taken together, there is no good functional criterion to define
macrophages and monocyte-derived DCs (figure 5), since they represent not just two differ‐
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ent cell populations, but various cell subtypes. As they are derived from a common precur‐
sor, it is really hard to fully identify macrophages and DCs as two separate entities.
6. Pro-and anti-atherogenic properties of various DC subtypes
We and others discovered a profoundly altered circulating DC compartment in patients
with coronary artery disease (CAD), the clinical manifestation of atherosclerosis, as com‐
pared to healthy donors [75,76,77,78,79,80]. In 2006, we reported for the first time a decrease
in circulating DC precursors (BDCA-1+ mDCs, BDCA-2+ pDCs) in CAD patients by flow cy‐
tometry. CAD was determined by angiography and defined as more than 50% stenosis in
one or more coronary arteries [77]. In parallel, Yilmaz et al. [79] found a marked reduction in
mDC precursors in CAD patients, though the decline in pDCs was less pronounced. Next,
we studied whether the lower blood DC counts in CAD patients were related to the extent
of atherosclerosis (one- versus three-vessel disease) or type (stable versus unstable angina
pectoris) of CAD. Again, we observed significantly lower relative and absolute numbers of
pDCs and mDCs in patients with coronary atherosclerosis [78]. Interestingly, the overall lin‐
eage-negative HLA-DR-positive blood DCs, which also include other blood DCs (such as
BDCA-3+) or more mature blood DCs, confirmed the decline of BDCA+ DC precursors. How‐
ever, the counts of circulating DCs dropped to the same extent in three groups of CAD pa‐
tients, irrespective of the number (one or three) of affected arteries or the type (stable or
unstable) of angina [78]. Consistent with our results, Yilmaz and colleagues [79] reported no
differences between clinically stable or unstable CAD. Yet, in a later and more extended
study with a cohort of 290 patients, in which a more refined ‘CAD score’ was used to classi‐
fy patients, they found that the numbers of pDCs, mDCs, and total DCs decreased when the
extent of coronary atherosclerosis increased [80].
Besides  flow  cytometric  studies,  we  performed  immunohistochemical  analyses  demon‐
strating  increased  intimal  DC counts  with  evolving  plaque  stages,  in  close  relationship
with lesional  T cells  [81].  These findings strongly suggest  that  blood DCs migrate  from
the circulation to the atherosclerotic lesion, possibly attracted by chemokines produced by
the inflammatory infiltrate in the plaque, and subsequently stimulate T cell  proliferation
[7].  However, it  is unlikely that accumulation of DC into a single tissue site is responsi‐
ble for the major changes in the number of  circulating DCs in CAD [12].  Possibly,  DCs
may leave the blood to migrate into lymphoid tissues in response to systemic inflammato‐
ry activation, which redirects trafficking and compartmentalization of antigen-presenting
DCs as well  as lymphocytes.  Indeed, it  has been mentioned that DC numbers of lymph
nodes attached to atherosclerotic wall segments exceed those in lymph nodes attached to
non-atherosclerotic  arteries  [7].  The  declined  circulating  DC  numbers  in  atherosclerosis
might also be the result of impaired differentiation from bone marrow progenitors. Inter‐
estingly, we recently showed that plasma Flt3 ligand (Flt3L) concentrations were reduced
in CAD patients [75]. Flt3L is a major cytokine involved in both pDC and mDC develop‐
ment from haematopoietic stem cells and their release from the bone marrow [82,83,84].
As plasma Flt3L correlated with blood DC counts, the reduced blood DCs in CAD might
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be caused by impaired DC differentiation from bone marrow progenitors.  Until  now, it
remains  unclear  why plasma Flt3L levels  are  lowered in  CAD.  Other  possible  explana‐
tions for the decrease of circulating DC subsets in CAD patients include DC activation re‐
sulting  in  enhanced  migration  or  in  loss  of  subset  markers,  drug-induced  changes,  or
increased DC turnover, and are reviewed elsewhere [7].
The finding that blood DCs are decreased in CAD patients and that atherosclerotic arteries
display a marked increase in the number of DCs suggest the involvement of DCs in the
pathogenesis of atherosclerosis. Yet, the exact role of DCs in atherogenesis has not been fully
clarified. Moreover, increasing evidence points to different behaviour of DC subsets in the
initiation and progression of the disease. We have recently demonstrated in vitro that mDCs
in CAD operate in a normal way, whereas pDCs from CAD patients are not only reduced in
number, but also seem to be functionally impaired [75].
Most evidence points to a proatherogenic role for mDCs. Apolipoprotein E (ApoE)/IL-12 dou‐
ble knockout mice develop smaller atherosclerotic lesions than ApoE deficient (ApoE-/-) mice,
illustrating the proatherogenic effect of IL-12, which is the main cytokine secreted by mDCs
[85]. Moreover, daily IL-12 administration promotes atherosclerosis in ApoE-/- mice [86]. Be‐
cause mDCs from CAD patients are still able to mature [75], it is plausible that the blood mDCs
that are activated by atherosclerosis-favouring factors in the circulation migrate to the athero‐
sclerotic plaque or the lymph nodes attached to the atherosclerotic wall segments. Once ar‐
rived,  they might  initiate  and maintain the inflammatory response by continuous T-cell
stimulation. Nevertheless, DCs are not only implicated in the immune response in atheroscle‐
rosis, they are also involved in cholesterol homeostasis. A recent study using a mouse model in
which the receptor for diphtheria toxin was expressed under the CD11c promoter (CD11c-
DTR) showed that (transient) depletion of CD11c+ cDCs resulted in enhanced cholesterolae‐
mia [87]. The latter indicates that DCs are important in regulating the accumulation of lipids
during the earliest stages of plaque formation. In contrast, enhancement of the life span and
immunogenicity of DCs by specific overexpression of the anti-apoptotic gene hBcl-2 under the
control of the CD11c promoter was associated with an atheroprotective decrease in plasma
cholesterol levels, neutralizing the proatherogenic signature of enhanced T cell activation, a
Th1 and Th17 cytokine expression profile, and elevated production of T-helper 1–driven IgG2c
autoantibodies directed against oxidation-specific epitopes. -As a net result, there was no ac‐
celeration of atherosclerotic plaque progression [87].
It is not yet clear whether pDCs are proatherogenic or atheroprotective. PDCs might be in‐
volved in plaque destabilization, as they have the unique ability of producing large amounts of
type I IFNs. This cytokine exerts strong antiviral effects, but more importantly, it induces
marked upregulation  of  tumour  necrosis  factor  (TNF)-related  apoptosis-inducing  ligand
(TRAIL) on CD4+ T cells, which might lead to killing of plaque-resident cells, potentially weak‐
ening the scaffold of the lesion and rendering the plaque vulnerable [88]. In addition, nucleoti‐
des released from necrotic or apoptotic cells can induce IFN-α production by pDCs in the
presence of antimicrobial peptides released from inflammatory cells [89]. Plaque-residing
pDCs have also been shown to respond to CpGs (containing motifs typically found in microbi‐
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ent cell populations, but various cell subtypes. As they are derived from a common precur‐
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mDC precursors in CAD patients, though the decline in pDCs was less pronounced. Next,
we studied whether the lower blood DC counts in CAD patients were related to the extent
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differences between clinically stable or unstable CAD. Yet, in a later and more extended
study with a cohort of 290 patients, in which a more refined ‘CAD score’ was used to classi‐
fy patients, they found that the numbers of pDCs, mDCs, and total DCs decreased when the
extent of coronary atherosclerosis increased [80].
Besides  flow  cytometric  studies,  we  performed  immunohistochemical  analyses  demon‐
strating  increased  intimal  DC counts  with  evolving  plaque  stages,  in  close  relationship
with lesional  T cells  [81].  These findings strongly suggest  that  blood DCs migrate  from
the circulation to the atherosclerotic lesion, possibly attracted by chemokines produced by
the inflammatory infiltrate in the plaque, and subsequently stimulate T cell  proliferation
[7].  However, it  is unlikely that accumulation of DC into a single tissue site is responsi‐
ble for the major changes in the number of  circulating DCs in CAD [12].  Possibly,  DCs
may leave the blood to migrate into lymphoid tissues in response to systemic inflammato‐
ry activation, which redirects trafficking and compartmentalization of antigen-presenting
DCs as well  as lymphocytes.  Indeed, it  has been mentioned that DC numbers of lymph
nodes attached to atherosclerotic wall segments exceed those in lymph nodes attached to
non-atherosclerotic  arteries  [7].  The  declined  circulating  DC  numbers  in  atherosclerosis
might also be the result of impaired differentiation from bone marrow progenitors. Inter‐
estingly, we recently showed that plasma Flt3 ligand (Flt3L) concentrations were reduced
in CAD patients [75]. Flt3L is a major cytokine involved in both pDC and mDC develop‐
ment from haematopoietic stem cells and their release from the bone marrow [82,83,84].
As plasma Flt3L correlated with blood DC counts, the reduced blood DCs in CAD might
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clarified. Moreover, increasing evidence points to different behaviour of DC subsets in the
initiation and progression of the disease. We have recently demonstrated in vitro that mDCs
in CAD operate in a normal way, whereas pDCs from CAD patients are not only reduced in
number, but also seem to be functionally impaired [75].
Most evidence points to a proatherogenic role for mDCs. Apolipoprotein E (ApoE)/IL-12 dou‐
ble knockout mice develop smaller atherosclerotic lesions than ApoE deficient (ApoE-/-) mice,
illustrating the proatherogenic effect of IL-12, which is the main cytokine secreted by mDCs
[85]. Moreover, daily IL-12 administration promotes atherosclerosis in ApoE-/- mice [86]. Be‐
cause mDCs from CAD patients are still able to mature [75], it is plausible that the blood mDCs
that are activated by atherosclerosis-favouring factors in the circulation migrate to the athero‐
sclerotic plaque or the lymph nodes attached to the atherosclerotic wall segments. Once ar‐
rived,  they might  initiate  and maintain the inflammatory response by continuous T-cell
stimulation. Nevertheless, DCs are not only implicated in the immune response in atheroscle‐
rosis, they are also involved in cholesterol homeostasis. A recent study using a mouse model in
which the receptor for diphtheria toxin was expressed under the CD11c promoter (CD11c-
DTR) showed that (transient) depletion of CD11c+ cDCs resulted in enhanced cholesterolae‐
mia [87]. The latter indicates that DCs are important in regulating the accumulation of lipids
during the earliest stages of plaque formation. In contrast, enhancement of the life span and
immunogenicity of DCs by specific overexpression of the anti-apoptotic gene hBcl-2 under the
control of the CD11c promoter was associated with an atheroprotective decrease in plasma
cholesterol levels, neutralizing the proatherogenic signature of enhanced T cell activation, a
Th1 and Th17 cytokine expression profile, and elevated production of T-helper 1–driven IgG2c
autoantibodies directed against oxidation-specific epitopes. -As a net result, there was no ac‐
celeration of atherosclerotic plaque progression [87].
It is not yet clear whether pDCs are proatherogenic or atheroprotective. PDCs might be in‐
volved in plaque destabilization, as they have the unique ability of producing large amounts of
type I IFNs. This cytokine exerts strong antiviral effects, but more importantly, it induces
marked upregulation  of  tumour  necrosis  factor  (TNF)-related  apoptosis-inducing  ligand
(TRAIL) on CD4+ T cells, which might lead to killing of plaque-resident cells, potentially weak‐
ening the scaffold of the lesion and rendering the plaque vulnerable [88]. In addition, nucleoti‐
des released from necrotic or apoptotic cells can induce IFN-α production by pDCs in the
presence of antimicrobial peptides released from inflammatory cells [89]. Plaque-residing
pDCs have also been shown to respond to CpGs (containing motifs typically found in microbi‐
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al DNA) leading to enhanced IFN-α expression. This process amplifies inflammatory TLR-4,
TNF-α, and IL-12 expression by mDCs, and correlates with plaque instability [90]. A recent
study in ApoE-/- mice reported that administration of a plasmacytoid dendritic cell antigen-1
(PDCA-1) antibody to deplete pDCs protected from lesion formation [91], demonstrating that
pDCs indeed exert proatherogenic functions during early lesion formation. In contrast, pDC
depletion by administration of the 120G8 monoclonal antibody promoted plaque T-cell accu‐
mulation and exacerbated lesion development and progression in LDLr⁻/⁻ mice [92]. PDC de‐
pletion was accompanied by increased CD4⁺ T-cell proliferation, IFN-γ expression by splenic
T cells, and plasma IFN-γ levels, pointing to a protective role for pDCs in atherosclerosis. Thus,
the exact role of pDCs in atherosclerosis remains to be further unravelled.
7. DCs as therapeutic targets
Until now, it is impossible to fully inhibit the formation or progression of atherosclerotic le‐
sions in the clinic. Current therapies for atherosclerosis (e.g. statins, stent placement) focus
on relieving symptoms, and consequently many patients remain at high risk for future acute
coronary events. A very effective strategy in other immune-related pathologies is vaccina‐
tion, where the culprit protein or the weakened/dead version of the micro-organism is in‐
jected to the body in order to create a highly specific primary humoral immune-response
[93]. New vaccines have recently been developed that deliver relevant antigens and adju‐
vants to redirect the immune system for the individual’s benefit [94]. Because DCs are the
most effective antigen presenting cells that initiate and regulate the immune response, they
seem extremely suitable as vaccine basis. On the one hand, they can activate T cells, on the
other hand, they can specifically silence unwanted immune reactions by inducing tolerance
[95]. They might function as natural adjuvants for the induction of antigen-specific T-cell re‐
sponses. Approaches using DCs in atherosclerosis immunotherapy may be comparable to
those already used for cancer immunotherapy [96,97,98], although a different immune re‐
sponse is required. One approach that is already intensively studied is the immunization
with autologous, monocyte-derived DCs from the patient that are loaded with appropriate
antigens ex vivo [96]. Such ex vivo generated and antigen-loaded DCs have nowadays been
used as vaccines to improve immunity in patients with cancer [99] and chronic human im‐
munodeficiency virus (HIV) infection [100,101], providing a “proof of principle” that DC
vaccines can work.
In the context of atherosclerosis, immunization of hypercholesterolemic animals with oxLDL
or specific epitopes of ApoB100 has already been shown to inhibit atherosclerosis
[102,103,104,105,106]. When LDL receptor-deficient (LDLr-/-) rabbits were immunized with
malondialdehyde modified LDL (MDA-LDL), a reduction in the extent of atherosclerotic le‐
sions was observed in the aortic tree [102]. These observations were confirmed in LDLr-/- and
apolipoprotein E deficient (ApoE-/-) mice [103,104]. Also hypercholesterolemic rabbits that
were immunized with oxLDL showed reduced atherosclerotic lesions in the proximal aorta
[107]. Possibly, oxLDL-pulsed DCs or DCs pulsed with immunogenic components of oxLDL
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could be used for vaccination as well, thereby avoiding the side effects of direct vaccination
with oxLDL [108]. A series of studies have already used pulsed DCs as an immunotherapy
for atherosclerosis in mice, however, results were not always consistent. Repeated injection
of LDLr-/- mice with oxLDL-pulsed mature DCs resulted in attenuation of lesion develop‐
ment with a decreased amount of macrophages and increased collagen content, contributing
to a more stable plaque phenotype [109]. Moreover, a similar approach was carried out us‐
ing mice expressing the full-length human ApoB100 in the liver and humanized lipoprotein
profiles [110]. Those mice were repeatedly injected with mature DCs that were incubated
with IL-10 and ApoB100, prior to the initiation of a Western diet. The immunosuppressive
cytokine IL-10 was used to induce tolerogenic DCs [110]. This approach resulted in attenua‐
tion of atherosclerotic lesion development in the aorta, which was associated with decreased
cellular immunity to ApoB100. Also, decreased Th1 and Th2 responses most likely due to
enhanced regulatory T cell (Treg) expansion were observed [110]. In contrast, subcutaneous
injection of DCs that were simultaneously pulsed with LPS and MDA-LDL into ApoE-/- mice
at frequent intervals during lesion formation caused a significant increase in lesion size in
the aortic root [111]. These differential effects may be due to different forms of antigen pre‐
sentation leading to qualitatively different immune responses. Apart from oxLDL, DCs
might also be pulsed ex vivo by cultivating them with a total extract or suspension of athero‐
sclerotic plaque tissue, for example, from patients undergoing carotid endarterectomy
[95,108] (figure 6). A major advantage of such a therapy, where a patient is vaccinated with
its own DCs pulsed by its own antigens is the efficiency, because it would imitate events as
they occur in plaques in situ in the patient.
Figure 6. Promising areas for further research to treat immune-mediated diseases, such as atherosclerosis. Immuniza‐
tion of patients with autologous, monocyte-derived DCs that are loaded with appropriate antigens ex vivo. This ap‐
proach has already been proven successful in cancer and HIV patients.
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vants to redirect the immune system for the individual’s benefit [94]. Because DCs are the
most effective antigen presenting cells that initiate and regulate the immune response, they
seem extremely suitable as vaccine basis. On the one hand, they can activate T cells, on the
other hand, they can specifically silence unwanted immune reactions by inducing tolerance
[95]. They might function as natural adjuvants for the induction of antigen-specific T-cell re‐
sponses. Approaches using DCs in atherosclerosis immunotherapy may be comparable to
those already used for cancer immunotherapy [96,97,98], although a different immune re‐
sponse is required. One approach that is already intensively studied is the immunization
with autologous, monocyte-derived DCs from the patient that are loaded with appropriate
antigens ex vivo [96]. Such ex vivo generated and antigen-loaded DCs have nowadays been
used as vaccines to improve immunity in patients with cancer [99] and chronic human im‐
munodeficiency virus (HIV) infection [100,101], providing a “proof of principle” that DC
vaccines can work.
In the context of atherosclerosis, immunization of hypercholesterolemic animals with oxLDL
or specific epitopes of ApoB100 has already been shown to inhibit atherosclerosis
[102,103,104,105,106]. When LDL receptor-deficient (LDLr-/-) rabbits were immunized with
malondialdehyde modified LDL (MDA-LDL), a reduction in the extent of atherosclerotic le‐
sions was observed in the aortic tree [102]. These observations were confirmed in LDLr-/- and
apolipoprotein E deficient (ApoE-/-) mice [103,104]. Also hypercholesterolemic rabbits that
were immunized with oxLDL showed reduced atherosclerotic lesions in the proximal aorta
[107]. Possibly, oxLDL-pulsed DCs or DCs pulsed with immunogenic components of oxLDL
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ment with a decreased amount of macrophages and increased collagen content, contributing
to a more stable plaque phenotype [109]. Moreover, a similar approach was carried out us‐
ing mice expressing the full-length human ApoB100 in the liver and humanized lipoprotein
profiles [110]. Those mice were repeatedly injected with mature DCs that were incubated
with IL-10 and ApoB100, prior to the initiation of a Western diet. The immunosuppressive
cytokine IL-10 was used to induce tolerogenic DCs [110]. This approach resulted in attenua‐
tion of atherosclerotic lesion development in the aorta, which was associated with decreased
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[95,108] (figure 6). A major advantage of such a therapy, where a patient is vaccinated with
its own DCs pulsed by its own antigens is the efficiency, because it would imitate events as
they occur in plaques in situ in the patient.
Figure 6. Promising areas for further research to treat immune-mediated diseases, such as atherosclerosis. Immuniza‐
tion of patients with autologous, monocyte-derived DCs that are loaded with appropriate antigens ex vivo. This ap‐
proach has already been proven successful in cancer and HIV patients.
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Another promising area for further research is the development of tolerogenic vaccines for
immune-mediated diseases (figure 7). Both foreign and self-antigens can be targets of tolero‐
genic processes. DCs can be converted to ‘tolerogenic DCs’ by addition of various immuno‐
modulating agents, including IL-10, transforming growth factor-beta (TGF-β) and 1,25-
dihydroxyvitamin D3 [8], or they can be generated by using small interfering RNA (siRNA)
that specifically targets IL-12p35 gene [112] (figure 7). Tolerogenic DC-based immunothera‐
py has recently been tested in mice as a possible novel approach to induce immunological
tolerance for prevention or treatment of atherosclerosis [110]. Hermansson et al. [110] used
IL-10 to induce tolerogenic DCs. Another group showed that oral administration of calci‐
triol, the active form of vitamin D3, induced the generation of tolerogenic DCs as well as a
significant increase in Foxp3+ Tregs in the lymph nodes, spleen, and atherosclerotic lesions
of ApoE-/- mice, which resulted in an inhibition of atherosclerosis [113]. This was associated
with increased IL-10 and decreased IL-12 mRNA expression. Furthermore, DCs from the
calcitriol group showed reduced CD80 and CD86 expression and decreased proliferative ac‐
tivity of T lymphocytes, indicating that tolerogenic or maturation-resistant DCs show some
similarities with immature DCs [113]. Hussain and colleagues [114] hypothesized that aspir‐
in may also induce tolerogenic DCs and CD4+ CD25+ FoxP3+ Treg cells activity/augmenta‐
tion in experimental models of autoimmune atherosclerosis. Aspirin-induced tolerogenic
DCs initiated regulatory activity in responder T cells as they showed a decreased expression
of costimulatory molecules and an increased expression of immunoglobulin-like transcript 3
(ILT-3), which is a co-inhibitor of T cell activation required to induce Tregs [114,115,116]. In‐
deed, the presentation of antigen complexes to T cells in the absence of costimulatory signals
could lead to anergy or apoptosis of T cells, or the induction of Treg. Therefore, it might also
be useful to adjust the expression of costimulatory molecules on pulsed DCs ex vivo prior to
the vaccination [96,98,97,94,117,118].
Figure 7. Generation of tolerogenic DCs to develop tolerogenic vaccines. Tolerogenic DC-based immunotherapy has
recently been successfully tested in mice as a possible novel approach to induce immunological tolerance for preven‐
tion or treatment of atherosclerosis.
A completely different strategy that might be used in therapeutic intervention implicates the
use of DCs to deplete specific immune cells, such as the detrimental Th1 or Th17 cells, in
atherosclerosis. The opposite approach has been shown to work in a mouse model of athero‐
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sclerosis. Van Es et al. [119] used DCs to deplete atheroprotective Tregs by vaccinating
LDLr-/- mice with DCs which were transfected with Foxp3 encoding mRNA. This approach
resulted in a cytotoxic T lymphocyte (CTL) response against Foxp3 and a subsequent deple‐
tion of Foxp3+ Tregs. Vaccination against Foxp3 aggravated atherosclerosis, it resulted in a
reduction of Foxp3+ regulatory T cells in spleen, lymph nodes and circulation, and in an in‐
crease in initial atherosclerotic lesion formation. Besides an increase in lesion size, vaccina‐
tion against Foxp3 also induced a 30% increase in cellularity of the initial lesions, which may
indicate an increase in inflammation within the lesions [119].
Another approach for therapeutic intervention against atherosclerosis might involve the di‐
rect targeting of DCs in vivo by manipulating the functions of different DC subsets [95].
Based on the hypothesis that cDCs act rather proatherogenic, whereas pDCs might be athe‐
roprotective (see section 4), suppression of the myeloid DC subset and activation of the lym‐
phoid subset might enable immune reactions in atherosclerosis to be regulated [95]. For
future studies, it would be very useful to isolate DCs resident in plaques to be able to identi‐
fy a unique antigen(s) on their surface. That would possibly lead to new strategies where
plaque DCs can be targeted to deliver biologically active substances to atherosclerotic le‐
sions. The challenge is to selectively identify regulatory molecules and novel therapies in or‐
der to inhibit DC migration and function during atherogenesis without affecting normal DC
function under physiological conditions.
8. Conclusion
As it is now well accepted that atherosclerosis is an immune-mediated disease, the target‐
ing of its cellular components might open possibilities for new therapeutic strategies to at‐
tenuate  the  progression  of  the  disease.  DCs  seem  to  initiate  and  regulate  immune
responses in atherosclerosis and they are also involved in controlling cholesterol homeo‐
stasis  by  yet  unknown  mechanisms.  It  would  be  important  to  identify  the  pathway(s)
through which CD11c+  cells  may modulate the levels of  plasma cholesterol.  One should
take into account that DCs represent a very heterogeneous population, with many subsets
that have different phenotypes, functions, origin and anatomical distribution. So far, it is
unclear if all DCs have equal antigen-presenting capacities, and very little is known about
a preferential DC subset that is responsible for T cell-induced inflammation in the vessel
wall. Moreover, there is a close relationship between DCs and macrophages, and the dis‐
tinction  between  both  cell  types  is  even  further  complicated  by  their  plasticity.  Future
studies  are  essential  to  determine which DC subtypes  exert  pro-  or  anti-atherogenic  ef‐
fects. It is crucial to understand the diversity in DC subsets to target DCs for immunomo‐
dulation  therapies.  Furthermore,  functional  differences  between  phenotypically  similar
mouse and human DC subtypes should also be studied. Nevertheless, DC-based vaccina‐
tion strategies have been proven successful and animal studies provide some promising
data for the treatment of atherosclerosis as well. Yet, several issues, such as the most ap‐
propriate antigen(s) for loading DCs and the optimal type of DC used for vaccination re‐
main to be further investigated.
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Another promising area for further research is the development of tolerogenic vaccines for
immune-mediated diseases (figure 7). Both foreign and self-antigens can be targets of tolero‐
genic processes. DCs can be converted to ‘tolerogenic DCs’ by addition of various immuno‐
modulating agents, including IL-10, transforming growth factor-beta (TGF-β) and 1,25-
dihydroxyvitamin D3 [8], or they can be generated by using small interfering RNA (siRNA)
that specifically targets IL-12p35 gene [112] (figure 7). Tolerogenic DC-based immunothera‐
py has recently been tested in mice as a possible novel approach to induce immunological
tolerance for prevention or treatment of atherosclerosis [110]. Hermansson et al. [110] used
IL-10 to induce tolerogenic DCs. Another group showed that oral administration of calci‐
triol, the active form of vitamin D3, induced the generation of tolerogenic DCs as well as a
significant increase in Foxp3+ Tregs in the lymph nodes, spleen, and atherosclerotic lesions
of ApoE-/- mice, which resulted in an inhibition of atherosclerosis [113]. This was associated
with increased IL-10 and decreased IL-12 mRNA expression. Furthermore, DCs from the
calcitriol group showed reduced CD80 and CD86 expression and decreased proliferative ac‐
tivity of T lymphocytes, indicating that tolerogenic or maturation-resistant DCs show some
similarities with immature DCs [113]. Hussain and colleagues [114] hypothesized that aspir‐
in may also induce tolerogenic DCs and CD4+ CD25+ FoxP3+ Treg cells activity/augmenta‐
tion in experimental models of autoimmune atherosclerosis. Aspirin-induced tolerogenic
DCs initiated regulatory activity in responder T cells as they showed a decreased expression
of costimulatory molecules and an increased expression of immunoglobulin-like transcript 3
(ILT-3), which is a co-inhibitor of T cell activation required to induce Tregs [114,115,116]. In‐
deed, the presentation of antigen complexes to T cells in the absence of costimulatory signals
could lead to anergy or apoptosis of T cells, or the induction of Treg. Therefore, it might also
be useful to adjust the expression of costimulatory molecules on pulsed DCs ex vivo prior to
the vaccination [96,98,97,94,117,118].
Figure 7. Generation of tolerogenic DCs to develop tolerogenic vaccines. Tolerogenic DC-based immunotherapy has
recently been successfully tested in mice as a possible novel approach to induce immunological tolerance for preven‐
tion or treatment of atherosclerosis.
A completely different strategy that might be used in therapeutic intervention implicates the
use of DCs to deplete specific immune cells, such as the detrimental Th1 or Th17 cells, in
atherosclerosis. The opposite approach has been shown to work in a mouse model of athero‐
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sclerosis. Van Es et al. [119] used DCs to deplete atheroprotective Tregs by vaccinating
LDLr-/- mice with DCs which were transfected with Foxp3 encoding mRNA. This approach
resulted in a cytotoxic T lymphocyte (CTL) response against Foxp3 and a subsequent deple‐
tion of Foxp3+ Tregs. Vaccination against Foxp3 aggravated atherosclerosis, it resulted in a
reduction of Foxp3+ regulatory T cells in spleen, lymph nodes and circulation, and in an in‐
crease in initial atherosclerotic lesion formation. Besides an increase in lesion size, vaccina‐
tion against Foxp3 also induced a 30% increase in cellularity of the initial lesions, which may
indicate an increase in inflammation within the lesions [119].
Another approach for therapeutic intervention against atherosclerosis might involve the di‐
rect targeting of DCs in vivo by manipulating the functions of different DC subsets [95].
Based on the hypothesis that cDCs act rather proatherogenic, whereas pDCs might be athe‐
roprotective (see section 4), suppression of the myeloid DC subset and activation of the lym‐
phoid subset might enable immune reactions in atherosclerosis to be regulated [95]. For
future studies, it would be very useful to isolate DCs resident in plaques to be able to identi‐
fy a unique antigen(s) on their surface. That would possibly lead to new strategies where
plaque DCs can be targeted to deliver biologically active substances to atherosclerotic le‐
sions. The challenge is to selectively identify regulatory molecules and novel therapies in or‐
der to inhibit DC migration and function during atherogenesis without affecting normal DC
function under physiological conditions.
8. Conclusion
As it is now well accepted that atherosclerosis is an immune-mediated disease, the target‐
ing of its cellular components might open possibilities for new therapeutic strategies to at‐
tenuate  the  progression  of  the  disease.  DCs  seem  to  initiate  and  regulate  immune
responses in atherosclerosis and they are also involved in controlling cholesterol homeo‐
stasis  by  yet  unknown  mechanisms.  It  would  be  important  to  identify  the  pathway(s)
through which CD11c+  cells  may modulate the levels of  plasma cholesterol.  One should
take into account that DCs represent a very heterogeneous population, with many subsets
that have different phenotypes, functions, origin and anatomical distribution. So far, it is
unclear if all DCs have equal antigen-presenting capacities, and very little is known about
a preferential DC subset that is responsible for T cell-induced inflammation in the vessel
wall. Moreover, there is a close relationship between DCs and macrophages, and the dis‐
tinction  between  both  cell  types  is  even  further  complicated  by  their  plasticity.  Future
studies  are  essential  to  determine which DC subtypes  exert  pro-  or  anti-atherogenic  ef‐
fects. It is crucial to understand the diversity in DC subsets to target DCs for immunomo‐
dulation  therapies.  Furthermore,  functional  differences  between  phenotypically  similar
mouse and human DC subtypes should also be studied. Nevertheless, DC-based vaccina‐
tion strategies have been proven successful and animal studies provide some promising
data for the treatment of atherosclerosis as well. Yet, several issues, such as the most ap‐
propriate antigen(s) for loading DCs and the optimal type of DC used for vaccination re‐
main to be further investigated.
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1. Introduction
Atherosclerosis is an endothelial dysfunction induced by elevated and modified low-density
lipoproteins (LDL), free radicals, infectious microorganisms, shear stress, hypertension, tox‐
ins after smoking or combinations of these and other factors[1], which is characterized by
decreased nitric oxide synthesis, local oxidation of circulating lipoproteins and their entry
into the vessel wall[2]. Intracellularreactive oxygen species similarly induced by the multi‐
ple atherosclerosis risk factors lead to enhanced oxidative stress in vascular cells and further
activate intracellular signaling molecules involved in gene expression[3].
Up regulation of celladhesion molecules facilitates adherence of leukocytes to the dysfunc‐
tional endothelium and their subsequent transmigration into the vessel wall.The evolving
inflammatory reaction is instrumental in the initiation of atherosclerotic plaques and their
destabilization. There are evidence[4] supporting a pathophysiological role of T cells, B cells
and macrophages in the development of atherosclerosis in general[5].
2. Atherogenesis and cardiovascular diseases
Decades ago, the endothelium was considered just a barrier non thrombogenic, vascular
control which was attributed primarily to the sympathetic nervous system and circulating
vasoactive hormones. The discovery that the endothelium synthesizes important vasodila‐
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tors such as nitric oxide and prostacyclin, and vasoconstrictors such as endothelin, aroused
great interestin endothelial function and role of vascular control, both in physiological proc‐
esses and in pathological conditions. The model ‘response to injury’ of the endothelium ex‐
plains more precisely this complex pathophysiological mechanism. In this model the
endothelium is injured by hemodynamic stimulus, such as hypertension, or bychemical at‐
tack, such as in smoking, begins to operate in a manner dysfunctional. This endothelial dys‐
function leads to compensatory responses that alter the normal homeostatic properties of
the endothelium to a reduction in nitric oxide synthesis and an increase inpermeability of
the endothelium which binds to LDL cholesterol in the vessel wall[6]. Adhesion molecules
begin to be expressed on the surface of the endothelium will lead to attraction of monocytes
and lymphocytes to the arterial wall[7].
LDL  modified  by  oxidation  is  a  major  cause  of  injury  to  the  endothelium.  Many  au‐
thors believe that  LDL oxidation does not  take place in the circulation,  and therefore it
must  occur  in  the  subendothelial  space  of  the  arterial  wall.  After  being  trapped in  the
artery  wall,  it  is  internalized  by  macrophages  via  the  scavenger  receptor  surfaces  of
these  cells  which leads  to  the  formation of  foam cells.  Inflammation mediators  such as
tumor necrosis  factor  α,  interleukin-1  and macrophage colony-stimulating factor  further
increase  the  binding  of  LDL  to  the  endothelium  and  smooth  muscle  and  increase  the
transcription  of  the  LDL  receptor  gene.  Experimental  studies  in  mice  show  that  oxi‐
dized  LDL  (oxLDL)  promotes  atherosclerosis,  however,  clinical  trials  of  antioxidants
were not effective in reducing cardiovascular events[8],[9].Increased levels of  oxLDL are
presentin  human  gingival  crevicular  fluid  compared  to  plasma  of  healthy  individuals,
indicating  that  oxLDL  could  be  generated  in  inflamed  extra-arterial  tissues,  transferred
to the circulation, rapidly taken up into the arterial  wall,  and contribute to the perpetu‐
ation ofatherosclerosis[10].
Early  ‘fatty-streak’  lesions  consist  of  T  cells  and  monocyte-derived  macrophage-like
foam  cells  loaded  with  lipids  and  after  successive  accumulation  of  apoptotic  cells,  de‐
bris  and cholesterol  crystals  forms a necrotic  core.  Initial  lesions most  commonly devel‐
opin  places  where  laminar  blood  flow  is  altered,  as  in  the  bifurcations  of  the  vessels,
which  interferes  with  the  shear  stress  and  adequate  production  of  nitric  oxide[11].  In
these  places,  substances  are  produced  by  the  endothelium  that  promote  adhesion,  mi‐
gration and accumulation of  monocytes  and T cells.  The flow changes,  leading to  a  re‐
duced  shear  stress,  modifies  the  expression  of  genes  such  as  intercellular  adhesion
molecule, platelet derived growth factor B chain[12],[13].
The mature atherosclerotic plaque shows in addition to cells, two distinct structural compo‐
nents: a lipid core, very dense, and fibrous cap that is its fibrotic component. The higher the
fibrotic component less prone to disruption (less unstable) is the atherosclerotic plaque. The
lipid core is highly thrombogenic. When it makes contact with the blood stream by rupture
of the fibrous cap or endothelial erosion, occurring phenomena of platelet adhesion and ag‐
gregation, thrombin generation and fibrin, with underlying thrombus formation, which rep‐
resents the common starting point of acute coronary syndromes[14].
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Apart from traditional risk factors, numerous evidences have shown an association between
atherosclerosis and genetic variants which should allow in the future, a new understanding
of the molecular mechanisms of cardiovascular disease[15].
3. Schistosomiasis mansoni infection may affect the natural history of
atherogenesis
Infections of Schistosoma mansoni, the adult worms significantly reduced atherogenesis in
apolipoprotein E gene knockout (apoE(-/-)) mice. These effects occurred in tandem with a
lowering of serum total cholesterol levels in both apoE(-/-) and random-bred laboratory
mice and a beneficial increase in the proportion of HDL to LDL cholesterol. The serum cho‐
lesterol-lowering effect is mediated by factors released from S. mansoni eggs, while the pres‐
ence of adult worms seemed to have little or no effect. High levels of lipids, particularly
triacylglycerols and cholesterol esters, present in the uninfected livers of both random-bred
and apoE(-/-)mice fed a high-fat diet were not present in livers of the schistosome-infected
mice[16].ApoE-deficient mice chronically exposed to the eggs of Schistosomamansoni over a
period of 16 weeks showed thattotal serum cholesterol and low-density lipoprotein (LDL)
were reduced in egg-exposed ApoE-deficient mice fed a diet high in cholesterol compared
to unexposed controls. However, exposure to eggs has no effect on atherosclerotic lesion
size or progression in these animals. Macrophages isolated from egg-exposed mice had an
enhanced ability to take up LDL but not acetylated LDL (acLDL). This suggests that schisto‐
some eggs alone may alter serum lipid profiles through enhancing LDL uptake by macro‐
phages, but these changes do not ultimately affect atherosclerotic lesion development[17].
Previous studies have shown that people infected with schistosomiasis have lower levels of
serum cholesterol than uninfected controls. In human beings the first manifestations of car‐
diovascular disease from atherogenesis arise at an advanced stage of atherosclerosis. How‐
ever, patients with hepatosplenic schistosomiasis mansoni have abnormal lipid
peroxidation, with elevated erythrocyte-conjugated dienes implying dysfunctional cell
membranes, and also imply that this may be attenuated by the redox capacity of antioxidant
agents, which prevent accumulation of plasma malondialdehyde (MDA)[18]. These lipid
metabolism changes affect the natural history of atherogenesis including the risk factors.
The alterations in the arterial wall occur during the subclinical period of atherogenesis, char‐
acterized by progressive thickening of the endothelium. This endocrine organ is responsible
for physiological processes that are vital to vascular homeostasis[19].
When risk factors exist, endothelial thickening can be detected already in childhood, and
can be predictive of cardiovascular events in adults[20]-[22]. Since the first anatomopatho‐
logical description, several articles have been published associating ultrasound measure‐
ments (intima-media thickening – the identifiable portion of the endothelium) with
cardiovascular diseases[23].
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tors such as nitric oxide and prostacyclin, and vasoconstrictors such as endothelin, aroused
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molecule, platelet derived growth factor B chain[12],[13].
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lipid core is highly thrombogenic. When it makes contact with the blood stream by rupture
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gregation, thrombin generation and fibrin, with underlying thrombus formation, which rep‐
resents the common starting point of acute coronary syndromes[14].
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mice and a beneficial increase in the proportion of HDL to LDL cholesterol. The serum cho‐
lesterol-lowering effect is mediated by factors released from S. mansoni eggs, while the pres‐
ence of adult worms seemed to have little or no effect. High levels of lipids, particularly
triacylglycerols and cholesterol esters, present in the uninfected livers of both random-bred
and apoE(-/-)mice fed a high-fat diet were not present in livers of the schistosome-infected
mice[16].ApoE-deficient mice chronically exposed to the eggs of Schistosomamansoni over a
period of 16 weeks showed thattotal serum cholesterol and low-density lipoprotein (LDL)
were reduced in egg-exposed ApoE-deficient mice fed a diet high in cholesterol compared
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size or progression in these animals. Macrophages isolated from egg-exposed mice had an
enhanced ability to take up LDL but not acetylated LDL (acLDL). This suggests that schisto‐
some eggs alone may alter serum lipid profiles through enhancing LDL uptake by macro‐
phages, but these changes do not ultimately affect atherosclerotic lesion development[17].
Previous studies have shown that people infected with schistosomiasis have lower levels of
serum cholesterol than uninfected controls. In human beings the first manifestations of car‐
diovascular disease from atherogenesis arise at an advanced stage of atherosclerosis. How‐
ever, patients with hepatosplenic schistosomiasis mansoni have abnormal lipid
peroxidation, with elevated erythrocyte-conjugated dienes implying dysfunctional cell
membranes, and also imply that this may be attenuated by the redox capacity of antioxidant
agents, which prevent accumulation of plasma malondialdehyde (MDA)[18]. These lipid
metabolism changes affect the natural history of atherogenesis including the risk factors.
The alterations in the arterial wall occur during the subclinical period of atherogenesis, char‐
acterized by progressive thickening of the endothelium. This endocrine organ is responsible
for physiological processes that are vital to vascular homeostasis[19].
When risk factors exist, endothelial thickening can be detected already in childhood, and
can be predictive of cardiovascular events in adults[20]-[22]. Since the first anatomopatho‐
logical description, several articles have been published associating ultrasound measure‐
ments (intima-media thickening – the identifiable portion of the endothelium) with
cardiovascular diseases[23].
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The accuracy, reproducibility and rapidity of Doppler ultrasound have made this method a
powerful tool for early diagnosis, as well as in the monitoring of atheroscletrotic lesions and
even when evaluating results in population studies[24].
There are already several well-established risk factors for atherosclerosis, such as hyperten‐
sion, dyslipidemia, smoking and diabetes[25]. However, there are other factors which are
still controversial as to the predictive value of findings. Among those factors, bacterial (C.
pneumoniae, H. pylori), as well as viral (herpes simplex, Epstein-Barr) and parasitic (T.cruzi,
S.mansoni) infections[26].
Schistosomiasis, an endemic disease in several regions in the world and with high preva‐
lence in Pernambuco, Brazil, has been the target of research studies on disease prevention,
clinical and surgical treatments to alleviate the effects of hypertension on the portal system,
hypersplenism and child hypoevolutism[27],[28].
Important alterations have been demonstrated in the lipid profile of those who present with
advanced disease[29]. Speculations are made as to whether those findings could influence
the behavior of the intima-media complex. On the other hand, whether the lipid alterations
in human hepatosplenic schistosomiasis mansoni (HSM) patients interfere with atherogene‐
sis has been investigated[30].
The hepatic lesions in patients with hepatsplenic schistosomiasis mansoni produce changes
in the lipid profile. There is a tendency toward normalization after surgical treatment of por‐
tal hypertension[31]. Since those changes are related to the extent of the lesion to endothelial
cells, Doppler ultrasound is used to assess whether those HSM influence intima-media
thickness in humans[32].
The relation of lipoproteins to atherosclerosis is known[30]. However, several years passed
before an insight was achieved into the association between the biochemical findings and
the structural lesions found in the wall, especially in the vascular endothelium. The partici‐
pation of cells such as lymphocytes, macrophages and monocytes is decisive in the inflam‐
matory component of that disease.
Hypertension, dyslipidemia, diabetes and smoking constitute risk factors already largely as‐
sociated with atherogenesis. The interfaces of atherosclerosis with infections are very com‐
plex. This is due to the mechanisms used by the infectious agents and the different forms of
response from the host organism. Infection and inflammation induce an acute phase re‐
sponse, which, in turn, leads to alterations in lipids and proteins. These changes initially
protect the host from the deleterious effects of bacteria, viruses and parasites; however, if
extended, they could contribute to atherogenesis[33].
Changes take place in the metabolism of total and HDL cholesterol and in their reverse
transport over the course of an infection. The responses are not fully understood, but lipopo‐
lysaccharides (LPS) and cytokines are known to reduce total cholesterol serum levels and
produce various effects in rodents[34].
The incidence of coronary artery disease and stroke is higher in patients with chronic infec‐
tions. Some lesions are supposedly produced by the infectious agent itself, as in the case of
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C. pneumoniae and Cytomegalovirus, while other lesions seem to be induced by humoral
mechanisms, as in the case of H. pylori and chronic urinary, respiratory and oral infec‐
tions[35].
Since atherosclerosis itself is an inflammatory disease, and given that infections induce a
proatherogenic change in lipoproteins, a cycle is started that tends to aggravate the athero‐
sclerotic lesions[36].In certain instances of bacterial infections, beneficial effects can be found
from the alterations in lipoprotein metabolism. The conjugation of LPS to lipoproteins pro‐
tects animals from hypotension, LPS-induced fever and death.
Regarding parasite infestations, complex mechanisms are triggered, since both the direct
action of the parasite and immune reactions induced by its  presence have been demon‐
strated[37].
Atherosclerosis-resistant rats developed early atherosclerotic plaques when infested with
T.cruzi, while rats that were susceptible to atherosclerosis sustained fewer atherosclerotic le‐
sions when infested with S. mansoni. On the basis of those findings, it is postulated that in‐
fection by S. mansoni may produce a protective effect against atherosclerosis[38].
The IMT has been study in infectious processes[39].  The attempt to identify early mark‐
ers of atherosclerosis has been the object of several studies.  The ankle-arm index, which
has been used since the 1970's  to  assess  blood flow to the lower limbs,  has been intro‐
duced in  the  armamentarium of  cardiologists  and atherogenesis  experts  as  a  marker  of
diffuse atherosclerosis[40].
Brachial artery distensibility, coronary flow reserve, pulse wave analysis, pulse wave veloci‐
ty and plethysmography have also been used to detect endothelial dysfunction and also
considered to be risk markers for cardiovascular disease[16].
Some authors have proposed the validation criteria of surrogate markers for clinical anal‐
ysis. They established three conditions for validity: the first is that the marker should be
more sensitive and more readily available than clinical conclusions, in addition to being
easy  to  assess,  preferably  through noninvasive  methods.  Second,  the  causative  relation‐
ship between the marker and the clinical conclusions should be established on epidemio‐
logic  and  pathophysiological  bases,  as  well  as  clinical  studies.  It  is  a  prerequisite  that
patients  with  and  without  vascular  disease  exhibit  differences  in  the  marker  readings.
Third,  in  intervention  studies,  expected  clinical  benefits  (benefit  assessment)  should  be
anticipated  from changes  observed  in  the  markers.  This  last  argument  implies  that  the
development  of  markers  is  not  only  a  matter  of  time/cost.  Moreover,  other  diagnostic
methods  for  measuring  IMT such  as  the  transesophageal  echocardiogram,  intravascular
ultrasound  and  magnetic  resonance  imaging,  in  addition  to  being  more  expensive  and
more invasive, are not appropriate for screening[21],[41].
The Doppler ultrasound scan with an automatic calibrator becomes minimally sonographer-
dependent. Normal limits for IMT measurements have been established as between 0.4 mm
and 1.0 mm, whereas those above 1.5 mm are interpreted as a plaque. The results are imme‐
diately ready for printout or to be saved on an HD or CD-ROM for occasional and future
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The accuracy, reproducibility and rapidity of Doppler ultrasound have made this method a
powerful tool for early diagnosis, as well as in the monitoring of atheroscletrotic lesions and
even when evaluating results in population studies[24].
There are already several well-established risk factors for atherosclerosis, such as hyperten‐
sion, dyslipidemia, smoking and diabetes[25]. However, there are other factors which are
still controversial as to the predictive value of findings. Among those factors, bacterial (C.
pneumoniae, H. pylori), as well as viral (herpes simplex, Epstein-Barr) and parasitic (T.cruzi,
S.mansoni) infections[26].
Schistosomiasis, an endemic disease in several regions in the world and with high preva‐
lence in Pernambuco, Brazil, has been the target of research studies on disease prevention,
clinical and surgical treatments to alleviate the effects of hypertension on the portal system,
hypersplenism and child hypoevolutism[27],[28].
Important alterations have been demonstrated in the lipid profile of those who present with
advanced disease[29]. Speculations are made as to whether those findings could influence
the behavior of the intima-media complex. On the other hand, whether the lipid alterations
in human hepatosplenic schistosomiasis mansoni (HSM) patients interfere with atherogene‐
sis has been investigated[30].
The hepatic lesions in patients with hepatsplenic schistosomiasis mansoni produce changes
in the lipid profile. There is a tendency toward normalization after surgical treatment of por‐
tal hypertension[31]. Since those changes are related to the extent of the lesion to endothelial
cells, Doppler ultrasound is used to assess whether those HSM influence intima-media
thickness in humans[32].
The relation of lipoproteins to atherosclerosis is known[30]. However, several years passed
before an insight was achieved into the association between the biochemical findings and
the structural lesions found in the wall, especially in the vascular endothelium. The partici‐
pation of cells such as lymphocytes, macrophages and monocytes is decisive in the inflam‐
matory component of that disease.
Hypertension, dyslipidemia, diabetes and smoking constitute risk factors already largely as‐
sociated with atherogenesis. The interfaces of atherosclerosis with infections are very com‐
plex. This is due to the mechanisms used by the infectious agents and the different forms of
response from the host organism. Infection and inflammation induce an acute phase re‐
sponse, which, in turn, leads to alterations in lipids and proteins. These changes initially
protect the host from the deleterious effects of bacteria, viruses and parasites; however, if
extended, they could contribute to atherogenesis[33].
Changes take place in the metabolism of total and HDL cholesterol and in their reverse
transport over the course of an infection. The responses are not fully understood, but lipopo‐
lysaccharides (LPS) and cytokines are known to reduce total cholesterol serum levels and
produce various effects in rodents[34].
The incidence of coronary artery disease and stroke is higher in patients with chronic infec‐
tions. Some lesions are supposedly produced by the infectious agent itself, as in the case of
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C. pneumoniae and Cytomegalovirus, while other lesions seem to be induced by humoral
mechanisms, as in the case of H. pylori and chronic urinary, respiratory and oral infec‐
tions[35].
Since atherosclerosis itself is an inflammatory disease, and given that infections induce a
proatherogenic change in lipoproteins, a cycle is started that tends to aggravate the athero‐
sclerotic lesions[36].In certain instances of bacterial infections, beneficial effects can be found
from the alterations in lipoprotein metabolism. The conjugation of LPS to lipoproteins pro‐
tects animals from hypotension, LPS-induced fever and death.
Regarding parasite infestations, complex mechanisms are triggered, since both the direct
action of the parasite and immune reactions induced by its  presence have been demon‐
strated[37].
Atherosclerosis-resistant rats developed early atherosclerotic plaques when infested with
T.cruzi, while rats that were susceptible to atherosclerosis sustained fewer atherosclerotic le‐
sions when infested with S. mansoni. On the basis of those findings, it is postulated that in‐
fection by S. mansoni may produce a protective effect against atherosclerosis[38].
The IMT has been study in infectious processes[39].  The attempt to identify early mark‐
ers of atherosclerosis has been the object of several studies.  The ankle-arm index, which
has been used since the 1970's  to  assess  blood flow to the lower limbs,  has been intro‐
duced in  the  armamentarium of  cardiologists  and atherogenesis  experts  as  a  marker  of
diffuse atherosclerosis[40].
Brachial artery distensibility, coronary flow reserve, pulse wave analysis, pulse wave veloci‐
ty and plethysmography have also been used to detect endothelial dysfunction and also
considered to be risk markers for cardiovascular disease[16].
Some authors have proposed the validation criteria of surrogate markers for clinical anal‐
ysis. They established three conditions for validity: the first is that the marker should be
more sensitive and more readily available than clinical conclusions, in addition to being
easy  to  assess,  preferably  through noninvasive  methods.  Second,  the  causative  relation‐
ship between the marker and the clinical conclusions should be established on epidemio‐
logic  and  pathophysiological  bases,  as  well  as  clinical  studies.  It  is  a  prerequisite  that
patients  with  and  without  vascular  disease  exhibit  differences  in  the  marker  readings.
Third,  in  intervention  studies,  expected  clinical  benefits  (benefit  assessment)  should  be
anticipated  from changes  observed  in  the  markers.  This  last  argument  implies  that  the
development  of  markers  is  not  only  a  matter  of  time/cost.  Moreover,  other  diagnostic
methods  for  measuring  IMT such  as  the  transesophageal  echocardiogram,  intravascular
ultrasound  and  magnetic  resonance  imaging,  in  addition  to  being  more  expensive  and
more invasive, are not appropriate for screening[21],[41].
The Doppler ultrasound scan with an automatic calibrator becomes minimally sonographer-
dependent. Normal limits for IMT measurements have been established as between 0.4 mm
and 1.0 mm, whereas those above 1.5 mm are interpreted as a plaque. The results are imme‐
diately ready for printout or to be saved on an HD or CD-ROM for occasional and future
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comparisons. Questions that might be raised concerning loss of sensitivity with this type of
equipment have already been addressed in a comparison with conventional machines[42].
The carotid artery ensures easy access to the examiner; for its anatomy, as it is a superfi‐
cial  artery and follows a more or less straight path along the cervical  segment,  in addi‐
tion  to  being  a  vessel  with  abundant  elastic  fibers  that  respond  promptly  to
hemodynamic "stress"[23].
A study with populations at difference ages showed that IMT increases at a rate of [IMTmm
= 0.009 x age+0.35], i.e., it is a biological phenomenon that can be quantified[30].
The means for IMT values of common and internal carotids are higher among patients with
some risk factor (hypertension, age and smoking). This pattern occurs in normal subjects
and patients with hepatosplenic schistosomiasis mansoni clinical and surgical treated, but
this phenomenon is not observed in these patients without any treatment[43]. These find‐
ings lend support to the hypothesis that hepatosplenic schistosomiasis mansoni may be a
protective factor against atherogenesis[30].
4. HIV infection may affect the natural history of atherogenesis
Individuals infected with human immunodeficiency virus (HIV) have a different condition
of life of the population free of infection with regard to morbidity and mortality from pre‐
mature atherosclerosis and cardiovascular, and its related complications[44]-[47].
Atherosclerosis is a systemic disorder characterized by the formation of cholesterol plaques,
especially at the level of the intima of the arterial wall. All arteries can be affected, but the
clinical consequences are more important at the level of coronary and carotid arteries of the
lower limbs (LL).
Arterial  disease  is  chronic,  along with coronary artery disease and ischemic stroke,  one
of three clinical manifestations of the same pathophysiological process: atherothrombosis.
The  classic  risk  factors  of  atherosclerosis  are:  smoking,  hypertension  (HTN),  diabetes
mellitus  (DM),  hypercholesterolemia,  and  obesidade[48].  Atherosclerosisisamajor  cause
ofmortality worldwidemobility,  andlow life expectancyis mainly due to heart attack and
stroke(CVA)[49]-[51].
The morbidity and mortality among HIV-infected individuals with advanced disease was
very high until the advent of potent antiretroviral therapy (HAART), which produced an
improvement in quality and increased expectation [52]-[55].
This  therapy,  however  has  been  associated  with  a  variety  of  adverse  effects,  which  in‐
clude metabolic changes such as changes lypodistrophy, insulin resistance, lactic acidosis
and dislipidemia[46],[56]. All these changes are pro-atherogenic and its consequences are
often fatal.  The development of cardiovascular disease in HIV-infected individuals is re‐
lated  to  endothelial  dysfunction.  This  dysfunction  and  accelerated  atherosclerosis  is  a
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consequence  of  HIV  itself  that  activates  the  endothelial  directly  or  indirectly  through
production of citocinas[57].
There is evidence that both pathophysiological HIV to antiretroviral therapy may affect the
profile lipídico[58],[59], insulina resistance[60],[61] and the response of vasodilatação[62].
The increased mortality in individuals with HIV due to cardiovascular events in young pa‐
tients, often without classic risk factors for atherosclerosis, is cause for concern and the sub‐
ject of new studies[44],[46].
Antiretroviral therapy is associated with pro-atherogenic metabolic abnormalities such as
metabolic syndrome, type II diabetes, abnormal distribution of body fat, these conditions al‐
so associated with arterial disease coronariana[63],[64]. Some studies suggest that class of
drugs known as protease inhibitors (PI) can be associated with premature atherosclerosis
and cardiovascular events, vasculares[47]. It is not clear, but what is the real contribution of
ART in HIV and increased risk of cardiovascular disease.
The measurement of intima-media complex (IMT) by ultrasonography (USG) is a nonin‐
vasive marker of early atherosclerosis and may reflect the increased overall cardiovascu‐
lar risk and is associated with increased risk of acute myocardial infarction (AMI) and /
or AVC[65]-[67].
The IMT can be used as a predictor of atherosclerotic disease in coronary arteries independ‐
ently of classical risk factors: age, sex, smoking, hypertension, dyslipidemia, diabetes and
family history of coronary artery disease (CAD). IMTcan be consideredas a markerfor the
evaluation ofatherosclerosissubclínica[68]-[70].
The study using IMT has been performed in patients with acquired immunodeficiency syn‐
drome (AIDS) in the investigation of risk factors for atherosclerosis as an early marker, but
there are few studies prospectivos[71],[72].
In AIDS patients the automatic measurement of MIC performed in right and left common
carotid, with software determining produces the following measures: average, maximum
and minimum (Figure 1). In this same place three manual measurements can be performed.
Thus, it is possible to calculate the arithmetic mean of the measure in manual right and left
common carotid and the maximum and minimum extent (Figure 2). In the right and left in‐
ternal carotid it can be performed as manual. The gold standard can be represented by the
mean of automatic measurements from the right common carotid (RCA) and left common
carotid (LCA)[73],[74]. We have measured population of 50 years AIDS patients, the MIC
was considered thickened if > 0.8 mm[75] was considered the presence of a thickening dem‐
onstrated plate when WCC > 1.5mm[73],[76].
The ankle-brachial index (ABI) is a simple, noninvasive, high predictive value for peripheral
artery disease and has significant association with risk of cardiovascular mortality. It is a
good method to be safe, reproducible, low cost, outpatient use and validated in the general
population. Early diagnosis of atherosclerosis identifies people at high risk for cardiovascu‐
lar events and thus provides effective treatment and control of factors risco[55].
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The carotid artery ensures easy access to the examiner; for its anatomy, as it is a superfi‐
cial  artery and follows a more or less straight path along the cervical  segment,  in addi‐
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= 0.009 x age+0.35], i.e., it is a biological phenomenon that can be quantified[30].
The means for IMT values of common and internal carotids are higher among patients with
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and patients with hepatosplenic schistosomiasis mansoni clinical and surgical treated, but
this phenomenon is not observed in these patients without any treatment[43]. These find‐
ings lend support to the hypothesis that hepatosplenic schistosomiasis mansoni may be a
protective factor against atherogenesis[30].
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Individuals infected with human immunodeficiency virus (HIV) have a different condition
of life of the population free of infection with regard to morbidity and mortality from pre‐
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especially at the level of the intima of the arterial wall. All arteries can be affected, but the
clinical consequences are more important at the level of coronary and carotid arteries of the
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Arterial  disease  is  chronic,  along with coronary artery disease and ischemic stroke,  one
of three clinical manifestations of the same pathophysiological process: atherothrombosis.
The  classic  risk  factors  of  atherosclerosis  are:  smoking,  hypertension  (HTN),  diabetes
mellitus  (DM),  hypercholesterolemia,  and  obesidade[48].  Atherosclerosisisamajor  cause
ofmortality worldwidemobility,  andlow life expectancyis mainly due to heart attack and
stroke(CVA)[49]-[51].
The morbidity and mortality among HIV-infected individuals with advanced disease was
very high until the advent of potent antiretroviral therapy (HAART), which produced an
improvement in quality and increased expectation [52]-[55].
This  therapy,  however  has  been  associated  with  a  variety  of  adverse  effects,  which  in‐
clude metabolic changes such as changes lypodistrophy, insulin resistance, lactic acidosis
and dislipidemia[46],[56]. All these changes are pro-atherogenic and its consequences are
often fatal.  The development of cardiovascular disease in HIV-infected individuals is re‐
lated  to  endothelial  dysfunction.  This  dysfunction  and  accelerated  atherosclerosis  is  a
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consequence  of  HIV  itself  that  activates  the  endothelial  directly  or  indirectly  through
production of citocinas[57].
There is evidence that both pathophysiological HIV to antiretroviral therapy may affect the
profile lipídico[58],[59], insulina resistance[60],[61] and the response of vasodilatação[62].
The increased mortality in individuals with HIV due to cardiovascular events in young pa‐
tients, often without classic risk factors for atherosclerosis, is cause for concern and the sub‐
ject of new studies[44],[46].
Antiretroviral therapy is associated with pro-atherogenic metabolic abnormalities such as
metabolic syndrome, type II diabetes, abnormal distribution of body fat, these conditions al‐
so associated with arterial disease coronariana[63],[64]. Some studies suggest that class of
drugs known as protease inhibitors (PI) can be associated with premature atherosclerosis
and cardiovascular events, vasculares[47]. It is not clear, but what is the real contribution of
ART in HIV and increased risk of cardiovascular disease.
The measurement of intima-media complex (IMT) by ultrasonography (USG) is a nonin‐
vasive marker of early atherosclerosis and may reflect the increased overall cardiovascu‐
lar risk and is associated with increased risk of acute myocardial infarction (AMI) and /
or AVC[65]-[67].
The IMT can be used as a predictor of atherosclerotic disease in coronary arteries independ‐
ently of classical risk factors: age, sex, smoking, hypertension, dyslipidemia, diabetes and
family history of coronary artery disease (CAD). IMTcan be consideredas a markerfor the
evaluation ofatherosclerosissubclínica[68]-[70].
The study using IMT has been performed in patients with acquired immunodeficiency syn‐
drome (AIDS) in the investigation of risk factors for atherosclerosis as an early marker, but
there are few studies prospectivos[71],[72].
In AIDS patients the automatic measurement of MIC performed in right and left common
carotid, with software determining produces the following measures: average, maximum
and minimum (Figure 1). In this same place three manual measurements can be performed.
Thus, it is possible to calculate the arithmetic mean of the measure in manual right and left
common carotid and the maximum and minimum extent (Figure 2). In the right and left in‐
ternal carotid it can be performed as manual. The gold standard can be represented by the
mean of automatic measurements from the right common carotid (RCA) and left common
carotid (LCA)[73],[74]. We have measured population of 50 years AIDS patients, the MIC
was considered thickened if > 0.8 mm[75] was considered the presence of a thickening dem‐
onstrated plate when WCC > 1.5mm[73],[76].
The ankle-brachial index (ABI) is a simple, noninvasive, high predictive value for peripheral
artery disease and has significant association with risk of cardiovascular mortality. It is a
good method to be safe, reproducible, low cost, outpatient use and validated in the general
population. Early diagnosis of atherosclerosis identifies people at high risk for cardiovascu‐
lar events and thus provides effective treatment and control of factors risco[55].
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Figure 1. Medida automática do CMI em CCD
Figure 2. Medida manual do CMI em CCD
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The reduction of the ABI values below 0.9 is associated with a significantly increased cardio‐
vascular risk, particularly by acute myocardial infarction and ischemic stroke, independent
of other factors[77],[78]. The increase in ABI (> 1.3) is due more to changes in arterial compli‐
ance than the stenosis, which would be responsible for a decrease in ABI. The high preva‐
lence of high ABI in patients with HIV may be mediated by the involvement of vascular
elasticity as well as the formation of atheromatous plaques. A meta-analysis of six retrospec‐
tive studies the ABI has been studied in patients with HIV. The populations were selected
with varying criteria and there was no consensus about the risk factors responsible for ab‐
normal ABI. The increased prevalence of ABI was higher than in the general population. In
the population with HIV/AIDS remains whether the high prevalence of altered ABI is asso‐
ciated with increased incidence of cardiovascular events.
We selected 70 cases with HIV in use antirratrovirais (ARV) for at least five years of service
reference in the State of Pernambuco and 70 controls without HIV, matched by sex and age,
which were assessed by automatic measurement of carotid IMT in and ABI. It was taken in‐
to account the classical risk factors of atherosclerosis, anthropometric measurements and
treatment with protease inhibitors (PI). We performed the analysis of homogeneity of
groups. The groups were homogeneous at the 95% confidence.
The ABI was raised in a single patient in the case group (0.7%) and no change in the control
group ABI. The WCC was not thickened in any individual. There was no statistically signifi‐
cant difference between case and control groups with respect to the ABI and the WCC, even
when considering the type of treatment. There was no significant difference between the
groups regarding presence of atheromatous plaques in the common carotid.
Maggi et al. evaluating patients with HIV and advocate the hypothesis that CMI is thick‐
ened more in the HIV group, which use the IP protocol is the cause of the thickening and
that the lesions found in these patients are similar to arteritis and substantially different
from atherosclerotic plaques[66],[69],[71],[72]. The present study does not confirm this hy‐
pothesis of thickening CMI in patients with HIV. In 70 patients there was no thickening in
the common carotid, while also presenting the same classic risk factors for atherosclerosis,
including having more hypercholesterolemia and hypertriglyceridemia than the control
group. One possible explanation for the lack of thickening of the WCC in this population is
the fact that the patients are young (mean 40.5 years), having long-term treatment (mean
8.16 years), have fewer risk factors than other atherosclerosis studies and found to be clini‐
cally stable (84% had an undetectable current CV with current median CD4 670.57) with less
aggression endothelium.
It can be concluded that HIV-infected individuals do not run a higher risk of atherosclerosis
than the control population, taking into consideration the classical risk factors of atheroscle‐
rosis and the specific characteristics of HIV-infected patients.
The result of this study is essential because as the population was very young, phase detec‐
tion of atherosclerotic disease earlier period can be after cutting realized. The follow-up of a
cohort for a new sectional assessment later is very important for early detection of athero‐
sclerosis in HIV patients on antiretroviral therapy.
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The reduction of the ABI values below 0.9 is associated with a significantly increased cardio‐
vascular risk, particularly by acute myocardial infarction and ischemic stroke, independent
of other factors[77],[78]. The increase in ABI (> 1.3) is due more to changes in arterial compli‐
ance than the stenosis, which would be responsible for a decrease in ABI. The high preva‐
lence of high ABI in patients with HIV may be mediated by the involvement of vascular
elasticity as well as the formation of atheromatous plaques. A meta-analysis of six retrospec‐
tive studies the ABI has been studied in patients with HIV. The populations were selected
with varying criteria and there was no consensus about the risk factors responsible for ab‐
normal ABI. The increased prevalence of ABI was higher than in the general population. In
the population with HIV/AIDS remains whether the high prevalence of altered ABI is asso‐
ciated with increased incidence of cardiovascular events.
We selected 70 cases with HIV in use antirratrovirais (ARV) for at least five years of service
reference in the State of Pernambuco and 70 controls without HIV, matched by sex and age,
which were assessed by automatic measurement of carotid IMT in and ABI. It was taken in‐
to account the classical risk factors of atherosclerosis, anthropometric measurements and
treatment with protease inhibitors (PI). We performed the analysis of homogeneity of
groups. The groups were homogeneous at the 95% confidence.
The ABI was raised in a single patient in the case group (0.7%) and no change in the control
group ABI. The WCC was not thickened in any individual. There was no statistically signifi‐
cant difference between case and control groups with respect to the ABI and the WCC, even
when considering the type of treatment. There was no significant difference between the
groups regarding presence of atheromatous plaques in the common carotid.
Maggi et al. evaluating patients with HIV and advocate the hypothesis that CMI is thick‐
ened more in the HIV group, which use the IP protocol is the cause of the thickening and
that the lesions found in these patients are similar to arteritis and substantially different
from atherosclerotic plaques[66],[69],[71],[72]. The present study does not confirm this hy‐
pothesis of thickening CMI in patients with HIV. In 70 patients there was no thickening in
the common carotid, while also presenting the same classic risk factors for atherosclerosis,
including having more hypercholesterolemia and hypertriglyceridemia than the control
group. One possible explanation for the lack of thickening of the WCC in this population is
the fact that the patients are young (mean 40.5 years), having long-term treatment (mean
8.16 years), have fewer risk factors than other atherosclerosis studies and found to be clini‐
cally stable (84% had an undetectable current CV with current median CD4 670.57) with less
aggression endothelium.
It can be concluded that HIV-infected individuals do not run a higher risk of atherosclerosis
than the control population, taking into consideration the classical risk factors of atheroscle‐
rosis and the specific characteristics of HIV-infected patients.
The result of this study is essential because as the population was very young, phase detec‐
tion of atherosclerotic disease earlier period can be after cutting realized. The follow-up of a
cohort for a new sectional assessment later is very important for early detection of athero‐
sclerosis in HIV patients on antiretroviral therapy.
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1. Introduction
Peripheral artery disease is a clinical manifestation of atherosclerosis with significant morbid‐
ity and mortality (Sharma Sharma & Aronow, 2012; Resnick et al. 2004; Diehm et al. 2009).
Despite well-recognized significance of traditional risk factors in the initiation and progression
of the disease, not all causes and mechanisms leading to disease development have been
identified so far. Inflammation, angiogenesis, and endothelial activation are important
processes contributing to the pathogenesis of peripheral arterial disease which are related in
a complex and interdependent manner (Li et al., 2007; Brevetti et al., 2010; Brevetti Get al.,
2003; Brevetti et al., 2008; Findley et al., 2008).
Pathophysiologic events in peripheral artery disease are represented by ishaemic tissue
damage, and the severity of clinical presentation depends on the site and extent of stenosis
and availability of collateral circulation (Meru et al., 2006; Cooke 2008). Angiogenesis and
arteriogenesis (collateral growth) are different forms of vessel growth, which contribute to the
compensation for an occluded artery. Hypoxia is known to trigger angiogenesis in the setting
of ischaemia, whereas fluid shear stress might be the most important stimulus for initiation of
collateral growth. Besides these specific initial triggers, angiogenesis and collateral growth
share growth factors, chemokines, proteases, and inflammatory cells, which play different
roles in promoting and refining these processes ( Silvestre et al., 2008).
During an tissue ischemia,  hypoxia-inducible factor 1 (HIF-1)  drives transcriptional  acti‐
vation of hundreds of genes involved in vascular reactivity, angiogenesis,  arteriogenesis,
the  mobilization  of  bone  marrow-derived  angiogenic  cells  (Rey  &  Semenza  2010).  The
current  evidence  suggests  considerable  overlap between the  molecular  mechanisms and
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physical  stimuli  that trigger angiogenesis and inflammation (Costa et  al.,  2007).  Further‐
more, there is compelling evidence that HIF-1 contributes to both processes by regulating
angiogenesis  and  functions  of  inflammatory  cells.  Many  inflammatory  stimuli  can  acti‐
vate the angiogenic programme of endothelial cells. Inflammatory cells, especially mono‐
cytes/macrophages  secrete  many angiogenic  factors  such as  vascular  endothelial  growth
factor (VEGF), CXCL8 (interleukin-8), granulocyte colony stimulating factor, transforming
growth factor-α and β, platelet-derived growth factor, tumor necrosis factor-α, and pros‐
taglandins. The angiogenic factors bind to cognate receptors which are expressed on the
surface  of  vascular  endothelial  cells  and  vascular  pericytes/smooth  muscle  cells.  Recep‐
tor–ligand interaction activates  these  cells  and promotes  the  angiogenic  response.  Com‐
munication  between  endothelial  cells  and  monocytes/macrophages  appears  to  be
bidirectional,  because  endothelial  cell–secreted  factors  also  induce  chemotaxis  and  in‐
creased angiogenic activity in monocytes/macrophages, thus initiating a positive feedback
cycle (Shireman, 2007).
The angiogenesis are tightly regulated in a complex balance between pro- and anti-angiogenic
mechanisms (Carmeliet, 2003; Otrock et al., 2007). The most important proangiogenic growth
factors are VEGF and angiopoietins. VEGF and angiopoietins, acting as the modulators of
endothelial activation via receptor tyrosine kinase Tie-2, are important for angiogenesis and
vascular remodeling. VEGF increases microvascular permeability and induces the prolifera‐
tion, migration, and differentiation of endothelial cells (Hoeben et al., 2009; Stuttfeld &,
Ballmer-Hofer, 2009; Olsson et al., 2006). Angiopoietin-2 is a natural endogenous antagonist
of the Tie-2, which acts as an autocrine negative regulator of endothelial function (Augustin
et al., 2009; Scharpfenecker et al., 2004; Fiedler & Augustin, H2006; Fukuhara et al., 2010). In
the presence of VEGF, it mounts an inflammatory response by endothelial activation and
induction of permeability, and in the absence of VEGF, it destabilizes the existing vessels and
leads to vascular regression. Soluble receptors of angiogenic growth factors which are being
released to circulation can act as the inhibitors of angiogenesis and, in some cases, may correlate
with the disease severity independently of altered haemodynamics (Findley et al., 2008).
The findings of the large prospective investigations have confirmed the significance of high-
sensitivity C-reactive protein (hs-CRP) as a marker of progression, functional activity, and
adverse cardiovascular outcome in patients with peripheral artery disease (Abdellaoui & Al-
Khaffaf, 2007).
Platelet activating factor acetylhydrolase (PAF-AH; E.C. 3.1.1.47) also named lipoprotein-
associated  phospholipase  A(2)  (Lp-PLA(2))  is  a  novel  inflammatory  biomarker  that  has
an active role in atherosclerotic development and progression. This enzyme is character‐
ized by its  ability  to  specifically  hydrolyze  the  short  acyl  group at  the  sn-2  position of
the phospholipids in oxidized LDL, which leads to production of the pro-inflammatory,
atherogenic  by-products  lysophosphatidylcholine  and  oxidized  nonesterified  fatty  acids.
These bioactive lipid mediators act as chemoattractants for monocytes, impair endothelial
function,  disrupt  plasma membranes,  and induce  apoptosis  in  smooth muscle  cells  and
macrophages. Epidemiologic studies demonstrate that elevated circulating levels of PAF-
AH predict an increased risk of myocardial infarction and stroke, whereas histologic ex‐
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amination of diseased human coronary arteries reveals intense presence of the enzyme in
atherosclerotic  plaques  that  are  prone to  rupture.  The biological  role  of  PAF-AH in the
development of  peripheral  arterial  disease is  controversial  because substrates  and prod‐
ucts  of  the  catalytic  reactions  implicating  PAF-AH  have  proatherogenic  properties  (Za‐
lewski &, Macphee, 2005; Gazi et al.,  2005; Srinivasan & Bahnson, 2010; Tsimikas et. Al.,
2007; Münzel & Gori, 2009; Ballantyne et al., 2007; Daniels et al., 2008; Garza et al., 2007;
Koenig et al., 2004).
The hypothesis set out in this investigation is that PAF-AH, as a novel biomarker of inflam‐
mation, and VEGF, Ang-2, and its receptor Tie-2, as new biomarkers of angiogenesis, play a
significant role in the development and progression of peripheral artery disease. The aim of
this study was to investigate the association of the catalytic concentrations of platelet activating
factor acetylhydrolase (PAF-AH), the concentrations of VEGF, angiopoietin 2 (Ang-2) and its
receptor Tie-2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology
domains), as novel biomarkers of inflammation and angiogenesis with the lipid status and
CRP, as a nonspecific marker of inflammation and cardiovascular risk factor in patients with
peripheral arterial disease and matched control group. In the group of patients with peripheral
arterial disease, the relationship between the biochemical parameters under study and the
anatomical extent of peripheral arterial atherosclerotic changes, will be explored, and those
will be evaluated through their potential clinical utility as novel diagnostic and prognostic
tools in peripheral arterial atherosclerosis.
2. Patients and methods
2.1. Patients
The study included 110 patients, 19 women and 91 men, with clinically and angiographically
confirmed diagnosis of peripheral arterial disease. The study population was referred to the
Digital subtraction angiography (DSA) in order to determine the precise extent and localization
of peripheral limb atherosclerosis and assess the technical possibility to perform percutaneous
transluminal angioplasty (PTA). Based on the angiographic findings, for the purpose of the
present investigation the angiographic score was assessed for each patient. The angiographic
score takes into consideration the extent (percentage of vessel lumen reduction) and diffusion
of peripheral arterial disease (involved segments of vascular tree). The distal aorta plus 10
segments (common iliac artery, external iliac artery, common femoral artery, profunda femoral
artery, superficial femoral artery, popliteal artery, truncus tibiofibularis, anterior tibial artery,
posterior tibial artery and fibular artery) on each side were scored on the basis of vessel lumen
reduction: 1 if stenoses involved a reduction in the vessel lumen of <50%, 2 if stenoses involved
50 to 99% reduction, and 3 if total occlusion was present. The sum of the points assigned to
each of these arteries was called the angiographic score.
The control group consisted of 118 patients, 61 female and 57 male with suspected symptoms
of peripheral arterial disease referred to Doppler examination. At the Doppler examination,
all of them had normal triphasic waveforms of the peripheral arteries.
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physical  stimuli  that trigger angiogenesis and inflammation (Costa et  al.,  2007).  Further‐
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All Doppler and DSA procedures were performed at the Institute for Diagnostic and Inter‐
ventional Radiology of the Merkur University Hospital. Doppler examinations were per‐
formed at a center of excellence with more than 3,000 examinations performed per year. DSA
was performed by an experienced vascular interventional radiologist. All participants gave
their informed written consent. This study was approved by the Ethics Committee of the
Merkur University Hospital, Zagreb, Croatia.
2.2. Samples
Blood samples were taken under controlled pre-analytical conditions in the morning after 12-
h fast. Serum was separated by centrifuging the samples at 4°C at 3000 rpm for 15 minutes.
2.3. Methods
2.3.1. The lipid status and CRP
Analytical methods for measurement of the lipid status, including serum triglyceride, total
cholesterol, LDL and HDL-cholesterol concentrations as well as CRP used in this study have
been accredited according to ISO 15189, Medical laboratories - Particular requirements for
quality and competence (ISO 15189, 2008) (Flegar-Meštrić et al., 2010). All measurements were
performed on fresh sera on the day of blood collection using standard commercial kits
(Olympus Diagnostic GmbH, Hamburg, Germany) on the Olympus AU 600 analyzer (Olym‐
pus Mishima Co., Ltd., Shizuoka, Japan). Serum triglyceride and total cholesterol were
measured by enzymatic PAP- method. HDL cholesterol was measured with direct method
based on selective inhibition of the non-HDL fractions by means of polyanions. A homogene‐
ous assay for the selective measurement of LDL cholesterol in serum was used. The index of
atherosclerosis and the established risk factor were calculated as the ratio of LDL cholesterol
to HDL cholesterol and total cholesterol to HDL cholesterol. CRP concentrations were
determined by high-sensitivity latex-enhanced immunoturbidimetric assay.
2.3.2. The catalytic concentrations of PAF-AH
The catalytic concentrations of PAF-AH were determined in serum by spectrophotometric
method described by Kosaka T. et al. (2000) using the AZWELL Auto PAF-AH Assay Kits
(AZWELL Inc., Osaka, Japan) on a biochemical analyzer Olympus AU600 (Olympus Mishima
Co., Ltd., Shizuoka, Japan). Serum samples were kept frozen at -80°C until the day of analysis.
PAF-AH hydrolyzes the sn-2 position of the substrate (1-myristoyl-2-(4-nitrophenylsuccinyl)
phosphatidylcholine), producing 4-nitrophenyl succinate. This compound immediately
degrades in aqueous solution and liberates 4-nitrophenol. In the first phase, 2 µL of serum was
added to 240 µL of 200 mmol/L HEPES (N-2-hydroxyethylpiperazine–N´-2-ethanesulfonic
acid) buffer (Reagent 1), pH 7.6 and pre-incubated at 37ºC for 5 min. The reaction was started
by adding 80 µL of 20 mmol/L citric acid monohydrate buffer, pH 4.5 containing 90 mmol/L
1-myristoyl-2-(4-nitrophenylsuccinyl)phosphatidylcholine (Reagent 2). The liberation of 4-
nitrophenol was measured by reading differences in absorbance at 405 nm (main wavelength)
and 505 nm (subwavelength) between 1 and 3 minutes after addition of the substrate. The
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catalytic concentrations of PAF-AH are expressed in international units per liter of serum and
standardized against concentration of LDL-cholesterol.
2.3.3. The concentrations of angiogenesis biomarkers: VEGF, Ang-2 and Tie-2 receptor
Commercially available ELISA kits for VEGF (DVE00), Ang2 (DANG 20) and Tie2 (DTE 200)
were purchased from R&D Systems (Minneapolis, MN, USA) and used according to the
manufacturer’s instruction. Serum samples were kept frozen at -80°C until the day of analysis.
Briefly, the microtitre plates were coated with monoclonal antibodies specific for either VEGF-
A, Ang-2 or Tie-2 and the first step was to add standards and samples to the wells. During the
following incubation period, the VEGF-A, Ang-2 or Tie-2 present in standards and samples
were bound to the immobilized antibody. After a thorough wash, an a horseradish peroxidase-
linked polyclonal antibody specific for VEGF, Ang-2 or Tie-2 was pipetted into the wells and
following a second incubation and wash step a substrate solution was added and colour
developed in proportion to the amount of VEGF-A, Ang-2 or Tie-2. After further washings to
remove any unbound antibody–enzyme reagent, tetramethylbenzidine was added. The colour
development was subsequently stopped and the intensity of colour was measured by using
Stat Fax®2100, Microplate reader, Awareness Technology Inc., Palm City, FL, USA. The values
were calculated using a standard curve generated with specific standards provided by the
manufacturer. The detection limit for VEGF, Ang-2 and Tie-2 was 9 ng/L, 8,3 ng/L, and 14 ng/
L, respectively. The intra-assay and interassay coefficients of variation were in the range given
by the manufacturer <6,7% and <8,8% for VEGF, < 6,9% and <10,4% for Ang-2 and< 5,3% and
<8,5% for Tie-2 receptor.
2.4. Statistical analysis
Statistical analyses were performed using the SPSS software package for Windows, version 13
(SPSS Inc, Chicago, IL, USA). Descriptive analyses were performed and data were presented
as mean, median, S.D. and percentile. Normal distribution of the study variables was tested
using Kolmogorov–Smirnov test. Student t test and Mann-Whitney U test or the Kruskal–
Wallis test applied according to the normal or non-normal distribution. Spearman coefficient
of correlation was calculated to evaluate relationships between different variables.
3. Results
3.1. Patients
Demographic and clinical characteristics of the participants are shown in Table 1.
3.2. The lipid status and CRP
The patients had significantly higher concentrations of CRP, triglyceride, index of atheroscle‐
rosis, the ratio of total and HDL cholesterol, and lower concentrations of total, LDL and HDL-
cholesterol (Table2).
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Age (years), x±sd 64,33 ± 9,79 59,11± 7,31 P<0,001
Male sex, n (%) 91 (83%) 57 (48%) P<0,001
Body mass index (kg/m2), x±sd 26,63 ± 4,04 26,51± 3,08 P = 0,795
Systolic blood pressure >140 mm Hg, n(%) 74 (67%) 0 P<0,001
Diastolic and systolic blood pressure >90 mm
Hg, n (%)
30 (27%) 0 P<0,001
Diabetes, n (%) 39 (35%) 0 P<0,001
Active smokers, n (%) 49 (45%) 13 (11%) P<0,001
Hypolipemic therapy, n (%) 64 (58%) 0 P<0,001
Antihypertensive therapy, n (%) 69 (63%) 0 P<0,001
Cerebrovascular simptoms, (%) 11 (10%) 0 P<0,001
Coronary artery disease symptoms, n (%) 26 (24%) 0 P<0,001
Table 1. Demographic and clinical characteristics of the study groups: patients with peripheral arterial disease (PAD)








Triglyceride (mmol/L) 1,89 (1,30-2,36) 1,42 (1,03-1,76) <0,001
Total cholesterol (mmol/L) 5,45 (4,68-6,10) 6,35 (5,66-6,89) <0,001
HDL-cholesterol (mmol/L) 1,10 (0,98-1,30) 1,60 (1,39-1,81) <0,001
LDL- cholesterol (mmol/L) 3,30 (2,70-3,90) 3,96 (3,40-4,55) <0,001
CRP (mg/L) 3,70 (1,78-7,40) 1,40 (0,60-2,43) <0,001
Mann–Whitney's tests
Table 2. The lipid status and CRP concentrations in the patients with peripheral arterial disease (PAD) and controls.
Data are given as median (interquartile range).
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3.3. The catalytic concentrations of PAF-AH
The catalytic concentrations of PAF-AH did not differ between the two groups, while LDL
standardized catalytic concentrations of PAF-AH (U/mmol) showed significant difference
(Table 3). The catalytic concentrations of PAF-AH were higher in men than in women in control
subjects (Table 4.), whereas no gender difference was observed in patients with peripheral
arterial disease (Table 5.).
A significant difference in the catalytic concentrations of PAF-AH was found between subjects
on lipolythic therapy and subjects off therapy (P=0,032), with the median concentration of PAF-
AH in subjects off therapy being higher than that observed in subjects on lipolythic therapy:
425, interquartile range 351-494 U/L vs 364, interquartile range, 316-427 U/L. There was no
difference in catalytic concentrations of PAF-AH between smokers and non-smokers, diabetic
and nondiabetic subjects nor between the subjects on antihypertensive therapy and subjects
off therapy.
A statistically significant correlation was found between the catalytic concentration of PAF-








PAF-AH (U/L) 405 (330-471) 406 (359-479) 0,591
PAF-AH/LDL (U/mmol ) 121 (107-139) 98 (86-120) <0,001
Mann–Whitney's tests
Table 3. The catalytic concentrations of PAF-AH in the patients with peripheral arterial disease (PAD) and control







PAF-AH (U/L) 459 (383- 519) 385 (319-437) 0,005
PAF-AH/LDL (U/mmol ) 121 (95-137) 92 (79-103) <0,001
Mann–Whitney's tests
Table 4. The catalytic concentrations of PAF-AH in the male and female control subjects. Data are given as median
(interquartile range).
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3.3. The catalytic concentrations of PAF-AH
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PAF-AH/LDL (U/mmol ) 121 (95-137) 92 (79-103) <0,001
Mann–Whitney's tests
Table 4. The catalytic concentrations of PAF-AH in the male and female control subjects. Data are given as median
(interquartile range).









PAF-AH (U/L) 405 (331- 477) 409 (329-442) 0,722
PAF-AH/LDL (U/mmol ) 123 (108-141) 110 (100- 119) 0,031
Mann–Whitney's tests
Table 5. The catalytic concentrations of PAF-AH in male and female patients with peripheral arterial disease. Data are






r P r P
Triglyceride (mmol/L) 0,33 0,001 0,41 0,001
Total cholesterol (mmol/L) 0,70 <0,001 0,32 0,010
HDL-cholesterol (mmol/L) -0,22 0,035 -0,33 0,009
LDL- cholesterol (mmol/L) 0,70 <0,001 0,33 0,009
CRP (mg/L) -0,09 0,371 -0,06 0,617
Table 6. Relationships between the catalytic concentrations of PAF-AH and serum lipids parameters and CRP
concentrations in the study groups: patients with peripheral arterial disease (PAD) and controls
3.4. Serum VEGF, Ang-2 and Tie-2 concentrations
The concentration of VEGF did not differ significantly between groups (Figure 1., Table 7.).
The patients had higher concentrations of Ang-2 and Tie-2 receptor. (Figure 2.,3., Table 7.).
A significant difference in the concentrations of VEGF was found between diabetic and
nondiabetic subjects (P= 0,006), with the median (interquartile range) concentration of VEGF
in diabetics being higher than that observed in nondiabetic subjects: 358 (210-463) vs. 197
(130-335) ng/L. There was no difference in concentrations of VEGF, Ang-2, and Tie-2 receptor
between smokers and non-smokers, nor between the subjects on lipolythic and antihyperten‐
sive therapy and subjects off therapy. All three serum biomarkers of angiogenesis correlated
with the CRP concentrations (Table 8). The concentrations of HDL- cholesterol, VEGF, Ang-2,
and Tie-2 were statistically significantly different among the subjects with various cardiovas‐
cular risk according to CRP concentrations (Table 9.). Post hoc tests (Mann–Whitney's test)
suggested a significant difference in HDL -cholesterol values between the low risk subjects
(CRP<1,0 mg/L) compared with the moderate (CRP between 1,0-3,0 mg/L) (P=0,004) and high
risk (P=0,011) subjects (CRP >3,0 mg/L). The subject groups of moderate and high cardiovas‐
cular risk did not differ significantly in the HDL cholesterol concentration (P=0,666). Statisti‐
cally significant difference was found in the concentrations of VEGF (P=0,011), Ang-2 (P<0,001),
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and Tie-2 receptor (P=0,005) between low and high risk subjects, as well as in the concentrations
of VEGF (P=0,012), Ang-2 (P<0,001), and Tie-2 receptor (P=0,02) between the moderate and
high cardiovascular risk subjects, whereas there were no statistically significant differences in
the concentrations of VEGF (P=0,377), Ang-2 (P=0,438), and Tie-2 receptor (P=0,673) between
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PAF-AH (U/L) 405 (331- 477) 409 (329-442) 0,722
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Mann–Whitney's tests
Table 5. The catalytic concentrations of PAF-AH in male and female patients with peripheral arterial disease. Data are
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Figure 2. Comparison of Ang-2 concentrations (median, interquartile range) in the patients with peripheral arterial
disease (PAD) and control subjects.
Biochemical parameters (units) VEGF( ng/L) Ang-2 (ng/L) Tie-2 (μg/L)
r P r P r P
Triglyceride (mmol/L) 0,01 0,955 -0,07 0,489 0,02 0,861
Total cholesterol (mmol/L) -0,13 0,182 -0,02 0,839 0,08 0,424
HDL-cholesterol (mmol/L) -0,26 0,006 -0,14 0,134 0,03 0,735
LDL- cholesterol (mmol/L) -0,05 0,581 0,01 0,955 0,01 0,909
CRP (mg/L) 0,45 <0,001 0,36 <0,001 0,25 0,008
Table 8. Spearman coefficient of correlation between the lipid profile, CRP and biomarkers of angiogenesis in patients
with peripheral arterial disease (n=110).
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Figure 4. Correlation between serum concentrations of VEGF and CRP in patients with peripheral arterial disease.













Figure 3. Comparison of Tie-2 concentrations (median, interquartile range) in the patients with peripheral arterial dis‐
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Figure 5. Correlation between serum concentrations of Ang-2 and CRP in patients with peripheral arterial disease.
Sperman coefficient of correlation r= 0,36; P<0,001.
Figure 6. Correlation between serum concentrations of Tie-2 and CRP in patients with peripheral arterial disease.
Sperman coefficient of correlation r= 0,25; P=0,008.
3.5. The relationship between the biochemical parameters under study and the anatomical
extent of peripheral arterial atherosclerotic changes
None of the biochemical parameters investigated correlated with the angiographic score as a
measure of the anatomic extent of atherosclerotic alterations in the peripheral arteries.
(Table 10). From among the traditional risk factors, only the subject age correlated significantly
with the angiographic score (r=0.33; P<0,001). The patients with diabetes had a statistically
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significant increase in the score compared with nondiabetic subjects (13.77 ± 6.67 compared




Triglyceride (mmol/L) -0,13 0,167
Total cholesterol (mmol/L) -0,14 0,156
HDL-cholesterol (mmol/L) 0,06 0,539
LDL- cholesterol (mmol/L) -0,12 0,208
CRP (mg/L) 0,07 0,461
VEGF (ng/L) 0,08 0,406
PAF-AH (U/L) -0,08 0,450
Ang-2 (ng/L) 0,04 0,684
Tie-2 (μg/L) 0,13 0,171
Table 10. Spearman coefficient of correlation between the biochemical parameters and angiographic score in
patients with peripheral arterial disease (n=110).
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PAF-AH (U/L) 350 (294-458) 417 (355-468) 399 (322-480) 0,452
Table 9. Biochemical parameters in the patients with peripheral arterial disease (PAD) according to CRP
concentrations as a cardiovascular risk marker. Levels of CRP below 1mg/L are considered low; levels of 1 - 3 mg/L are
considered moderate and levels greater than 3 mg/L are considered high risk. Data are given as median (interquartile
range).
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Peripheral artery disease is a systemic manifestation of atherosclerosis with significant
morbidity and mortality. Pathophysiological processes implicated in the development,
progression, and complications of the disease are complex and interdependent and include
interactions between genetic and environmental factors. Pathophysiological events associated
with peripheral artery disease include tissue ischaemia, and the severity of clinical presentation
is dependent of the site and extent of peripheral arterial stenotic-occlusive changes and the
availability of collateral circulation. Ischaemia incites a cascade of biochemical reactions,
leading directly or indirectly to endothelial homeostasis disturbance. Dysfunctional endothe‐
lium is incapable of maintaining adhesiveness coagulation neutrality within the circulating
blood, or regulating tonic arterial activity. In addition to disturbing vessel movements and
promoting atherosclerosis formation, endothelium actively modulates the architecture of
already present atherosclerotic plaques and increases vulnerability of the lesions which thus
become prone to rupture and lead directly to the development of thromboembolic incidents.
The role of the new biomarkers of inflammation, thrombosis, lipoprotein metabolism and
oxidative stress, which are involved in the regulation of vascular homeostasis, is under an
intensive investigation aimed at earlier detection and better understanding of the aetiology
and progression of peripheral artery disease, as well as development of new therapeutic
possibilities.
The catalytic concentrations of PAF-AH did not differ significantly between the subjects and
the control group, contrary to their standardized catalytic concentrations (PAF-AH/LDL)
which were statistically significantly higher (<0,001) in the subjects analyzed compared with
the control group. The catalytic levels of PAF-AH were significantly different between the
genders in the control group, females (n=36) having lower values than males (n=28), which is
consistent with the literature data (Winkler et al., 2005; Iribarren, 2010). Moreover, females also
had lower PAF-AH standardized catalytic concentrations in both groups studied. Changes in
the PAF-AH catalytic levels depend on the concentrations of lipid status parameters, whereat
the PAF-AH catalytic concentrations show a statistically significant positive correlation with
the concentration of triglicerides, total and LDL cholesterol, the atherosclerosis index, and the
total/HDL cholesterol ratio. Statistically significant negative correlation was found between
the catalytic concentration of PAF-AH and the concentration of HDL cholesterol in the control
group, which is consistent with literature data (Winkler et al., 2005; Flegar-Meštrić et al.,
2003; Kamisako et al., 2003; Flegar-Meštrić et al., 2008; Flegar-Meštrić et al, 2012). PAF-AH
catalytic levels did not correlate with the CRP concentration in either of the groups examined.
The results of the present study are consistent with our previous results obtained for the
patients with lesions of the cerebral arteries (Flegar-Meštrić et al., 2003; Flegar-Meštrić et al.,
2008; Flegar-Meštrić et al., 2012). However, in this investigation, we failed to confirm our
previous results in 182 patients with peripheral arterial disease in whom PAF-AH catalytic
concentrations were significantly higher compared with the control group (Perkov et al.,
2010). The differences in the results obtained can be explained by the differences in the number
of patients included in the analysis. Furthermore, the PAF-AH catalytic concentrations are in
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a significant positive correlation with the concentrations of triglicerides, total and LDL
cholesterol. Thus, changes in enzymatic acitivities may also result from the changed concen‐
trations of lipid parameters, particularly if standardized catalytic PAF-AH concentrations are
observed in relation to LDL cholesterol.
The development of vascular endothelial dysfunction is a key mechanism linking the risk
factors and atherosclerosis, and it plays an important role in the pathophysiology of peripheral
artery disease ( Brevetti et al., 2010). Vascular remodeling, as an adaptive response to haemo‐
dynamic and biochemical stressors, is characterized by progressive structural and functional
alterations in blood vessel walls, preceding the development of a cardiovascular disease.
Recent investigations suggest that a crucial role in the regulation of vascular homeostasis is
played by the Tie ligand receptor system. Some smaller scale clinical trials have revealed that
the concentrations of Ang-2, Tie-2, or both, are found in the patients with peripheral arterial
disease (Findley et al., 2008), congestive heart failure (Chong et al., 2004), acute coronary
syndrome (Lee et al., 2004), hypertension (Lim et al., 2004), and that they have a predictive
ability for myocardial infarction (Patel et al., 2005).
In our investigation, the serum concentrations of Ang-2 and its tyrosine kinase receptor, Tie-2,
in the subjects analyzed were statistically significantly higher compared with those in the
control subjects, which is in agreement with the results by Findley et al., (2008) (8). However,
contrary to their results, the VEFG concentrations were not found to be statistically signifi‐
cantly different between our groups. The above mentioned differences in the results may be
accounted for by the great biological variability observed for VEGF. In fact, it is well known
that interindividual and intraindividual variability of VEFG differ significantly depending on
the kind of material used. Analysis samples include serum, whole blood, and plasma. The
intraindividual variation of VEGF in serum, plasma, and whole blood is 10.7%, 14.1%, and
14.1%, respectively, and the interindividual variation of VEGF in serum, whole blood, and
plasma is 47.6%, 28.8%, and 18.1%, respectively (Meo et al., 2005). The greater intraindividual
variability in the whole blood is impacted by the release of VEGF from lymphocytes, granu‐
locytes, monocytes, and megakariocytes, variability also being dependent on the process of
leukocyte lysis, irrespective of the use of standardized methods (Meo et al., 2005) In light of
the potential clinical utility of VEGF in the prognosis, patient selection, and follow-up of anti-
VEFG therapeutic effects, Kong et al., (2008) (49) have constructed the reference intervals for
VEFG in the serum and plasma of the population of the Republic of North Korea using the
ELISA method with R&D Systems reagents. The reference intervals were calculated in 131
subjects, aged 20 to 78 years (68 males and 63 females). Reference intervals differ considerably
in serum and plasma, whereat the values in serum are ten- to twenty eight- fold higher than
those in plasma.
Moreover, plasma concentrations of VEGF depend on the kind of anticoagulant, with the
values being considerably higher when determined by EDTA as an anticoagulant than when
determined using heparin as an anticoagulant. In addition to VEGF, concentrations of Ang-2
and Tie-2 also statistically significantly differ according to gender and kind of material used
(Lieb et al., 2010).
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From among the parameters analyzed, only VEGF showed a statistically significant negative
relationship with age in the control subjects. The Ang-2 concentrations were statistically
significantly higher in the control group females. Other parameters were not statistically
significantly different between male and female subjects of the groups studied.
The levels of VEGF, Ang-2, and Tie-2 determined in the serum of the control group were
within the value range for healthy individuals set out by the manufacturer and other au‐
thors using the same method and reagent from the same manufacturer (Lieb et al., 2010;
Nylaende et al., 2006).
A significant difference in the concentrations of VEGF was found between diabetic and
nondiabetic subjects, with the median concentration of VEGF in diabetics being higher than
that observed in nondiabetic subjects. There was no difference in concentrations of VEGF,
Ang-2, and Tie-2 receptor between smokers and non-smokers, nor between the subjects on
lipolythic and antihypertensive therapy and subjects off therapy.
In the patients with peripheral arterial disease, VEGF significantly correlated with CRP (r=0,45,
P<0.001) and HDL cholesterol (r= - 0,26, P=0,006). Angiopoietin-2 significantly correlated with
CRP (r=0,36, P<0,001), as well as Tie-2 which showed a weak but significant association with
CRP (r=0,25, P=0,008).
Because all three markers of angiogesis correlated with the CRP concentration in the group
studied, compared with the controls, and a correlation between the concentrations of VEGF
and HDL cholesterol was found, we examined whether the concentrations of the biochemical
parameters under study differed depending on the CRP concentration as a cardiovascular risk
factor. The concentrations of HDL- cholesterol, VEGF, Ang-2, and Tie-2 were statistically
significantly different among the subjects with various cardiovascular risk profiles, with the
HDL -cholesterol values being significantly higher in the low risk subjects (CRP<1,0 mg/L)
compared with the moderate (CRP between 1,0-3,0 mg/L) (P=0,004) and high risk (P=0,011)
subjects (CRP >3,0 mg/L). The subject groups of moderate and high cardiovascular risk did
not differ significantly in the HDL cholesterol concentration (P=0,666). Statistically significant
difference was found in the concentrations of VEGF (P=0,011), Ang-2 (P<0,001), and Tie-2
receptor (P=0,005) between low and high risk subjects, as well as in the concentrations of VEGF
(P=0,012), Ang-2 (P<0,001), and Tie-2 receptor (P=0,02) between the moderate and high
cardiovascular risk subjects, whereas there were no statistically significant differences in the
concentrations of VEGF (P=0,377), Ang-2 (P=0,438), and Tie-2 receptor (P=0,673) between the
groups of low and moderate cardiovascular risk subjects. The results are suggestive of an
association between inflammation and angiogenesis in peripheral arterial disease.
In this investigation, no association was found of the biochemical parameters under study,
namely, triglycerides, total, HDL-, LDL-cholesterol, CRP, and novel biomarkers of inflamma‐
tion (PAF-AH) and angiogenesis (VEGF, Ang-2, and Tie-2 receptor) with the angiographic
score as a measure of the anatomic extent of atherosclerotic alterations in the peripheral
arteries.
It has been well documented that inflammation is implicated in all stages of the atherosclerotic
process. The role of CRP, as a nonspecific marker of inflammation and cardiovascular risk
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factor in the development and progression of atherosclerosis, is extensively investigated.
Tzoulaki et al., (2005), in a large prospective trial nested within the Edinburgh Artery Study
confirmed the role of CRP, interleukin-6 (IL-6), and intercellular adhesion molecule (ICAM)
in the progression of peripheral artery disease in the general population. The trial included
1582 individuals, ranging in age 55 to 75 years, and atherosclerotic progression was defined
as reduction in the ankle brachial index (ABI) over the period of 5 and 12 years. In the
investigation of the patients with peripheral arterial disease who had ABI<0.90, the CRP levels
greater than 3.0 mg/L had an additive predictive value to risk assessment for adverse cardio‐
vascular events (Khawaja & Kullo, 2009). Although in the clinical practice, ABI measurement
is considered a simple method of assessing peripheral artery disease progression, and the ABI
values correlate well with the degree of peripheral arterial atherosclerotic changes as measured
using the digital subtraction angiography method, these two methods represent different
aspects of severity assessment of peripheral arterial disease, and cannot be directly compared
( Nylaende et al., 2006). Nylaende et al., (2006) evaluated the relationship between inflamma‐
tory markers and the severity of peripheral artery disease assessed on the basis of the angio‐
graphic score and ABI determined with and without Treadmill test. The study was conducted
in 127 patients, range 45-79 years, with the simptoms of intermittent claudication in whom the
angiographic score was determined based on the angiographic criteria for haemodynamically
significant stenosis. The results of their study demonstrated significant associations of MCP-1,
CD40L, IL-6, and TNF-alpha with the angiographic score contrary to the concentrations of
CRP, IL-10, E-selectin, P-selectin, ICAM-1, and VCAM-1 for which no significant associations
with the angiographic score were observed. ICAM-1 and IL-6 showed a statistically significant
correlation with the maximum walking distance on the treadmill, and neither of the markers
under study correlated with the ABI. Based on the available data, this is the only investigation
into the association between the inflammation marker and the extent of angiographically
detected atherosclerotic alterations in the patients with peripheral aterosclerosis. A substantial
number of studies have investigated the correlation between the marker of inflammation and
the degree of angiographically demonstrated atherosclerotic changes in cerebral and coronary
atherosclerosis. Flegar-Meštrić et al., ( 2007), in a study of 119 patients, age range between 43
and 80 years, with stenosis of extracranial cerebral arteries found a significant association
between the CRP level and stenotic extent greater than 70% compared with the control group
with normal-appearing cerebral arteries on ultrasonography. The association with CRP of
angiographically confirmed coronary atherosclerosis is controversial. Coronary disease and
CRP are considered to independently and additively contribute to the risk for adverse
cardiovascular events. Angiographic imaging seems to detect stable and instable plaques, and
the value of CRP lies in its ability to predict myocardial infarction or fatal outcome independ‐
ently of the result of angiography (Niccoli et al., 2008; Geluk et al., 2008). Niccoli et al., (2008),
in an investigation of 97 patients with unstable angina, failed to demonstrate any correlation
between the basal CRP values and the severity of angiographic changes. In a prospective study
within the Prevention of Renal and Vascular Endstage Disease (PREVEND) trial, including
8,139 individuals with no presence of coronary artery disease, Geluk et al., (2008) found weak
correlations between the basal CRP concentrations and the degree of alterations demonstrated
on angiogram in 216 patients who developed coronary disease over a 5-year period.
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CRP (r=0,36, P<0,001), as well as Tie-2 which showed a weak but significant association with
CRP (r=0,25, P=0,008).
Because all three markers of angiogesis correlated with the CRP concentration in the group
studied, compared with the controls, and a correlation between the concentrations of VEGF
and HDL cholesterol was found, we examined whether the concentrations of the biochemical
parameters under study differed depending on the CRP concentration as a cardiovascular risk
factor. The concentrations of HDL- cholesterol, VEGF, Ang-2, and Tie-2 were statistically
significantly different among the subjects with various cardiovascular risk profiles, with the
HDL -cholesterol values being significantly higher in the low risk subjects (CRP<1,0 mg/L)
compared with the moderate (CRP between 1,0-3,0 mg/L) (P=0,004) and high risk (P=0,011)
subjects (CRP >3,0 mg/L). The subject groups of moderate and high cardiovascular risk did
not differ significantly in the HDL cholesterol concentration (P=0,666). Statistically significant
difference was found in the concentrations of VEGF (P=0,011), Ang-2 (P<0,001), and Tie-2
receptor (P=0,005) between low and high risk subjects, as well as in the concentrations of VEGF
(P=0,012), Ang-2 (P<0,001), and Tie-2 receptor (P=0,02) between the moderate and high
cardiovascular risk subjects, whereas there were no statistically significant differences in the
concentrations of VEGF (P=0,377), Ang-2 (P=0,438), and Tie-2 receptor (P=0,673) between the
groups of low and moderate cardiovascular risk subjects. The results are suggestive of an
association between inflammation and angiogenesis in peripheral arterial disease.
In this investigation, no association was found of the biochemical parameters under study,
namely, triglycerides, total, HDL-, LDL-cholesterol, CRP, and novel biomarkers of inflamma‐
tion (PAF-AH) and angiogenesis (VEGF, Ang-2, and Tie-2 receptor) with the angiographic
score as a measure of the anatomic extent of atherosclerotic alterations in the peripheral
arteries.
It has been well documented that inflammation is implicated in all stages of the atherosclerotic
process. The role of CRP, as a nonspecific marker of inflammation and cardiovascular risk
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factor in the development and progression of atherosclerosis, is extensively investigated.
Tzoulaki et al., (2005), in a large prospective trial nested within the Edinburgh Artery Study
confirmed the role of CRP, interleukin-6 (IL-6), and intercellular adhesion molecule (ICAM)
in the progression of peripheral artery disease in the general population. The trial included
1582 individuals, ranging in age 55 to 75 years, and atherosclerotic progression was defined
as reduction in the ankle brachial index (ABI) over the period of 5 and 12 years. In the
investigation of the patients with peripheral arterial disease who had ABI<0.90, the CRP levels
greater than 3.0 mg/L had an additive predictive value to risk assessment for adverse cardio‐
vascular events (Khawaja & Kullo, 2009). Although in the clinical practice, ABI measurement
is considered a simple method of assessing peripheral artery disease progression, and the ABI
values correlate well with the degree of peripheral arterial atherosclerotic changes as measured
using the digital subtraction angiography method, these two methods represent different
aspects of severity assessment of peripheral arterial disease, and cannot be directly compared
( Nylaende et al., 2006). Nylaende et al., (2006) evaluated the relationship between inflamma‐
tory markers and the severity of peripheral artery disease assessed on the basis of the angio‐
graphic score and ABI determined with and without Treadmill test. The study was conducted
in 127 patients, range 45-79 years, with the simptoms of intermittent claudication in whom the
angiographic score was determined based on the angiographic criteria for haemodynamically
significant stenosis. The results of their study demonstrated significant associations of MCP-1,
CD40L, IL-6, and TNF-alpha with the angiographic score contrary to the concentrations of
CRP, IL-10, E-selectin, P-selectin, ICAM-1, and VCAM-1 for which no significant associations
with the angiographic score were observed. ICAM-1 and IL-6 showed a statistically significant
correlation with the maximum walking distance on the treadmill, and neither of the markers
under study correlated with the ABI. Based on the available data, this is the only investigation
into the association between the inflammation marker and the extent of angiographically
detected atherosclerotic alterations in the patients with peripheral aterosclerosis. A substantial
number of studies have investigated the correlation between the marker of inflammation and
the degree of angiographically demonstrated atherosclerotic changes in cerebral and coronary
atherosclerosis. Flegar-Meštrić et al., ( 2007), in a study of 119 patients, age range between 43
and 80 years, with stenosis of extracranial cerebral arteries found a significant association
between the CRP level and stenotic extent greater than 70% compared with the control group
with normal-appearing cerebral arteries on ultrasonography. The association with CRP of
angiographically confirmed coronary atherosclerosis is controversial. Coronary disease and
CRP are considered to independently and additively contribute to the risk for adverse
cardiovascular events. Angiographic imaging seems to detect stable and instable plaques, and
the value of CRP lies in its ability to predict myocardial infarction or fatal outcome independ‐
ently of the result of angiography (Niccoli et al., 2008; Geluk et al., 2008). Niccoli et al., (2008),
in an investigation of 97 patients with unstable angina, failed to demonstrate any correlation
between the basal CRP values and the severity of angiographic changes. In a prospective study
within the Prevention of Renal and Vascular Endstage Disease (PREVEND) trial, including
8,139 individuals with no presence of coronary artery disease, Geluk et al., (2008) found weak
correlations between the basal CRP concentrations and the degree of alterations demonstrated
on angiogram in 216 patients who developed coronary disease over a 5-year period.
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In our investigation, we found no evidence of associations between the CRP level and the
extent of peripheral arterial changes on angiography, which is consistent with the results by
Nylaende M. et al. (2006). It is also possible that some of the biomarkers for which a difference
in concentrations between the groups studied has been found are involved in other mecha‐
nisms of vascular homeostasis regulation, and that they have importance in earlier phases of
development of peripheral arterial atherosclerotic changes, which evade detection by the
digital subtraction angiography method.
5. Conclusion
This study confirmed the role of hypertriglyceridemia and CRP as risk factors in the develop‐
ment of peripheral arterial disease. Lower concentrations of HDL cholesterol in patients could
indicate its reduced protective role in preventing the atherogenic process. PAF-AH can not be
considered a reliable diagnostic indicator of peripheral arterial disease since the changes in
enzyme activity may reflect the altered lipid parameters. Correlation between the CRP
concentrations and the concentrations of VEGF, Ang-2 and its receptor Tie-2 appears to suggest
an association between inflammation and angiogenesis in the development of peripheral
arterial disease. An increased concentration of Ang-2 and Tie-2 receptor could indicate
increased vascular remodeling in response to the presence of risk factors and could be
considered new biomarkers of angiogenesis which indicate the presence of peripheral arterial
disease. The absence of significant correlation between the concentrations of the biochemical
parameters investigated and the angiographic score suggests that other factors play a more
important role in the progression of the disease. Further research is needed on larger groups
of subjects to confirm the value of PAF-AH, VEGF, Ang-2 and Tie-2 receptor, as new diagnostic
indicators of atherosclerosis of peripheral arteries.
Acknowledgements
This work was supported by a grant of the Ministry of Science, Education and Sports of the
Republic of Croatia (No. 044-0061245-0551).
Author details
Sonja Perkov1, Mirjana Mariana Kardum Paro1, Vinko Vidjak2 and Zlata Flegar-Meštrić1
1 Institute of Clinical Chemistry and Laboratory Medicine, Merkur University Hospital, Za‐
greb, Croatia
2 Clinical Department for Diagnostic and Clinical Radiology, Merkur University Hospital,
Zagreb, Croatia
Current Trends in Atherogenesis114
References
[1] Abdellaoui, A. & Al-Khaffaf, H. (2007). C-Reactive Protein (CRP) as a Marker in Pe‐
ripheral Vascular Disease. European Journal of Vascular & Endovascular Surgery, Vol.34,
No.1, pp.18-22, ISSN:1078-5884
[2] Augustin, HG.; Koh, GY.; Thurston, G. & Alitalo, K. (2009). Control of vascular mor‐
phogenesis and homeostasis through the angiopoietin-Tie system. Nature Reviews
Molecular Cell Biology, Vol.10, pp. 165-167, ISSN: 1471-0080
[3] Ballantyne, C.; Cushman, M.; Psaty, B. et al. (2007). Collaborative meta-analysis of in‐
dividual participant data from observational studies of Lp-PLA2 and cardiovascular
diseases. European Journal of Cardiovascular Prevention & Rehabilitation, Vol. 14, No.1,
(February 2007), pp. 3–11, ISSN 1741-8267
[4] Brevetti, G.; Silvestro, A.; Di Giacomo, S.; Bucur, R.; Di Donato, A.; Schiano, V. & Sco‐
pacasa, F. (2003). Endothelial dysfunction in peripheral arterial disease is related to
increase in plasma markers of inflammation and severity of peripheral circulatory
imparment but not to classic risk factor aand atherosclerotic burden. Journal of Vascu‐
lar Surgery, Vol.38, pp. 374-379, ISSN: 0741-5214
[5] Brevetti, G.; Schiano, V.; Chiarello M. (2008). Endothellil dysfunction: A key to the
patophysiology and natural history of peripheral arterial disease? Atherosclerosis, Vol.
197, pp. 1-11, ISSN:1523-3804
[6] Brevetti, G.; Guigliano, G.; Brevetti, L.; Hiatt WR. (2010). Inflammation in Peripheral
Artery Disease. Circulation, Vol.122, pp. 1862-1875, ISSN: 0009-7322
[7] Carmeliet, P. (2003). Angiogenesis in health and disease. Nature Medicine, Vol.9, pp.
653-660, ISSN: 1078-8956
[8] Chong, AY.; Caine, GJ.; Freestone, B.; Blann, AD.& Lip, GYH. (2004). Plasma angio‐
poietin - 1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive hearth
failure. Journal of the American College of Cardiology, Vol. 43, pp. 423-428, ISSN:
0735-1097
[9] Cooke, JP. (2008). Critical Determinants of Limb Ischemia, Journal of the American Col‐
lege of Cardiology, Vol.52, pp. 394-396, ISSN: 0735 -1097
[10] Costa, C.; Incio, J. & Soares, R. (2007). Angiogenesis and chronic inflammation: cause
or consequence? Angiogenesis, Vol. 10, pp. 149-166, ISSN:0969-6970
[11] Daniels, LB.; Laughlin, GA .; Sarno, MJ.; Bettencourt, R.; Wolfert, RL.; Barrett-Connor
E. (2008). Lipoprotein-associated phospholipase A2 is an independent predictor of
incident coronary heart disease in an apparently healthy older population: the Ran‐
cho Bernardo Study. Journal of the American College of Cardiology, Vol.51, pp. 913-919,
ISSN:0735-1097
The Evaluation of New Biomarkers of Inflammation and Angiogenesis in Peripheral Arterial Disease
http://dx.doi.org/10.5772/53341
115
In our investigation, we found no evidence of associations between the CRP level and the
extent of peripheral arterial changes on angiography, which is consistent with the results by
Nylaende M. et al. (2006). It is also possible that some of the biomarkers for which a difference
in concentrations between the groups studied has been found are involved in other mecha‐
nisms of vascular homeostasis regulation, and that they have importance in earlier phases of
development of peripheral arterial atherosclerotic changes, which evade detection by the
digital subtraction angiography method.
5. Conclusion
This study confirmed the role of hypertriglyceridemia and CRP as risk factors in the develop‐
ment of peripheral arterial disease. Lower concentrations of HDL cholesterol in patients could
indicate its reduced protective role in preventing the atherogenic process. PAF-AH can not be
considered a reliable diagnostic indicator of peripheral arterial disease since the changes in
enzyme activity may reflect the altered lipid parameters. Correlation between the CRP
concentrations and the concentrations of VEGF, Ang-2 and its receptor Tie-2 appears to suggest
an association between inflammation and angiogenesis in the development of peripheral
arterial disease. An increased concentration of Ang-2 and Tie-2 receptor could indicate
increased vascular remodeling in response to the presence of risk factors and could be
considered new biomarkers of angiogenesis which indicate the presence of peripheral arterial
disease. The absence of significant correlation between the concentrations of the biochemical
parameters investigated and the angiographic score suggests that other factors play a more
important role in the progression of the disease. Further research is needed on larger groups
of subjects to confirm the value of PAF-AH, VEGF, Ang-2 and Tie-2 receptor, as new diagnostic
indicators of atherosclerosis of peripheral arteries.
Acknowledgements
This work was supported by a grant of the Ministry of Science, Education and Sports of the
Republic of Croatia (No. 044-0061245-0551).
Author details
Sonja Perkov1, Mirjana Mariana Kardum Paro1, Vinko Vidjak2 and Zlata Flegar-Meštrić1
1 Institute of Clinical Chemistry and Laboratory Medicine, Merkur University Hospital, Za‐
greb, Croatia
2 Clinical Department for Diagnostic and Clinical Radiology, Merkur University Hospital,
Zagreb, Croatia
Current Trends in Atherogenesis114
References
[1] Abdellaoui, A. & Al-Khaffaf, H. (2007). C-Reactive Protein (CRP) as a Marker in Pe‐
ripheral Vascular Disease. European Journal of Vascular & Endovascular Surgery, Vol.34,
No.1, pp.18-22, ISSN:1078-5884
[2] Augustin, HG.; Koh, GY.; Thurston, G. & Alitalo, K. (2009). Control of vascular mor‐
phogenesis and homeostasis through the angiopoietin-Tie system. Nature Reviews
Molecular Cell Biology, Vol.10, pp. 165-167, ISSN: 1471-0080
[3] Ballantyne, C.; Cushman, M.; Psaty, B. et al. (2007). Collaborative meta-analysis of in‐
dividual participant data from observational studies of Lp-PLA2 and cardiovascular
diseases. European Journal of Cardiovascular Prevention & Rehabilitation, Vol. 14, No.1,
(February 2007), pp. 3–11, ISSN 1741-8267
[4] Brevetti, G.; Silvestro, A.; Di Giacomo, S.; Bucur, R.; Di Donato, A.; Schiano, V. & Sco‐
pacasa, F. (2003). Endothelial dysfunction in peripheral arterial disease is related to
increase in plasma markers of inflammation and severity of peripheral circulatory
imparment but not to classic risk factor aand atherosclerotic burden. Journal of Vascu‐
lar Surgery, Vol.38, pp. 374-379, ISSN: 0741-5214
[5] Brevetti, G.; Schiano, V.; Chiarello M. (2008). Endothellil dysfunction: A key to the
patophysiology and natural history of peripheral arterial disease? Atherosclerosis, Vol.
197, pp. 1-11, ISSN:1523-3804
[6] Brevetti, G.; Guigliano, G.; Brevetti, L.; Hiatt WR. (2010). Inflammation in Peripheral
Artery Disease. Circulation, Vol.122, pp. 1862-1875, ISSN: 0009-7322
[7] Carmeliet, P. (2003). Angiogenesis in health and disease. Nature Medicine, Vol.9, pp.
653-660, ISSN: 1078-8956
[8] Chong, AY.; Caine, GJ.; Freestone, B.; Blann, AD.& Lip, GYH. (2004). Plasma angio‐
poietin - 1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive hearth
failure. Journal of the American College of Cardiology, Vol. 43, pp. 423-428, ISSN:
0735-1097
[9] Cooke, JP. (2008). Critical Determinants of Limb Ischemia, Journal of the American Col‐
lege of Cardiology, Vol.52, pp. 394-396, ISSN: 0735 -1097
[10] Costa, C.; Incio, J. & Soares, R. (2007). Angiogenesis and chronic inflammation: cause
or consequence? Angiogenesis, Vol. 10, pp. 149-166, ISSN:0969-6970
[11] Daniels, LB.; Laughlin, GA .; Sarno, MJ.; Bettencourt, R.; Wolfert, RL.; Barrett-Connor
E. (2008). Lipoprotein-associated phospholipase A2 is an independent predictor of
incident coronary heart disease in an apparently healthy older population: the Ran‐
cho Bernardo Study. Journal of the American College of Cardiology, Vol.51, pp. 913-919,
ISSN:0735-1097
The Evaluation of New Biomarkers of Inflammation and Angiogenesis in Peripheral Arterial Disease
http://dx.doi.org/10.5772/53341
115
[12] Diehm, C.; Allenberg, J.R; Trampisch, H.J. et al. (2009). Mortality and vascular mor‐
bidity in older adults with asymptomatic versus symptomatic peripheral artery dis‐
ease. Circulation, 120, 2053-2061. doi:10.1161/CIRCULATIONAHA.109.865600, ISSN:
0009-7322
[13] Fiedler, U. & Augustin, HG. (2006). Angiopoietins: a link between angiogenesis and
inflammation. Trends in Immunology, Vol.27, No.12, pp. 552-558, ISSN: 1471-4906
[14] Findley, CM.; Mitchell, RG.; Duscha, BD.; Annex, BH.; Kontos, CD. (2008). Plasma
levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb
ischemia from intermittent claudication in patients with peripheral arterial disease.
Journal of the American College of Cardiology, Vol.52, pp. 387-393, ISSN:0735-1097
[15] Flegar-Meštrić, Z.; Vrhovski-Hebrang, D.; Juretić, D.; Perkov, S.; Preden-Kereković,
V.; Hebrang, A.; Vidjak, V.; Odak, D.; Grga, A. & Kosaka, T. (2003). Serum plateletac‐
tivating factor acetyl-hydrolase activity in patients with angiographically established
cerebrovascular stenosis. Proceedings of 15th IFCC – FESCC European Congress of Clini‐
cal Chemistry, EUROMEDLAB, Barcelona 2003; Monduzzi Editore; International Pro‐
ceedings Division, pp. 369-372
[16] Flegar-Meštrić, Z.; Vrhovski-Hebrang, D.; Preden-Kereković, V.; Perkov, S.; Hebrang,
A.; Grga, A.; Januš, D. & Vidjak, V. (2007). C-Reactive protein level in severe stenosis
of cerebral arteries. Cerebrovascular Disease, Vol. 23, No.5-6 (April 2007), pp. 430-434,
ISSN 1015-9770
[17] Flegar-Meštrić, Z.; Kardum Paro, MM.; Perkov, S.; Šiftar, Z.; Vidjak, V.; Grga, A. et al.
(2008). Serum Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activity
in Severe Stenosis of Cerebral Arteries. Clinical Chemystry and Laboratory Medicine,
Vol. 46: Special Suppl, pp. S1-S859., ISSN:1437-4331
[18] Flegar-Meštrić, Z.; Nazor, A.; Perkov, S.; Šurina, B.; Kardum-Paro, MM.; Šiftar, Z.; Si‐
kirica, M.; Sokolić, I.; Ožvald, I. & Vidas Ž. (2010). Accreditation of medical laborato‐
ries in Croatia – experiences of the Institute of clinical chemistry, University Hospital
Merkur, Zagreb. Collegium Antropologicum, Vol. 34, No.1, (Mart 2010), pp. 181- 186,
ISSN 0350-6134
[19] Flegar-meštric, Z, Nazor, A, Perkov, S, Šurina, B, Kardum-paro, M. M, Šiftar, Z, Sikir‐
ica, M, Sokolic, I, Ožvald, I, & Vidas, Ž. (2010). Accreditation of medical laboratories
in Croatia- experiences of the Institute of clinical chemistry, University Hospital Mer‐
kur, Zagreb. Collegium Antropologicum, Mart 2010), 0350-6134, 34(1), 181-186.
[20] Flegar-Meštrić, Z.; Kardum Paro, MM.; Perkov, S; Vidjak, V. & Grdić Rajković, M.
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1. Introduction
Vascular Smooth Muscle Cells (VSMC) are highly specialized cells whose principal functions
are contraction and regulation of blood vessel tone-diameter, blood pressure, and blood flow
distribution. In healthy adult blood vessels, these cells proliferate at a very low rate, exhibit
very low synthetic and migratory activity and express a unique repertoire of contractile
proteins, ion channels, and signalling molecules required for the cell's contractile function.
VSMC undergo significant phenotypic modulation following vascular injuries including
hypoxia, oxidative stress and mechanical injury. This phenotypic transition is mainly charac‐
terized by the loss of contractility and the acquisition of a proliferative, migratory and synthetic
phenotype. These drastic phenotypic alterations allow VSMCs to migrate from the media to
the intima of the arterial wall where they proliferate and secrete an extracellular matrix and
pro-inflammatory molecules. This phenotypic transition, also called the trans-differentiation
process, plays a critical role in pathological vascular remodellings such as atherosclerosis, post-
angioplasty restenosis, bypass vein graft failure, and cardiac allograft vasculopathy [1,2].
Hypoxia, mechanical stress and oxidative stress can induce VSMC trans-differentiation
directly or indirectly by stimulating the release of pro-inflammatory molecules and growth
factors from endothelium, macrophages, T lymphocytes or VSMC themselves. Signalling
pathways involved in VSMC trans-differentiation are diverse. Among them, the 3’-5’-cyclic
adenosine monophosphate (cAMP) signalling pathway stands out since cAMP is not only
described to play important roles both in differentiated and transdifferentiated VSMCs, but
can also have opposite effects in VSMCs with the same phenotype. Indeed, in trans-differen‐
tiated VSMCs, cAMP has dual opposite effects on migration and inflammation and stops cell
proliferation. Alternatively, in differentiated VSMCs, cAMP induces relaxation, expression of
© 2013 Glorian and Limon; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Progressive Peripheral Atherosclerosis in the General Population. Circulation, Vol.
112, pp. 976- 983,ISSN:0009-7322
[54] Tsimikas, S.; Tsironis, LD. & Tselepsis, AD. (2007). New Insights Into the Role of Lip‐
oprotein (a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis
and Cardiovascular Disease. Arteriosclerosis Thrombosis and Vascular Biology, Vol.27,
No.10, (October 2007), pp. 2094-2099, ISSN 1079-5642
[55] Zalewski, A. & Macphee, C. (2005). Role of Lipoprotein-Associated Phospholipase
A2 in Atherosclerosis Biology, Epidemiology, and Possible Therapeutic Target. Arte‐
riosclerosis, Thrombosis and Vascular Biology, Vol.25, No.5, (May 2005), pp. 923- 931,
ISSN 1049-8834
[56] Winkler, K.; Winkelmann, BR.; Scharnagl, H.; Hoffmann, MM.; Grawitz, AB.; Nauck,
M. et al. (2005). Platelet-Activating Factor Acetylhydrolase Activity Indicates Angio‐
graphic Coronary Artery Disease Independently of Systemic Inflammation and Oth‐
er Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study.
Circulation, Vol. 111, No.8, pp. 980-987,ISSN :0009-7322
Current Trends in Atherogenesis120
Chapter 6
The Role of Cyclic 3’-5’ Adenosine Monophosphate
(cAMP) in Differentiated and Trans-Differentiated
Vascular Smooth Muscle Cells
Martine Glorian and Isabelle Limon
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54726
1. Introduction
Vascular Smooth Muscle Cells (VSMC) are highly specialized cells whose principal functions
are contraction and regulation of blood vessel tone-diameter, blood pressure, and blood flow
distribution. In healthy adult blood vessels, these cells proliferate at a very low rate, exhibit
very low synthetic and migratory activity and express a unique repertoire of contractile
proteins, ion channels, and signalling molecules required for the cell's contractile function.
VSMC undergo significant phenotypic modulation following vascular injuries including
hypoxia, oxidative stress and mechanical injury. This phenotypic transition is mainly charac‐
terized by the loss of contractility and the acquisition of a proliferative, migratory and synthetic
phenotype. These drastic phenotypic alterations allow VSMCs to migrate from the media to
the intima of the arterial wall where they proliferate and secrete an extracellular matrix and
pro-inflammatory molecules. This phenotypic transition, also called the trans-differentiation
process, plays a critical role in pathological vascular remodellings such as atherosclerosis, post-
angioplasty restenosis, bypass vein graft failure, and cardiac allograft vasculopathy [1,2].
Hypoxia, mechanical stress and oxidative stress can induce VSMC trans-differentiation
directly or indirectly by stimulating the release of pro-inflammatory molecules and growth
factors from endothelium, macrophages, T lymphocytes or VSMC themselves. Signalling
pathways involved in VSMC trans-differentiation are diverse. Among them, the 3’-5’-cyclic
adenosine monophosphate (cAMP) signalling pathway stands out since cAMP is not only
described to play important roles both in differentiated and transdifferentiated VSMCs, but
can also have opposite effects in VSMCs with the same phenotype. Indeed, in trans-differen‐
tiated VSMCs, cAMP has dual opposite effects on migration and inflammation and stops cell
proliferation. Alternatively, in differentiated VSMCs, cAMP induces relaxation, expression of
© 2013 Glorian and Limon; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
contractile proteins, maintenance of a low proliferation rate and can stimulate or inhibit
apoptosis (Figure 1). The diversity of cAMP effects in VSMC (and in cells in general), is due to
the ability of this second messenger to transduce extracellular signals in a compartmentalized
manner, allowing individual stimuli to produce distinct pools of cAMP localized in discrete
subcellular regions. These pools of cAMP are produced near a subset of cAMP effectors,
themselves located near their substrates and engage specific cell responses according to the
cellular context [3]. Adenylyl cyclases (AC), phosphodiesterases (PDE) and the scaffolding
proteins A kinase anchored proteins (AKAPs) play a determinant role in cAMP compartmen‐
talization. Final cAMP effect depends on which isoforms of these proteins are expressed.
During the VSMC trans-differentiation process, important changes in the expressions of such
proteins occur, allowing a re-organization of the cAMP signalling compartmentalization,
therefore giving VSMC the ability to acquire properties specific to the trans-differentiated state.
After a presentation of the cAMP signalling pathway, this chapter discusses data demonstrat‐
ing the diversity of roles of cAMP in differentiated and transdifferentiated VSMCs.
Figure 1. Roles of cAMP (3’-5’ adenosine monophosphate) in differenciated and trans-differentiated vascular smooth
muscle cells (VSMC); AC8: adenylyl cyclase 8.
2. the c-AMP signaling pathway
2.1. Overview
The c-AMP signalling pathway begins with the release of cAMP into the cell which is mostly
initiated by the activation of G-protein coupled receptors (GPCRs) by several different
hormones and neurotransmitters. The ligand-bound GPCR catalyzes the exchange of GDP for
GTP on the α-subunit of the coupled heterotrimeric G protein, which results in the activation
of the α-subunit and its dissociation from the βγ dimer. Both the α and the βγ subunits can
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then activate or inhibit distinct intracellular signalling cascades. The αs of the Gs subtype
activates adenylyl cyclases (AC) witch catalyzes the synthesis of cAMP from ATP. Increased
levels of cAMP are translated into cellular responses by cAMP effectors. The best known is the
c-AMP dependant protein kinase A (PKA), but also include cyclic-nucleotide gated ion
channels (CNGCs) and the recently discovered Rap1-guanine nucleotide exchange factor
(Epac), three effectors known to mediate a multitude of cAMP signalling pathways. (Figure
2). The end of cAMP signalling is achieved by its decomposition into AMP catalyzed by
phosphodiesterases (PDEs) and its active efflux through transporters of the multidrug
resistance-assocuated protein (MRP) family [4,5]. One particularity of the cAMP signalling
pathway is its high degree of compartmentalization. Multiprotein complexes organize the
location of the different cAMP effectors to specific subcellular locations and allow cAMP to
propagate a plethora of cell responses in a spatio-temporal manner [3]. These multiprotein
complexes are at the foundation of cAMP compartmentalization, they involve AC, the
scaffolding proteins AKAPs and PDEs.
Figure 2. Cyclic adenosine 3’, 5’-monophosphate (cAMP) is produced from ATP by adenylyl cyclase (AC) upon activa‐
tion of Gs-protein coupled receptors. The local concentration and distribution of cAMP gradients is limited by phos‐
phodiesterases (PDE) which generate localized pools of cAMP throughout the cell. The increase in cAMP is translated
to cellular responses by the cAMP effectors protein kinase A (PKA), EPAC (exchange protein activated by cAMP) and
cyclic nucleotide -gated ion channels (CNGCs). A kinase anchored proteins (AKAPs) target cAMP effectors to distinct
cell compartments. They also intract with AC, PDE, cAMP effectors substrates and further scaffolding proteins, provid‐
ing spatial and temporal specificity of the cAMP pathway.
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to cellular responses by the cAMP effectors protein kinase A (PKA), EPAC (exchange protein activated by cAMP) and
cyclic nucleotide -gated ion channels (CNGCs). A kinase anchored proteins (AKAPs) target cAMP effectors to distinct
cell compartments. They also intract with AC, PDE, cAMP effectors substrates and further scaffolding proteins, provid‐
ing spatial and temporal specificity of the cAMP pathway.
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2.2. Components of the c-AMP signalling pathway
2.2.1. Formation of c-AMP is regulated by adenylyl cyclases
In mammals, cAMP is synthesized from ATP by members of the Class-III AC (Adenylyl Cy‐
clase)/ADCY family (E.C 4.6.1.1)1 [6]. This class is comprised of nine trans-membrane (tm)
AC enzymes and one soluble AC (sAC). tmAC are grouped into three major sub-families:
group 1: AC1, AC3, AC8; group 2: AC2, AC4, AC7; and group 3: AC5, AC6. All nine tmAC
can be activated by GTP-bound Gαs and, with the exception of AC9, by the plant diterpen
forskolin. Nevertheless, each isoform has a specific pattern of regulation by G proteins, calci‐
um/calmodulin, and proteine kinases [7-9]. For example, differences in patterns of regula‐
tion by G proteins have been associated with isoform-specific differences in AC activation.
Whereas AC1, AC5, AC6 and AC8 are inhibited by Gαi, AC2, AC4, AC7 are not. Further‐
more, whereas Gβγ subunits inhibit isoforms AC1 and AC8, they stimulate AC2, AC4 and
AC7. GTP-bound Gαs, the activator of all tmAC, is the result of the exchange of GDP for
GTP on the α-subunit of G protein and its subsequent dissociation from the βγ dimer. This
activation can be a consequence of the binding of GPCR by several different hormones or
neurotransmitters (e.g., β-adrenergic, H2-histamine, EP2-prostaglandin, α2a adrenergic and
M2-muscarinic receptor), making GPCRs guanine nucleotide exchange factors (GEFs) for
Gα subunits. The exchange of GDP for GTP can also be mediated independently from con‐
ventional GPCR/G protein signalling. This way involves entities called “non-GPCR GEFs”,
such as the recently identified cholinesterase -8a (Ric8a), a cytosolic protein reported to bind
to and act as a GEF for numerous Gα in mammalian cells [10]. Signal de-activation is ach‐
ieved by Gα-mediated GTP hydrolysis (endogenous GTPase activity) allowing return of the
Gα subunit to the inactive GDP-bound and its association with Gβγ dimer to form a Gα βγ-
heterotrimeric complex.
Beyond their synthase activity, ACs can function as scaffolds, and therefore contribute to the
cAMP signalling compartmentalization. Indeed, several works have shown that specific AC
isoforms have the capacity to interact with several proteins/enzymes on their N-terminus
allowing an isoform selective coupling with specific downstream signalling cascades [11,12].
AC isoforms are themselves confined in several structural specific cellular compartments. The
best characterized is their association with caveolar, lipid-rafts and the anchoring proteins
AKAP [13,14]. Selective adenylyl cyclase isoform localization, regulation and coupling with
specific downstream targets provide adenylyl cyclase isoform-selective patterns of signalling,
that links specific AC isoforms to distinct cell processes [15,16]. For example, alteration of the
AC population expressed in DDT1-MF2 cells (derived from hamster vas deferens smooth
muscle) changes the processing of stimulatory and inhibitory input [17] and differential
expression of AC isoforms in two VSMC models account for opposite effect of isoprenaline on
cAMP production [18].
1 Adenylyl cyclases (ACs) are currently grouped in six classes based on their primary amino acid sequences. Class I ACs
have been found exclusively in γ -proteobacteria. Class II ACs are toxins secreted by Bacillus anthracis, Bordetella
pertussis and Pseudomonas aeruginosa. Only few members of class IV, V and VI ACs have been described to date and
consists in bacterial enzymes. Class III ACs is universal. Class III ACs is found in metazoa, protozoa, fungi, eubacteria,
some archaebacteria and certain green algae. Neither class III ACs nor any other type of AC has ever been conclusively
identified in higher plants (Embryophyta).
Current Trends in Atherogenesis124
Differentiated  VSMC  have  been  shown  to  express  different  isoforms  of  AC  [18,19].
AC3-5-6 are clearly the most highly expressed isoenzymes in VSMCs, while Type 8 AC
(AC8) is undetectable in differentiated VSMCs and is strongly induced in trans-differenti‐
ated VSMC [20,21].
2.2.2. Degradation of cAMP is regulated by the cyclic nucleotide phosphodiesterases
Phosphodiesterases (PDE) comprise a large superfamily of enzymes; 11 families (PDE1-
PDE11) have been characterized on the basis of their amino acid sequences, substrate specif‐
icity, allosteric regulatory characteristics and pharmacological properties [22,23]. In total, the
superfamily of PDEs encompasses 25 genes in mammals giving rise to 200 reported distinct
gene products corresponding to different splice variants that are often expressed in a tissue-
specific manner. The substrate specificity of PDEs includes cAMP-specific, cGMP specific, and
dual-specific PDE. PDE 4-7-8 are highly specific for the hydroysis of cAMP, PDE5, 6, 9 are
cGMP specific and PDE1, -2, -3, -10, -11 hydrolyse both cAMP and cGMP. There are four major
PDE families found in VSMCs: PDE1, PDE3, and PDE4 PDE5 [24]. PDE3 and PDE4 have been
shown to account for the majority of cAMP hydrolysis, whereas PDE1 and PDE5 are mainly
responsible for cGMP-hydrolysis [25,26]. PDE1A and -1B, are expressed in differentiated
VSMC. PDE1A has the particularity to be localized in different cell compartments according
to the VSMC phenotype; it is predominantly cytoplasmic in medial contractile VSMC and
becomes nuclear in neointimal synthetic VSMC [27]. PDE1C is specifically induced in trans-
differentiated VSMC [28]. PDE3A, the main isoform expressed in arterial tissue, platelets and
cardiac tissue is found is VSMCs as well as PDE3B. The largest PDE family to date, the cAMP
specific PDE4 family, is expressed in numerous tissues, notably in vascular tissue. Four genes
(PDE4A/B/C/D) encode over 20 distinct PDE4 isoforms as a result of mRNA splicing and the
use of distinct promoters [29]. It was reported that two PDE4 “long forms”, PDE4D3 and
PDE4D5 are expressed in rat and human VSMC [30,31] and that the two “short forms” PDE4D1
and PDE4D2 are specifically expressed in trans-differentiated VSMC [32]. PDE5A is the major
cGMP hydrolyzing PDE expressed in arterial tissues[33,34].
2.2.3. Effectors of cAMP action
2.2.3.1. PKA
The first intracellular target of cAMP identified is the well characterized PKA holoenzyme.
cAMP-PKA-mediated signalling is known to affect numerous intracellular targets in response
to a wide variety of molecular signals. Numerous studies over the past 40 years have identified
hundreds of PKA substrates in the plasma membrane, nucleus, and cytoplasm of cells. The
PKA holoenzyme is a tetramere consisting of two catalytic subunits (C) that are maintained in
an inactive conformation by a regulatory (R) subunit dimer [35]. Binding of two cAMP
molecules on each R subunit leads to a conformational change and dissociation of two
catalycally active C monomers, which phosphorylate serine and threonine residues on specific
substrate proteins. Molecular cloning identified 4 R subunits and 4 C subunits called respec‐
tively RIα, RIβ, RIIα, RΙΙβ, Cα, Cβ, Cγ, and PRKX (the human X chromosome-encoded protein
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2.2. Components of the c-AMP signalling pathway
2.2.1. Formation of c-AMP is regulated by adenylyl cyclases
In mammals, cAMP is synthesized from ATP by members of the Class-III AC (Adenylyl Cy‐
clase)/ADCY family (E.C 4.6.1.1)1 [6]. This class is comprised of nine trans-membrane (tm)
AC enzymes and one soluble AC (sAC). tmAC are grouped into three major sub-families:
group 1: AC1, AC3, AC8; group 2: AC2, AC4, AC7; and group 3: AC5, AC6. All nine tmAC
can be activated by GTP-bound Gαs and, with the exception of AC9, by the plant diterpen
forskolin. Nevertheless, each isoform has a specific pattern of regulation by G proteins, calci‐
um/calmodulin, and proteine kinases [7-9]. For example, differences in patterns of regula‐
tion by G proteins have been associated with isoform-specific differences in AC activation.
Whereas AC1, AC5, AC6 and AC8 are inhibited by Gαi, AC2, AC4, AC7 are not. Further‐
more, whereas Gβγ subunits inhibit isoforms AC1 and AC8, they stimulate AC2, AC4 and
AC7. GTP-bound Gαs, the activator of all tmAC, is the result of the exchange of GDP for
GTP on the α-subunit of G protein and its subsequent dissociation from the βγ dimer. This
activation can be a consequence of the binding of GPCR by several different hormones or
neurotransmitters (e.g., β-adrenergic, H2-histamine, EP2-prostaglandin, α2a adrenergic and
M2-muscarinic receptor), making GPCRs guanine nucleotide exchange factors (GEFs) for
Gα subunits. The exchange of GDP for GTP can also be mediated independently from con‐
ventional GPCR/G protein signalling. This way involves entities called “non-GPCR GEFs”,
such as the recently identified cholinesterase -8a (Ric8a), a cytosolic protein reported to bind
to and act as a GEF for numerous Gα in mammalian cells [10]. Signal de-activation is ach‐
ieved by Gα-mediated GTP hydrolysis (endogenous GTPase activity) allowing return of the
Gα subunit to the inactive GDP-bound and its association with Gβγ dimer to form a Gα βγ-
heterotrimeric complex.
Beyond their synthase activity, ACs can function as scaffolds, and therefore contribute to the
cAMP signalling compartmentalization. Indeed, several works have shown that specific AC
isoforms have the capacity to interact with several proteins/enzymes on their N-terminus
allowing an isoform selective coupling with specific downstream signalling cascades [11,12].
AC isoforms are themselves confined in several structural specific cellular compartments. The
best characterized is their association with caveolar, lipid-rafts and the anchoring proteins
AKAP [13,14]. Selective adenylyl cyclase isoform localization, regulation and coupling with
specific downstream targets provide adenylyl cyclase isoform-selective patterns of signalling,
that links specific AC isoforms to distinct cell processes [15,16]. For example, alteration of the
AC population expressed in DDT1-MF2 cells (derived from hamster vas deferens smooth
muscle) changes the processing of stimulatory and inhibitory input [17] and differential
expression of AC isoforms in two VSMC models account for opposite effect of isoprenaline on
cAMP production [18].
1 Adenylyl cyclases (ACs) are currently grouped in six classes based on their primary amino acid sequences. Class I ACs
have been found exclusively in γ -proteobacteria. Class II ACs are toxins secreted by Bacillus anthracis, Bordetella
pertussis and Pseudomonas aeruginosa. Only few members of class IV, V and VI ACs have been described to date and
consists in bacterial enzymes. Class III ACs is universal. Class III ACs is found in metazoa, protozoa, fungi, eubacteria,
some archaebacteria and certain green algae. Neither class III ACs nor any other type of AC has ever been conclusively
identified in higher plants (Embryophyta).
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Differentiated  VSMC  have  been  shown  to  express  different  isoforms  of  AC  [18,19].
AC3-5-6 are clearly the most highly expressed isoenzymes in VSMCs, while Type 8 AC
(AC8) is undetectable in differentiated VSMCs and is strongly induced in trans-differenti‐
ated VSMC [20,21].
2.2.2. Degradation of cAMP is regulated by the cyclic nucleotide phosphodiesterases
Phosphodiesterases (PDE) comprise a large superfamily of enzymes; 11 families (PDE1-
PDE11) have been characterized on the basis of their amino acid sequences, substrate specif‐
icity, allosteric regulatory characteristics and pharmacological properties [22,23]. In total, the
superfamily of PDEs encompasses 25 genes in mammals giving rise to 200 reported distinct
gene products corresponding to different splice variants that are often expressed in a tissue-
specific manner. The substrate specificity of PDEs includes cAMP-specific, cGMP specific, and
dual-specific PDE. PDE 4-7-8 are highly specific for the hydroysis of cAMP, PDE5, 6, 9 are
cGMP specific and PDE1, -2, -3, -10, -11 hydrolyse both cAMP and cGMP. There are four major
PDE families found in VSMCs: PDE1, PDE3, and PDE4 PDE5 [24]. PDE3 and PDE4 have been
shown to account for the majority of cAMP hydrolysis, whereas PDE1 and PDE5 are mainly
responsible for cGMP-hydrolysis [25,26]. PDE1A and -1B, are expressed in differentiated
VSMC. PDE1A has the particularity to be localized in different cell compartments according
to the VSMC phenotype; it is predominantly cytoplasmic in medial contractile VSMC and
becomes nuclear in neointimal synthetic VSMC [27]. PDE1C is specifically induced in trans-
differentiated VSMC [28]. PDE3A, the main isoform expressed in arterial tissue, platelets and
cardiac tissue is found is VSMCs as well as PDE3B. The largest PDE family to date, the cAMP
specific PDE4 family, is expressed in numerous tissues, notably in vascular tissue. Four genes
(PDE4A/B/C/D) encode over 20 distinct PDE4 isoforms as a result of mRNA splicing and the
use of distinct promoters [29]. It was reported that two PDE4 “long forms”, PDE4D3 and
PDE4D5 are expressed in rat and human VSMC [30,31] and that the two “short forms” PDE4D1
and PDE4D2 are specifically expressed in trans-differentiated VSMC [32]. PDE5A is the major
cGMP hydrolyzing PDE expressed in arterial tissues[33,34].
2.2.3. Effectors of cAMP action
2.2.3.1. PKA
The first intracellular target of cAMP identified is the well characterized PKA holoenzyme.
cAMP-PKA-mediated signalling is known to affect numerous intracellular targets in response
to a wide variety of molecular signals. Numerous studies over the past 40 years have identified
hundreds of PKA substrates in the plasma membrane, nucleus, and cytoplasm of cells. The
PKA holoenzyme is a tetramere consisting of two catalytic subunits (C) that are maintained in
an inactive conformation by a regulatory (R) subunit dimer [35]. Binding of two cAMP
molecules on each R subunit leads to a conformational change and dissociation of two
catalycally active C monomers, which phosphorylate serine and threonine residues on specific
substrate proteins. Molecular cloning identified 4 R subunits and 4 C subunits called respec‐
tively RIα, RIβ, RIIα, RΙΙβ, Cα, Cβ, Cγ, and PRKX (the human X chromosome-encoded protein
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kinase X, a cAMP dependent kinase that forms a catalytically inactive holoenzyme only with
the RI subunit). The R subunits exhibit different cAMP binding affinities and can form both
homo and heterodimers leading to a large number of combinations. The subcellular localiza‐
tion of PKA is determined by PKA binding to A kinase ankoring proteins, AKAPs. AKAPs act
as scaffolds which give PKA access to substrates localized in specific compartments within the
cell and participate to cAMP signalling compartmentalization as depicted below [36,37].
2.2.3.2. Epac family
Epac proteins are the most recent addition to the group of cAMP signalling effectors. Their
discovery explains various effects of cAMP that could not be attributed to the established
targets PKA and CNGs. Epac was identified in a database screen conducted to explain the
independent activation of the small G protein Rap by cAMP [38]. At the same time, a screen
for proteins containing cyclic-nucleotide-binding domains revealed the presence of two
isoforms of Epac, Epac1 and Epac2 [39]. Epac proteins function as guanine nucleotide exchange
factors (GEFs) both for Rap1 and Rap2. Rap1 and rap2 proteins belong to the Ras family of
small G proteins, which cycle between an inactive GDP-bound state and an active GTP-bound
state. The GTP-bound Rap mediates signalling by associating with and activating effector
proteins. GEFs catalyze the exchange of GDP for GTP and thereby the activation of the small
G protein (Figure 3). Herein, Epac1 and Epac2 proteins are also called cAMP-GEF I and II
respectively. Their subcellular localizations are determined, like PKA, by binding to AKAPs.
Epac1 and Epac2 are present in most tissues, though with different expression levels. Epac1 is
highly abundant in blood vessels, kidney, adipose tissue, central nervous system, ovary and
uterus, whereas Epac2 is mostly expressed in the central nervous system, adrenal gland, and
pancreas. Epac proteins are implicated in many cAMP-regulated processes such as insulin
secretion, cardiac contraction, vascular permeability, cell migration, neurotransmitter release
and immunity [40,41].
2.2.3.3. CNG famly
Cyclic nucleotide-gated (CNG) channels are non-selective cation channels first identified in
retinal photoreceptors and olfactory sensory neurons. They are opened by the direct binding
of cAMP and cGMP. Although their activity shows very little voltage dependence, CNG
channels belong to the super-family of voltage-gated ion channels.
CNG channels consists in heterotetrameric complexes resulting from the association of two or
three subunits. Six different genes encoding CNG channels, four A subunits (A1 to A4) and
two B subunits (B1 and B3), give rise to different channels. Their activity is modulated, at least
in part, by Ca2+/calmodulin and by phosphorylation. The role of CNG channels has been
established in retinal photoreceptors and in olfactory sensory neurons. Mutations in CNG
channel genes give rise to retinal degeneration and color blindness [42].
CNG channels are widely expressed in vascular tissues across species and vascular beds
[43,44]. Specifically, CNGA1 was found to be very expressed in the endothelium layer and,
with a much lower extent, in VSMC [44]. In contrast, strong expression of CNGA2 has been
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found in both the endothelium and media of human arteries [43]. Functionally, CNG channels
play an important role in endothelium dependent vascular dilatation to a number of cAMP-
elevating agents including adenosine, adrenaline and ATP [45-47]. Concerning the function of
CNG in differentiated VSMC, to our knowledge, only one report demonstrates that CNG
contributes to thromboxaneA2-induced contraction of rat small mesenteric arteries[48].
Figure 3. The Rap1 GTPases cycle between a GTP-bound (active state) and GDP- bound (inactive state). Cycling be‐
tween the active and inactive states is facilitated by guanine nucleotide exchange factors (GEFs) that release GDP and
allow binding of GTP, as well as GTPase activation proteins (GAPs) wich accelerate GTP hydrolysis.
2.3. ACs, PDEs and AKAPs are essential to cAMP signaling
compartimentalization
The idea of compartimentalized pools of cAMP originated in 1979 when Brunton et al. showed
that while both the β-adrenergic receptor agonist isoprotrenol and prostaglandin E1 increased
cAMP concentration in perfused rat hearts, only isoproterenol increased glycogen metabolism
and phosphorylation of troponin [49]. These results illustrated the fact that different hormones
may act through the same messenger to generate different pools of cAMP and mediate distinct
physiological responses. An increasing number of results support now the existence of distinct
cAMP microdomains that control cAMP signalling. ACs, PDEs and the scaffolding proteins
AKAPs are at the foundation of this cAMP signalling compartmentalization [50,51]. As
mentioned, -ACs can orchestrate their own microenvironment by recruiting a variety of
signalling and scaffolding molecules, - PDEs mediate local cAMP degradation and literally
sculpt gradients of cAMP surrounding specific signalling complexes and therefore regulate
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kinase X, a cAMP dependent kinase that forms a catalytically inactive holoenzyme only with
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state. The GTP-bound Rap mediates signalling by associating with and activating effector
proteins. GEFs catalyze the exchange of GDP for GTP and thereby the activation of the small
G protein (Figure 3). Herein, Epac1 and Epac2 proteins are also called cAMP-GEF I and II
respectively. Their subcellular localizations are determined, like PKA, by binding to AKAPs.
Epac1 and Epac2 are present in most tissues, though with different expression levels. Epac1 is
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pancreas. Epac proteins are implicated in many cAMP-regulated processes such as insulin
secretion, cardiac contraction, vascular permeability, cell migration, neurotransmitter release
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retinal photoreceptors and olfactory sensory neurons. They are opened by the direct binding
of cAMP and cGMP. Although their activity shows very little voltage dependence, CNG
channels belong to the super-family of voltage-gated ion channels.
CNG channels consists in heterotetrameric complexes resulting from the association of two or
three subunits. Six different genes encoding CNG channels, four A subunits (A1 to A4) and
two B subunits (B1 and B3), give rise to different channels. Their activity is modulated, at least
in part, by Ca2+/calmodulin and by phosphorylation. The role of CNG channels has been
established in retinal photoreceptors and in olfactory sensory neurons. Mutations in CNG
channel genes give rise to retinal degeneration and color blindness [42].
CNG channels are widely expressed in vascular tissues across species and vascular beds
[43,44]. Specifically, CNGA1 was found to be very expressed in the endothelium layer and,
with a much lower extent, in VSMC [44]. In contrast, strong expression of CNGA2 has been
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play an important role in endothelium dependent vascular dilatation to a number of cAMP-
elevating agents including adenosine, adrenaline and ATP [45-47]. Concerning the function of
CNG in differentiated VSMC, to our knowledge, only one report demonstrates that CNG
contributes to thromboxaneA2-induced contraction of rat small mesenteric arteries[48].
Figure 3. The Rap1 GTPases cycle between a GTP-bound (active state) and GDP- bound (inactive state). Cycling be‐
tween the active and inactive states is facilitated by guanine nucleotide exchange factors (GEFs) that release GDP and
allow binding of GTP, as well as GTPase activation proteins (GAPs) wich accelerate GTP hydrolysis.
2.3. ACs, PDEs and AKAPs are essential to cAMP signaling
compartimentalization
The idea of compartimentalized pools of cAMP originated in 1979 when Brunton et al. showed
that while both the β-adrenergic receptor agonist isoprotrenol and prostaglandin E1 increased
cAMP concentration in perfused rat hearts, only isoproterenol increased glycogen metabolism
and phosphorylation of troponin [49]. These results illustrated the fact that different hormones
may act through the same messenger to generate different pools of cAMP and mediate distinct
physiological responses. An increasing number of results support now the existence of distinct
cAMP microdomains that control cAMP signalling. ACs, PDEs and the scaffolding proteins
AKAPs are at the foundation of this cAMP signalling compartmentalization [50,51]. As
mentioned, -ACs can orchestrate their own microenvironment by recruiting a variety of
signalling and scaffolding molecules, - PDEs mediate local cAMP degradation and literally
sculpt gradients of cAMP surrounding specific signalling complexes and therefore regulate
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the availability of cAMP/cGMP to their effectors –AKAPs dynamically assemble the three
different cAMP effectors to control the cellular actions of cAMP [37]. As their name implies,
AKAPs were originally described to target PKA to distinct subcellular locations and confine
activation to only a subset of potential targets. In reality, these proteins have the ability to form
complexes with other signalling molecules including Epac proteins, protein kinases, phos‐
phatases, phosphodiesterases, AC, as well as GPCR and ion channels. AKAPs are localized to
numerous cellular sites, including the plasma membrane, Golgi, centrosome, nucleus,
mitchondria and cytosol. The first AKAP to be characterized was microtubule associated
protein-2 (MAP2), initially identified because of it co-purified with RII from brain extract [52].
The AKAP family has grown and includes more than 50 structurally diverse, but functionally
similar members. Despite their diversity, AKAP orthologues have been identified in a range
of species, including yeast, nematodes, mice and humans. All AKAPs share common proper‐
ties: 1) they contain a PKA-anchoring domain 2) compartmentalization of individual AKAP-
PKA units occur through specialized targeting domains that are present on each anchoring
protein 3) they have the ability to form complexes with other signalling molecules including
protein kinases, phosphatases, phosphodiesterases, AC, as well as GPCR and ion channels 4)
AKAPs are recruited into much larger multiprotein complexes through the interactions with
other adaptator molecules such as PDZ and SH3 domain containing proteins. These four
properties of AKAPs allow these proteins to integrate multiple signalling pathways, allowing
the convergence of signals to a common target [36,37].
3. Roles of cAMP in differentiated VSMCs
3.1. cAMP induces relaxation of differentiated VMCs
Elevation of intracellular cAMP after activation of Gs coupled receptors by vasorelaxing
hormones such as adrenaline, noradrenaline and the endothelium-derived prostaglandine I2
(PGI2) induces a rapid and efficient relaxation of mature differentiated SMCs [53]. Moreover,
the cAMP elevating agent forskolin induces a relaxant effect in VSMCs in vivo which is
potentiated by inhibitors of PDE3 and PDE4, the two main PDE isoforms expressed in VSMCs
[25,26,30] [54]. In SMCs, cAMP contributes to muscle relaxation through two different
mechanisms; one through the stimulation of the Ca pump at the sarcolemmal membrane (Ca
extrusion) and sarcoplasmic reticulum (Ca accumulation), and the other through the de-
phosphorylation of myosin light chain kinase (MLCK). De-phosphorylation of MLCK is
accomplished by the myosin light chain phosphatase (MLCP) which is well known to be
activated upon phoshorylation by the cAMP target PKA or the cGMP dependent protein kinase
G (PKG) [55,56]. Conversely, when phosphorylated by Rho-associated kinase (ROCK) or PKC,
MLCP activity is inhibited, resulting in contraction. A new mechanism of cAMP-mediated
relaxation has been recently described in airway and aortic smooth muscle cells involving
Epac, the last cAMP effector identified. Activation of Epac by an Epac selective cAMP analog
in pre-contracted aortic smooth muscle cells and airway smooth muscle cells results in the
down regulation of RhoA activity and in the increase of Rap1 or Rac1 activities, leading to cell
relaxation [57,58]. cAMP pools involved in SMC relaxation may be mainly generated by the
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type 6 adenylyl cyclase (AC6). Indeed, overexpression of only AC6 (and not AC5, AC2, or
AC1) in primary aortic VSMCs enhances smooth muscle relaxation [59]. Furthemore, a recent
study using selective short interfering RNA sequences reveals that AC6 is the predominant
isoenzyme involved in vasodilator-mediated cAMP accumulation in aortic VSMCs, account‐
ing for 60% of the total response to β-adrenoceptor (β-AR) stimulation [60].
3.2. cAMP maintains a low rate of proliferation in differentiated VSMC
A cause to effect relationship between the decreased expression of some specific components
of the cAMP signalling and proliferative capacity of VSMC has been demonstrated. Inversely,
emergence of PDEs in trans-differentiated VSMC allows them to proliferate.
3.2.1. Role of CREB
The cAMP Response Element Binding Protein (CREB) is a transcription factor, well known to
be phosphorylated and activated by PKA. CREB expression has been shown to be dramatically
decreased in cultured trans-differentiated VSMCs and in the media of numerous rodent and
porcine models of vascular diseases. Depletion of this transcription factor in vivo elicits changes
consistent with those observed in SMCs from pathologically remodelled arteries whereas
forced depletion of CREB with small interfering RNA in aortic SMCs is sufficient to induce
their proliferation, hypertrophy, migration, de-differentiation, and ECM production. Furthe‐
more, CREB is inactivated in VSMCs by several proliferative stimuli and overexpression of
wild type or constitutively active CREB, in primary cultures of SMC arrests cell cycle progres‐
sion induced by these stimuli [61-66]. Additionally, Transforming growth factor beta and
thiazolidinediones activate CREB to oppose to aortic SMC proliferation induced by growth
factors [62,67]. Nevertheless, some apparent contradictory studies show that CREB is involved
in VSMC proliferation induced by ATP and thrombin [68,69].
3.2.2. Role of CREB AKAP12β and AKAP5
AKAP12β, a member of the AKAP family, is markedly decreased in human and rodent
vascular lesions. Overexpression of AKAP12 β attenuates serum-induced SMC growth in vitro
and a causal relationship exists between the induction of the expression of this protein and the
inhibition of serum-induced VSMC proliferation by all trans retinoic acid [70]. An other AKAP
shown to repress VSMC growth is AKAP5 (AKAP79/AKAP75/AKAP150 in human, bovine,
rat respectively) since over-expression of this protein inhibits serum-induced VSMC prolifer‐
ation and local delivery of AKAP5 to balloon-injured vessels wall reduced the extent of
neointimal burden [71].
3.2.3. Role of PDE1-C
PDE1C, a PDE isoform hydrolyzing both cAMP and cGMP, is expressed in proliferating
human VSMCs but is absent in quiescent cells. In vivo, PDE1C is expressed in human foetal
aortas containing proliferating SMCs, but not in newborn aortas in which SMC proliferation
has ceased. Moreover, a causal relationship has been established between the emergence of
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the availability of cAMP/cGMP to their effectors –AKAPs dynamically assemble the three
different cAMP effectors to control the cellular actions of cAMP [37]. As their name implies,
AKAPs were originally described to target PKA to distinct subcellular locations and confine
activation to only a subset of potential targets. In reality, these proteins have the ability to form
complexes with other signalling molecules including Epac proteins, protein kinases, phos‐
phatases, phosphodiesterases, AC, as well as GPCR and ion channels. AKAPs are localized to
numerous cellular sites, including the plasma membrane, Golgi, centrosome, nucleus,
mitchondria and cytosol. The first AKAP to be characterized was microtubule associated
protein-2 (MAP2), initially identified because of it co-purified with RII from brain extract [52].
The AKAP family has grown and includes more than 50 structurally diverse, but functionally
similar members. Despite their diversity, AKAP orthologues have been identified in a range
of species, including yeast, nematodes, mice and humans. All AKAPs share common proper‐
ties: 1) they contain a PKA-anchoring domain 2) compartmentalization of individual AKAP-
PKA units occur through specialized targeting domains that are present on each anchoring
protein 3) they have the ability to form complexes with other signalling molecules including
protein kinases, phosphatases, phosphodiesterases, AC, as well as GPCR and ion channels 4)
AKAPs are recruited into much larger multiprotein complexes through the interactions with
other adaptator molecules such as PDZ and SH3 domain containing proteins. These four
properties of AKAPs allow these proteins to integrate multiple signalling pathways, allowing
the convergence of signals to a common target [36,37].
3. Roles of cAMP in differentiated VSMCs
3.1. cAMP induces relaxation of differentiated VMCs
Elevation of intracellular cAMP after activation of Gs coupled receptors by vasorelaxing
hormones such as adrenaline, noradrenaline and the endothelium-derived prostaglandine I2
(PGI2) induces a rapid and efficient relaxation of mature differentiated SMCs [53]. Moreover,
the cAMP elevating agent forskolin induces a relaxant effect in VSMCs in vivo which is
potentiated by inhibitors of PDE3 and PDE4, the two main PDE isoforms expressed in VSMCs
[25,26,30] [54]. In SMCs, cAMP contributes to muscle relaxation through two different
mechanisms; one through the stimulation of the Ca pump at the sarcolemmal membrane (Ca
extrusion) and sarcoplasmic reticulum (Ca accumulation), and the other through the de-
phosphorylation of myosin light chain kinase (MLCK). De-phosphorylation of MLCK is
accomplished by the myosin light chain phosphatase (MLCP) which is well known to be
activated upon phoshorylation by the cAMP target PKA or the cGMP dependent protein kinase
G (PKG) [55,56]. Conversely, when phosphorylated by Rho-associated kinase (ROCK) or PKC,
MLCP activity is inhibited, resulting in contraction. A new mechanism of cAMP-mediated
relaxation has been recently described in airway and aortic smooth muscle cells involving
Epac, the last cAMP effector identified. Activation of Epac by an Epac selective cAMP analog
in pre-contracted aortic smooth muscle cells and airway smooth muscle cells results in the
down regulation of RhoA activity and in the increase of Rap1 or Rac1 activities, leading to cell
relaxation [57,58]. cAMP pools involved in SMC relaxation may be mainly generated by the
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type 6 adenylyl cyclase (AC6). Indeed, overexpression of only AC6 (and not AC5, AC2, or
AC1) in primary aortic VSMCs enhances smooth muscle relaxation [59]. Furthemore, a recent
study using selective short interfering RNA sequences reveals that AC6 is the predominant
isoenzyme involved in vasodilator-mediated cAMP accumulation in aortic VSMCs, account‐
ing for 60% of the total response to β-adrenoceptor (β-AR) stimulation [60].
3.2. cAMP maintains a low rate of proliferation in differentiated VSMC
A cause to effect relationship between the decreased expression of some specific components
of the cAMP signalling and proliferative capacity of VSMC has been demonstrated. Inversely,
emergence of PDEs in trans-differentiated VSMC allows them to proliferate.
3.2.1. Role of CREB
The cAMP Response Element Binding Protein (CREB) is a transcription factor, well known to
be phosphorylated and activated by PKA. CREB expression has been shown to be dramatically
decreased in cultured trans-differentiated VSMCs and in the media of numerous rodent and
porcine models of vascular diseases. Depletion of this transcription factor in vivo elicits changes
consistent with those observed in SMCs from pathologically remodelled arteries whereas
forced depletion of CREB with small interfering RNA in aortic SMCs is sufficient to induce
their proliferation, hypertrophy, migration, de-differentiation, and ECM production. Furthe‐
more, CREB is inactivated in VSMCs by several proliferative stimuli and overexpression of
wild type or constitutively active CREB, in primary cultures of SMC arrests cell cycle progres‐
sion induced by these stimuli [61-66]. Additionally, Transforming growth factor beta and
thiazolidinediones activate CREB to oppose to aortic SMC proliferation induced by growth
factors [62,67]. Nevertheless, some apparent contradictory studies show that CREB is involved
in VSMC proliferation induced by ATP and thrombin [68,69].
3.2.2. Role of CREB AKAP12β and AKAP5
AKAP12β, a member of the AKAP family, is markedly decreased in human and rodent
vascular lesions. Overexpression of AKAP12 β attenuates serum-induced SMC growth in vitro
and a causal relationship exists between the induction of the expression of this protein and the
inhibition of serum-induced VSMC proliferation by all trans retinoic acid [70]. An other AKAP
shown to repress VSMC growth is AKAP5 (AKAP79/AKAP75/AKAP150 in human, bovine,
rat respectively) since over-expression of this protein inhibits serum-induced VSMC prolifer‐
ation and local delivery of AKAP5 to balloon-injured vessels wall reduced the extent of
neointimal burden [71].
3.2.3. Role of PDE1-C
PDE1C, a PDE isoform hydrolyzing both cAMP and cGMP, is expressed in proliferating
human VSMCs but is absent in quiescent cells. In vivo, PDE1C is expressed in human foetal
aortas containing proliferating SMCs, but not in newborn aortas in which SMC proliferation
has ceased. Moreover, a causal relationship has been established between the emergence of
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PDE1-c in VSMCs and their capacity to proliferate, since specific inhibition of PDE1C in SMCs
isolated from normal aorta or from lesions of atherosclerosis results in suppression of SMC
proliferation [72].
3.3. Others roles of cAMP in differentiated VSMC
3.3.1. cAMP maintains the contractile phenotype of differentiated VSMCs
As mentioned above, CREB depletion elicits changes consistent with those observed in SMCs
from pathologically remodelled arteries in vivo. These changes include modifications in the
expression of SMC markers and contractile factors such as SM myosin, and strongly suggest
that cAMP is important in maintaining the contractile phenotype of differentiated VSMCs [64].
The role of CREB in the maintenance of the contractile phenotype is reinforced by a recent
publication showing that cAMP elevation by cilostazol, a potent type 3 phosphodiesterase
inhibitor, promotes VSMC differentiation through CREB [73].
3.3.2. cAMP has dual opposite effects on apoptosis of differentiated VSMCs
Some studies demonstrate that cAMP is pro-apoptotic in SMCs whereas others present cAMP
as an anti-apoptotic factor in these cells. The opposite effect of cAMP on apoptosis in the same
type cell can be explained by the compartmentalization of cAMP signalling since these studies
use different ways to elevate intracellular cAMP. Some studies use cAMP elevating agents,
whereas others use hormones such as prostacyclin. In aortic VSMC, Torella et al. show that
cAMP analogs inhibits apoptosis through Ser83 phosphorylation of p85αPI3K [77]. Addition‐
ally, in the same model, the AC activator forskolin reduces apoptosis in serum-deprived rat
aortic VSMC at a site upstream of caspase 3 via activation of PKA [78]. In line with these studies,
inhibition of CREB function in aortic VSMC induces apoptosis of rat aortic VSMC, possibly
through downregulation of bcl2 expression [79]. Adversely, cAMP elevation in response to
prostacyclin induces apoptosis in rat aortic VSMC through the inhibition of extracellular
signal-regulated kinase activity [80].
4. Roles of cAMP in trans-differentiated VSMCs
4.1. cAMP inhibits proliferation of trans-differentiated VMCs
cAMP is well known to diminish cell growth and to promote cell-differentiation in general, it
can even be antagonistic to the effect of growth factors [81]. The first clue that cAMP might
have a role in controlling growth of cultured cells emerged from two studies. Burk observed
that two drug inhibitors of cAMP phosphodiesterase activity, caffeine and theophylline,
slowed the growth of normal and transformed baby hamster kidney (BHK) cells [82]. At the
same time, Ryan and Heidrick reported that cAMP itself inhibited the growth of Hela cells [83].
The first demonstration that cAMP inhibits proliferation of VSMCs was done by Southgate
and Newby showing the inhibitory effect of 8-Br-CAMP on serum-induced proliferation of
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rabbit aortic smooth muscle cells [84]. This inhibitory effect of cAMP on VSMC growth was
confirmed in vitro [85,86] and in vivo by Indolfi et al., demonstrating that local or oral admin‐
istration of cell-permeable, cyclic AMP analog, 8-Br-cAMP and non-selective phosphodiester‐
ase-inhibitor drugs to rats markedly inhibits neo-intimal formation after balloon injury in
vivo and/or in vitro in SMC [87,88]. Selective inhibitors of PDE3A and PDE4D, the two main
PDE isoforms expressed in VSMCs that account for cAMP hydrolysis [25,26,30] were also
shown to inhibit proliferation of trans-differentiated VSMCs. PDE3 and PDE4 inhibitors
markedly potentiate both the anti-proliferative effect and the increase in cAMP caused by
forskolin and PGI2 and significantly inhibit PDGF-induced VSMC proliferation and migration
[89,90]. [Of note, PDE4D is the first gene that has been linked to common forms of stroke such
as cardiogenic and carotid strokes [91]. Moreover, PDE3 inhibitors administred orally are able
to inhibit VSMC proliferation in a model of photochemically-induced vascular injury (Kondo
et al., Atherosclerosis, 1999), and a recent publication clearly demonstrates that PDE3A
depletion in vitro and in vivo inhibits mitogen-induced VSMC proliferation [61]. The AC
isoform that could play a role in cAMP-mediated inhibition of VSMC growth is the type 3
adenylyl cyclase (AC3) since Wong et al. demonstrated that this protein mediates the inhibitory
effect of prostaglandin E2 (PGE2) on basal and PDGF-BB-induced proliferation in murine and
human arterial VSMC [51]. Various molecular mechanisms have been proposed to explain
AMP-mediated inhibition of VSMCs. Such mechanisms include subsequent suppression of
growth factor-mediated activation of mitogenic protein kinases in VSMCs. Indeed, cAMP can
oppose to the mitogen-activated protein (MAP) kinases ERK1/2 [61,92], to JNK1 [93] as well
as to the phosphatidylinositol 3-kinase effector S6K1 [92]. In addition, cAMP can regulate gene/
protein expression which may contribute to its anti-proliferative action. For example, cAMP
elevating agents restore expression of p53-p21 in response to PDGF [61,94], prevents serum-
induced expression of cyclin-dependent kinases [95], inhibits basal and glucose-induced
VSMC growth by a down-regulation of the transcription factor E2F [25] and can reduce the
serum-induced expression of the S-Phase kinase-Associated Protein 2 (Skp2), an important
factor for cell cycle progression in VSMCs [96]. Furthermore, prostacyclin-induced cAMP
intracellular elevation inhibits the proliferation of arterial smooth muscle cells by inhibiting
the smad1/5 driven expression of Id1 (inhibitor of DNA binding protein) gene [97]. Some of
the genic effects of cAMP in VSMCs may be mediated by CREB since this transcription factor
has been demonstrated to inhibit the expression of a number of cell-cycle and mitogenic genes
in trans-differentiated VSMCs as well as genes encoding growth factors, growth factor
receptors, and cytokines [61,64,98]. The cAMP effectors PKA and Epac both are involved in
cAMP VSMC growth inhibition. Indeed, PKA inhibitors have been shown to reverse or, at
least, inhibit the effect of cAMP elevating agents on VSMC proliferation [71,77,87,88,99].
Concerning the involvement of Epac in VSMC proliferation, Mayer and collaborators and
Hewer and collaborators respectively demonstrated that Epac is involved in the adenosine-
mediated decrease of cell proliferation in human VSMCs and acts synergically with PKA to
mediate cAMP-dependent cell-cycle arrest and associated induction of a stellate- morphology
in VSMCs [100,101].
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PDE1-c in VSMCs and their capacity to proliferate, since specific inhibition of PDE1C in SMCs
isolated from normal aorta or from lesions of atherosclerosis results in suppression of SMC
proliferation [72].
3.3. Others roles of cAMP in differentiated VSMC
3.3.1. cAMP maintains the contractile phenotype of differentiated VSMCs
As mentioned above, CREB depletion elicits changes consistent with those observed in SMCs
from pathologically remodelled arteries in vivo. These changes include modifications in the
expression of SMC markers and contractile factors such as SM myosin, and strongly suggest
that cAMP is important in maintaining the contractile phenotype of differentiated VSMCs [64].
The role of CREB in the maintenance of the contractile phenotype is reinforced by a recent
publication showing that cAMP elevation by cilostazol, a potent type 3 phosphodiesterase
inhibitor, promotes VSMC differentiation through CREB [73].
3.3.2. cAMP has dual opposite effects on apoptosis of differentiated VSMCs
Some studies demonstrate that cAMP is pro-apoptotic in SMCs whereas others present cAMP
as an anti-apoptotic factor in these cells. The opposite effect of cAMP on apoptosis in the same
type cell can be explained by the compartmentalization of cAMP signalling since these studies
use different ways to elevate intracellular cAMP. Some studies use cAMP elevating agents,
whereas others use hormones such as prostacyclin. In aortic VSMC, Torella et al. show that
cAMP analogs inhibits apoptosis through Ser83 phosphorylation of p85αPI3K [77]. Addition‐
ally, in the same model, the AC activator forskolin reduces apoptosis in serum-deprived rat
aortic VSMC at a site upstream of caspase 3 via activation of PKA [78]. In line with these studies,
inhibition of CREB function in aortic VSMC induces apoptosis of rat aortic VSMC, possibly
through downregulation of bcl2 expression [79]. Adversely, cAMP elevation in response to
prostacyclin induces apoptosis in rat aortic VSMC through the inhibition of extracellular
signal-regulated kinase activity [80].
4. Roles of cAMP in trans-differentiated VSMCs
4.1. cAMP inhibits proliferation of trans-differentiated VMCs
cAMP is well known to diminish cell growth and to promote cell-differentiation in general, it
can even be antagonistic to the effect of growth factors [81]. The first clue that cAMP might
have a role in controlling growth of cultured cells emerged from two studies. Burk observed
that two drug inhibitors of cAMP phosphodiesterase activity, caffeine and theophylline,
slowed the growth of normal and transformed baby hamster kidney (BHK) cells [82]. At the
same time, Ryan and Heidrick reported that cAMP itself inhibited the growth of Hela cells [83].
The first demonstration that cAMP inhibits proliferation of VSMCs was done by Southgate
and Newby showing the inhibitory effect of 8-Br-CAMP on serum-induced proliferation of
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rabbit aortic smooth muscle cells [84]. This inhibitory effect of cAMP on VSMC growth was
confirmed in vitro [85,86] and in vivo by Indolfi et al., demonstrating that local or oral admin‐
istration of cell-permeable, cyclic AMP analog, 8-Br-cAMP and non-selective phosphodiester‐
ase-inhibitor drugs to rats markedly inhibits neo-intimal formation after balloon injury in
vivo and/or in vitro in SMC [87,88]. Selective inhibitors of PDE3A and PDE4D, the two main
PDE isoforms expressed in VSMCs that account for cAMP hydrolysis [25,26,30] were also
shown to inhibit proliferation of trans-differentiated VSMCs. PDE3 and PDE4 inhibitors
markedly potentiate both the anti-proliferative effect and the increase in cAMP caused by
forskolin and PGI2 and significantly inhibit PDGF-induced VSMC proliferation and migration
[89,90]. [Of note, PDE4D is the first gene that has been linked to common forms of stroke such
as cardiogenic and carotid strokes [91]. Moreover, PDE3 inhibitors administred orally are able
to inhibit VSMC proliferation in a model of photochemically-induced vascular injury (Kondo
et al., Atherosclerosis, 1999), and a recent publication clearly demonstrates that PDE3A
depletion in vitro and in vivo inhibits mitogen-induced VSMC proliferation [61]. The AC
isoform that could play a role in cAMP-mediated inhibition of VSMC growth is the type 3
adenylyl cyclase (AC3) since Wong et al. demonstrated that this protein mediates the inhibitory
effect of prostaglandin E2 (PGE2) on basal and PDGF-BB-induced proliferation in murine and
human arterial VSMC [51]. Various molecular mechanisms have been proposed to explain
AMP-mediated inhibition of VSMCs. Such mechanisms include subsequent suppression of
growth factor-mediated activation of mitogenic protein kinases in VSMCs. Indeed, cAMP can
oppose to the mitogen-activated protein (MAP) kinases ERK1/2 [61,92], to JNK1 [93] as well
as to the phosphatidylinositol 3-kinase effector S6K1 [92]. In addition, cAMP can regulate gene/
protein expression which may contribute to its anti-proliferative action. For example, cAMP
elevating agents restore expression of p53-p21 in response to PDGF [61,94], prevents serum-
induced expression of cyclin-dependent kinases [95], inhibits basal and glucose-induced
VSMC growth by a down-regulation of the transcription factor E2F [25] and can reduce the
serum-induced expression of the S-Phase kinase-Associated Protein 2 (Skp2), an important
factor for cell cycle progression in VSMCs [96]. Furthermore, prostacyclin-induced cAMP
intracellular elevation inhibits the proliferation of arterial smooth muscle cells by inhibiting
the smad1/5 driven expression of Id1 (inhibitor of DNA binding protein) gene [97]. Some of
the genic effects of cAMP in VSMCs may be mediated by CREB since this transcription factor
has been demonstrated to inhibit the expression of a number of cell-cycle and mitogenic genes
in trans-differentiated VSMCs as well as genes encoding growth factors, growth factor
receptors, and cytokines [61,64,98]. The cAMP effectors PKA and Epac both are involved in
cAMP VSMC growth inhibition. Indeed, PKA inhibitors have been shown to reverse or, at
least, inhibit the effect of cAMP elevating agents on VSMC proliferation [71,77,87,88,99].
Concerning the involvement of Epac in VSMC proliferation, Mayer and collaborators and
Hewer and collaborators respectively demonstrated that Epac is involved in the adenosine-
mediated decrease of cell proliferation in human VSMCs and acts synergically with PKA to
mediate cAMP-dependent cell-cycle arrest and associated induction of a stellate- morphology
in VSMCs [100,101].
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4.2. cAMP has dual opposite effects on migration of trans- differentiated VMCs
4.2.1. cAMP inhibit migration of trans-differentiated VSMCs
A growing body of evidence emerged in the beginning of the 1990’s implicating cAMP in the
inhibition of trans-differentiated VSMC migration. These studies, using analogs of cAMP,
activators of ACs and cAMP raising agents in VSMCs, have demonstrated that an increase in
cAMP positively correlates with the inhibition of VSMC migration. Indeed, raising the
intracellular concentration of cAMP either with dopamine, acting throught D1 receptors,
adrenomedullin, or forskolin, inhibited migration of VSMCs stimulated with PDGF or serum
[102-104]. Studies in rat aortic SMCs suggest that vasoactive agents that elevate intracellular
cAMP inhibit cell movement by disassembling actin stress fibers of the cytoskeleton [105,106].
Furthermore, downregulation of PKA abrogates inhibition of VSMC chemotaxis by forskolin
[89]. The inhibitory effect of cAMP on VSMC migration is re-inforced by the fact that inhibiting
all together PDE3 and PDE4D, the two main PDE isoforms expressed in VSMCs that account
for cAMP hydrolysis in VSMC [26,30,107] markedly potentiated both the anti-migratory effect
and the increase in cAMP caused by forskolin and significantly inhibited PDGF-induced
VSMC proliferation and migration [90,108,109]. In addition, Newman et al demonstrated that
forskolin inhibits TNFα-induced interleukin 6 expression and migration in human vascular
smooth muscle cells [110]. This effect could involve the transcription factor CREB since PDGF-
induced migration was decreased by active CREB and augmented with dominant negative
CREB [66,95] ; In addition, a negative correlation has been described between the CREB level
and the PDGF-activated SMC migration [64]. Nonetheless, the role of CREB in SMC migration
remains unclear since CREB has been demonstrated to be involved in UTP, arachidonic acid
and TNF alpha-induced SMC migration of VSMCs [111,112]. Moreover, recent studies show
that oxidized and non-oxidized fatty acids induce SMC motility through this transcription
factor [113,114].
4.2.2. A specific endogenous pool of cAMP induces migration of trans- differentiated VSMCs
By demonstrating that differential  expression of ACs isoforms in two VSMC models ac‐
count for opposite effects of isoprenaline on cAMP production in VSMC, Webb and co-
workers suggested for the first time that changes of AC isoform(s) expression in VSMCs
could account for the manifestation of vascular diseases [18].  In line with this study, Li‐
mon’s  group recently  demonstrated that  the  emergence of  the  calcium/calmodulin posi‐
tively regulated AC isoform 8 (AC8) in trans-differentiated VSMCs is involved in VSMC
migration. Type 8 AC is barely undetectable in differentiated VSMCs and is strongly in‐
duced in trans-differentiated VSMCs. A causal relationship between AC8 apparition and
the  migratory  capacities  of  VSMCs has  been  established.  Indeed,  authors  show that  10
days after  balloon angioplasty2,  rat  carotid artery displayed high AC8 immuno-labelling
only in the neo-intima and was no longer detectable when it  was analyzed after the re-
endothelization  phenomenon  during  which  VSMC migration/proliferation  halted.  More‐
2 Balloon angioplasty in rat carotid artery serves as an in vivo model of VSMC migration and proliferation.
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over,  the  forced  expression  of  AC8  in  primary  rat  VSMC  cultures  triggered  the  re-
colonization  of  a  wounded  zone,  whereas  blocking  it  in  IL-1β−cells  stopped  the  IL-1β-
induced  migration  [21]  This  finding  was  extending  in  vivo,  on  human  samples,  where
only the neo-intimal VSMCs a high level of AC8. Of note, AC8 is well known for its role
in  stress  adaptation,  mood disorders  and  opiate  dependence  [115].  The  involvement  of
this  enzyme in  VSMC trans-differentiation was  therefore  unexpected.  Molecular  mecha‐
nisms  underlying  AC8-mediated  VSMC  migration  does  not  involve  PKA  but  could  in‐
volve  Epac1  since  it  has  been  shown  that  Epac  1  expression  is  upregulated  in  the
neointima  after  vascular  injury  of  mouse  arteries  and  induces  VSMC  migration.  More‐
over Rap1, one of the described targets of Epac, is well known for its involvement in cell
migration [116].
4.3. cAMP has dual opposite effects on inflammation of trans-differentiated VMCs
A study from Adkins and coll. demonstrate that the elevation of intracellular cAMP by
rapamycin inhibits the secretion of the pro-inflammatory molecule Tumor Necrosis Factor
alpha (TNF-α) in lipopolyssacharide treated VSMCs from human saphenous vein segments
[110]. Adversely, Clement and collaborators suggest that the production of cAMP specifically
by AC8 is involved in the potentiator effect of prostaglandin E2 (PGE2) on the secretion of
phospholipase A2 (sPLA2), a marker of inflammation, in response to interleukine 1 β (IL1β)
in primary cultures of rat aortic smooth muscle cells [20]. In details, authors show that PGE2
i) induces the transition of CMLV towards a trans-differentiated/ inflammatory state through
the activation of the subtype 4 Gs-linked PGE2 receptor EP4, ii) acts in synergy with IL1β to
potentiate the secretion of phospholipase A2 and the disorganization of the alpha actin
cytoskeleton. This potentiator effect is the result of a simultaneous activation of PGE2 receptors
EP4 and EP3: in differentiated VSMC, EP3 receptors inhibit cyclase activity induced by EP4
and become activator of this activity in trans-differentiated VSMC. This switch of regulation
is the result of the emergence of AC8 in IL1β−treated VSMC.
4.4. cAMP inhibits collagen synthesis of trans-differentiated VSMCs
Synthetic VSMCs, in the atherosclerotic and neointimal lesions, produce an abundant exra-
cellular matrix (ECM), rich in type I collagen (collagen I). This ECM plays an important role
in vessel wall thickening and in the occlusion of the vessel lumen. In addition, collagen I in
vascular lesions may also regulate VSMC proliferation/migration, platelet circulation, mono‐
cyte activation, lipid accumulation, calcification, and plaque stability [74]. cAMP elevating
agents have been shown to inhibit collagen I synthesis induced by fetal calf serum- and TGF-
β [75]. Emergence of PDE1-c in trans-differentiated SMCs from rat aortic and human saphe‐
nous vein explants opposes the inhibitory effect of cAMP on collagen 1 synthesis, and accounts,
at least in part, for the increase of collagen 1 expression in trans-differentiated VSMCs. The
use of specific pharmacological inhibitors and si-RNA reveal that the cAMP-mediated
inhibitory effect on collagen 1 synthesis involves cyclic nucleotide gated channels but not PKA,
nor Epac [76].
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4.2. cAMP has dual opposite effects on migration of trans- differentiated VMCs
4.2.1. cAMP inhibit migration of trans-differentiated VSMCs
A growing body of evidence emerged in the beginning of the 1990’s implicating cAMP in the
inhibition of trans-differentiated VSMC migration. These studies, using analogs of cAMP,
activators of ACs and cAMP raising agents in VSMCs, have demonstrated that an increase in
cAMP positively correlates with the inhibition of VSMC migration. Indeed, raising the
intracellular concentration of cAMP either with dopamine, acting throught D1 receptors,
adrenomedullin, or forskolin, inhibited migration of VSMCs stimulated with PDGF or serum
[102-104]. Studies in rat aortic SMCs suggest that vasoactive agents that elevate intracellular
cAMP inhibit cell movement by disassembling actin stress fibers of the cytoskeleton [105,106].
Furthermore, downregulation of PKA abrogates inhibition of VSMC chemotaxis by forskolin
[89]. The inhibitory effect of cAMP on VSMC migration is re-inforced by the fact that inhibiting
all together PDE3 and PDE4D, the two main PDE isoforms expressed in VSMCs that account
for cAMP hydrolysis in VSMC [26,30,107] markedly potentiated both the anti-migratory effect
and the increase in cAMP caused by forskolin and significantly inhibited PDGF-induced
VSMC proliferation and migration [90,108,109]. In addition, Newman et al demonstrated that
forskolin inhibits TNFα-induced interleukin 6 expression and migration in human vascular
smooth muscle cells [110]. This effect could involve the transcription factor CREB since PDGF-
induced migration was decreased by active CREB and augmented with dominant negative
CREB [66,95] ; In addition, a negative correlation has been described between the CREB level
and the PDGF-activated SMC migration [64]. Nonetheless, the role of CREB in SMC migration
remains unclear since CREB has been demonstrated to be involved in UTP, arachidonic acid
and TNF alpha-induced SMC migration of VSMCs [111,112]. Moreover, recent studies show
that oxidized and non-oxidized fatty acids induce SMC motility through this transcription
factor [113,114].
4.2.2. A specific endogenous pool of cAMP induces migration of trans- differentiated VSMCs
By demonstrating that differential  expression of ACs isoforms in two VSMC models ac‐
count for opposite effects of isoprenaline on cAMP production in VSMC, Webb and co-
workers suggested for the first time that changes of AC isoform(s) expression in VSMCs
could account for the manifestation of vascular diseases [18].  In line with this study, Li‐
mon’s  group recently  demonstrated that  the  emergence of  the  calcium/calmodulin posi‐
tively regulated AC isoform 8 (AC8) in trans-differentiated VSMCs is involved in VSMC
migration. Type 8 AC is barely undetectable in differentiated VSMCs and is strongly in‐
duced in trans-differentiated VSMCs. A causal relationship between AC8 apparition and
the  migratory  capacities  of  VSMCs has  been  established.  Indeed,  authors  show that  10
days after  balloon angioplasty2,  rat  carotid artery displayed high AC8 immuno-labelling
only in the neo-intima and was no longer detectable when it  was analyzed after the re-
endothelization  phenomenon  during  which  VSMC migration/proliferation  halted.  More‐
2 Balloon angioplasty in rat carotid artery serves as an in vivo model of VSMC migration and proliferation.
Current Trends in Atherogenesis132
over,  the  forced  expression  of  AC8  in  primary  rat  VSMC  cultures  triggered  the  re-
colonization  of  a  wounded  zone,  whereas  blocking  it  in  IL-1β−cells  stopped  the  IL-1β-
induced  migration  [21]  This  finding  was  extending  in  vivo,  on  human  samples,  where
only the neo-intimal VSMCs a high level of AC8. Of note, AC8 is well known for its role
in  stress  adaptation,  mood disorders  and  opiate  dependence  [115].  The  involvement  of
this  enzyme in  VSMC trans-differentiation was  therefore  unexpected.  Molecular  mecha‐
nisms  underlying  AC8-mediated  VSMC  migration  does  not  involve  PKA  but  could  in‐
volve  Epac1  since  it  has  been  shown  that  Epac  1  expression  is  upregulated  in  the
neointima  after  vascular  injury  of  mouse  arteries  and  induces  VSMC  migration.  More‐
over Rap1, one of the described targets of Epac, is well known for its involvement in cell
migration [116].
4.3. cAMP has dual opposite effects on inflammation of trans-differentiated VMCs
A study from Adkins and coll. demonstrate that the elevation of intracellular cAMP by
rapamycin inhibits the secretion of the pro-inflammatory molecule Tumor Necrosis Factor
alpha (TNF-α) in lipopolyssacharide treated VSMCs from human saphenous vein segments
[110]. Adversely, Clement and collaborators suggest that the production of cAMP specifically
by AC8 is involved in the potentiator effect of prostaglandin E2 (PGE2) on the secretion of
phospholipase A2 (sPLA2), a marker of inflammation, in response to interleukine 1 β (IL1β)
in primary cultures of rat aortic smooth muscle cells [20]. In details, authors show that PGE2
i) induces the transition of CMLV towards a trans-differentiated/ inflammatory state through
the activation of the subtype 4 Gs-linked PGE2 receptor EP4, ii) acts in synergy with IL1β to
potentiate the secretion of phospholipase A2 and the disorganization of the alpha actin
cytoskeleton. This potentiator effect is the result of a simultaneous activation of PGE2 receptors
EP4 and EP3: in differentiated VSMC, EP3 receptors inhibit cyclase activity induced by EP4
and become activator of this activity in trans-differentiated VSMC. This switch of regulation
is the result of the emergence of AC8 in IL1β−treated VSMC.
4.4. cAMP inhibits collagen synthesis of trans-differentiated VSMCs
Synthetic VSMCs, in the atherosclerotic and neointimal lesions, produce an abundant exra-
cellular matrix (ECM), rich in type I collagen (collagen I). This ECM plays an important role
in vessel wall thickening and in the occlusion of the vessel lumen. In addition, collagen I in
vascular lesions may also regulate VSMC proliferation/migration, platelet circulation, mono‐
cyte activation, lipid accumulation, calcification, and plaque stability [74]. cAMP elevating
agents have been shown to inhibit collagen I synthesis induced by fetal calf serum- and TGF-
β [75]. Emergence of PDE1-c in trans-differentiated SMCs from rat aortic and human saphe‐
nous vein explants opposes the inhibitory effect of cAMP on collagen 1 synthesis, and accounts,
at least in part, for the increase of collagen 1 expression in trans-differentiated VSMCs. The
use of specific pharmacological inhibitors and si-RNA reveal that the cAMP-mediated
inhibitory effect on collagen 1 synthesis involves cyclic nucleotide gated channels but not PKA,
nor Epac [76].




Depending on the relative abundance and localization of the components of the cAMP signal‐
ling pathways, cAMP effects on VSMC vary in differentiated and trans-differentiated VSMCs
(Figure 4). Because trans-differentiated VSMCs play a crucial role in atherosclerosis and are
solely  responsible  for  post-angioplasty  restenosis,  understanding  molecular  mechanisms
leading to VSMC trans-differentiation is crucial to develop novel therapeutic strategies. Re‐
ducing post-angioplasty restenosis which affects 20-25% of patients treated with bare metal
stents, is one of the major challenges in cardiovascular medicine. At the beginning of 2000’s,
the apparition of stents locally releasing anti-proliferative drugs (ie drug-eluting stents (DES),
have significantly changed interventional cardiology, due to their remarkable ability to reduce
restenosis compared to bare metal stents, However, their overwhelming success has quickly
decreased since is limited due to an increased risk of late stent thrombosis. Poor re-endothelial‐
ization remains the major important pathologic predictor of late stent thrombosis [117], there‐
fore, it has been suggested that DES should ideally have a selective anti-migratory and/or
proliferative effect on VSMCs, without affecting, or, even better, promoting re-endothelializa‐
tion [77,118]. Identifying the specific components of the cAMP pathway specifically involved
in VSMC trans-differentiation may be a novel concept for the development of new drugs for
DES, therefore improving the treatment of pathological vascular remodellings.
Figure 4. Expression of cAMP components in differentiated and trans-differentiated VSMC and consequences on
VSMC functions. AC adenylyl cyclase; AKAP A-kinase anchoring proteins; Epac exchange proteins directly activated by
cAMP; CREB cAMP response element binding protein; PDE phosphodiesterases.
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1. Introduction
Although until recently it is presumed that the greater portion of the genome has no biological
role, the current advances in genome research and RNA biology have provided evidence
indicating that a large section of the human and most eukaryotic genome is transcribed as non-
protein-coding RNAs or non-coding RNAs (ncRNAs)[1,2]. Only about 2% of the eukaryotic
genome sequence codes for protein encoding genes and the remaining so called “junk” DNA
are thought to have no functional significance [3, 4]. Based on large scale studies of human and
other eukaryotic genomes it is estimated that about 98 % of the transcriptional output of their
genomes is RNA that does not encode protein implying that the genomes are gorged with
either inept RNA transcripts or with ncRNA transcripts that exhibit unanticipated functions
in eukaryotic biology. However, recent development of new technologies in molecular biology
and human genetics such as genome tiling [4,5], microarrays, and next generation RNA-
sequencing (RNA-Seq) [6,7] have enabled the discovery of different types of ncRNAs that do
not code for protein product [8-10]. Even though ncRNAs do not encode proteins, they play
pivotal roles in the complex networks that are necessary to regulate cellular functions via
transcriptional and translational regulation of protein coding genes that are crucial to normal
development and physiology, and to disease [11]. Moreover, many of the ncRNAs are highly
conserved and susceptible to epigenetic and genetic defects that affect normal development
and disease process significantly [12-15].
There are copious non-coding transcripts that participate principally in regulating cellular
protein synthesis, which are grouped into different classes based on their size, function and
association with transcription start site [1, 12, 16-18]. According to their size, ncRNAs are
categorized into: small ncRNAs, 20 to 200 nucleotides long, which includes microRNAs
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(miRNAs), PIWI-interacting RNAs (piRNAs) and small nucleolar RNAs (snoRNAs); long
ncRNAs (lncRNAs) that are longer than 200 nucleotides; and macro ncRNAs, longer than 200
nucleotides that can reach 100 kilobases (kb) longer without being processed into small
ncRNAs [1,7,12,18]. Based on where they are derived from within the genome, lncRNAs can
be distinguished from each other. There are intronic lncRNAs (transcribed between exons of
genes), intergenic lncRNAs (transcribed from the space between two genes) and lncRNAs that
are derived from the regions that overlap both exon and intron of a coding gene. Furthermore,
each of these ncRNAs may also be in the sense or in the antisense direction. According to
functional significance, ncRNAs can be divided into: (1) housekeeping ncRNAs and (2)
regulatory ncRNAs. Housekeeping ncRNAs include constitutively expressed ncRNAs that are
crucial for the normal function and cellular viability, which include transfer RNAs, ribosomal
RNAs, small nuclear RNAs, and snoRNAs [18]. On the contrary, regulatory ncRNAs or
riboregulators include ncRNAs such as miRNAs and lncRNAs that are expressed in response
to external signals, during different cellular states such as cellular differentiation or at certain
stages of development, influencing the expression of other genes at transcription and transla‐
tional levels [1, 7, 12, 18]. Regarding ncRNAs that are associated with transcription start sites
of genes, there are different classes of ncRNAs such as promoter-associated small RNAs
(PASRs) [16], transcription start site-associated RNAs (TSSa-RNAs) [19], promoter upstream
transcripts (PROMPTs) [20] and transcription initiation RNAs (tiRNAs) [21]. Even though their
functional roles are poorly delineated, perhaps they have a regulatory role in transcription.
Among the ncRNAs, the most widely studied and comparatively well delineated regarding
their functional relevance to normal development and physiology, and to pathogenesis of
disease are, small microRNAs [1, 12, 22-25]. miRNA deficiencies or surpluses have been
correlated with diverse clinically important diseases including various types of cancers,
neurological diseases, metabolic diseases, cardiovascular diseases, and many others [22,
25-32]. Here, we provide an overview of the current knowledge of miRNAs that participate in
the regulation of vascular smooth muscle cells (VSMC) phenotypic modulation and present
the potential opportunities for miRNA-based therapeutic and diagnostic approaches for
vascular proliferative diseases due to atherosclerosis and restenosis. Finally, we briefly
describe our preliminary unpublished data on miRNA expression profile of VSMC in response
to butyrate, a histone deacetylase (HDAC) inhibitor.
2. Atherosclerosis and restenosis
Vascular cell activation and remodeling are the principle events in vascular pathologies such
as atherosclerosis, transplant vasculopathy, post angioplasty restenosis, in-stent restenosis and
bypass graft failure [33, 34]. It is realized that injury to vessel wall by various atherogenic
insults sets-off inflammatory response causing endothelial cell dysfunction. Following
endothelial cell dysfunction, VSMC in the media that are quiescent and contractile in nature,
migrate to intima in response to local inflammation and become proliferative cells. VSMC are
highly specialized cells whose principal function is to regulate the attributes of blood vessels
in the body by appropriately responding to changes in the volume of blood vessels and the
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local blood pressure to facilitate distribution of oxygenated blood to different parts of the body.
In adult vessels, VSMC proliferate at very low rate; display reduced synthetic activity; and
express a unique compilation of proteins that is characteristic of contractile phenotype such as
contractile proteins, ion channels, and signaling molecules. Yet, they still maintain remarkable
plasticity and retain the ability to undergo extreme and reversible changes in phenotype in
response to their local environmental signals, especially during vascular development, and in
response to vascular injury as a key mechanism in wound healing. It is recognized vascular
injury provoked by various atherogenic insults such as mechanical, chemical and immuno‐
logical injuries triggered by different disease risk factors promote VSMC activation, migration
and proliferation, which are precursors to the development of atherosclerosis and neointimal
hyperplasia [34, 35]. VSMC also undergo phenotypic modification from contractile to prolif‐
erative or synthetic phenotype in conjunction with vessel remodeling by altering the cell
number and composition of vessel wall as the primary pathophysiological mechanism in
different clinical pathologies such as postangioplasty restenosis, in-stent restenosis, and vein
bypass graft failure and transplant vasculopathy [34-37]. However, the molecular mechanisms
involved in VSMC phenotypic control are still vague.
During the last few years there is an upsurge in ncRNA research specifically pertaining to a
novel class of small miRNAs because of their role in various biological functions. In a variety
of eukaryotic organisms miRNAs have been demonstrated to play key roles in various cellular
processes including proliferation, differentiation, and apoptosis [38-40], which are central to
normal development and physiology, and pathogenesis of diseases. As such, dysregulation of
miRNAs has been linked to different diseases, including different cancers, neurological,
cardiovascular and other diseases [22, 25-32]. Because of their effects on cellular processes as
gene expression regulators, impairment of miRNAs as evidenced in many cancers, suggest
involvement of miRNAs in the phenotypic modulation of VSMC both in normal and disease
states. Here we briefly describe miRNAs, their biogenesis and mechanism of action and then
summarize the recent progress in the functional significance of miRNAs in VSMC phenotypic
modulation and response to injury.
3. miRNAs
miRNAs are endogenous, well conserved, small ncRNAs, usually 20 to 26 nucleotides, that
mediate posttranscriptional gene silencing by complimentary binding to the 3’-untranslated
region (3’-UTR) of their target mRNA, leading to direct target mRNA degradation or transla‐
tional repression, a key phenomenon for controlling gene expression in a tissue- and devel‐
opment-specific manner [1, 38-40]. They were first detected in Caenorhabditis elegans as
regulators of development in 1993 [41] and since then they have been found in many species
of plants and animals. There are several differences between plants and eukaryotic mRNAs.
In plants, transcriptional repressions require a perfect or near-perfect target match, whereas
mismatched target can cause gene silencing at the translational level in eukaryotes. In eukar‐
yotes, miRNA complementarity typically includes the 5’ bases 2-7 of the miRNAs, which is
referred as miRNA “seed” region, Furthermore, one miRNA can target many different sites
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(miRNAs), PIWI-interacting RNAs (piRNAs) and small nucleolar RNAs (snoRNAs); long
ncRNAs (lncRNAs) that are longer than 200 nucleotides; and macro ncRNAs, longer than 200
nucleotides that can reach 100 kilobases (kb) longer without being processed into small
ncRNAs [1,7,12,18]. Based on where they are derived from within the genome, lncRNAs can
be distinguished from each other. There are intronic lncRNAs (transcribed between exons of
genes), intergenic lncRNAs (transcribed from the space between two genes) and lncRNAs that
are derived from the regions that overlap both exon and intron of a coding gene. Furthermore,
each of these ncRNAs may also be in the sense or in the antisense direction. According to
functional significance, ncRNAs can be divided into: (1) housekeeping ncRNAs and (2)
regulatory ncRNAs. Housekeeping ncRNAs include constitutively expressed ncRNAs that are
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transcripts (PROMPTs) [20] and transcription initiation RNAs (tiRNAs) [21]. Even though their
functional roles are poorly delineated, perhaps they have a regulatory role in transcription.
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disease are, small microRNAs [1, 12, 22-25]. miRNA deficiencies or surpluses have been
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neurological diseases, metabolic diseases, cardiovascular diseases, and many others [22,
25-32]. Here, we provide an overview of the current knowledge of miRNAs that participate in
the regulation of vascular smooth muscle cells (VSMC) phenotypic modulation and present
the potential opportunities for miRNA-based therapeutic and diagnostic approaches for
vascular proliferative diseases due to atherosclerosis and restenosis. Finally, we briefly
describe our preliminary unpublished data on miRNA expression profile of VSMC in response
to butyrate, a histone deacetylase (HDAC) inhibitor.
2. Atherosclerosis and restenosis
Vascular cell activation and remodeling are the principle events in vascular pathologies such
as atherosclerosis, transplant vasculopathy, post angioplasty restenosis, in-stent restenosis and
bypass graft failure [33, 34]. It is realized that injury to vessel wall by various atherogenic
insults sets-off inflammatory response causing endothelial cell dysfunction. Following
endothelial cell dysfunction, VSMC in the media that are quiescent and contractile in nature,
migrate to intima in response to local inflammation and become proliferative cells. VSMC are
highly specialized cells whose principal function is to regulate the attributes of blood vessels
in the body by appropriately responding to changes in the volume of blood vessels and the
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local blood pressure to facilitate distribution of oxygenated blood to different parts of the body.
In adult vessels, VSMC proliferate at very low rate; display reduced synthetic activity; and
express a unique compilation of proteins that is characteristic of contractile phenotype such as
contractile proteins, ion channels, and signaling molecules. Yet, they still maintain remarkable
plasticity and retain the ability to undergo extreme and reversible changes in phenotype in
response to their local environmental signals, especially during vascular development, and in
response to vascular injury as a key mechanism in wound healing. It is recognized vascular
injury provoked by various atherogenic insults such as mechanical, chemical and immuno‐
logical injuries triggered by different disease risk factors promote VSMC activation, migration
and proliferation, which are precursors to the development of atherosclerosis and neointimal
hyperplasia [34, 35]. VSMC also undergo phenotypic modification from contractile to prolif‐
erative or synthetic phenotype in conjunction with vessel remodeling by altering the cell
number and composition of vessel wall as the primary pathophysiological mechanism in
different clinical pathologies such as postangioplasty restenosis, in-stent restenosis, and vein
bypass graft failure and transplant vasculopathy [34-37]. However, the molecular mechanisms
involved in VSMC phenotypic control are still vague.
During the last few years there is an upsurge in ncRNA research specifically pertaining to a
novel class of small miRNAs because of their role in various biological functions. In a variety
of eukaryotic organisms miRNAs have been demonstrated to play key roles in various cellular
processes including proliferation, differentiation, and apoptosis [38-40], which are central to
normal development and physiology, and pathogenesis of diseases. As such, dysregulation of
miRNAs has been linked to different diseases, including different cancers, neurological,
cardiovascular and other diseases [22, 25-32]. Because of their effects on cellular processes as
gene expression regulators, impairment of miRNAs as evidenced in many cancers, suggest
involvement of miRNAs in the phenotypic modulation of VSMC both in normal and disease
states. Here we briefly describe miRNAs, their biogenesis and mechanism of action and then
summarize the recent progress in the functional significance of miRNAs in VSMC phenotypic
modulation and response to injury.
3. miRNAs
miRNAs are endogenous, well conserved, small ncRNAs, usually 20 to 26 nucleotides, that
mediate posttranscriptional gene silencing by complimentary binding to the 3’-untranslated
region (3’-UTR) of their target mRNA, leading to direct target mRNA degradation or transla‐
tional repression, a key phenomenon for controlling gene expression in a tissue- and devel‐
opment-specific manner [1, 38-40]. They were first detected in Caenorhabditis elegans as
regulators of development in 1993 [41] and since then they have been found in many species
of plants and animals. There are several differences between plants and eukaryotic mRNAs.
In plants, transcriptional repressions require a perfect or near-perfect target match, whereas
mismatched target can cause gene silencing at the translational level in eukaryotes. In eukar‐
yotes, miRNA complementarity typically includes the 5’ bases 2-7 of the miRNAs, which is
referred as miRNA “seed” region, Furthermore, one miRNA can target many different sites
MicroRNAome of Vascular Smooth Muscle Cells: Potential for MicroRNA-Based Vascular Therapies
http://dx.doi.org/10.5772/54636
149
on the same mRNA or many different mRNAs, and a single mRNA can be under stringent but
redundant control of several miRNAs. Another difference is the location of target sites on
mRNAs. In eukaryotes miRNA target sites are in the 3’-UTRs of the mRNAs. In plants, target
sites are normally in the coding region but they can be present in the 3’-UTRs.
miRNAs are predicted to target about 60% of protein coding transcripts [12, 42, 43]. At present
the number of miRNA sequences deposited in miRBase (Release 16) include over 15,000
miRNA loci, expressing over 17,000 distinct mature miRNA sequences from 142 species [44].
Moreover, recent appreciation in miRNA research in eukaryotes implicates that these key gene
expression regulators control various biological processes as diverse as cell proliferation, cell
differentiation, apoptosis, and stem cell division particularly in mammalian development
[38-40, 45]. In spite of tremendous advances in miRNA research, the role of miRNAs in
physiological and pathophysiological processes is just emerging. Recent miRNA expression
studies demonstrate miRNAs in cardiovascular development [46], brain development [47],
viral infection [48], metabolism [29], different types cancer, neurologic and cardiovascular
diseases [22, 25-32] suggesting link between miRNAs and wide range of tissue development
and diseases. In effect, miRNAs are considered as trans-acting gene regulatory molecules,
similar to and as important as transcription factors in the control of gene expression [49].
Although miRNAs are considered to act as intracellular RNAs to control gene expression at
posttranscriptional level, recent studies have detected miRNAs in circulating blood and in cell
culture medium indicating they may be useful as biomarkers of disease [50, 51].
4. Biogenesis of miRNAs
The transcription of miRNAs depends on their location within the genome. Most of the miRNA
genes are located throughout the genome in introns, exons and intergenic regions with many
miRNAs produced from clusters of coexpressed genes. Some miRNA transcription depends
on same RNA polymerase II promoters that drive the transcription of mRNAs. miRNA genes
located in intronic regions that includes half of known miRNAs genes often depend on the
expression of host gene [52, 53]. Some miRNA genes with independent promoters are tran‐
scribed from their own RNA polymerase II promoters. Additionally a small number of
miRNAs genes are transcribed by RNA polymerase III. Those miRNAs organized in clusters
for example, miRNA-17-92-family, share the same transcriptional regulation and are grouped
together in one cluster on a single unprocessed transcript and expressed together [54].
5. The pathway of miRNA biogenesis and gene silencing
The process of miRNA biogenesis starts in the nucleus as depicted in the following Figure [12,
31, 32]. miRNAs are transcribed as hundreds or thousands of base long large primary miRNA
species (pri-miRNA) by RNA polymerase II or RNA polymerase III. These pri-miRNA
transcripts fold into a stem loop or hairpin structures with capped 5’ end and polyadenylated
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(poly A) tail on 3’ end [55]. Following transcription by RNA polymerase II/III, pri-miRNA
transcripts are trimmed to about 60 to 100 nucleotide hairpin structures with ~2 nucleotide 3’
overhang to form precursor miRNAs (pre-miRNAs) by the action of nuclear microprocessor
complex. Microprocessor complexes are formed of Drosha (RNASEN), a nuclear ribonuclease
RNase III enzyme and its partner DGCR8 (DiGeorge critical region 8) also called as Pasha
(Partner of Drosha). The pre-miRNA transcripts are then shuttled to cytoplasm for further
processing via Exportin5 and Ran-GTP6. Pre-miRNAs are processed further in the cytoplasm
by the action of Dicer, another RNase III enzyme, with the assistance of double-stranded RNA
binding proteins (dsRBPs) including TRBP (tar RNA binding protein), resulting in the cleavage
of hairpin loop of pre-miRNAs leading to formation of ~22 nucleotide mature miRNA
duplexes. Mature duplex is composed of a matured miRNA strand referred as guide strand
and a complimentary strand referred as the passenger strand. The gene silencing capability
depends on Dicer-mediated loading of one of the miRNA strands, usually guide strand, in the
RNA-induced silencing complex (RISC) together with Argonaute (Ago) protein. The RISC
guides the miRNA to bind to its complementary sequence within the 3’-UTR of its target
mRNA. The degree of complementarity between the seed sequence of the miRNA and the 3’-
UTR of its target mRNA determines whether to mediate mRNA degradation or to disrupt
translation.
6. MicroRNAome of VSMC
miRNAs are relatively new regulatory molecules that are identified about a decade ago and
demonstrated to have regulatory role in every organism and in every biological functions
influencing normal biology and disease process. Once again, oncology research is in the
leading position in understanding miRNA involvement in human diseases. Although most of
the miRNA knowledge is coming from cancer research, during the past few years their role in
other systems and diseases are emerging and rapidly being evaluated with new technologies
such as deep sequencing. It is not surprising that interest in miRNA is also on the raise in
cardiovascular research field. Literature on the roles and functions of miRNAs in normal
cardiovascular development and in vascular pathologies is escalating [32, 46, 56-60]. Further‐
more, importance of miRNAs in the regulation of VSMC development and phenotypic
modification, and response to injury is swiftly being explored because VSMC proliferation and
migration are important events in vascular proliferative diseases. Here we will summarize
recent updates on the significance of miRNAs in VSMCs and their role in phenotypic modu‐
lation of VSMC, thus to vascular proliferative diseases [32, 57-60]. Most of the knowledge of
VSMC miRNAs is coming from culture cells, animal models and blood samples of cardiovas‐
cular disease patients.
7. Evaluation of essential role of miRNAs in VSMC
Because activity of Dicer is essential for the miRNA processing, loss of Dicer activity should
result in global loss of miRNAs. Importance of miRNAs for VSMC development and biolo‐
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(poly A) tail on 3’ end [55]. Following transcription by RNA polymerase II/III, pri-miRNA
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depends on Dicer-mediated loading of one of the miRNA strands, usually guide strand, in the
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guides the miRNA to bind to its complementary sequence within the 3’-UTR of its target
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UTR of its target mRNA determines whether to mediate mRNA degradation or to disrupt
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miRNAs are relatively new regulatory molecules that are identified about a decade ago and
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influencing normal biology and disease process. Once again, oncology research is in the
leading position in understanding miRNA involvement in human diseases. Although most of
the miRNA knowledge is coming from cancer research, during the past few years their role in
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such as deep sequencing. It is not surprising that interest in miRNA is also on the raise in
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cardiovascular development and in vascular pathologies is escalating [32, 46, 56-60]. Further‐
more, importance of miRNAs in the regulation of VSMC development and phenotypic
modification, and response to injury is swiftly being explored because VSMC proliferation and
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recent updates on the significance of miRNAs in VSMCs and their role in phenotypic modu‐
lation of VSMC, thus to vascular proliferative diseases [32, 57-60]. Most of the knowledge of
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gy can be validated by knocking out the miRNA processing enzyme Dicer in VSMC. To
demonstrate the importance of miRNAs in VSMC development and function, a smooth
muscle restricted -Dicer knockout model, SM-Dicer KO mice, is investigated recently [59,61].
Outcomes of the study indicate deletion of Dicer causes embryonic lethality due to de‐
creased VSMC proliferation and differentiation resulting in thinner vessel walls, impaired
contractility and hemorrhage as well as reduced expression of VSMC-specific genes and
proteins [59, 61]. Overall, these observations suggest that Dicer-generated miRNAs are cru‐
cial for normal VSMC development, differentiation and contractile function.
Figure 1. Biogenesis of miRNA and gene silencing pathway. The miRNA synthesis starts in the nucleus where pri-
miRNA transcript is cleaved by Drosha/ DGCR8 to form ~60-100 nucleotides long hairpin loop pre-miRNA. Pre-miRNA
is then transported to cytoplasm through the mediation of Exportin5 and Ran-GTP6 where it is further processed by
RNase activity of Dicer to ~22 nucleotides mature miRNA duplex. The miRNA duplex then loads onto Ago in the RISC
complex and undergoes strand separation. The guide strand of the miRNA mediates gene silencing by degrading the
target mRNA or interfering with translational process. The passenger strand gets degraded.
8. miRNA regulation of VSMC phenotype
VSMC exhibit remarkable plasticity by adapting to local conditions via phenotypic modula‐
tion. Phenotypic modulation of VSMC is a highly complex process regulated by transcription
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factors and other gene products and multiple pathways that are still vaguely understood.
Recently several reports have demonstrated the involvement of miRNA-mediated gene
silencing in the regulation of VSMC proliferation, migration and differentiation in normal
vascular development and in vascular pathologies. A list of a few selected miRNAs that
regulate VSMC proliferation and differentiation in cell cultures and animal models with
angioplasty is shown in Table 1 along with factors that regulate miRNA expression, their
validated target proteins and function of the target proteins. While some of these miRNAs
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Table 1. miRNAs regulating vascular smooth muscle cell phenotype
9. miRNAs in the mediation of VSMC proliferation
Some miRNAs, such as miR-21, miRNA-221, miRNA-222 and 146a are demonstrated to
promote VSMC proliferation in balloon-injured rat carotid arteries and cultured rat VSMC by
silencing their target proteins (Table 1). Among these, miRNA-21 is the first miRNA that is
recognized to regulate VSMC growth and survival by silencing phosphatase and tensin
homolog (PTEN), a tumor suppressor protein and increasing B-cell lymphoma 2 (Bcl-2), which
increased VSMC proliferation and survival [32,59-62]. Interestingly, this same miRNA is
shown to regulate features of both proliferative and contractile phenotype by separate
mechanisms. Through the regulation of processing of the miRNA-21 primary transcript to the
mature miRNA -21 transcript, transforming growth factor-β (TGF-β) and bone morphogenetic
proteins (BMPs) increased the miRNA-21. This increased miRNA-21 is shown to promote
VSMC differentiation by upregulating VSMC restricted contractile proteins by silencing
programmed cell death 4, a tumor suppressor protein [63].
Other miRNAs that stimulated proliferative phenotype include miRNA-221 and -222. Their
proliferative effect on VSMC is mediated through silencing of their target proteins, p27kip1
and p57kip2, respectively, both of which are negative regulators of cell cycle progression [32,
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64]. miRNA-146a is shown to directly target Krupple-like factor-4 (KLF-4) and promote VSMC
proliferation in cultured rat VSMC and vascular neointimal hyperplasia [32, 60, 65]. KLF-4 and
miRNA-146a appear to exhibit a feedback relationship regulating each other’s expression.
While miRNA-146a inhibits KLF-4 expression by targeting the 3’-UTR region of KLF-4, KLF-4
inhibits miRNA-146a at the transcriptional level. KLF-5, another member of KLF family
promoted the transcription of miRNA-146a. It appears these molecules form a regulatory
control to appropriately modulate VSMC proliferation [32, 60].
10. miRNAs in the suppression of VSMC proliferation
Certain miRNAs including miRNA-143, miRNA-145 and miRNA-26a alter VSMC phenotype
by causing suppression of VSMC proliferation (Table 1). Among these miRNAs, miRNA-143
and -145 are considered master regulators of contractile phenotype by promoting contractile
protein expression [32, 58, 60]. Moreover, miRNA-145 not only stimulates differentiation of
adult VSMC, but also promotes differentiation of multipotent neural crest stem cells into
VSMC [57]. In normal vessel walls the miRNA-143/145 cluster is lavishly expressed. However,
both miRNAs are dramatically reduced not only in injured carotid arteries following angio‐
plasty [32, 58, 60, 66] but also downregulated in different cancer cell lines [67]. Further studies
proved that miRNA-145 is a critical modulator of VSMC differentiation via its target gene
KLF-5. Consistent with this, while the use of miRNA-145 oligonucleotide mimics upregulated
the expression of VSMC differentiation marker genes such as SM α-actin, calponin, and SM-
MHC, both at gene and protein levels, overexpression of KLF-5 reduced the gene expression
of SM α-actin implicating a relationship between miRNA-145 and KLF-5 gene in VSMC
differentiation.
Analysis of growth arrested human aortic VSMC by miRNA array screening identified
upregulation of miRNA-26a in differentiated VSMC, which is associated with reduction in
SMAD activity [59, 60, 68]. This miRNA is dramatically downregulated in two murine models
of aneurysm.
Embryonic stem cells are known to differentiate to VSMC and one of the factors that induces
VSMC differentiation is all trans retinoic acid, which in addition to regulating a wide variety
of protein coding genes it also regulates expression of miRNAs that affect smooth muscle cell
differentiation. It is found that expression of miRNA-10a contributes to retinoic acid-induced
VSMC differentiation by negatively regulating its target histone deacetylase 4 [69]. Involve‐
ment of miRNAs in stem cell and vessel wall progenitor cell differentiation has significant
implications in the pathogenesis of atherosclerosis, the response to vascular injury and
vascular remodeling.
11. Circulating miRNAs
Recently presence of miRNAs is demonstrated in circulating blood, which may be useful as
biomarkers for diseases [51]. Analysis of serum or plasma for circulating levels of miRNAs in
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normal individuals and in patients with coronary artery disease revealed circulating levels of
angiogenesis-related miRNA-126 and miRNA-92a, the inflammation-associated miRNA-155;
and VSMC-enriched miRNA-145 and miRNA-17 are significantly reduced in patients with
coronary artery disease compared to normal individuals [51]. Whereas cardiac muscle-
enriched miRNAs, miRNA-133a and -208a are elevated in patients with disease. These
observations suggest that circulating miRNAs can be used as biomarkers for diagnosis of
cardiovascular diseases.
12. miRNAs in atherosclerosis and neointimal hyperplasia
Although  roles  of  various  miRNAs and  their  participation  in  biological  processes  have
been  recognized  in  various  cultured  cells  or  animal  models,  and  expression  profiles  of
circulating miRNAs in patients of cardiovascular diseases [50, 51], involvement of miRNAs
in human atherosclerotic plaques has received little attention. However, one of the recent
studies investigated miRNA/mRNA expression profiles of human atherosclerotic plaques
from peripheral arteries in comparison to nonatherosclerotic left internal thoracic arteries
to determine the relationship between miRNA/mRNA expression profiles  and biological
processes  in  atherosclerosis  [70].  Results  of  this  study  revealed  significant  amounts  of
miRNA-21,-34a,  -146a,  -146b-5p,  and  -210  expressions  in  atherosclerotic  lesions.  Consis‐
tent with this there was downregulation of several predicted targets of these miRNAs in
atherosclerotic  plaques.  According  to  the  combination  of  miRNA/mRNA  profiles  and
bioinformatic  analysis,  nine  KEGG  pathways  including  immunodeficiency,  metabolism,
p53  and  cell  proliferation  signaling  pathways  enriched  with  predicted  targets  were
significantly upregulated. On the contrary, VSMC contraction and purine metabolism were
downregulated.
13. miRNAs in restenosis
Role of miRNAs in restenosis is mainly studied using the common rat carotid artery balloon
injury animal model. miRNA profiles in the carotid artery is determined by using miRNA
arrays [62]. One of the miRNA that was aberrantly overexpressed in injury-induced neointimal
lesions is miRNA-21. miRNA-21 promotes VSMC proliferation and inhibits apoptosis of
VSMC by directly targeting PTEN and programmed cell death 4, respectively [32]. Similarly
miRNA-221 and -222, which are encoded by a gene cluster on X chromosome, share the same
seed sequence, identical targets and similar functions were upregulated in balloon-injured
carotid arteries. Consistent with their upregulation, their target genes, p27kip1 and p57kip2
were downregulated [32, 64]. Additionally, miRNA-143 and miRNA-145 that promote VSMC
differentiation and expressed highly in vascular tissue, were significantly reduced in apoli‐
poprotein E knockout mice where vascular injury was induced by hypercholesterolemic diet
[71]. Cooperatively, both miRNA-143 and miRNA-145 target a network of transcription factors
such as Elk1, KLF-4 and myocardin to stimulate differentiation and inhibit proliferation of
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biomarkers for diseases [51]. Analysis of serum or plasma for circulating levels of miRNAs in
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normal individuals and in patients with coronary artery disease revealed circulating levels of
angiogenesis-related miRNA-126 and miRNA-92a, the inflammation-associated miRNA-155;
and VSMC-enriched miRNA-145 and miRNA-17 are significantly reduced in patients with
coronary artery disease compared to normal individuals [51]. Whereas cardiac muscle-
enriched miRNAs, miRNA-133a and -208a are elevated in patients with disease. These
observations suggest that circulating miRNAs can be used as biomarkers for diagnosis of
cardiovascular diseases.
12. miRNAs in atherosclerosis and neointimal hyperplasia
Although  roles  of  various  miRNAs and  their  participation  in  biological  processes  have
been  recognized  in  various  cultured  cells  or  animal  models,  and  expression  profiles  of
circulating miRNAs in patients of cardiovascular diseases [50, 51], involvement of miRNAs
in human atherosclerotic plaques has received little attention. However, one of the recent
studies investigated miRNA/mRNA expression profiles of human atherosclerotic plaques
from peripheral arteries in comparison to nonatherosclerotic left internal thoracic arteries
to determine the relationship between miRNA/mRNA expression profiles  and biological
processes  in  atherosclerosis  [70].  Results  of  this  study  revealed  significant  amounts  of
miRNA-21,-34a,  -146a,  -146b-5p,  and  -210  expressions  in  atherosclerotic  lesions.  Consis‐
tent with this there was downregulation of several predicted targets of these miRNAs in
atherosclerotic  plaques.  According  to  the  combination  of  miRNA/mRNA  profiles  and
bioinformatic  analysis,  nine  KEGG  pathways  including  immunodeficiency,  metabolism,
p53  and  cell  proliferation  signaling  pathways  enriched  with  predicted  targets  were
significantly upregulated. On the contrary, VSMC contraction and purine metabolism were
downregulated.
13. miRNAs in restenosis
Role of miRNAs in restenosis is mainly studied using the common rat carotid artery balloon
injury animal model. miRNA profiles in the carotid artery is determined by using miRNA
arrays [62]. One of the miRNA that was aberrantly overexpressed in injury-induced neointimal
lesions is miRNA-21. miRNA-21 promotes VSMC proliferation and inhibits apoptosis of
VSMC by directly targeting PTEN and programmed cell death 4, respectively [32]. Similarly
miRNA-221 and -222, which are encoded by a gene cluster on X chromosome, share the same
seed sequence, identical targets and similar functions were upregulated in balloon-injured
carotid arteries. Consistent with their upregulation, their target genes, p27kip1 and p57kip2
were downregulated [32, 64]. Additionally, miRNA-143 and miRNA-145 that promote VSMC
differentiation and expressed highly in vascular tissue, were significantly reduced in apoli‐
poprotein E knockout mice where vascular injury was induced by hypercholesterolemic diet
[71]. Cooperatively, both miRNA-143 and miRNA-145 target a network of transcription factors
such as Elk1, KLF-4 and myocardin to stimulate differentiation and inhibit proliferation of
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VSMC. Taken together, these studies indicate significant role of miRNA-143/miRNA-145 in
VSMC differentiation and vascular disease.
14. miRNAs in histone deacetylase (HDAC) inhibitor arrested VSMC
proliferation
Butyrate, a dietary-derived epigenetic histone modifier and a histone deacetylase (HDAC)
inhibitor, is a strong inhibitor of VSMC proliferation [72-75]. Butyrate elicits many cytoprotec‐
tive,  chemopreventive  and chemotherapeutic  activities  mainly  through inhibition  of  cell
proliferation, induction of cell death or stimulation of cell differentiation by selectively modulat‐
ing gene expression via epigenetic changes [72-75]. Incidentally, the cellular effects that are
stimulated by butyrate are also regulated by miRNAs and expression of some of these miR‐
NAs is regulated by epigenetic mechanisms including DNA methylation and histone modifica‐
tion [76, 77]. Because butyrate is an established epigenetic histone modifier it is possible that
butyrate may alter expression of some of the miRNAs in butyrate arrested VSMC proliferation.
To explore this possibility, we recently examined expression profile of 650 miRNAs in butyrate
inhibited rat VSMC proliferation by qRT-PCR array platform. Our preliminary unpublished data
indicates differential expression of about 60 miRNAs. Among these, members of the miR‐
NA-17-92 cluster are some of the miRNAs that are downregulated by butyrate in VSMC
suggesting that antiproliferation action of butyrate is linked to downregulation of miRNAs of
miRNA-17-92 cluster (Table 2). Studies have shown that the miRNAs of this cluster are not only
involved in normal development of heart, lung and immune system but they also exhibit essential















*Values represent fold changes relative to untreated rat VSMC.
Table 2. Changes in miRNA-17-92 cluster mature miRNAs levels in butyrate treated rat VSMC
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The miRNA-17-92 cluster is a polycistronic miRNA gene, which is titled as oncomir-1 in
humans because of their oncogenic properties and overexpression in different cancers [79].
The miRNA-17-92 primary transcript encodes six mature miRNAs: miRNA-17,-18a, 19a, 20a,
19b-1, and 92a-1 that are tightly grouped within an 800 base-pair region of human chromosome
13 [80]. For some of these members corresponding target genes have been identified, which
include cell cycle inhibitor CDKN1A (p21Cip1) and pro- apoptotic PTEN and BCL2L11 (Bim).
Furthermore, transcription of miRNA-17-92 has been shown to be activated by c-myc tran‐
scription factor [78]. In our earlier studies butyrate has been shown to downregulate c-myc [81]
and upregulate CDKN1A (p21Cip1) [72-75] in proliferation inhibited VSMC. Based on these
observations, it appears by downregulating c-myc expression potentially via epigenetic
modification, butyrate inhibits expression of miRNA-17-92 cluster with a corresponding
increase in miRNA-17-92 target genes such as CDKN1A (p21Cip1). Taken together, our
preliminary miRNA expression data emphasizes role of miRNAs in antiproliferative and
chemoprotective effects of butyrate in VSMC. Further studies are under investigation to
confirm the role of miRNA-17-92 cluster in the regulation of VSMC proliferation by investi‐
gating the effects of miRNA mimics of miRNA-17-92 cluster in reversing the effect of butyrate
on VSMC proliferation and on decreasing the levels of their target proteins. Utilization of this
information is beneficial in targeting miRNAs aimed to decrease the level of pathogenic/
aberrantly expressed miRNAs or to increase miRNAs with valuable functions in the interven‐
tion of occlusive vascular proliferative diseases.
15. miRNAs as new therapeutic targets for vascular proliferative diseases
Despite the substantial progress in understanding the etiology and clinical management of
vascular proliferative diseases, they are still life threatening diseases responsible for the global
burden of cardiovascular diseases. Clinically, medications and surgical procedures are the only
methods of treatment for patients with atherosclerotic disease. Atherosclerotic patients are
generally treated by angioplasty with stent replacement but it commonly leads to restenosis
in significant number of angioplasty patients. Phenotypic modification of VSMC from
contractile differentiated state to proliferative dedifferentiation state is the primary pathophy‐
siological mechanism in the development of atherosclerosis and in different clinical patholo‐
gies such as postangioplasty restenosis, in-stent restenosis, vein bypass graft failure and
transplant vasculopathy [33,34]. Therefore, understanding the molecular mechanisms of
VSMC proliferation may offer novel insights into disease pathogenesis leading to targeted
therapies. Vascular phenotypic modulation is a multifactorial process involving multiple
pathways and multiple genes. Based on the current understanding of the roles of miRNAs in
the normal development and in disease pathogenesis, it appears miRNA-based therapy has a
potential in vascular proliferative diseases, particularly because one endogenous miRNA can
target its multiple target genes. Moreover, demonstration of changes in expression of certain
miRNAs that is specifically associated with particular VSMC phenotype in different models
of studies, as depicted in this article, clearly suggests that expression analysis of miRNA will
provide insights into vascular proliferative disease mechanisms and possibly identifies novel
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VSMC. Taken together, these studies indicate significant role of miRNA-143/miRNA-145 in
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Butyrate, a dietary-derived epigenetic histone modifier and a histone deacetylase (HDAC)
inhibitor, is a strong inhibitor of VSMC proliferation [72-75]. Butyrate elicits many cytoprotec‐
tive,  chemopreventive  and chemotherapeutic  activities  mainly  through inhibition  of  cell
proliferation, induction of cell death or stimulation of cell differentiation by selectively modulat‐
ing gene expression via epigenetic changes [72-75]. Incidentally, the cellular effects that are
stimulated by butyrate are also regulated by miRNAs and expression of some of these miR‐
NAs is regulated by epigenetic mechanisms including DNA methylation and histone modifica‐
tion [76, 77]. Because butyrate is an established epigenetic histone modifier it is possible that
butyrate may alter expression of some of the miRNAs in butyrate arrested VSMC proliferation.
To explore this possibility, we recently examined expression profile of 650 miRNAs in butyrate
inhibited rat VSMC proliferation by qRT-PCR array platform. Our preliminary unpublished data
indicates differential expression of about 60 miRNAs. Among these, members of the miR‐
NA-17-92 cluster are some of the miRNAs that are downregulated by butyrate in VSMC
suggesting that antiproliferation action of butyrate is linked to downregulation of miRNAs of
miRNA-17-92 cluster (Table 2). Studies have shown that the miRNAs of this cluster are not only
involved in normal development of heart, lung and immune system but they also exhibit essential
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19b-1, and 92a-1 that are tightly grouped within an 800 base-pair region of human chromosome
13 [80]. For some of these members corresponding target genes have been identified, which
include cell cycle inhibitor CDKN1A (p21Cip1) and pro- apoptotic PTEN and BCL2L11 (Bim).
Furthermore, transcription of miRNA-17-92 has been shown to be activated by c-myc tran‐
scription factor [78]. In our earlier studies butyrate has been shown to downregulate c-myc [81]
and upregulate CDKN1A (p21Cip1) [72-75] in proliferation inhibited VSMC. Based on these
observations, it appears by downregulating c-myc expression potentially via epigenetic
modification, butyrate inhibits expression of miRNA-17-92 cluster with a corresponding
increase in miRNA-17-92 target genes such as CDKN1A (p21Cip1). Taken together, our
preliminary miRNA expression data emphasizes role of miRNAs in antiproliferative and
chemoprotective effects of butyrate in VSMC. Further studies are under investigation to
confirm the role of miRNA-17-92 cluster in the regulation of VSMC proliferation by investi‐
gating the effects of miRNA mimics of miRNA-17-92 cluster in reversing the effect of butyrate
on VSMC proliferation and on decreasing the levels of their target proteins. Utilization of this
information is beneficial in targeting miRNAs aimed to decrease the level of pathogenic/
aberrantly expressed miRNAs or to increase miRNAs with valuable functions in the interven‐
tion of occlusive vascular proliferative diseases.
15. miRNAs as new therapeutic targets for vascular proliferative diseases
Despite the substantial progress in understanding the etiology and clinical management of
vascular proliferative diseases, they are still life threatening diseases responsible for the global
burden of cardiovascular diseases. Clinically, medications and surgical procedures are the only
methods of treatment for patients with atherosclerotic disease. Atherosclerotic patients are
generally treated by angioplasty with stent replacement but it commonly leads to restenosis
in significant number of angioplasty patients. Phenotypic modification of VSMC from
contractile differentiated state to proliferative dedifferentiation state is the primary pathophy‐
siological mechanism in the development of atherosclerosis and in different clinical patholo‐
gies such as postangioplasty restenosis, in-stent restenosis, vein bypass graft failure and
transplant vasculopathy [33,34]. Therefore, understanding the molecular mechanisms of
VSMC proliferation may offer novel insights into disease pathogenesis leading to targeted
therapies. Vascular phenotypic modulation is a multifactorial process involving multiple
pathways and multiple genes. Based on the current understanding of the roles of miRNAs in
the normal development and in disease pathogenesis, it appears miRNA-based therapy has a
potential in vascular proliferative diseases, particularly because one endogenous miRNA can
target its multiple target genes. Moreover, demonstration of changes in expression of certain
miRNAs that is specifically associated with particular VSMC phenotype in different models
of studies, as depicted in this article, clearly suggests that expression analysis of miRNA will
provide insights into vascular proliferative disease mechanisms and possibly identifies novel
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targets for future vascular therapy. This information is important in targeting miRNAs aimed
to decrease the level of abnormally expressed miRNAs and/or to increase miRNAs with
valuable functions in the intervention of occlusive vascular proliferative diseases.
The  recent  demonstration  that  changes  in  expression  of  certain  miRNAs  in  neointimal
lesions, particularly upregulation of miRNA-21 and miRNA-221/-222 and downregulation
of miRNA-145 support proliferative phenotype of VSMC suggests targeting miRNAs may
represent a new form of therapy for vascular proliferative diseases [62, 64]. Furthermore,
silencing  of  miRNA-21  and  miRNA-221/222  by  the  local  delivery  of  chemically  engi‐
neered oligonucleotide-based miRNA inhibitors referred as “antigomirs” are efficient and
specific  silencers  targeted  for  miRNA-21  and  miRNA-221/222  was  shown  to  reduce
neointima formation [62, 64]. Similarly, use of an antagomir against miRNA -122, specifical‐
ly silenced miRNA-122 expression in the liver, lung, intestine, heart, skin and bone marrow
for more than a week after one intravenous injection [82]. In another method, silencing of
mir-145 or miRNA- 143 was achieved by adenovirus-mediated delivery of these miRNAs
to vascular lesion, which appears to restore miRNA profile of vascular lesion that resem‐
bles  normal  tissue [66,  71].  Although these  studies  suggest  that  targeting miRNAs may
represent a new therapy for vascular proliferative diseases, the miRNA-based technology
is still long way from being translated to clinical therapy.
16. Conclusion
Exploring the microRNAome that controls VSMC phenotype and analysis of their targets have
greater possibilities for unraveling unforeseen regulatory pathways and disease mechanisms,
development of novel therapeutic approaches. miRNAs in cardiovascular research are a newly
emerging powerful biomolecules, which demonstrate several unique opportunities for
microRNAs-based therapeutics. Although some of the studies appear to indicate targeting
certain miRNAs presents a potential therapy for atherosclerosis, knowledge of full scope of
miRNAs in vascular pathogenesis is limited. With 1,000 or more microRNAs encoded by the
human genome, only a few of which have been analyzed appear to be linked to vascular
proliferative diseases. Considering the complexity of the multifactorial vascular proliferative
diseases including atherosclerosis and restenosis, there may be several miRNAs and even
several clusters of miRNAs, similar to miRNA-17-92 cluster, which impact the development
of vascular pathogenesis. Therefore, several issues have to be addressed prior to use of miRNA-
based technology can be translated to clinical therapy such as: profile of miRNAs responsible
for vascular proliferative diseases needs to be determined; detailed effects of these miRNAs
in the prevention and treatment of vascular proliferative diseases requires investigation;
procedures for in vivo miRNA silencing needs to be improved to minimize off-target effects;
technology for miRNA upregulation in arterial vessel wall requires development; and
potential toxicity of miRNA-based therapy should be determined. Developing miRNAs into
therapeutics reveals other significant challenges, such as methods of delivery and duration of
action. Methods for local delivery to the arteries via catheters or coated stents may avert these
challenges and should minimize off-target effects on other tissues. Besides their therapeutic
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potential, identification of circulating miRNAs released from injured tissues or highly
expressed in patients with cardiovascular diseases suggest miRNAs can also be useful as
potential biomarkers for clinical diagnosis of cardiovascular disease patients.
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1. Introduction
This review describes theories of human atherogenesis and experimental results evaluating
gene or protein expression in the pigeon model for spontaneous atherosclerosis. The spontane‐
ous disease in the pigeon differentiates from other animal models that require manipulation
(genetic, nutritional, environmental) to induce the disease state. Both susceptible and resistant
pigeons have been studied with susceptibility being inherited as an autosomal recessive trait.
The aims are to present the pigeon data in comparison to current theories of the human disease.
Atherosclerotic cardiovascular disease is the leading cause of death in economically devel‐
oped countries. The underlying cause(s) remains unclear despite a variety of hypotheses
that have attempted to explain the initiation of atherosclerotic lesions. Many genetic factors
that contribute to lesion progression and the probability of plaque rupture have been identi‐
fied in the general population. All forms of heart disease have a strong familial component.
However, little is known about the specific genes that determine disease predisposition or
how such genes interact with each other and the environment to initiate foam cell formation
in any one individual. Numerous, complex gene-environment interactions are believed to be
involved in the disease [1] and “although there has been considerable success in identifying
genes for the rare disorders associated with atherosclerosis, the understanding of genes in‐
volved in the more common forms is largely incomplete” [2]. New molecular markers need
to be developed in order to identify susceptible individuals prior to the appearance of clinical
symptoms. Until the heritable component of atherosclerosis susceptibility is understood,
correlation of various risk factors with specific metabolic or pathological features will be dif‐
ficult to assess, and prevention efforts will remain equivocal.
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2. Theories of human atherogenesis
Many theories have been proposed to explain atherosclerotic lesion initiation in the aorta al‐
though there are model-specific differences in the order of events. The pathological steps
common to all theories of atherogenesis are:
a. Site specific proliferation of intimal smooth muscle cells
b. Elaboration of excessive and/or abnormal extracellular components
c. Accumulation of lipids within and around cells
d. Entry of monocytes/macrophages into area of proliferation
The abnormal accumulation of lipid within smooth muscle and macrophage cells could arise
from increased infiltration (influx), increased retention, decreased efflux, and/or increased
lipid biosynthesis by the cells themselves [3-9].
2.1. Lipid infiltration theory
The lipid infiltration theory states that arterial wall cells will accumulate lipid if there is a
high circulating blood lipid concentration, or a consistently elevated low-density lipopro‐
teins (LDL). In the healthy human aorta, circulating LDL particles are incorporated into vas‐
cular smooth muscle cells (VSMC) by receptor-mediated endocytosis. In atherosclerosis, the
rate of LDL influx could overwhelm these receptors, causing the excess lipid to be taken up
by scavenger receptors. Modified lipoproteins such as oxidized [10], acetylated [11], or par‐
ticularly small (<70 nm) [12], LDL are thought to slip through the loose junctions between
endothelial cells and accumulate in the intima intact. In these cases, because of their altered
conformation, it is hypothesized that the modified LDL molecules are readily incorporated
into VSMC by uncharacterized scavenger receptors. As foam cells develop and burst, mac‐
rophage cells are recruited to the region. The precise mechanism of how cholesterol from
circulating LDL enters the intima to be incorporated in the developing foam cell is not clear.
In addition, the lipid infiltration theory does not, on its own, account for the SMC prolifera‐
tion observed prior to lipid accretion.
If  lipid infiltration of  any type is  coupled with decreased HDL levels,  there  will  be  re‐
duced cholesterol clearance (efflux) from the cells, and the sterol will remain trapped. In
addition,  the  innermost  arterial  cells  are  in  a  state  of  chronic  hypoxia  ]13].  If  the  fatty
acids  released  by  neutral  cholesterol  ester  hydrolase  (NCEH)  are  not  completely  oxi‐
dized,  the  metabolites  will  accumulate  at  an  accelerated  rate  [14],  and  can  potentially
serve  as  substrate  for  endogenous  cholesterol  and/or  triacylglycerol  (TAG)  synthesis.
There is compelling evidence indicating that the increase of intracellular cholesterol is at
least  partly the result  of  biosynthesis,  and not circulating lipoprotein [15]  uptake.  How‐
ever,  this  mechanism  is  not  explained  by  any  of  the  current  theories  of  atherogenesis,
which  are  mainly  focused  on  the  infiltration  and  retention  of  plasma  lipids  and  their
subsequent inflammatory effects.
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2.2. Response to retention theory
The response to retention theory [16] is a proposed explanation for increased circulating
blood lipid retention. According to this theory, as proteoglycans (PG), especially versican
[12, 17], accumulate in the extracellular matrix (ECM) of the proliferating smooth muscle
and recruited macrophage cells, they bind to incoming LDL particles. Electrostatic interac‐
tion between the LDL apoB and the sulfated chains on the core PG protein binds the LDL to
the cell surface [18] where its solubility is decreased [19]. PG-bound LDL is also more likely
to become oxidized, and in either case, the trapped lipoprotein is incorporated into the de‐
veloping foam cell. Presumably the lipid enters the individual cells by the action of scaveng‐
er receptors, but the proponents of this theory do not directly address this element. Despite
this omission, the response to retention theory does provide a concrete mechanism for the
adherence of circulating lipoproteins to the arterial intima. Therefore, advocates of this theo‐
ry [16] claim that essentially all later progression can be traced to the initial attraction of cir‐
culating LDL to ECM proteoglycans.
The aforementioned lipid infiltration and retention theories provide mechanistic evidence of
how lipoproteins can accumulate in the arterial intima, but key steps of atherogenesis are
not addressed. Neither theory offers direct evidence for how cholesterol esters form within
early foam cells, nor do they explain the initial VSMC proliferation prior to lipid accumula‐
tion. Neither theory explains the subsequent entry of monocytes and macrophages to the in‐
filtration region, nor do they explain the predictable locations of lesion development along
the arterial tree.
2.3. Response to injury theory
The observation that both smooth muscle and macrophage cell types were actively recruited
to balloon catheterization sites led to the response to injury hypothesis [20]. According to
this theory, the arterial endothelium is compromised by various perturbations such as envi‐
ronmental chemicals, high concentrations of blood lipids, certain types of bacteria and virus‐
es, autoimmunity, and/or hemodynamic stress [21]. In response, the endothelial cells either
slough off or become porous, allowing the subsequent lipoproteins and macrophages influx
into the arterial intima. Once initial damage has occurred, the exposed intimal cells are in‐
creasingly vulnerable to additional hemodynamic and environmental aggravation, thus per‐
petuating the original injury and eliciting an immune response. Although endothelial
denudation or injury is not necessary for foam cell formation, an obvious and observable in‐
flammatory response seems to exacerbate the developing atherosclerotic plaque during the
disease’s progressive stage.
2.4. Inflammation theory
Atherosclerosis is now considered a chronic inflammatory disease [22], largely because signs
of inflammation occur concomitantly with hypercholesterolemia [23-26] in a variety of ani‐
mal models. This inflammation theory proposes that the immune system is activated as a
direct result of lipid infiltration [27, 28] and so readily explains the presence of monocytes
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2. Theories of human atherogenesis
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and macrophages in the fatty streak. These cells express scavenger receptors that not only
ingest lipid, especially oxidized LDL; they actively secrete cytokines and recruit adhesion
molecules to the region. These actions are thought to be directly responsible for the increase
in extracellular components observed during later stages of atherogenesis [29]. Increasing
complexity of the matrix between cells advances opportunities for proteoglycans to bind
and transform lipid molecules, thereby perpetuating the entire macrophage recruitment and
cytokine signaling process.
In addition to macrophages, endothelial cells, VSMC, and platelets in the developing lesion
are all capable of synthesizing and/or releasing chemoattractants and growth factors [9].
These cellular interactions work together to expand the initial fatty streak to a mature, fi‐
brous plaque over time. The inflammatory response is well correlated with plaque stability,
and there are already blood tests available that will assess the risk of thrombosis based on
the levels of inflammatory markers [30]. However, as with other theories of atherogenesis,
the inflammatory response does not account for the initial VSMC proliferation prior to lipid
accumulation and macrophage recruitment. Nor does it explain that, in humans, early foam
cells are primarily myogenic. For these reasons, the inflammatory theory explains the mech‐
anisms of plaque progression and the likelihood of disease endpoint better than it explains
atherogenesis itself.
2.5. Monoclonal origin theory
A fourth theory of atherogenesis, that has not gained wide acceptance, states that the VSMC
that abnormally proliferate and accumulate lipid are transformed and of monoclonal origin
[31, 32]. The VSMC which develop into foam cells are phenotypically different from their
counterparts in the normal media [33, 34] in that they actively secrete ECM components
such as proteoglycans and collagen [35]. Healthy, fully differentiated VSMC proliferate
slowly and do not synthesize an extensive ECM [36]. Loss of cell cycle control and the ability
to regulate cholesterol metabolism are early hallmarks of cancerous cells, pathological phe‐
notypes that are seen in atherogenesis. However, technological advances in DNA sequence
analyses have confirmed that although VSMC in general are largely heterogenic, subsets of
cells involved in atherogenic events are derived from specific clones [37, 38] that seem to
proliferate in patches [39]. A second observation that supports this controversial theory is
existence of hypo-methylated DNA in atherosclerotic lesions [40]. Decreased methylation is
significantly correlated with increases in transcriptional activity. During cancer develop‐
ment, normally silent oncogenes can be expressed because of under methylation [41]. The
precise atherogenic role of hypo-methylated DNA and clonal VSMC cells is not determined.
Although the  monoclonal  origin  theory  explains  the  proliferation  of  an  altered  popula‐
tion of lipid-accumulating, ECM-producing SMC in the arterial intima, no specific trans‐
formation event or set of pathological conditions have been proposed that would account
for the initial change in differentiation state, methylation status, and/or the increased mi‐
totic rate in a specific VSMC subpopulation. In addition, animal and human examples in
which atherosclerotic  lesions appear  to  regress  [42-44],  are  not  readily  explained by the
monoclonal theory.
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2.6. Smooth muscle cell phenotypic reversion theory
Smooth muscle cell differentiation is a complex process that requires multiple transcription
factors to be successful [45]. The developing embryo’s VSMC are in the synthetic state as
they are actively proliferating and synthesizing their contractile elements, myofilaments,
and ECM to form the arterial intima [35, 46]. Once the blood vessels are fully formed, the
VSMC further differentiate to the contractile state where they stop proliferating and func‐
tion to facilitate muscle contraction in response to stimuli. A healthy vessel wall is able to
maintain both contractility and the quiescent state [34, 47].
During atherogenesis, VSMC seem to revert to the synthetic state where they abnormally
produce an extensive ECM [48]. This phenotypic modulation [35] is believed to occur before
the cells begin to replicate and migrate to the arterial intima, but the stimulus for this change
is unknown. An alternative explanation is that in individuals predisposed to atherosclerosis,
the VSMC never fully differentiate. In either case, modified VSMC are characterized by a de‐
crease in the alpha/beta actin isoform ratio [33, 34, 49, 50] and the loss of the intermediate
filament proteins such as vinculin and desmin [34, 49, 50]. Ongoing efforts have focused on
identifying more VSMC phenotypic markers [36, 45, 51] to clearly define the state of differ‐
entiation including elements driving its change [52, 53]. Despite the narrow focus on the
VSMC role that does not address macrophage recruitment, this idea is a valid attempt to de‐
scribe the earliest cellular atherogenic events [54].
2.7. Hemodynamic stress theory
Hemodynamic stress is a pervasive factor in all atherogenesis theories, because lesions typi‐
cally develop at aortic regions of bi-directional flow. However, if it were simply a matter of
arterial architecture, any organism with a branching aorta would spontaneously develop
foam cells and initiate the atherosclerotic pathology. Because this is not the case, there must
be some as yet unidentified factor intrinsic to the resistant individuals’ vessel wall that can
withstand the low shear stress effects while maintaining the cells in a contractile phenotype.
Many theories explain lipid accumulation in the arterial wall, some describe the preferred
site of fatty streak formation and the appearance of macrophage cells, but none completely
describe the entire series of events that occurs in atherogenesis. Genetic factors clearly influ‐
ence cholesterol metabolism [55], replication rates [56], the immune response [26, 57] and
the mitochondrial oxidative capacity for cellular lipids [58, 59], thereby manifesting an un‐
derlying influence on all aspects of atherogenesis that warrants additional investigation.
3. Pigeon model of atherogenesis
The susceptible-resistant pigeon (Columba livia) model has been employed to understand
genetic components of this disease [60]. White Carneau (WC-As) pigeons develop spontane‐
ous atherosclerosis without known risk factors [61, 62]. The pigeon lesions [63, 64], have
greater similarities to human atherosclerosis than any other animal model of heart disease.
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St. Clair [65] has reviewed multiple studies clearly demonstrating that WC-As susceptibility
resides at the level of the arterial wall. The Show Racer (SR-Ar) pigeon is resistant to the de‐
velopment of atherosclerosis under identical diet and housing conditions, and with similar
blood cholesterol levels [61]. Crossbreeding and backcross experiments demonstrated aortic
atherosclerosis susceptibility to be inherited in a pattern consistent with an autosomal reces‐
sive Mendelian trait [66].
3.1. Differential gene expression
Representational Difference Analysis (RDA) was used in reciprocal experiments to identify
genes expressed differentially between WC-As and SR-Ar aortic VSMC. Difference products
were cloned, sequenced and identified by BLAST against the chicken genome. We found 134
genes with differential expression. An abridged list of the seventy-two transcripts upregu‐
lated in WC-As (Table 1) included caveolin (CAV1) and enolase (ENO1). CAV1, reported as
WAG-65N20 Clone, was not yet annotated in the original analysis. Its subsequent identifica‐
tion was crucial data because CAV1 represented the biggest difference between breeds. Lu‐
mican (LUM) and cytochrome b (CYTB) were among the sixty-two genes upregulated in the
SR-Ar. The abridged list is shown in Table 2.
We  originally  placed  each  individual  transcript  in  6  thematic  metabolic  pathways  us‐
ing  the  Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG)  [67]  and  Pathway  Studio
[68].  These  included  energy  metabolism,  VSMC  phenotype,  transcriptional  regulation,
translational  regulation,  cell  signaling,  and  an  immune  response.  Energy  metabolism
and contractility  pathways  exhibited  the  most  striking  disparity.  Genes  associated  with
glycolysis  and  a  synthetic  VSMC  phenotype  were  expressed  in  WC-As  cells  whereas
SR-Ar  cells  expressed  genes  indicative  of  oxidative  phosphorylation  and  a  contractile
VSMC  phenotype.  In  WC-As  cells,  the  alternatives  of  insufficient  ATP  production  lim‐
iting  contractile  function  or  the  lack  of  functional  contractile  elements  down-regulating
ATP  synthesis  cannot  be  distinguished  due  to  the  compressed  in-vitro  versus  in-vivo
developmental  time frame.  However,  the genetic  potential  for  effectively coupling ener‐
gy  production  to  muscle  contraction  present  in  the  resistant  SR-Ar  was  lacking  in  the
susceptible  WC-As [69,  70].
For this review, we employed the Metacore database [71] from GeneGo (Carlsbad, CA) to
automatically place genes into networks according to their biological function and known
interactions. Monosaccharide catabolism, translation, and multicellular organism develop‐
ment were the most significant biological processes operating in the WC-As VSMC (Table
3). Monosaccharide catabolism was represented by ENO1, lactate dehydrogenase A
(LDHA), transketolase (TKT1), and glucose-phosphate isomerase (GPI). Fourteen genes in‐
volved in translation were upregulated in our experiment including ribophorin (RPN1), Li‐
gatin (LGTN), and a number of ribosomal proteins. Although many genes participate in
multicellular organism development, 46 were upregulated in the WC-As including cyclin D
(CCND2), annexin (ANXA2), collagen (COL5A2), beta actin (ACTB), vimentin (VIM), trans‐
membrane protein 126a (TMEM126A), subunit 3 of the 26S Proteasome ATPase (PSMC3)
and diacylglycerol O-acetyltransferase (DGAT2).
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Gene Product Gene WC-As copies SR-Ar copies
Caveolin-1 CAV1 39 1
Enolase, alpha ENO1 30 0
Retinol binding protein 7 RBP7 19 2
Cleavage & polyadenylation specific factor 2 CPSF2 18 0
Mitochondrial ribosomal protein L27 MRPL27 18 0
N-acetyltransferase 13 (aka MAK3) NAT13 18 0
Ribophorin I RPN1 16 0
Stromal cell-derived factor 1 (aka SDF-1) CXCL12 16 2
Diacylglycerol O-acetyltransferase 2 DGAT2 14 0
26S Proteasome ATPase Subunit 2 PSMC2 14 0
Ribosomal Protein Large Subunit 32 RPL32 9 0
Actin, beta ACTB 9 1
Dachshund homolog-1c DACH1 9 1
Annexin A2 ANXA2 8 0
Ligatin LGTN 8 0
Sec61 alpha SEC61A 8 2
Transketolase TKT1 6 0
Collagen, alpha-2 type I COL1A2 6 1
Aldehyde dehydrogenase E3 ALDH9A1 5 1
Solute carrier protein 25/A6 (ATP/ADP antiporter) SLC25A6 5 3
Nucleoside diphosphate kinase CNDPK 4 0
TNF-alpha induced protein 8 TNFAIP8 4 0
Lactate dehydrogenase subunit A LDHA 3 0
Macrophage erythroblast attacher MAEA 3 0
26S Proteasome ATPase Subunit 3 PSMC3 3 0
Spondin 1 SPON1 3 0
Transmembrane protein 167 TMEM167 3 0
Decorin (dermatan sulfate PG) DCN 2 0
Table 1. Genes with the highest differential expression in White Carneau (WC-As) vascular smooth muscle cells
(VSMC) in representational difference analysis abridged from [70].
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Gene Product Gene WC-As copies SR-Ar copies
Ribosomal Protein Large Subunit 3 RPL3 6 73
Lumican Precursor (keratan sulafate PG) LUM 2 47
Cytochrome b CYTB 0 41
Fibulin-5 precursor (aka DANCE) FBLN5 0 30
Fbronectin type 1 FN1 0 29
Cytochrome Oxidase Subunit II CO II 11 28
Lactate dehydrogenase subunit B LDHB 21 25
Peroxiredoxin 1 PRDX1 8 20
NADH subunit 4 ND4 4 19
Eukaryotic translation initiation factor 4A2 EIF4A2 8 19
SMC Myosin Heavy Chain 11 MYH11 0 12
Proteosome maturation factor UMP1 POMP 6 10
Tropomyosin, alpha TPM1 0 9
26S Proteasome Regulatory Lid (non ATPase) PSMD1 0 8
Myosin light chain kinase; telokin MYLK 0 7
Actin, alpha-2 ACTA2 0 6
Coactosin-like 1 COTL1 0 5
Cytochrome Oxidase Subunit I CO I 0 5
Mariner 1 transposase gene (similar to) SETMAR 0 3
RAS oncogene family (GTP binding) RAB1A 0 3
Sec61 gamma SEC61G 0 3
Squalene epoxidase SQLE 0 3
Ribosomal Protein Small Subunit 8 RPS8 1 3
F0-ATP synthase subunits 6 & 8 ATP6/8 2 3
Fatty acid binding protein 4 FABP4 2 3
Prohibitin 2 (aka B-cell receptor protein 37) PHB2 2 3
Activin A/TGFB Receptor 1 ACVR1 0 2
Fumarate hydratase/fumarase FH 0 2
26S Proteasome ATPase Subunit 4 PSMC1 0 2
Table 2. Genes with the highest differential expression in Show Racer (SR-Ar) vascular smooth muscle cells (VSMC) in
representational difference analysis abridged from [70].
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Biological Process
Ratio of significant expressed genes
from total number of genes involved in
process P-value
monosaccharide catabolic process 8/91 4.737E-09
Translation 14/452 6.498E-09
multicellular organismal development 46/4895 6.897E-09
glucose catabolic process 7/69 1.657E-08
system development 41/4195 2.773E-08
alcohol catabolic process 8/114 2.834E-08
developmental process 47/5334 3.512E-08
establishment of protein localization in endoplasmic
reticulum 8/119 3.970E-08
protein targeting to ER 8/119 3.970E-08
anatomical structure development 473/4620 4.356E-08
Table 3. Biological processes (GeneGo, Carlsbad, CA) upregulated in White Carneau (WC-As) vascular smooth muscle
cells (VSMC) based on representational difference analysis.
The most relevant network from the dataset connects 8 identified genetic transcripts (Figure
1) including the extracellular signals decorin (DCN), and chemokine ligand 12 (CXCL12),
the cytoskeletal components ezrin (VIL2), ACTB, and PSMC3, as well as the nuclear tran‐
scripts ENO1, CCND2, and daschund homoglog 1c (DACH1). The expression of ENO1, a
glycolytic enzyme and a transcription factor, is promoted by three separate network factors.
First, its expression is influenced by DACH1 directly. Second, ENO1 is activated indirectly
by CXCL12, where it works through c-src (not in dataset) and ACTB. Finally, DCN, by way
of talin (not in dataset) also activates ACTB. Once expressed, ENO1 participates generally in
monosaccharide catabolism and specifically accelerates cell proliferation via CCND2.
Smooth muscle contraction and myofibril assembly were the most significant biological
processes in the SR-Ar VSMC (Table 4). These pathways included alpha actin (ACTA2), my‐
osin heavy chain (MYH11), tropomyosin (TPM1) and the telekin transcript from myosin
light chain kinase (MYLK). There were also major differences in cellular component organi‐
zation between the two breeds, with the SR-Ar expressing not only MYH11, but LUM, fibro‐
nectin (FN1), high mobility group transcription factor (HMG1), and activin 1, a receptor for
transforming growth factor beta (TGF1), among many others.
The Figure 2 network depicts the critical nature of SP1, a transcription factor known to regu‐
late VSMC differentiation by turning on the gene for myosin heavy chain [73]. Although SP1
was not found in our experiment, a required cofactor, CRSP2, was upregulated in the SR-Ar.
SP1 also appears to influence alpha actin (ACTA2) activity. ACTA2, expressed in contractile
VSMC of SR-Ar does not seem to influence transcription as does the beta isoform, which is
associated with the synthetic phenotype found in Wc-As.
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Figure 1. Network analysis (GeneGo, Carlsbad, CA) incorporating genes upregulated in White Carneau (WC-As) vascu‐
lar smooth muscle cells (VSMC) based on representational difference analysis. Abbreviations listed in [72].
Biological Process
Ratio of signifcant expressed
genes from total number of
genes involved in process P-value
smooth muscle contraction 12/76 2.981E-17
muscle contraction 14/258 2.311E-13
myofibril assembly 9/64 1.004E-12
muscle system process 14/305 2.247E-12
cellular component organization at cellular level 38/3480 3.841E-12
skeletal myofibril assembly 6/14 4.050E-12
actomyosin structure organization 9/76 5.025E-12
cellular component organization or biogenesis at cellular level 38/3604 1.144E-11
cellular catabolic process 28/1908 1.199E-11
muscle tissue development 14/347 1.270E-11
Table 4. Biological processes (GeneGo, Carlsbad, CA) upregulated in Show Racer (SR-Ar) vascular smooth muscle cells
(VSMC) based on representational difference analysis.
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3.2. Differential protein expression
DNA transcripts of a species do not directly reveal the protein complexity of that organism
[74]. A more complete elucidation of gene expression can be achieved through characteriza‐
tion of the proteins, the biological determinants of phenotype. Towards that goal, soluble
proteins in aortic smooth muscle cells cultured from WC-As and SR-Ar pigeons were ex‐
tracted and separated on two-dimensional electrophoresis gels.
Proteins differentially-expressed were arrayed on a map, plotting molecular weight against
isoelectric point (pI). Eight discrete zones were identified, five which included proteins
unique to susceptible cells and three which included proteins unique to resistant cells. Of
the 88 differentially-expressed proteins from WC-As cells, 41 were located in unique zones
while 29 of 82 differentially-expressed proteins from Sr-Ar cells were in unique zones. Se‐
lected proteins from susceptibility and resistance zones were annotated by peptide mass
fragments, molecular weights, pIs, and correspondence with genes differentially-expressed
between cells from the two breeds. Eight proteins were unique to the WC-As, and eight pro‐
teins were exclusively expressed in the SR-Ar (Table 5). Some of the annotated proteins in‐
cluded smooth muscle myosin phosphatase (MYPT1), myosin heavy chain (MYH11) –and
fatty acid binding protein (FABP) in the SR-Ar. Ribophorin (RPN1), heat shock protein
(HSP70), cyclin (CCND2) and TNFα-inducing factor (TNF) were found in WC-As [75]. Ribo‐
phorin, cyclin, TNFα Induced Protein 8, FABP and MYH11 were also differentially ex‐
pressed in the RDA experiments and are likely important to the atherosclerotic phenotype in
pigeon VSMC.
Figure 2. Network analysis (GeneGo, Carlsbad, CA) incorporating genes upregulated in Show Racer (SR-Ar) vascular
smooth muscle cells (VSMC) based on representational difference analysis. Abbreviations listed in [72].
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Heat shock protein HSP70 WC-As






Inhibitor of kappa light polypeptide enhancer in B cells IKBKAP WC-As
Serine threonine kinase STK SR-Ar
Smooth muscle myosin phosphatase MYPT1 SR-Ar
Activin binding protein FST SR-Ar
Myosin heavy chain MHY11 SR-Ar
Serine threonine protein kinase STK24 SR-Ar
Phosphoglucomutase PGM SR-Ar
Fatty acid binding protein FABP SR-Ar
Peroxiredoxin PRDX1 SR-Ar
Table 5. Annotated differentially-expressed soluble proteins extracted from vascular smooth muscle cells (VSMC) of
White Carneau (WC-As) and Show Racer (SR-Ar) pigeons abridged from [75].
All 16 annotated proteins were entered into GeneGo (Carlsbad, CA) to elucidate the meta‐
bolic networks operating in each breed. In the WC-As, regulation of molecular function, reg‐
ulation of inclusion body assembly, and response to unfolded protein were the most
significant biological processes (Table 6). Heat shock protein contributed to each of these
processes, and was joined by CCND2, TPM1, TNF, and inhibitor of kappa light polypeptide
enhancer in B cells (IKBKAP) in overall regulation of molecular function. In addition to
those mentioned previously, TPM1 and IKBKAP were also differentially expressed in the
RDA experiments. The major biological processes operating in the SR-Ar were myosin thick
filament assembly and organization (Table 7), represented primarily by the proteins MHY11
and MYPT1. This was similar to the RDA experiment, where smooth muscle contraction and
myofibril assembly were indicated by multiple genetic transcripts.
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Biological Process
Ratio of significant expressed
genes from total number of
genes involved in process P-value
negative regulation of inclusion body assembly 3/5 1.604E-09
regulation of molecular function 11/2707 5.827E-09
regulation of inclusion body assembly 3/8 8.975E-09
response to unfolded protein 5/156 2.053E-08
response to topologically incorrect protein 5/162 2.481E-08
regulation of catalytic activity 10/2242 2.507E-08
regulation of cellular component biogenesis 6/379 3.864E-08
negative regulation of myeloid cell apoptosis 3/13 4.576E-08
negative regulation of vasoconstriction 3/14 5.822E-08
protein refolding 3-16 8.951E-08
Table 6. Biological processes (GeneGo, Carlsbad, CA) upregulated in proteomic analysis of White Carneau (WC-As)
vascular smooth muscle cells (VSMC).
Biological Process
Ratio of significant expressed
genes from total number of
genes involved in process P-value
skeletal muscle myosin thick filament assembly 4/8 3.53E-12
striated muscle myosin thick filament assembly 4/8 3.53E-12
myosin filament assembly 4/11 1.66E-11
cardiac muscle fiber development 4/11 1.66E-11
elastic fiber assembly 4/11 1.66E-11
myosin filament organization 4/11 1.66E-11
skeletal myofibril assembly 4/14 5.04E-11
extracellular matrix assembly 4/14 5.04E-11
myofibril assembly 4/64 3.15E-08
actomyosin structure organization 4/76 6.34E-08
Table 7. Biological processes (GeneGo, Carlsbad, CA) upregulated in proteomic analysis of Show Racer (SR-Ar) vascular
smooth muscle cells (VSMC).
The major network operating in the protein data set is depicted in Figure 3. This network
shows the cellular signaling cascade initiated by the cytokine TNFα. Although TNFα itself
was not found in either experiment, its activity is suggested by the induced factors ex‐
pressed in the WC-As. The transcription factors c-Jun and Ap-1 activate TNFα, which then
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induces JAK1 gene expression via two receptors, TNFR1 and TNFR2. JAK1 turns on STAT1
and this pathway is known to regulate VSMC inflammatory processes [76]. TNFα also exerts
its biological effect on apoptotic peptidase activating factor 1 (Apaf-1), which induces apop‐
tosis via TRADD and the cellular caspases. This would be a simple story of inflammation
and apoptosis, if it wasn’t for the concomitant HSP70 expression in the WC-As. This heat
shock protein also works through JAK1, but has an inhibitory effect on Apaf-1 [77]. There‐
fore, although Apaf-1 expression is stimulated by c-Jun, both via TNFα and cytochrome c,
HSP70 simultaneously blocks Apaf-1, possibly causing problematic cells to resist apoptosis
and continue to proliferate. This pathway is not present in the SR-Ar.
4. Relevance to atherogenic theories
The idea that susceptible and resistant populations exhibit differences in VSMC differentia‐
tion is vigorously supported by our data. Both experiments showed SR-Ar VSMC to be in
the contractile phase, while this was clearly not the case for WC-As. The WC-As did not ex‐
press myosin-related genes or proteins, and the presence of beta actin correlates with a syn‐
thetic phenotype. Contractility was a major difference in our previous gene analysis [70], so
finding related proteins strengthens this pathway’s relevance to the resistant phenotype.
Contraction depends on the ATP produced by oxidative phosphorylation. Although mito‐
chondrial respiration was a significant biological process in this analysis, monosaccharide
catabolism was upregulated in the WC-As.
Glycolytic enzymes ENO1 and lactate dehydrogenase A (LDHA), both found in the WC-As,
contain hypoxia response elements [78]. This may indicate that during oxygen deficit,
VSMC shift their energy production from oxidative phosphorylation, which has an absolute
oxygen requirement, to glycolysis, which is anaerobic. Glycolysis does not produce enough
ATP to support a contractile phenotype, and the upregulation of ENO1 to support glycoly‐
sis would be problematic, given its dual role as a transcription factor (Figure 1). In the ab‐
sence of oxygen, lipids cannot be fully oxidized which could have a two-fold effect. First,
more substrate is available for cholesterol and TAG synthesis, an idea supported by DGAT2
expression in the WC-As. Second, the increased ROS generation from partially-oxidized lip‐
ids could be triggering the observed WC-As inflammatory pathway.
The theory that atherosclerosis is a chronic inflammatory disease is supported by the data
sets, although the chemokines expressed in the WC-As are secondary indicators of inflam‐
mation, and the primary mediator remains unclear. In addition to the TNF alpha pathway
uncovered in the WC-As proteomics experiment (Figure 3), CXCL12 was significantly upre‐
gulated in the RDA experiments. This is relevant to the human disease as it was recently
identified as a CVD- susceptibility locus in a genome wide association study [79, 80]. Al‐
though newly implicated in atherosclerosis, CXCL12 is thought to exacerbate the probability
of plaque rupture during the advanced stages of the disease [81]. The over-expression of
CXCL12 in the earliest stages of atherogenesis is an important observation in the WC-As, es‐
pecially given that it activates c-src (Figure 1). As described earlier in this review, c-src acti‐
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vates beta actin (synthetic phenotype) and enolase (glycolytic enzyme), and, like ENO1,
CXCL12 has a hypoxia response element in its promoter [82]. CXCL12 has been implicated
in the metastasis and angiogenesis of some cancers, and is an “independent predictor” of
ovarian cancer survival rates [83]. In this capacity, it may contribute to the migration and
proliferation of VSMC that occur early in atherogenesis.
Figure 3. Network analysis (GeneGo, Carlsbad, CA) incorporating annotated differentially-expressed soluble proteins
extracted from vascular smooth muscle cells (VSMC) of White Carneau (WC-As) and Show Racer (SR-Ar) pigeons. Ab‐
breviations listed in [72].
The response to retention theory is marginally supported by the data. Ribophorin and man‐
nosidase expression in both experiments suggests increased glycosylation in the WC-As, a
prerequisite of lipid retention. Lipid retention was further suggested by the expression of
CAV1 in the WC-As. This finding is important because APOE knockout mice studies have
shown that the loss of CAV1 is actually protective against atherosclerosis [84]. Therefore, its
differential expression in the pigeon model may play an important role in the susceptible/
resistant phenotypes. Finally, the response to injury, monoclonal nature, and the effect of he‐
modynamic stress were not tested in either experiment, so their contribution to atherosclero‐
sis in the pigeon model could not be determined.
Gene and protein expression in susceptible and resistant pigeon VSMC support current the‐
ories of human atherogenesis. Many genetic factors have been identified that contribute to
plaque progression, but the gene or genes responsible for initiation of the disease remain un‐
clear. The autosomal inheritance of spontaneous atherosclerosis in the White Carneau sug‐
gests that the affected gene is one having broad effects, such as a transcription factor.
Because pigeon VSMC genes and proteins are differentially expressed prior to foam cell for‐
mation, the pigeon is a valuable model for studying the earliest events of atherogenesis.
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extracted from vascular smooth muscle cells (VSMC) of White Carneau (WC-As) and Show Racer (SR-Ar) pigeons. Ab‐
breviations listed in [72].
The response to retention theory is marginally supported by the data. Ribophorin and man‐
nosidase expression in both experiments suggests increased glycosylation in the WC-As, a
prerequisite of lipid retention. Lipid retention was further suggested by the expression of
CAV1 in the WC-As. This finding is important because APOE knockout mice studies have
shown that the loss of CAV1 is actually protective against atherosclerosis [84]. Therefore, its
differential expression in the pigeon model may play an important role in the susceptible/
resistant phenotypes. Finally, the response to injury, monoclonal nature, and the effect of he‐
modynamic stress were not tested in either experiment, so their contribution to atherosclero‐
sis in the pigeon model could not be determined.
Gene and protein expression in susceptible and resistant pigeon VSMC support current the‐
ories of human atherogenesis. Many genetic factors have been identified that contribute to
plaque progression, but the gene or genes responsible for initiation of the disease remain un‐
clear. The autosomal inheritance of spontaneous atherosclerosis in the White Carneau sug‐
gests that the affected gene is one having broad effects, such as a transcription factor.
Because pigeon VSMC genes and proteins are differentially expressed prior to foam cell for‐
mation, the pigeon is a valuable model for studying the earliest events of atherogenesis.
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1. Introduction
Atherosclerosis and vascular disorders, which result from atherosclerosis, represent one of
the major problems in the modern medicine and public health. Atherosclerosis is character‐
ized by structural and functional changes of large arteries. The approaches for the treatment
of atherosclerosis require at least the prevention of growth of atherosclerotic lesions and re‐
duction in the lipid core mass, which would followed by plaque stabilization. Taken togeth‐
er, these approaches could theoretically result in the regression of arterial lesions.
Atherosclerosis develops in the arterial wall and remains asymptomatic until ischemia of distal
organs is evident. Therapy of clinical manifestations of atherosclerosis is largely aimed at
reducing symptoms or affecting hemodynamic response and often does not affect the cause
or course of disease, namely the atherosclerotic lesion itself. Of course, anti-atherosclerotic
effects of statins revealed in many prospective clinical trials may be considered; however,
statins have never been recognized as the drugs indicated just for direct treatment or preven‐
tion of atherosclerosis. They are used predominately in the course of hypolipidemic thera‐
py, and the effects of treatment are estimated by success in reaching the target level of low
density lipoprotein (LDL) cholesterol, but not the regression of atherosclerotic lesion or intima-
media thickness. The last should be considered as beneficial effect, which is mainly due to
pleiotropic mechanisms of action. Atherosclerosis develops over many years, so anti-athero‐
sclerotic therapy should be a long-term or even lifelong therapy. Tachyphylaxis, long-term
toxicity and cost amongst other issues may present problems for the use of conventional
medications in a long-term. Drugs based on natural products can be a good alternative.
© 2013 Orekhov et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Jour‐
nal of Biological Chemistry 1996; 271(51) 32529-32537.
[79] Samani NJ, 33 co-authors. Genomewide association of coronary artery disease. The
New England Journal of Medicine 2007; 357(5) 443-453.
[80] Zeller T, Blankenberg S, Diemert P. Genomewide association studies in cardiovascu‐
lar disease-an update 2011. Clinical Chemistry 2011; 58(1) 92-103.
[81] Farouk S, Rader DJ, Reilly P, Mehta NN. CXCL12: a new player in coronary artery
disease identified through human genetics. Trends in Cardiovascular Medicine 2010;
20(6) 204-209.
[82] Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL,
Zannettino A.C.W. Hypoxia-inducible factor-2 is a novel regulator of aberrant
CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010; 95(5)
776-784.
[83] Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM. The
chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.
British Journal of Cancer 2012; 106(7) 1306-1313.
[84] Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic ablation of
caveolin-1 confers protection against atherosclerosis. Arteriosclerosis Thrombosis
and Vascular Biology 2004; 24(1) 98-105.
Current Trends in Atherogenesis186
Chapter 9
Use of Natural Products for Direct
Anti-Atherosclerotic Therapy
Alexander N. Orekhov, Igor A. Sobenin,
Alexandra A. Melnichenko,
Veronika A. Myasoedova and Yuri V. Bobryshev
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52967
1. Introduction
Atherosclerosis and vascular disorders, which result from atherosclerosis, represent one of
the major problems in the modern medicine and public health. Atherosclerosis is character‐
ized by structural and functional changes of large arteries. The approaches for the treatment
of atherosclerosis require at least the prevention of growth of atherosclerotic lesions and re‐
duction in the lipid core mass, which would followed by plaque stabilization. Taken togeth‐
er, these approaches could theoretically result in the regression of arterial lesions.
Atherosclerosis develops in the arterial wall and remains asymptomatic until ischemia of distal
organs is evident. Therapy of clinical manifestations of atherosclerosis is largely aimed at
reducing symptoms or affecting hemodynamic response and often does not affect the cause
or course of disease, namely the atherosclerotic lesion itself. Of course, anti-atherosclerotic
effects of statins revealed in many prospective clinical trials may be considered; however,
statins have never been recognized as the drugs indicated just for direct treatment or preven‐
tion of atherosclerosis. They are used predominately in the course of hypolipidemic thera‐
py, and the effects of treatment are estimated by success in reaching the target level of low
density lipoprotein (LDL) cholesterol, but not the regression of atherosclerotic lesion or intima-
media thickness. The last should be considered as beneficial effect, which is mainly due to
pleiotropic mechanisms of action. Atherosclerosis develops over many years, so anti-athero‐
sclerotic therapy should be a long-term or even lifelong therapy. Tachyphylaxis, long-term
toxicity and cost amongst other issues may present problems for the use of conventional
medications in a long-term. Drugs based on natural products can be a good alternative.
© 2013 Orekhov et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
In epidemiological studies of hypercholesterolemia, a high level of plasma cholesterol and
the plasma concentration of LDL are significantly associated with the development of pre‐
mature atherosclerosis [1]. Cholesterol accumulation in the arterial wall is the main sign of
atherosclerosis. It was suggested that LDL is the major source of cholesterol deposited in the
vessel wall.
Accumulation of cholesterol and other lipids is the most prominent manifestation of athero‐
sclerosis at the arterial cell level. In addition to lipid accumulation, elevated proliferative ac‐
tivity of vascular cells and enhanced synthesis of the extracellular matrix are characteristics
of cellular atherogenesis. Collagen and glycoproteins are the main components of the extrac‐
ellular matrix which forms a fibrous plaque.
Intracellular lipid accumulation can be induced by LDL; however native lipoprotein does
not increase the cholesterol content of the cell [2]. On the other hand, incubation of cell cul‐
ture with chemically modified LDLs results in a massive accumulation of cholesterol in the
cells [2]. The in vitro studies revealed a great number of atherogenic modifications of LDL,
i.e. modifications which lead to cellular lipidosis [2]. This findings suggest that modified,
but not native LDLs are the source of lipids accumulated in arterial cells. Arterial intimal
cells populating atherosclerotic lesion are overloaded with lipids, their cytoplasm is almost
completely filled with lipid inclusions [3]. These cells are referred to as foam cells.
2. Cellular Mechanisms of Atherosclerosis
Recent studies of the cellular mechanisms of atherosclerosis carried out on cultured human
aortic cells have revealed the outlined below regularities.
Modified LDL circulates in the bloodstream. We have discovered modified (desialylated) LDL
in blood plasma of patients with coronary atherosclerosis [4-7]. This LDL induces accumula‐
tion of cholesterol in arterial cells [4-7]. Naturally occurring modified LDL has lesser sialic
acid, triglyceride and cholesterol contents, lesser particle size, greater density and negative
charge, higher aggregative activity and some other specific features [8]. We have discovered
an enzyme, trans-sialydase, responsible for desialylation of LDL particle in blood [9].
In addition to desialylated LDL, more electronegative LDL and small dense LDL were de‐
tected in human blood [10,11]. We have performed a comparative study of in vivo modified
LDLs. This study showed that more electronegative LDL isolated by ion-exchange chroma‐
tography is desialylated LDL [12]. Desialylated LDL isolated from patient blood [4-7] is
more electronegative LDL. These facts suggest that both desialylated LDL and electronega‐
tive LDL are similar if not identical.
We have found that a particle of desialylated LDL is smaller and denser than that of native
LDL, i.e., this LDL is small dense lipoprotein. On the other hand, La Belle and Krauss
showed that small dense LDL has a low content of sialic acid, i.e., is desialylated [13]. These
findings point out to a similarity between the two types of modified LDL.
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Glycosylation is another type of in vivo LDL modification. Glycosylated LDL was found in
the blood of patients with diabetes mellitus [14]. This LDL is also atherogenic, i.e. induces
intracellular lipid accumulation [15]. Oxidation is probably also one type of an atherogenic
modification of LDL in vivo. There are indirect evidences of the presence of oxidized LDL
in vivo [16].
Autoantibodies are produced in response to the appearance of modified LDL (either desialy‐
lated, glycosylated or oxidized) in the bloodstream [16-18]. Autoantibodies to desialylated
LDL react with both modified and, though with a lesser affinity, native lipoproteins
[17,19,20]. The interaction between anti-LDL autoantibodies and the lipoprotein results in
the formation of LDL-containing immune complexes [12]. Desialylated LDL which enter the
cells as a component of immune complexes possess a higher atherogenic potential compared
with free lipoprotein, i.e. induce a more intense cholesterol accumulation in the cell [21,22].
The interaction with anti-LDL converts native non-atherogenic LDL into atherogenic, i.e. en‐
ables it to induce intracellular cholesterol accumulation which accompanied by enhanced
cell proliferation and the extracellular matrix production [17,20]. We have found circulating
immune complexes consisting of LDL and anti-LDL autoantibodies in the blood of most
atherosclerotic patients [21,22]. A positive correlation between level of LDL-containing im‐
mune complexes and the severity of atherosclerosis has been demonstrated [23-25].
We and others have demonstrated that LDL is able to form complexes with cellular debris,
collagen, elastin, and proteoglycans of human aortic intima [26-28]. Addition of these com‐
plexes to cultured cells stimulated intracellular accumulation of lipids. Experiments with io‐
dinated LDL showed an increased uptake and decreased intracellular degradation of
lipoproteins in complexes.
In 1989 we showed that in vivo and in vitro modified LDLs are spontaneously self-associat‐
ed under cell culture conditions, while native LDLs do not forms self-associates [29]. A posi‐
tive correlation between atherogenic activity of modified LDLs and the degree of LDL self-
association has been established [30,31]. Lipoprotein associates isolated by gel filtration
induced a dramatic increase in the lipid accumulation by cultured human aortic intimal
cells. Removal of LDL associates from the incubation medium by filtration through filter
with pore diameter 0.1 µm completely prevented intracellular lipid accumulation. Thus,
self-association increases atherogenic potential of LDL.
Thus, we can conclude that formation of large complexes (self-associates, immune com‐
plexes, and complexes with connective tissue matrix) by modified LDL leads to intracellular
lipid accumulation through enhanced cellular uptake and slow intracellular degradation of
lipoprotein particles.
3. Anti-Atherogenic and Anti-Atherosclerotic Drugs
Taken together, our data allow us to identify possible targets for anti-atherosclerotic thera‐
py. The first target is atherogenic modification (desialylation) of LDL particle in blood. Pre‐
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vention of LDL modification may be an approach to anti-atherosclerosis therapy. The
second approach may be selective removal of modified LDLs from blood (target 2). The
third one may be based on prevention of modified LDL accumulation in arterial cells (target
3). Also one more approach is removal of excess lipids from foam cells (target 4). Figure 1
schematically represents these four approaches. We have used all of these approaches and
now we believe that the most suitable approach is the third one, namely, the prevention of
modified LDL accumulation in arterial cells. Bellow we describe the application of this ap‐
proach for the development of anti-atherosclerotic therapy.
Agents capable of preventing atherogenesis are anti-atherogenic drugs, agents promoting
the regression of atherosclerotic manifestations are anti-atherosclerotic drugs. Prevention of
intracellular lipid accumulation accompanied by the stimulation of arterial cell proliferation
and massive extracellular matrix production may be regarded as anti-atherogenic (preven‐
tive). In terms of arterial cells, any drug effect which does not prevent directly the conver‐
sion of the normal cell into an atherosclerotic one (foam cell) should be regarded as an
indirect anti-atherogenic action. Only that drug which exhibits its preventive activity at the
arterial level is a direct anti-atherogenic drug. At the arterial cell level, a drug with a direct
anti-atherosclerotic action should induce the regression of the major cellular manifestations
of atherosclerosis, i.e. reduce the intracellular lipid content, suppress cell proliferation and
inhibit the extracellular matrix production.
Figure 1. Targets of anti-atherosclerotic and anti-atherogenic drug actions
Solid circles, multiple modified LDL; open circles, native LDL
(see explanation in the text).
Thus, the drugs that affect atherosclerosis can be divided into 3 groups:
- anti-atherosclerotic;




The identification of anti-atherosclerotic or/and anti-atherogenic activities of a drug is asso‐
ciated with considerable difficulties. There are no simple and rapid techniques to estimate
the anti-atherogenic/anti-atherosclerotic effect of a drug in an animal model or in clinical tri‐
als. That is why we employ a culture of human atherosclerotic vascular cells in the screening
of potential drugs, investigation of their mechanisms of action and optimization of anti-athe‐
rosclerotic drug therapy.
We use human aortic cells to examine the effects of various agents on atherosclerosis-related
features of cultured cells. Cells are isolated from the subendothelial part of the human aortic
intima, i.e. from the part of aorta which is localized between the endothelial lining and the
media [32]. The intima of adult human aorta is a well-defined structure. The thickness of a
normal intima varies from 50 to 120 µm [32]. Sometimes a thickened intima is called a dif‐
fuse intimal thickening [32]. This term underlines its essential difference from a very thin in‐
tima of animal and adolescent aorta. Unaffected intima of adult human aorta contains 10-12
lines of subendothelial cells [32].
Using collagenase and elastase, cells are isolated from the subendothelial layer of the intima
of both normal and atherosclerotic parts of the aorta [33-36]. This approach makes it possible
to study a direct anti-atherosclerotic and anti-atherogenic action of a drug at the vascular
cell level. An important advantage of this technique is that human material is used and thus,
the results obtained are relevant to human atherosclerosis.
By the well-established criteria, the cells cultured from the intima can be classified as the cells
of smooth muscle origin. These cells are stained with antibodies to smooth muscle myosin
[33-35]. For further identification of cultured cells we have used a monoclonal antibody HHF-35
which reacts specifically with muscle α-actin and can reveal smooth muscle cells [37]. Accord‐
ing to our calculations, primary culture of subendothelial cells contains about 90% of smooth
muscle cells interacting with HHF-35. In addition, cells cultured from subendothelial part of
uninvolved (healthy) intima have the ultrastructural features characteristic of smooth mus‐
cle cells, namely: the basal membrane and filament bundles with dense bodies [33-36]. The
culture on which our experiments are performed is represented by mixed population of typical
and modified smooth muscle cells revealed in the human aorta earlier [32].
Cells of the subendothelial intima isolated from atherosclerotic lesions retain in primary cul‐
ture all major characteristics of atherosclerotic cells. Cells cultures from fatty streak and fatty
infiltration zones have an enhanced proliferative activity [38]. These cells have a higher pro‐
liferative activity as compared with the cells cultured from unaffected intima [38,39].
Many cells cultured from atherosclerotic lesions are so called foam cell containing numerous
inclusions filling the whole of the cytoplasm, these inclusions are lipid droplets [34]. The
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Figure 1. Targets of anti-atherosclerotic and anti-atherogenic drug actions
Solid circles, multiple modified LDL; open circles, native LDL
(see explanation in the text).
Thus, the drugs that affect atherosclerosis can be divided into 3 groups:
- anti-atherosclerotic;




The identification of anti-atherosclerotic or/and anti-atherogenic activities of a drug is asso‐
ciated with considerable difficulties. There are no simple and rapid techniques to estimate
the anti-atherogenic/anti-atherosclerotic effect of a drug in an animal model or in clinical tri‐
als. That is why we employ a culture of human atherosclerotic vascular cells in the screening
of potential drugs, investigation of their mechanisms of action and optimization of anti-athe‐
rosclerotic drug therapy.
We use human aortic cells to examine the effects of various agents on atherosclerosis-related
features of cultured cells. Cells are isolated from the subendothelial part of the human aortic
intima, i.e. from the part of aorta which is localized between the endothelial lining and the
media [32]. The intima of adult human aorta is a well-defined structure. The thickness of a
normal intima varies from 50 to 120 µm [32]. Sometimes a thickened intima is called a dif‐
fuse intimal thickening [32]. This term underlines its essential difference from a very thin in‐
tima of animal and adolescent aorta. Unaffected intima of adult human aorta contains 10-12
lines of subendothelial cells [32].
Using collagenase and elastase, cells are isolated from the subendothelial layer of the intima
of both normal and atherosclerotic parts of the aorta [33-36]. This approach makes it possible
to study a direct anti-atherosclerotic and anti-atherogenic action of a drug at the vascular
cell level. An important advantage of this technique is that human material is used and thus,
the results obtained are relevant to human atherosclerosis.
By the well-established criteria, the cells cultured from the intima can be classified as the cells
of smooth muscle origin. These cells are stained with antibodies to smooth muscle myosin
[33-35]. For further identification of cultured cells we have used a monoclonal antibody HHF-35
which reacts specifically with muscle α-actin and can reveal smooth muscle cells [37]. Accord‐
ing to our calculations, primary culture of subendothelial cells contains about 90% of smooth
muscle cells interacting with HHF-35. In addition, cells cultured from subendothelial part of
uninvolved (healthy) intima have the ultrastructural features characteristic of smooth mus‐
cle cells, namely: the basal membrane and filament bundles with dense bodies [33-36]. The
culture on which our experiments are performed is represented by mixed population of typical
and modified smooth muscle cells revealed in the human aorta earlier [32].
Cells of the subendothelial intima isolated from atherosclerotic lesions retain in primary cul‐
ture all major characteristics of atherosclerotic cells. Cells cultures from fatty streak and fatty
infiltration zones have an enhanced proliferative activity [38]. These cells have a higher pro‐
liferative activity as compared with the cells cultured from unaffected intima [38,39].
Many cells cultured from atherosclerotic lesions are so called foam cell containing numerous
inclusions filling the whole of the cytoplasm, these inclusions are lipid droplets [34]. The
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bulk of excess lipids in foam cells is represented by free cholesterol and cholesteryl esters
[34]. It should be noted that the content and composition of lipids in cultured cells within
the first 10-12 days in culture remain unchanged and correspond to the respective indices of
freshly isolated cells [34-39].
Cells cultured from the subendothelial intima are capable of synthesizing collagen, proteo‐
glycans and other components of extracellular matrix [40,41].
Thus, the cells isolated from an atherosclerotic lesion of human aorta retain in culture all the
main properties characteristic of atherosclerotic cells. They exhibit an enhanced proliferative
activity, contain excess cholesterol in the form of intracellular inclusions and synthesize the
extracellular matrix. This allows one to regard a culture of atherosclerotic cells as a conven‐
ient model for the investigation of the effects of various agents on atherosclerotic manifesta‐
tions [21]. Thus, the investigations in the cell culture model are carried out directly on
exactly the same cells which require a therapeutic action in vivo.
Using this model, we have examined the effects of different drugs and chemicals. By now
many substances have been tested [21]. The effects of several substances are summarized in
Table 1. Some of them elicited anti-atherosclerotic effects in culture, some proved to be inef‐
fective in this respect, while others even stimulated the development of atherogenic process‐
es.
5. Cardiovascular Drugs
Three classes of cardiovascular drugs: calcium antagonists, beta-blockers and nitrates have
been tested on our cellular model. These drugs are widely used in clinic for therapy of various
disorders resulting from atherosclerosis of different arteries. We attempted to find out how
calcium antagonists, beta-blockers and nitrates affect atherosclerotic indices of arterial cells.
First, we examined the effects of calcium antagonists on major atherosclerotic indices. It has
been found that calcium antagonist, verapamil, has a positive effect on all atherosclerotic
cellular indices. Within 48 hrs, verapamil added to culture reduced total intracellular choles‐
terol level by 3-fold, sharply decreased the [3H]thymidine incorporation into cellular DNA,
i.e. suppressed cell proliferative activity, and inhibited the collagen synthesis by cultured
cells [38,39]. Thus, this drug has a direct anti-atherosclerotic effect at the arterial cell level.
Several calcium antagonists: nifedipine, darodipine, isradipine, nicardipine, nitrendipine, fe‐
lodipine, tiapamil, gallopamil, diltiazem, papaverin, nicardipine, and others were also test‐
ed. Verapamil and nifedipine proved to be the most effective [49,55]. Within 24 hrs of
incubation with cultured cells all calcium antagonists substantially inhibited [3H] thymidine
incorporation and reduced intracellular cholesterol level [54,55]. Thus, calcium antagonists
produce a direct anti-atherosclerotic effect on the vascular cells normalizing the major athe‐
rosclerotic cell parameters.
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Agent References
ANTI-ATHEROSCLEROTIC
Cyclic AMP elevators [39,42 - 45]
Prostacyclin [39,46 - 50]
Prostaglandin E2 [39,46, 51]
Artificial HDL [52]
Antioxidants [39]
Calcium antagonists [39,49, 50, 53-56]











Table 1. Substances tested on cellular model
In addition to anti-atherosclerotic effects imitating the regression of atherosclerosis, anti-
atherogenic effects in culture imitating prevention of atherosclerosis were studied. Table 2
demonstrates the major differences between these two approaches. In the case of anti-athe‐
rosclerotic effect the regression of atherosclerosis is imitated, whereas in the case of anti-
atherogenic effect, the prevention of atherosclerosis is imitated. In the first case the cells
obtained from an atherosclerotic plaque are used, while in the second type of experiments
cells derived from unaffected intima are employed. When anti-atherosclerotic effect is exam‐
ined, cells are cultured in the presence of a standard fetal calf serum, while in the experi‐
ments on anti-atherogenic effect - atherogenic serum obtained from coronary heart disease
patients is added to culture. This serum induces the accumulation of cholesterol and stimu‐
lates other atherogenic manifestations in cultured cells [61-64]. In the case of anti-athero‐
sclerotic effect the efficacy of a drug is judged upon by its ability to decrease an elevated
content of cholesterol in cultured atherosclerotic cells but in the case of anti-atherogenic ef‐
fect, the efficacy of a drug is judged upon by the ability to prevent the deposition of intracel‐
lular cholesterol in normal cells.
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tions [21]. Thus, the investigations in the cell culture model are carried out directly on
exactly the same cells which require a therapeutic action in vivo.
Using this model, we have examined the effects of different drugs and chemicals. By now
many substances have been tested [21]. The effects of several substances are summarized in
Table 1. Some of them elicited anti-atherosclerotic effects in culture, some proved to be inef‐
fective in this respect, while others even stimulated the development of atherogenic process‐
es.
5. Cardiovascular Drugs
Three classes of cardiovascular drugs: calcium antagonists, beta-blockers and nitrates have
been tested on our cellular model. These drugs are widely used in clinic for therapy of various
disorders resulting from atherosclerosis of different arteries. We attempted to find out how
calcium antagonists, beta-blockers and nitrates affect atherosclerotic indices of arterial cells.
First, we examined the effects of calcium antagonists on major atherosclerotic indices. It has
been found that calcium antagonist, verapamil, has a positive effect on all atherosclerotic
cellular indices. Within 48 hrs, verapamil added to culture reduced total intracellular choles‐
terol level by 3-fold, sharply decreased the [3H]thymidine incorporation into cellular DNA,
i.e. suppressed cell proliferative activity, and inhibited the collagen synthesis by cultured
cells [38,39]. Thus, this drug has a direct anti-atherosclerotic effect at the arterial cell level.
Several calcium antagonists: nifedipine, darodipine, isradipine, nicardipine, nitrendipine, fe‐
lodipine, tiapamil, gallopamil, diltiazem, papaverin, nicardipine, and others were also test‐
ed. Verapamil and nifedipine proved to be the most effective [49,55]. Within 24 hrs of
incubation with cultured cells all calcium antagonists substantially inhibited [3H] thymidine
incorporation and reduced intracellular cholesterol level [54,55]. Thus, calcium antagonists
produce a direct anti-atherosclerotic effect on the vascular cells normalizing the major athe‐
rosclerotic cell parameters.
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atherogenic effects in culture imitating prevention of atherosclerosis were studied. Table 2
demonstrates the major differences between these two approaches. In the case of anti-athe‐
rosclerotic effect the regression of atherosclerosis is imitated, whereas in the case of anti-
atherogenic effect, the prevention of atherosclerosis is imitated. In the first case the cells
obtained from an atherosclerotic plaque are used, while in the second type of experiments
cells derived from unaffected intima are employed. When anti-atherosclerotic effect is exam‐
ined, cells are cultured in the presence of a standard fetal calf serum, while in the experi‐
ments on anti-atherogenic effect - atherogenic serum obtained from coronary heart disease
patients is added to culture. This serum induces the accumulation of cholesterol and stimu‐
lates other atherogenic manifestations in cultured cells [61-64]. In the case of anti-athero‐
sclerotic effect the efficacy of a drug is judged upon by its ability to decrease an elevated
content of cholesterol in cultured atherosclerotic cells but in the case of anti-atherogenic ef‐
fect, the efficacy of a drug is judged upon by the ability to prevent the deposition of intracel‐
lular cholesterol in normal cells.
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Four-hour preincubation of cultured cells with verapamil led to complete prevention of the
serum atherogenic effect [65]. Thus, verapamil possesses not only an atherosclerotic effect in
culture causing the regression of atherosclerotic manifestations at the cellular level but also
elicits an anti-atherogenic, i.e. preventive effect, eliminating atherogenic potential of the serum.
ANTI-ATHEROSCLEROTIC ANTI-ATHEROGENIC
Regression Prevention
Atherosclerotic plaque Uninvolved intima
Standard (nonatherogenic) serum Atherogenic patients' serum
Cholesterol fall Prevention of cholesterol accumulation
Table 2. Anti-atherosclerotic and anti-atherogenic drug effects in culture
The effect of several calcium antagonists on primary cholesterol accumulation in cultured
cells induced by the patients' serum was tested. Verapamil and nifedipine completely inhib‐
ited the accumulation of intracellular cholesterol induced by the serum while other calcium
antagonists: diltiazem, nicardipine, isradipine, darodipine rather substantially reduced cho‐
lesterol accumulation [65]. As it is known, the examined calcium antagonists manifested an‐
ti-atherogenic action in vivo inhibiting the development of experimental atherosclerosis in
animals [66,67]. Thus, our in vitro data obtained on cellular model correspond to the in vivo
observations. One can conclude that calcium antagonists elicit not only anti-atherosclerotic
but also anti-atherogenic, i.e. preventive effect at the arterial cell level.
Nitrates and beta-blockers have been tested to reveal their action on atherosclerotic cellular
indices. Nitrates had no effect on proliferative activity of atherosclerotic cells and practically
did not affect the cholesterol level [55]. On the other hand, all the examined beta-blockers,
propranolol, alprenolol, metoprolol, pindolol, and timolol, more or less increased athero‐
sclerotic manifestations, i.e. all of these drugs exhibited atherogenic activity in culture
[55,60]. If beta-blockers manifest a similar action in vivo, one may assume that these drugs
are atherogenic and realize the atherogenic action at the arterial cell level. Apparently, ni‐
trates are neutral, indifferent in this respect.
The influence of cardiovascular drugs on atherosclerosis-related effects of each other was
studied. The study was focused on metoprolol, nifedipine and nitroglycerin, the drugs
widely used in clinic [55]. Metoprolol caused an elevation of intracellular cholesterol, nifedi‐
pine reduced the cholesterol level while nitroglycerin was without effect on this index. The
use of nifedipine on the background of metoprolol did not modify the anti-atherosclerotic
action of the calcium antagonist. In this combination atherogenic action of metoprolol was
not revealed. The application of metoprolol in combination with nitroglycerin led to the
elimination of an atherogenic effect of the beta-blocker. Nifedipine used together with meto‐
prolol and nitroglycerin was just as effective as in the absence of these drugs. Thus, nifedi‐
pine produces its anti-atherosclerotic effects both by itself and in combination with widely
used nitrates and beta-blockers. These data suggest one important conclusion. Atherogenic
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action of beta-blockers can be inhibited if a beta-blocker is used in combination with a calci‐
um antagonist or nitrate. This finding allows to hoping that in the nearest future it will be
possible to develop beta-blockers devoid of atherogenic side effects.
Thus, three classes of cardiovascular drugs reveal different influence on cellular manifesta‐
tion of atherosclerosis. Calcium antagonists exhibit anti-atherosclerotic action. On the con‐
trary, beta-blockers are atherogenic. Nitrates are neutral, indifferent in this respect. Our data
obtained on cellular model were supported by results of clinical study. Loaldi et al. have re‐
ported that long-term per oral administration of propranolol aggravates coronary athero‐
sclerosis in patients with angina of effort as compared with the calcium antagonists,
nifedipiene, and isorobide dinitrate [68]. Nifedipine produced the best effect on coronary
atherosclerosis by suppressing the development of existing and preventing the appearance
of new atherosclerotic lesions. Isosorbide dinitrate was less effective in this respect, while
with propranolol therapy the situation was the worst. These clinical observations encourage
us to develop anti-atherosclerotic therapy using our cell culture model.
6. Ex Vivo Model
All the above conclusions and hypotheses are based on the data obtained in in vitro experi‐
ments. Obviously, the question arises, whether anti-atherosclerotic effects of calcium antago‐
nists and atherogenic effects of beta-blockers can be manifested in vivo and what is the
optimal anti-atherosclerotic therapy based on calcium antagonists and other drugs.
To optimize anti-atherosclerotic and anti-atherogenic drug therapy, ex vivo model was de‐
veloped. In case of ex vivo model not drug but blood serum taken from patients after oral
drug administration is added to cultured cells.
Calcium antagonists, verapamil and nifedipine, and beta-blockers, propranolol and pindo‐
lol, were examined using ex vivo model. Within 2-4 hrs after nifedipine or verapamil admin‐
istration, the patient's serum had anti-atherosclerotic properties, i.e. it was able to cause a
fall in the intracellular cholesterol and inhibited atherosclerotic cell proliferation [55,56]. On
the contrary, the serum of patients who received propranolol or pindolol was pro-athero‐
genic. Its pro-atherogenic properties manifested themselves at the arterial cell level in the
rise of intracellular cholesterol and stimulation of cell proliferation [55,56]. This finding al‐
lows to assuming that not only in vitro, but in vivo as well, calcium antagonists and beta-
blockers are anti-atherosclerotic and atherogenic drugs, respectively.
The effect of nifedipine on serum properties during a prolonged course was assessed. A pa‐
tient was on nifedipine for 7 days. He received 20 mg doses three times a day with an 8-hr
interval. Twenty-eight days after regular nifedipine therapy the initial atherogenicity of the
patient's serum was substantially lower than at the beginning. Directly after a dose of nifedi‐
pine the atherogenicity was practically completely eliminated [65]. On the contrary, as a re‐
sult of a prolonged therapy with a beta-blocker, propranolol, patient's serum acquired stable
atherogenic properties. At the beginning of the course the serum of this patient was nona‐
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Four-hour preincubation of cultured cells with verapamil led to complete prevention of the
serum atherogenic effect [65]. Thus, verapamil possesses not only an atherosclerotic effect in
culture causing the regression of atherosclerotic manifestations at the cellular level but also
elicits an anti-atherogenic, i.e. preventive effect, eliminating atherogenic potential of the serum.
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Regression Prevention
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Standard (nonatherogenic) serum Atherogenic patients' serum
Cholesterol fall Prevention of cholesterol accumulation
Table 2. Anti-atherosclerotic and anti-atherogenic drug effects in culture
The effect of several calcium antagonists on primary cholesterol accumulation in cultured
cells induced by the patients' serum was tested. Verapamil and nifedipine completely inhib‐
ited the accumulation of intracellular cholesterol induced by the serum while other calcium
antagonists: diltiazem, nicardipine, isradipine, darodipine rather substantially reduced cho‐
lesterol accumulation [65]. As it is known, the examined calcium antagonists manifested an‐
ti-atherogenic action in vivo inhibiting the development of experimental atherosclerosis in
animals [66,67]. Thus, our in vitro data obtained on cellular model correspond to the in vivo
observations. One can conclude that calcium antagonists elicit not only anti-atherosclerotic
but also anti-atherogenic, i.e. preventive effect at the arterial cell level.
Nitrates and beta-blockers have been tested to reveal their action on atherosclerotic cellular
indices. Nitrates had no effect on proliferative activity of atherosclerotic cells and practically
did not affect the cholesterol level [55]. On the other hand, all the examined beta-blockers,
propranolol, alprenolol, metoprolol, pindolol, and timolol, more or less increased athero‐
sclerotic manifestations, i.e. all of these drugs exhibited atherogenic activity in culture
[55,60]. If beta-blockers manifest a similar action in vivo, one may assume that these drugs
are atherogenic and realize the atherogenic action at the arterial cell level. Apparently, ni‐
trates are neutral, indifferent in this respect.
The influence of cardiovascular drugs on atherosclerosis-related effects of each other was
studied. The study was focused on metoprolol, nifedipine and nitroglycerin, the drugs
widely used in clinic [55]. Metoprolol caused an elevation of intracellular cholesterol, nifedi‐
pine reduced the cholesterol level while nitroglycerin was without effect on this index. The
use of nifedipine on the background of metoprolol did not modify the anti-atherosclerotic
action of the calcium antagonist. In this combination atherogenic action of metoprolol was
not revealed. The application of metoprolol in combination with nitroglycerin led to the
elimination of an atherogenic effect of the beta-blocker. Nifedipine used together with meto‐
prolol and nitroglycerin was just as effective as in the absence of these drugs. Thus, nifedi‐
pine produces its anti-atherosclerotic effects both by itself and in combination with widely
used nitrates and beta-blockers. These data suggest one important conclusion. Atherogenic
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action of beta-blockers can be inhibited if a beta-blocker is used in combination with a calci‐
um antagonist or nitrate. This finding allows to hoping that in the nearest future it will be
possible to develop beta-blockers devoid of atherogenic side effects.
Thus, three classes of cardiovascular drugs reveal different influence on cellular manifesta‐
tion of atherosclerosis. Calcium antagonists exhibit anti-atherosclerotic action. On the con‐
trary, beta-blockers are atherogenic. Nitrates are neutral, indifferent in this respect. Our data
obtained on cellular model were supported by results of clinical study. Loaldi et al. have re‐
ported that long-term per oral administration of propranolol aggravates coronary athero‐
sclerosis in patients with angina of effort as compared with the calcium antagonists,
nifedipiene, and isorobide dinitrate [68]. Nifedipine produced the best effect on coronary
atherosclerosis by suppressing the development of existing and preventing the appearance
of new atherosclerotic lesions. Isosorbide dinitrate was less effective in this respect, while
with propranolol therapy the situation was the worst. These clinical observations encourage
us to develop anti-atherosclerotic therapy using our cell culture model.
6. Ex Vivo Model
All the above conclusions and hypotheses are based on the data obtained in in vitro experi‐
ments. Obviously, the question arises, whether anti-atherosclerotic effects of calcium antago‐
nists and atherogenic effects of beta-blockers can be manifested in vivo and what is the
optimal anti-atherosclerotic therapy based on calcium antagonists and other drugs.
To optimize anti-atherosclerotic and anti-atherogenic drug therapy, ex vivo model was de‐
veloped. In case of ex vivo model not drug but blood serum taken from patients after oral
drug administration is added to cultured cells.
Calcium antagonists, verapamil and nifedipine, and beta-blockers, propranolol and pindo‐
lol, were examined using ex vivo model. Within 2-4 hrs after nifedipine or verapamil admin‐
istration, the patient's serum had anti-atherosclerotic properties, i.e. it was able to cause a
fall in the intracellular cholesterol and inhibited atherosclerotic cell proliferation [55,56]. On
the contrary, the serum of patients who received propranolol or pindolol was pro-athero‐
genic. Its pro-atherogenic properties manifested themselves at the arterial cell level in the
rise of intracellular cholesterol and stimulation of cell proliferation [55,56]. This finding al‐
lows to assuming that not only in vitro, but in vivo as well, calcium antagonists and beta-
blockers are anti-atherosclerotic and atherogenic drugs, respectively.
The effect of nifedipine on serum properties during a prolonged course was assessed. A pa‐
tient was on nifedipine for 7 days. He received 20 mg doses three times a day with an 8-hr
interval. Twenty-eight days after regular nifedipine therapy the initial atherogenicity of the
patient's serum was substantially lower than at the beginning. Directly after a dose of nifedi‐
pine the atherogenicity was practically completely eliminated [65]. On the contrary, as a re‐
sult of a prolonged therapy with a beta-blocker, propranolol, patient's serum acquired stable
atherogenic properties. At the beginning of the course the serum of this patient was nona‐
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therogenic, however, 28 days of regular propranolol therapy led to the emergence of athero‐
genicity revealed even before the drug administration [65]. Thus, a single dose of beta-
blockers brings about temporary atherogenicity of the serum. Prolonged therapy with beta-
blockers leads to the emergence of stable atherogenic properties of patients' blood serum.
7. Optimization of Dietary Therapy
Cellular model can be used not only to test drugs but foodstuffs as well. We have investigat‐
ed an anti-atherosclerotic, i.e. therapeutic, causing regression of atherosclerosis, and anti-
atherogenic, i.e. preventive activity of certain mushroom species and sea products.
Previously we have shown that alcohol and water extracts from 20 Korean mushroom spe‐
cies cause anti-atherosclerotic and anti-atherogenic activity in cell culture [59]. Thirteen of
the 20 extracts tested were anti-atherosclerotic in culture, i.e. they caused a decrease in the
cellular cholesterol and/or inhibited proliferation of atherosclerotic cells. Ten of 20 tested ex‐
tracts displayed anti-atherogenic activity in addition to anti-atherosclerotic effects. Four
mushroom species were chosen for the study of anti-atherosclerotic effects ex vivo. Cultiva‐
tion of atherosclerotic cells during 24 hrs in the presence of serum from healthy subjects who
had had mushroom meals resulted in a 21-30% decrease in the cellular cholesterol level, i.e.
caused anti-atherosclerotic effect [59]. The atherogenic serum obtained from atherosclerotic
patients after dietary mushroom consumption partly (30-41%) lost its ability to increase the
cellular cholesterol content [59]. Thus, tested mushrooms exhibited anti-atherosclerotic and
anti-atherogenic effects on ex vivo model.
Among sea products mollusk and krill meat were tested [36]. Specifically, the patients were
given canned meat of a mollusk belonging to genus Buccinum. Two hours after a single diet‐
ary load the patient's blood serum acquired marked anti-atherosclerotic properties. The ad‐
dition of this serum to cultured atherosclerotic cells led to a fall in intracellular cholesterol
level [36]. Four hours later the anti-atherosclerotic properties of the serum became even
more prominent.
Patients of another group had an initially atherogenic serum causing more then 2-fold in‐
crease in cholesterol content of cells derived from normal intima. These patients received a
single dietary load of Antarctic krill meat. Two hours later the atherogenicity of their blood
serum decreased and four hours later it was practically absent [36]. Thus, krill meat exhibits
a preventive anti-atherogenic action on arterial cells.
The results obtained suggest that the krill meat can be employed in diets aimed at the pre‐
vention of atherosclerosis. To develop a dietary therapy based on the krill meat, the effective
dose and proper regimen should be established. As the first step to develop a dietary thera‐
py, the below outlined study was undertaken to determine the effective dose.
The patients' blood sera were analyzed for atherogenicity. Patients whose blood serum had
an atherogenic potential were included in the study. The blood was collected from each pa‐
tient before, 2 and 4 hrs after a dose of krill meat. This protocol was repeated on the next day
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with another dose of krill meat. Blood serum samples were added to a culture of subendo‐
thelial cells isolated from uninvolved human aortic intima, and intracellular cholesterol ac‐
cumulation was assessed in each case. Anti-atherogenic activity of krill meat was evaluated
by the ability to reduce serum atherogenicity which manifested in cholesterol accumulation
in cultured cells (Figure 2). The dose-effect dependence was revealed by comparing the effi‐
cacy of two doses. The efficacy of each dose was evaluated by the analysis of at least 6 sera
obtained from different patients. In can be seen from that the krill meat elicits an anti-athe‐
rogenic effect at a dose of 10-20 g, half maximum effect was reached at a dose of 30 g and the
maximum effect - at a dose of 50 g.
We believe that this approach will be useful in the development and optimization of anti-
atherosclerotic and anti-atherogenic diet therapies.
Figure 2. Antiatherogenic effect of krill meat on blood serum of atherosclerotic patients
Blood serum atherogenicity was determined using primary culture of cells derived from un‐
involved intima of the human aorta.
8. Natural Products for Anti-Atherosclerotic Therapy
Anti-atherogenic effects of dietary products promote the development of anti-atherosclerotic
therapy on the basis of natural products. Atherosclerosis develops over many years, so the
anti-atherosclerotic therapy should be long-term or even lifelong therapy. For such a long-
term therapy conventional medicine might not work. Drugs based on natural products can
be a good alternative.
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therogenic, however, 28 days of regular propranolol therapy led to the emergence of athero‐
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cellular cholesterol and/or inhibited proliferation of atherosclerotic cells. Ten of 20 tested ex‐
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had had mushroom meals resulted in a 21-30% decrease in the cellular cholesterol level, i.e.
caused anti-atherosclerotic effect [59]. The atherogenic serum obtained from atherosclerotic
patients after dietary mushroom consumption partly (30-41%) lost its ability to increase the
cellular cholesterol content [59]. Thus, tested mushrooms exhibited anti-atherosclerotic and
anti-atherogenic effects on ex vivo model.
Among sea products mollusk and krill meat were tested [36]. Specifically, the patients were
given canned meat of a mollusk belonging to genus Buccinum. Two hours after a single diet‐
ary load the patient's blood serum acquired marked anti-atherosclerotic properties. The ad‐
dition of this serum to cultured atherosclerotic cells led to a fall in intracellular cholesterol
level [36]. Four hours later the anti-atherosclerotic properties of the serum became even
more prominent.
Patients of another group had an initially atherogenic serum causing more then 2-fold in‐
crease in cholesterol content of cells derived from normal intima. These patients received a
single dietary load of Antarctic krill meat. Two hours later the atherogenicity of their blood
serum decreased and four hours later it was practically absent [36]. Thus, krill meat exhibits
a preventive anti-atherogenic action on arterial cells.
The results obtained suggest that the krill meat can be employed in diets aimed at the pre‐
vention of atherosclerosis. To develop a dietary therapy based on the krill meat, the effective
dose and proper regimen should be established. As the first step to develop a dietary thera‐
py, the below outlined study was undertaken to determine the effective dose.
The patients' blood sera were analyzed for atherogenicity. Patients whose blood serum had
an atherogenic potential were included in the study. The blood was collected from each pa‐
tient before, 2 and 4 hrs after a dose of krill meat. This protocol was repeated on the next day
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with another dose of krill meat. Blood serum samples were added to a culture of subendo‐
thelial cells isolated from uninvolved human aortic intima, and intracellular cholesterol ac‐
cumulation was assessed in each case. Anti-atherogenic activity of krill meat was evaluated
by the ability to reduce serum atherogenicity which manifested in cholesterol accumulation
in cultured cells (Figure 2). The dose-effect dependence was revealed by comparing the effi‐
cacy of two doses. The efficacy of each dose was evaluated by the analysis of at least 6 sera
obtained from different patients. In can be seen from that the krill meat elicits an anti-athe‐
rogenic effect at a dose of 10-20 g, half maximum effect was reached at a dose of 30 g and the
maximum effect - at a dose of 50 g.
We believe that this approach will be useful in the development and optimization of anti-
atherosclerotic and anti-atherogenic diet therapies.
Figure 2. Antiatherogenic effect of krill meat on blood serum of atherosclerotic patients
Blood serum atherogenicity was determined using primary culture of cells derived from un‐
involved intima of the human aorta.
8. Natural Products for Anti-Atherosclerotic Therapy
Anti-atherogenic effects of dietary products promote the development of anti-atherosclerotic
therapy on the basis of natural products. Atherosclerosis develops over many years, so the
anti-atherosclerotic therapy should be long-term or even lifelong therapy. For such a long-
term therapy conventional medicine might not work. Drugs based on natural products can
be a good alternative.
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We have tested numerous natural products’ extracts to reveal their effects on blood athero‐
genicity, i.e., a capacity to prevent intracellular cholesterol accumulation caused by athero‐
genic blood sera from patients. Table 3 presents effective natural products only. As a fact,
among tested agents were revealed not only anti-atherogenic but also pro-atherogenic and











Table 3. Anti-atherogenic effects of natural products
We extended investigation of the in vitro effect of garlic extract on lipids of cultured hu‐
man aortic cells.  We have earlier shown that lipid accumulation in human aortic cells is
accompanied by stimulation of other cellular manifestation of atherosclerosis, namely: prolif‐
eration and extracellular matrix synthesis [41,63]. Thus, investigation of garlic action on cellular
lipid parameters is closely related to the study of the mechanism of garlic anti-atherosclero‐
sis effect.
A direct influence of garlic on atherosclerosis is discussed [70-73]. The anti-atherosclerotic
effect of garlic has been attributed to its hypolipidemic activity. Experimental and clinical
data have clearly demonstrated that garlic reduces blood cholesterol and LDL levels [74,75].
The cholesterol lowering effect of garlic results from inhibition of hepatic hydroxymethyl‐
glutaryl coenzyme A (HMG-CoA) [76]. In contrast to these studies, we examined not the hy‐
perlipidemic but the direct anti-atherosclerotic-related and anti-atherogenic-related effects
of garlic, i.e., the ability of garlic to act directly on atherosclerotic process in the vessel wall.
To investigate anti-atherosclerotic-related (therapeutic) effect we used smooth muscle cells
cultured from atherosclerotic plaques of human aorta. To study anti-atherogenic-related
(preventive) effect we imitated atherogenesis in primary cultures of smooth muscle cells de‐
rived from grossly uninvolved human aortic intima by adding atherogenic blood serum of
patients with angiographically assessed coronary atherosclerosis. Garlic decreased triglycer‐
ide, cholesteryl ester and free cholesterol contents of cells cultured from atherosclerotic pla‐
que and prevented atherogenic serum-induced accumulation of these lipids in cells cultured
from grossly normal aorta, i.e., elicited direct anti-atherosclerotic-related (therapeutic) and
Current Trends in Atherogenesis198
anti-atherogenic-related (preventive) effects. Garlic inhibits ACAT and stimulates CEH, thus
displaying a direct influence on synthesis and degradation of cholesteryl esters in the cell.
This finding may explain direct anti-atherosclerotic effects of garlic.
Further investigations of garlic anti-atherosclerotic effects included ex vivo study and ani‐
mal model study. Both types of studies confirmed the in vitro effects of garlic. Finally, we
have developed a drug on the basis of garlic powder and carried out atherosclerosis regres‐
sion clinical study of this drug.
9. Atherosclerosis Regression Clinical Studies of Natural Products
The AMAR study (Atherosclerosis Monitoring and Atherogenicity Reduction) was designed
to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on
the progression of carotid atherosclerosis in asymptomatic men in double-blinded placebo-
controlled randomized clinical trial. The primary outcome was the rate of atherosclerosis
progression, measured by high-resolution B-mode ultrasonography as the increase in caro‐
tid intima-media thickness (IMT) of the far wall of common carotid arteries.
Atherosclerosis affects most vascular beads, and noninvasive imaging of superficial arteries
by ultrasound has been recognized as a surrogate measure of overall atherosclerotic burden
in numerous studies. Extracoronary atherosclerotic lesions can be quickly and safely evalu‐
ated in the carotids, femoral arteries, and the abdominal aorta. The grade of atherosclerosis
in extracoronary sites correlates with a greater number of standard risk factors and, more
importantly, with greater cardiac risk [77]. Of the peripheral arterial surrogates, carotid
atherosclerosis has been most closely correlated with coronary artery disease [78-82]. Pe‐
ripheral arterial ultrasonography is regarded to be a sensitive tool for the detection of early
atherosclerosis and may be useful in assessing response to therapy. Thickening of the inti‐
ma-media of the arterial wall is the earliest detectable anatomic change in the development
and progression of atherosclerosis. High-resolution B-mode ultrasonography is widely used
for noninvasive quantification of carotid IMT as a measure of subclinical atherosclerosis
[83]. Carotid IMT is believed to be a marker of generalized atherosclerosis and is predictive
of clinical cardiovascular events [79,81,84-88]. Thus, ultrasound imaging of intima-media
thickening in carotid arteries served as a means of monitoring atherosclerosis during Allicor
long-term treatment. Indeed, Allicor significantly reduced carotid arterial intima-media
thickness compared to baseline and the placebo group. In Allicor recipients, a significant in‐
crease in the IMT in one or both carotid arteries was observed in 30 (32.2%) patients, and
was significantly reduced in 44 (47.3%) patients. In 8 patients (8.6%) there were no signifi‐
cant IMT changes in either the carotid artery, and in the remaining 11 patients (11.8%) diver‐
gent changes were observed, i.e. IMT increased in one carotid artery and decreased in the
other. IMT lesion progression was observed in 50 (48.5%) placebo cases, and decreased sig‐
nificantly in one or both arteries in 31 (30.1%) patients. Stable situation was observed in 11
(10.7%), and divergent changes occurred in the remaining 7 (6.8%) patients. The difference
in the IMT changes between Allicor and placebo recipients was statistically significant (Pear‐
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son’s chi-square 9.788, P=0.020). Thus, while spontaneous atherosclerosis progression pre‐
vailed in the placebo group, Allicor beneficially impacted early carotid atherosclerosis -
significantly increasing lesion regressions and reducing the net number of progressive
lesions (Figure 3). The trend to IMT reduction in Allicor recipients was observed already af‐
ter first 3 months of the study, and became statistically significant different from the base‐
line measures as well as from placebo group after the first 12 months of treatment. At the
end of the two-year study the difference between placebo and Allicor recipients increased
and remained statistically significant. The overall lesion progression was clearly different in
the treated and untreated groups. IMT in the common carotid artery rose 0.015±0.008 mm
annually and above a mean baseline IMT of 0.931±0.009 mm in the placebo group, and fell in
Allicor-treated patients at a rate of -0.022±0.007 mm per year (P=0.002). Though the benefit
of Allicor was more pronounced in year 1 (-0.028±0.008 mm) it remained significant and as a
statistically identical significant difference in year 2 (-0.016±0.007).
Figure 3. The dynamics of IMT changesSolid circles, Allicor-treated patients; open circles, placebo patients. *, signifi‐
cant IMT change as compared to baseline, P<0.05;#, significant difference from placebo group, P<0.05.
The beneficial effects of Allicor were also revealed in analysis of subgroups of patients who
had significant increase or reduction in IMT. IMT progression was almost 2.5 fold higher in
the 50 patients in the placebo group with progress (0.070±0.016 mm) than in Allicor-treated
patients with atherosclerosis progression (n=30, 0.029±0.011 mm increase, P=0.038). Similar‐
ly, spontaneous atherosclerosis regression in placebo recipients (n=31) was half as promi‐
nent (-0.041±0.014 mm) than in Allicor-treated patients (n=44, -0.082±0.015 mm, P=0.049).
The results obtained in our study are generally in good coincidence with the data from re‐
cent double-blinded placebo-controlled randomized study by Koscielny et al. [89]. It has
been demonstrated that 4-year treatment with garlic-based drug Kwai inhibited the increase
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in the volume of atherosclerotic plaques in carotid and femoral arteries by 5-18%. The age-
dependent representation of the plaque volume has shown an increase between 50 and 80
years that was diminished under garlic treatment by 6-13% related to 4 years. So, with garlic
application the plaque volume in the whole collective remained practically constant within
the age-span of 50-80 years [89].
Overall, the regression of subclinical atherosclerosis was much more frequently observed in
asymptomatic men who randomly received Allicor than in those who received placebo. A
rather high proportion of patients in placebo group who demonstrated spontaneous regres‐
sion, especially at early stages of atherosclerosis, reflects an interesting but poorly under‐
stood aspect of vascular biology that requires further study. The decrease in IMT achieved
during the AMAR study is quite comparable with the results of most successful trials with
other compounds (Table 4). Although, these studies employed potent lipid-lowering agents
either calcium antagonists whose beneficial effects of treatment were attributed to reduc‐
tion in LDL cholesterol,  the major risk factor for atherosclerosis development, or arterial
wall stress.
Trial Medication Mean annual IMT change, mm Reference
placebo treatment
PLAC II Pravastatin 0.068 0.059 [91]
KAPS Pravastatin 0.029 0.010 [90]
ASAP Simvastatin - -0.009 [92]
PREVENT Amlodipine 0.011 -0.015 [93]
ASAP Atorvastatin - -0.020 [92]
CLAS Cholestipol, niacin 0.010 -0.020 [94, 95]
MARS Lovastatin 0.015 -0.028 [94, 96]
VHAS Verapamil - -0.028 [97]
AMAR Allicor 0.015 -0.022 This study
Table 4. The comparative data from clinical trials on carotid atherosclerosis regression
The main scientific goal of the given double-blinded, placebo-controlled randomized study
was to test the hypothesis that long-term lowering of serum atherogenicity may prevent the
initial stage of atherogenesis, namely, the excessive deposition of cholesterol in the cells of
the arterial wall, thus inhibiting further formation of atherosclerosis lesion [41,62].
At the baseline, the sera from 17 patients in placebo group (16.5%) did not induce significant
cholesterol accumulation in cultured cells, while the sera from other 86 patients were athero‐
genic, i.e. induced a statistically significant (1.2- to 3.9-fold) increase in intracellular choles‐
terol content (mean result, 166.3±5.5, % of control value). In Allicor-treated patients, 23
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patients (24.7%) had non-atherogenic sera, and in other 70 patients the sera increased intra‐
cellular cholesterol by 1.2- to 3.5-fold (mean result, 172.1±5.8, % of control value).
Among patients with non-atherogenic sera at the baseline, in placebo recipients blood serum
atherogenicity arrived in 11 cases during the study; in Allicor-treated patients at the end of
the study serum atherogenicity was revealed in 9 cases, and in other 14 patients the sera re‐
mained non-atherogenic. The difference between Allicor and placebo recipients was statisti‐
cally significant (Pearson’s chi-square 11.023, P<0.001). Thus, Allicor treatment prevented
the upraise of blood serum atherogenicity.
Among patients with initially atherogenic sera, in placebo group blood serum atherogenici‐
ty spontaneously decreased in 26 patients, did not change significantly in 28 patients, and in
32 cases there was further increase in blood serum atherogenic potential. On the opposite, in
Allicor group serum atherogenicity was decreased in 39 patients by the end of the study, re‐
mained unchanged in 18 patients, and further increase in serum ability to induce intracellu‐
lar cholesterol accumulation was observed only in 13 cases. Again, the difference between
Allicor and placebo recipients was statistically significant (Pearson’s chi-square 11.274,
P=0.004). Thus, Allicor also induced a fall in blood serum atherogenicity, if it existed at the
beginning of treatment.
Figure 4. The dynamics of serum atherogenicity changesSolid circles, Allicor-treated patients; open circles, placebo pa‐
tients. *, significant IMT change as compared to baseline, P<0.05;#, significant difference from placebo group, P<0.05.
The overall dynamic of changes in serum atherogenicity is presented in Figure 4. At the
baseline, serum taken from patients was able to induce 1.56-fold increase in intracellular
cholesterol content in cell culture test. In the placebo group, the mean level of serum athero‐
genic potential did not change significantly during two years of the study. On the opposite,
in Allicor-treated patients the mean value for the ability of serum to induce intracellular lip‐
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id accumulation was significantly lowered (P=0.016) approximately by 30% of the initial lev‐
el (95% CI: 16.9, 41.0) already after first 3 months of study, and this effect was maintained
during the study. General linear model analysis has demonstrated the statistically signifi‐
cant difference in the dynamic of changes in serum atherogenicity between Allicor-treated
and placebo groups (P=0.008).
The presence or absence of serum atherogenicity at the baseline, as well as the extent of se‐
rum-induced intracellular cholesterol accumulation at the baseline, did not correlate with
the following changes in IMT. However, the statistically significant correlation has been re‐
vealed between the changes in blood serum atherogenicity during the study and the
changes in intima-media thickness of common carotid arteries (r=0.144, P=0.045 for the total
study sample). In patients with initially non-atherogenic sera, the correlation between
changes in atherogenicity and IMT was stronger (r=0.342, P=0.031). This correlation is ex‐
plained mainly by the arrival of serum atherogenicity during follow-up in a subgroup of
placebo recipients with initially non-atherogenic sera; in them the correlation between in‐
crease of atherogenicity and IMT dynamics was the highest (r=0.517, P=0.034).. In patients
with initially atherogenic sera, the correlation between changes in atherogenicity and IMT in
total group did not reach statistical significance (r=0.147, P=0.067), but in Allicor-treated pa‐
tients in most of whom the decrease in serum atherogenicity was observed, the above pa‐
rameters correlated well (r=0.254, P=0.034).
There is a substantial experimental background to explain the possible mechanisms under‐
lying a direct anti-atherosclerotic action of Allicor. The components of garlic can regulate
two main intracellular enzymes responsible for cholesterol intracellular metabolism. Garlic
extract stimulates cholesteryl ester hydrolase and inhibits acetyl coenzyme A : cholesterol
acyl transferase, thus diminishing intracellular content of cholesteryl esters [98]. Additional‐
ly, garlic extract inhibits cellular proliferative activity and the synthesis of connective tissue
matrix components [98,99]. Allicor also possesses antioxidant activity and lowers LDL sus‐
ceptibility to oxidation [99]. Allicor prevents serum-induced cholesterol accumulation in
cells cultured in the presence of patient’s serum taken after single dose of Allicor adminis‐
tration; in other words, it reduces serum atherogenic potential [99]. In animal studies, garlic-
based preparations inhibit the formation of neointimal thickening in cholesterol-fed rabbits
[100]. So, it could be easily proposed that long-term Allicor treatment produced a direct anti‐
atherosclerotic effect due to the prevention of lipid deposition and depletion of cholesterol
pool already accumulated in arterial wall.
Garlic contains a variety of organosulfur compounds, amino acids, vitamins and minerals
[101]. Some of the sulfur-containing compounds such as allicin, ajoene, S-allylcysteine, S-
methylcysteine, diallyl disulfide and sulfoxides may be responsible for antiatherosclerotic
activity of garlic [98,100]. Many garlic-based products are present on the market now. As
compared to other garlic preparations, dehydrated garlic powder is thought to retain the
same ingredients as raw garlic, both water-soluble and organic-soluble, although the pro‐
portions and amounts of various constituents may differ significantly [102,103]. Allicor con‐
tains just garlic powder; on the other hand, it possesses a prolonged mode of action, as its
antiatherogenic effect lasts for 12-16 hours after single dose administration [99]. So, Allicor
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differs greatly from other garlic-based preparations and may have considerable benefits in
medicinal use.
On the whole, the results of our study demonstrate that long-term treatment with time-re‐
leased garlic-based drug Allicor provides a direct anti-atherosclerotic effect on carotid athe‐
rosclerosis. Being the remedy of natural origin, Allicor is safe with the respect to adverse
effects and allows even perpetual administration, which may be quite necessary for preven‐
tion and treatment of subclinical atherosclerosis. These results encouraged clinical trials of
two other drugs based on natural products, including: Inflaminat, possessing anti-cytokine
activity and the phytoestrogen-rich drug Karinat, designed for postmenopausal women.
Atherosclerosis is regarded as a pathological process with elements of local aseptic inflam‐
mation, while inflammatory cytokines play a role at every stage of atherosclerosis develop‐
ment [104-107]. In this regard, drugs with systemic anti-inflammatory action may be
effective for the prevention of atherosclerosis. In our study, we investigated the atheroscle‐
rosis regression effect of natural drug Inflaminat based on calendula, elder and violet. These
plants are widely used in herbal medicine as anti-inflammatory agents. In a pilot study of
Inflaminat using a protocol similar to the AMAR study Inflaminat demonstrated atheroscle‐
rosis regression effects and statistically significant difference from the baseline as well as
from placebo group (Table 5). Thus, Inflaminat possesses atherosclerosis regression effect in
asymptomatic men.
Inflaminat Placebo р**









Table 5. Carotid IMT changes in 1-year Inflaminat pilot study* significant differences, p<0.05, Wilcoxon's signed
ranked test;**statistical significance of differences was estimated by Mann-Whitney U-test.
Atherosclerosis prevention in postmenopausal women is a striking problem, since modern
medicine does not provide any effective approach. Hormone replacement therapy was re‐
jected as a tool for atherosclerosis prevention in women due to the negative results of recent
studies – WHI, PEPI and HERS [108-113]. So, the development of novel approaches is highly
demanded. Phytoestrogens are often regarded as a possible alternative to hormone replace‐
ment therapy, but practically nothing is known on their effects on atherosclerosis.
We screened many natural phytoestrogen-rich components for their antiatherogenic activity
using an ex vivo test system [39,61,114-117]. The most promising of these compounds were:
garlic powder, extract of grape seeds, green tea leafs and hop cones - all produced a signifi‐
cant antiatherogenic effect. On the basis of their combination, the novel isoflavonoid-rich di‐
etary supplement Karinat was developed. It produces the most efficient antiatherogenic
effect in cell culture models and is characterized by improved phytoestrogen profile, provid‐
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ing additional amounts of biologically active polyphenols including resveratrol, genisteine
and daidzeine that are claimed to produce some effects on atherosclerosis development.
Karinat also contains additional amounts of β-carotene, α-tocopherol and ascorbic acid to
provide the necessary daily intake of antioxidants
A randomized double-blinded placebo-controlled pilot clinical study on atherosclerotic ef‐
fect of Karinat was performed in healthy peri- and postmenopausal women to understand
the risks and benefits of phytoestrogen therapy in relation to atherosclerosis progression.
The primary endpoint was the annual rate of changes in common carotid artery intima-me‐
dia thickening, and the secondary endpoint was the dynamics of climacteric syndrome, that
is monitored only in perimenopausal women. Table 6 demonstrates the effect of Karinat
treatment on the dynamics of carotid atherosclerosis in postmenopausal women. In the pla‐
cebo group an increase in the average IMT of more than 100 µm per year was observed.
Thus, the rate of the natural history of atherosclerosis in postmenopausal women is extreme‐
ly high: the average increase in IMT is 13% per year, and growth of atherosclerotic plaques
of 40% per year.
Karinat Р Placebo Р
Number of participants 80 - 77 -
IMT, μm +6 (85) p<0.05 +111 (91) p<0.02
Plaques, scores +0,21 (0,59) 0,009 +0,31 (0,55) <0,001
Table 6. Carotid IMT changes in 1-year Karinat pilot study on postmenopausal women
In the Karinat group a completely different picture was observed. The average IMT of caro‐
tid arteries was not changed (statistically insignificant increase of 6 µm per year, i.e. less
than 1%). However, the progression of existing plaques by 27% per year was detected.
The results of quantitative measurements of the degree of atherosclerosis in the dynamics
have shown that the use of phytoestrogen complex in postmenopausal women almost com‐
pletely suppresses the formation of new atherosclerotic lesions and 1.5-fold slows the pro‐
gression of existing lesions.
Thus, as in the AMAR trial Inflaminat caused regression of carotid atherosclerosis while
Karinat prevented its development. It should be noted that the anti-atherosclerotic effects of
drugs based on natural products are not inferior to the effects of such drugs as statins and
calcium antagonists (Table 4). Thus, natural products can be considered as promising drugs
for anti-atherosclerotic therapy.
10. Conclusion
This review illustrates the use of cultured human arterial cells for:
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- mass screening of drugs and chemicals (cyclic AMP elevators, calcium antagonists, prosta‐
glandins, - blockers, antioxidants, etc.);
- investigation of the mechanisms responsible for the atherosclerosis-related effects (calcium
antagonists and lovastatin);
- optimization of anti-atherosclerotic and anti-atherogenic drug and dietary therapy (β-
blockers, calcium antagonists, mushrooms, krill meat).
Cell cultures enable one to perform investigation on models: - in vitro (mass screening,
study of the mechanism of drug action);
- ex vivo (study of the mechanism of drug action, optimization of therapy);
- in vivo models (animals with experimental atherosclerosis) allowed us to confirm the re‐
sults obtained on in vitro and ex vivo models.
The in vitro and ex vivo models can be employed to reveal and investigate of:
- direct anti-atherosclerotic activity - regression of atherosclerosis (calcium antagonists, pros‐
taglandins, antioxidants, lipostabil, mushrooms, mollusk meat, etc.);
- direct anti-atherogenic activity - prevention of atherosclerosis (calcium antagonists, mush‐
rooms, krill meat);
- indirect anti-atherogenic activity (lovastatin);
- atherogenic activity (β-blockers, thromboxane, phenothiazines).
Natural products can be considered as promising drugs for anti-atherosclerotic therapy.
Two-year treatment with Allicor (garlic powder) has a direct anti-atherosclerotic effect on
carotid atherosclerosis in asymptomatic men. Inflaminat (calendula, elder and violet), pos‐
sessing anti-cytokine activity, caused regression of carotid atherosclerosis as a result of 1-
year treatment of asymptomatic men. Phytoestrogen-rich drug Karinat (garlic powder,
extract of grape seeds, green tea leafs, hop cones, β-carotene, α-tocopherol and ascorbic
acid) prevented development of carotid atherosclerosis in postmenopausal women.
Our basic studies have shown that cellular lipidosis is the principal event in genesis of athe‐
rosclerotic lesion. Using cellular models and natural products we have developed an ap‐
proach to prevent lipid accumulation in arterial cells. This led to regression of
atherosclerosis and/or prevention of its progression in patients. So, our basic findings were
successfully translated into clinical practice. As a result of this translation novel approach to
anti-atherosclerotic therapy was developed. On the basis of our knowledge we developed
drugs possessing direct anti-atherosclerotic activity. Our clinical trial confirmed the efficacy
both novel approach and novel drugs.
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1. Introduction
1.1. The societal burden of chronic stable angina
Chronic stable angina (CSA) is a cardinal symptom of coronary artery disease (CAD), charac‐
terized by pain or discomfort in the precordium, shoulder, back, arm, or jaw [1]. Angina pain
symptoms—or equivalents such as shortness of breath, fatigue, and nausea—are considered
stable if they are experienced over several weeks in the absence of major deterioration [1-3].
Those affected by CSA typically have CAD involving one or more large epicardial arteries,
although individuals diagnosed with hypertrophic cardiomyopathy, hypertension, endothe‐
lial dysfunction, or valvular stenosis/deficiencies may also exhibit angina [1]. Symptoms
usually occur predictably upon physical exertion and are relieved by rest or nitroglycerin [1].
The severity of symptoms experienced can vary, typically ranging from Canadian Cardiovas‐
cular Society [CCS] class I to class III angina. A number of factors can also aggravate symptoms
including heightened emotional states, diet, smoking, and weather [1,4].
As CAD survival rates increase, the global incidence and prevalence of CSA are also on the
rise. Prevalence estimates suggest that CSA affects more than 10 million Americans [5] and
nearly ½ million Canadians over the age of 12 [6]. In Scotland, CSA affects 2.6% of the general
population, with 28 per 1000 men and 25 per 1000 women diagnosed, respectively [7]. The age-
standardized annual incidence of angina, per 100 population in Finland, 2006 was 2.03 among
men and 1.89 among women [8].
Chronic stable angina poses significant risk for acute myocardial infarction, congestive heart
failure, atrial fibrillation, and stroke [9], as well as increased risk of cardiovascular-related
mortality or hospitalization (men: RR 1.62, women: RR 1.48) [10]. Moreover, multiple studies
have shown that people living with CSA are among the more severely debilitated across
several chronic illness populations including sciatica, arthritis, low back pain, diabetes and
© 2013 McGillion et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 10
Self-Management Training for Chronic Stable Angina:
Theory, Process, and Outcomes
M.H. McGillion, S. O’Keefe-McCarthy and S.L. Carroll
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54635
1. Introduction
1.1. The societal burden of chronic stable angina
Chronic stable angina (CSA) is a cardinal symptom of coronary artery disease (CAD), charac‐
terized by pain or discomfort in the precordium, shoulder, back, arm, or jaw [1]. Angina pain
symptoms—or equivalents such as shortness of breath, fatigue, and nausea—are considered
stable if they are experienced over several weeks in the absence of major deterioration [1-3].
Those affected by CSA typically have CAD involving one or more large epicardial arteries,
although individuals diagnosed with hypertrophic cardiomyopathy, hypertension, endothe‐
lial dysfunction, or valvular stenosis/deficiencies may also exhibit angina [1]. Symptoms
usually occur predictably upon physical exertion and are relieved by rest or nitroglycerin [1].
The severity of symptoms experienced can vary, typically ranging from Canadian Cardiovas‐
cular Society [CCS] class I to class III angina. A number of factors can also aggravate symptoms
including heightened emotional states, diet, smoking, and weather [1,4].
As CAD survival rates increase, the global incidence and prevalence of CSA are also on the
rise. Prevalence estimates suggest that CSA affects more than 10 million Americans [5] and
nearly ½ million Canadians over the age of 12 [6]. In Scotland, CSA affects 2.6% of the general
population, with 28 per 1000 men and 25 per 1000 women diagnosed, respectively [7]. The age-
standardized annual incidence of angina, per 100 population in Finland, 2006 was 2.03 among
men and 1.89 among women [8].
Chronic stable angina poses significant risk for acute myocardial infarction, congestive heart
failure, atrial fibrillation, and stroke [9], as well as increased risk of cardiovascular-related
mortality or hospitalization (men: RR 1.62, women: RR 1.48) [10]. Moreover, multiple studies
have shown that people living with CSA are among the more severely debilitated across
several chronic illness populations including sciatica, arthritis, low back pain, diabetes and
© 2013 McGillion et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
stroke [11-15]. Many of these patients suffer persistent pain episodes, poor general health, sleep
disturbance, impaired social role functioning, activity restriction, and reduced ability to self-
care [16-27].
As Lewin [28,29] and others [30] have argued, angina seems to have a disproportionately
severe impact on one’s self-perceived health status relative to other chronic illnesses. Extensive
work in the field to date has shown that negative emotional states, such as anxiety and
depression, are well-documented corollaries of CSA. For example, as part of a larger clinical
trial, Ketterer et al. [31] (n= 196) examined the psychological profile of patients with stable
CAD, angina symptoms during daily activities, and positive exercise stress tests. Anxiety and
depression were strongly associated with recent angina, as well as angina in the presence of
ischemia invoked by treadmill testing. Gravely-Witte et al. [32] found similar results in a
prospective study of 121 patients following surgical and percutaneous revascularization
procedures. Angina symptoms were predictive of higher levels of depression and lower levels
of emotional and social functioning [32].
The central role of emotional distress in CSA may be explained, in part, by the fact that angina
sufferers tend to hold erroneous and maladaptive beliefs about their condition. In Wynn’s
widely cited observational study (1967) [30], 23% of post-myocardial infarction patients
(n=400) reported being anxious due to the misconception that each angina episode reflected
further damage to the heart. In 40% of cases, failure to return to work was attributed to fear of
immanent death [30]. Since the time of Wynn’s seminal work, multiple studies have shown
that CSA patients routinely interpret their angina symptoms as ‘mini heart attacks’ [19,22-24,
30,33]. Consequently, many patients adopt sedentary lifestyles, relinquish their normal
routines, and/or retire early as means to avoid angina attacks [19,22-24,34,35]. Unfortunately,
out of concern, family members, peers [17,19,36], and health care professionals [37] alike often
reinforce such maladaptive coping behaviours which can evoke unintentional deconditioning
as well as reductions in coronary blood flow, sheer stress, and impetus for healthy collateral
coronary vessel formation [38].
Considering the high prevalence and major negative psychological impact of CSA, the cost
implications are significant. The total costs associated with CSA management in the United
States have been estimated to exceed 15 billion dollars per annum [1]. In the United Kingdom,
the direct cost of chronic angina in 2000, including prescriptions, repeated emergency depart‐
ment visits and other hospital admissions, outpatient referrals, and procedures, was estimated
at ₤669,000,000, accounting for 1.3% of the total National Health Service expenditure [39]. At
the patient level, a Canadian study [40] estimated the mean cost RFA-related disability (2003
– 2005) from a societal perspective including direct out-of-pocket costs to patients, indirect
costs expressed as forgone income and leisure time, and system-related costs paid by public
and private insurers. The total estimated annualized cost of CSA per patient was $19,209 [40].
In recent years, increasing attention has been given to angina self-management training [SMT]
interventions as a means to offset the societal burden of CSA. These interventions are multi-
modal educational packages that employ learning materials and cognitive-behavioural
strategies to achieve changes in knowledge and behaviour for effective disease self-manage‐
ment [41]. This chapter provides a brief overview of the concept of self-management and
discussion of background theory, key elements of intervention structure and process, as well
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as specific angina SMT models developed in the United Kingdom and Canada. The overall
effectiveness of SMT for angina will also be reviewed with respect to impact on symptoms,
HRQL outcomes, and cost. Implications for future research and practice will also be discussed.
2. Self-Management training: Overview
Self-management training emerged as a priority for health systems in the 1980’s and 90’s,
following a surge of population-based research on the prevalence of chronic illness in the 1960’s
and 70’s [42]. The realization of the global prevalence of divergent chronic illnesses, without
cure, led to major critiques of standard health care delivery models as too poorly integrated
and siloed to address the consequences of chronic illness and related therapies [42]. Similarly,
traditional patient education models have been critiqued as lacking adequate scope and
complexity to address an ageing population, multiple co-morbidities, and the complex needs
of individuals who must manage their chronic illnesses daily [42]. Traditional acute care
models and related patient education focus on diagnosis and cure, technological interventions,
and the imparting of specific disease-related information to inexperienced patients who act as
passive recipients of health teaching. Within this paradigm, the health care professional is
understood to be the knowledgeable, experienced authority on the patient’s care priorities
[42-44]. Thus, a fundamental premise of traditional models of care is that patient compliance
with specific direction and principles taught will lead to improved health behaviours and
outcomes [42-44].
In contrast, SMT interventions espouse the tenets of Wagner et al.’s Chronic Care Model (CCM)
[45]. According to the CCM, chronic disease management refers to a system of health care that
supports individuals with chronic illness to remain as healthy and independent as possible.
The process of disease management is conceptualized as patient-centered, with health care
professionals, the health care system, and the community at large collaborating with the patient
to facilitate optimum health and well-being. Implicit within the CCM is the concept that
patients should be well-informed about their illness, and should be active participants in their
care [45].
The emphasis of SMT, therefore, is the role of the patient as an active player engaged in
preventive and therapeutic health activities in partnership with health care professionals [46].
At the crux of such partnerships are patients’ everyday problems as a result if living with
chronic illnesses. As D’Zurilla [47] Lorig and Holman [44], and others [46] have argued,
effective SMT is fundamentally problem-oriented. A common starting ground for SMT
interventions in practice is identification, crystallization, and prioritization of patients’ chief
concerns [44-47]. Care is generally taken during this process to harmonize perspectives—
through deliberative discussion—as health care professionals will often conceptualize the
issues in terms of diagnosis and/or risk factor modification, whereas patients will think in
practical terms about the day-to-day difficulties their illnesses present [19,48]. The problem
list generated dictates the direction and scope of intervention for each patient [44-48].
Along with collaborative problem identification, additional key elements of SMT, which are
typical [45,48,49], include a) targeted goal setting: identifying meaningful, realistic goals in the
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sufferers tend to hold erroneous and maladaptive beliefs about their condition. In Wynn’s
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(n=400) reported being anxious due to the misconception that each angina episode reflected
further damage to the heart. In 40% of cases, failure to return to work was attributed to fear of
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routines, and/or retire early as means to avoid angina attacks [19,22-24,34,35]. Unfortunately,
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reinforce such maladaptive coping behaviours which can evoke unintentional deconditioning
as well as reductions in coronary blood flow, sheer stress, and impetus for healthy collateral
coronary vessel formation [38].
Considering the high prevalence and major negative psychological impact of CSA, the cost
implications are significant. The total costs associated with CSA management in the United
States have been estimated to exceed 15 billion dollars per annum [1]. In the United Kingdom,
the direct cost of chronic angina in 2000, including prescriptions, repeated emergency depart‐
ment visits and other hospital admissions, outpatient referrals, and procedures, was estimated
at ₤669,000,000, accounting for 1.3% of the total National Health Service expenditure [39]. At
the patient level, a Canadian study [40] estimated the mean cost RFA-related disability (2003
– 2005) from a societal perspective including direct out-of-pocket costs to patients, indirect
costs expressed as forgone income and leisure time, and system-related costs paid by public
and private insurers. The total estimated annualized cost of CSA per patient was $19,209 [40].
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interventions as a means to offset the societal burden of CSA. These interventions are multi-
modal educational packages that employ learning materials and cognitive-behavioural
strategies to achieve changes in knowledge and behaviour for effective disease self-manage‐
ment [41]. This chapter provides a brief overview of the concept of self-management and
discussion of background theory, key elements of intervention structure and process, as well
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cure, led to major critiques of standard health care delivery models as too poorly integrated
and siloed to address the consequences of chronic illness and related therapies [42]. Similarly,
traditional patient education models have been critiqued as lacking adequate scope and
complexity to address an ageing population, multiple co-morbidities, and the complex needs
of individuals who must manage their chronic illnesses daily [42]. Traditional acute care
models and related patient education focus on diagnosis and cure, technological interventions,
and the imparting of specific disease-related information to inexperienced patients who act as
passive recipients of health teaching. Within this paradigm, the health care professional is
understood to be the knowledgeable, experienced authority on the patient’s care priorities
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with specific direction and principles taught will lead to improved health behaviours and
outcomes [42-44].
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[45]. According to the CCM, chronic disease management refers to a system of health care that
supports individuals with chronic illness to remain as healthy and independent as possible.
The process of disease management is conceptualized as patient-centered, with health care
professionals, the health care system, and the community at large collaborating with the patient
to facilitate optimum health and well-being. Implicit within the CCM is the concept that
patients should be well-informed about their illness, and should be active participants in their
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The emphasis of SMT, therefore, is the role of the patient as an active player engaged in
preventive and therapeutic health activities in partnership with health care professionals [46].
At the crux of such partnerships are patients’ everyday problems as a result if living with
chronic illnesses. As D’Zurilla [47] Lorig and Holman [44], and others [46] have argued,
effective SMT is fundamentally problem-oriented. A common starting ground for SMT
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concerns [44-47]. Care is generally taken during this process to harmonize perspectives—
through deliberative discussion—as health care professionals will often conceptualize the
issues in terms of diagnosis and/or risk factor modification, whereas patients will think in
practical terms about the day-to-day difficulties their illnesses present [19,48]. The problem
list generated dictates the direction and scope of intervention for each patient [44-48].
Along with collaborative problem identification, additional key elements of SMT, which are
typical [45,48,49], include a) targeted goal setting: identifying meaningful, realistic goals in the
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context of patient priorities and preferences, b) self-reflection: sharing of feelings to provide
opportunities for discussion about the personal meaning of chronic illness and difficult
emotional responses, c) mini-lectures and supplemental reading/workbooks: providing opportuni‐
ties for brief information sharing about relevant educational content in accessible language
and formats, d) brainstorming and problem solving: facilitating discussion of the potential benefits
of various self-management strategies such as safe exercise, sound nutrition, energy conser‐
vation and pacing, identifying and reframing negative self-talk, etc., e) regular action plan‐
ning: learning the process of setting incremental positive behaviour change, and f) self-
monitoring, accountability, and feedback: reporting back to peers or counsellors about individual
progress and obtaining constructive feedback.
Self-management training programs have been delivered in a variety of formats including
individual counseling, small group sessions, or individual and group-based approaches in
combination. Programs that engage either health care professional facilitators or lay peer
leaders have been shown to be effective, as have programs that use these delivery methods in
combination [46,48,49]. Regardless of format, most established SMT interventions offer a range
of self-management techniques for participant rehearsal and uptake over the course of several
days or weeks [44-49]; typical settings for program delivery include clinical outpatient settings
and community centres.
3. Key theoretical underpinning: Self-efficacy
As discussed, the majority of contemporary SMT programs foster an individualized approach,
with a strong emphasis on coaching by a health care professional or peer leader [50]. A common
goal of SMT intervention developers is to maintain a focus on wellness in the foreground and
improve overall HRQL. In so doing, three key objectives of self-management coaching are to
prepare people to do the following a) take better care of their health through physical activity,
relaxation and stress reduction, and effective use of available treatments, b) maintain optimal
social and occupational role functioning, and c) manage challenging emotional responses to
chronic illness [51].
To facilitate effective coaching and desired health outcomes, most successful SMT interven‐
tions are developed on the basis of well-established psychological models of behavior change
[50]. Such models delineate the instrumental processes inherent in successful role modeling,
self-management skills acquisition, realistic goal setting, problem solving, and identification
and management of obstacles to health-related improvements [50].
A well-integrated model in SMT research and practice is Bandura’s Self-Efficacy Theory
[52-54]. Renowned sociologist Albert Bandura [53] defined the concept of self-efficacy as “The
exercise of human agency through people’s beliefs in their capabilities to produce desired
effects by their actions” (p iv). Bandura argued that fundamental to human nature is the need
for control, or causative capacity in everyday situations. Human enactments of control are
thought to be played out in the form of agency, or one’s intentional actions. People’s beliefs
about their self-efficacy drive their personal senses of agency [52-54]. Therefore, chronic
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disease self-management is not simply a question of knowing what to do; the process requires
incremental increases in one’s perceived capacity to organize and integrate cognitive, social
and behavioural skills to meet a variety of aims in managing illness from day to day [52-54].
Under the direction of Kate Lorig, the Stanford Patient Education Research Centre has been a
world leader in the application of self-efficacy theory to chronic disease SMT research and
implementation [55]. Lorig et al.s’ seminal work, the Arthritis Self-Management Program
(ASMP)—developed in 1978 and funded by the National Institutes of Health—has been widely
disseminated through national arthritis societies on three continents [56-61]. Multiple process
evaluations and randomized-controlled trials (RCTs) of the ASMP [56-61], and its prevalent,
generic adaptation, the Chronic Disease Self-Management Program (CDSMP) [62-71] (devel‐
oped in 1996), have shown that participation in a standardized SMT program results in
significantly improved levels of self-efficacy for those with chronic pain and other chronic
diseases. In the ASMP evaluations, improved self-efficacy was found consistently to mediate
sustained significant changes in HRQL, knowledge, pain, depression and disability. Reduc‐
tions in health care costs up to 4 years post intervention, without formal reinforcement of
program content, have also been found [60,61]. Similarly, self-efficacy enhancement in the
CDSMP trials has repeatedly demonstrated significant improvements in exercise, cognitive
symptom management, communication with physicians, self-reported general health, health
distress, fatigue, disability, and role and social functioning. Participants have also spent
significantly fewer days in hospital; sustained outcome improvements have been demonstrat‐
ed up to three years post-intervention [62-71].
Both the ASMP [56-61] and CDSMP [62-71] employ a standardized 6-week, community-based
format, Sessions are delivered in 2-hour sessions weekly for small groups of approximately 12
to 15 patients. As preeminent models of SMT, the ASMP and CDMSP programs have consis‐
tently supported [72] the following major precepts of Self-Efficacy Theory—summarized by
Lorig et al. [73], (p. 5-6)—as principal drivers of effective chronic disease self-management:
• The strength of people’s belief in their ability to achieve certain outcomes reliably predicts
motivation and behaviour.
• Perceived self efficacy can be enhanced via performance mastery, modeling, reinterpreta‐
tion of symptoms, and social persuasion.
• Enhanced self-efficacy belief leads to lasting improvements in behaviour, motivation,
thinking patterns, and emotional well-being.
4. Self-management training: Angina-specific models
Angina-specific SMT programs emerged in the early 1990s [74-76] and have been documented
as recently as 2012 [82]. The majority of RCT evidence to date includes individual counseling
or small-group interventions (i.e. 6-15 patients) employing varying combinations of educa‐
tional materials on CAD and medications, risk factor identification and modification, planned
exercise/physical activity, and cognitive-behavioural techniques targeted at lifestyle and
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angina symptom self-management, relaxation training and/or stress reduction, or enhance‐
ment of physical activity. Intervention durations, formats, and processes have varied [74-82].
A range of outcomes have been used to examine the effectiveness of angina SMT, including:
angina symptom profile (e.g. frequency, severity, stability) and related sublingual (SL) nitrate
use, objective measures of ischemia such as treadmill stress tests, and self-report measures of
HRQL and psychological well-being.
This review of the evidence will focus first on two more recent angina SMT models with clear
underpinnings in self-efficacy theory: The Angina Plan [78,79,82,83] and the Chronic Angina Self-
Management Program [17,81]. Second, results of meta-analyses [84,85] of the overall effective‐
ness of angina SMT will be discussed.
5. The angina plan
The Angina Plan, developed by Lewin, Furze et al. [78,79] is the most widely evaluated and
disseminated angina SMT program to date; over 20,000 patients have been enrolled [83]. The
Angina Plan is recognized in the United Kingdom [86] as a form of home-based cardiac
rehabilitation geared toward debunking common misconceptions about angina, promoting
relaxation, increasing physical activity and role functioning, and making positive changes in
lifestyle (e.g. nutrition). Risk factor identification, and educational materials on CAD, medi‐
cations, as well as seeking emergency medical assistance (as appropriate) are also key com‐
ponents [78,79]. The program materials are provided in a workbook and relaxation tape which
patients are oriented to by a nurse intervener during a structured, individualized interview
process [78,79]; this initial session is followed by a 12-week course of telephone-based support
to facilitate incremental goal setting and pacing of activities [78,79]. A 2002 RCT of the Angina
Plan (n=142), found that at 6 months follow-up, those assigned to the intervention group had
significant reductions in angina frequency, anxiety and depression, and SL nitrate usage, as
compared to controls who received standard education and counseling by a nurse [79]. Those
who received the Angina Plan also demonstrated significant improvements in physical
limitation scores, daily walking, and dietary habits [79]. A pragmatic RCT by Zetta et al. (n=
218) [82] found similar results for patients admitted to hospital for acute exacerbation of angina.
Angina Plan recipients reported significant improvements in knowledge and cardiac miscon‐
ceptions, social and leisure activities, perceived general health, and physical limitation.
Improvements in cardiac risk factors including body-mass index and exercise were also found
[82]. However, no significant improvements in anxiety and depression scores were found
based on intention-to-treat analyses; extracardiac depression was proposed as a potential
confounding factor diluting the treatment effect [82].
Recently, Furze et al. [83] evaluated (n= 142) a lay, peer-led adaptation of the Angina Plan in
response to healthcare resource constraints as well as increasing interest in lay-facilitated SMT
interventions. The Lay-facilitated Angina Management Program (LAMP) was delivered by
people who had experience with CAD either as patients or caregivers [83]; outcomes were
evaluated at 3 and 6 months post intervention. Compared to standard advice from a specialist
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nurse, the LAMP intervention did not significantly reduce the frequency of angina symptoms;
it was hypothesized that this may have been a function of effective medication regimens for
both groups [83]. Those in the intervention group did report significantly improved depression
(6 months), anxiety (3 and 6 months) and HRQL scores (3 and 6 months), compared to controls.
Significant improvements in hip-to-waist ratio were also found. The cost utility of the LAMP
was assessed in terms of quality-adjusted life years (QALY). A significant difference in average
QALY per patient of 0 045 (confidence interval [CI], 0 005-0 085) was found. Based on their
cost utility model, Furze et al. [83] estimated the average net benefit of the LAMP intervention
(over controls) at £354-360; there was some uncertainty around this estimate however due to
a lack of coefficient significance (from zero) [83]. While the LAMP was deemed cost-effective,
improvements in angina symptoms per se were not observed. Notably, this finding was in
contrast to evaluations of the nurse-facilitated version of the Angina Plan [79,82].
6. The chronic angina self-management program
The CASMP [17,81] is a disease-specific adaptation of the generic Stanford Chronic Disease
Self-Management Program (CDSMP). To develop the CASMP, McGillion et al. conducted a
qualitative evaluation of the self-management learning needs of individuals living with CSA;
perspectives from both patients and clinicians were solicited [19]. Based on this study,
adaptations of the CDSMP curriculum were made to address the following angina-specific
learning needs: safe exercise planning; relaxation and stress management; symptom monitor‐
ing, interpretation, and management techniques; CAD and related medication review;
decision making about seeking emergency medical assistance; diet; and, managing emotional
responses to angina [17,81]. The self-efficacy enhancing process elements of the original
CDSMP were retained [17,81].
The CASMP follows the CDSMP standardized 6-week, community small-group based format
(i.e. 2-hour sessions weekly, groups of 8-12 patients), but the program is delivered by nurse
facilitators rather than lay leaders. The program is delivered according to a facilitator manual
and participants receive a workbook to reinforce educational content. In a 2008 RCT (n=130),
the CASMP was found to significantly improve the frequency and stability of angina symp‐
toms compared to usual care at 3 months post-intervention. Significant improvements in self-
reported physical functioning, perceived self-efficacy, and general health status were also
found [81]. The CASMP did not reduce the financial burden of CSA on participants (estimated
from a societal perspective), perhaps due to the short time frame of the study [81].
Concomitant to the RCT [81], qualitative evaluation of the CASMP found positive shifts in the
perceived meaning of cardiac pain following self-management training [17]. CSA was initially
described by participants as a major negative life change characterized by fear, frustration,
limitations and anger [19]. Following the CASMP, chronic angina was interpreted more
constructively as a broad, ongoing health problem requiring continual self-management in
order to retain desired life goals and optimal levels of functioning [17]. Based on these positive
evaluations, plans to implement the CASMP at select cardiac centres in Canada are underway.
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angina symptom self-management, relaxation training and/or stress reduction, or enhance‐
ment of physical activity. Intervention durations, formats, and processes have varied [74-82].
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angina symptom profile (e.g. frequency, severity, stability) and related sublingual (SL) nitrate
use, objective measures of ischemia such as treadmill stress tests, and self-report measures of
HRQL and psychological well-being.
This review of the evidence will focus first on two more recent angina SMT models with clear
underpinnings in self-efficacy theory: The Angina Plan [78,79,82,83] and the Chronic Angina Self-
Management Program [17,81]. Second, results of meta-analyses [84,85] of the overall effective‐
ness of angina SMT will be discussed.
5. The angina plan
The Angina Plan, developed by Lewin, Furze et al. [78,79] is the most widely evaluated and
disseminated angina SMT program to date; over 20,000 patients have been enrolled [83]. The
Angina Plan is recognized in the United Kingdom [86] as a form of home-based cardiac
rehabilitation geared toward debunking common misconceptions about angina, promoting
relaxation, increasing physical activity and role functioning, and making positive changes in
lifestyle (e.g. nutrition). Risk factor identification, and educational materials on CAD, medi‐
cations, as well as seeking emergency medical assistance (as appropriate) are also key com‐
ponents [78,79]. The program materials are provided in a workbook and relaxation tape which
patients are oriented to by a nurse intervener during a structured, individualized interview
process [78,79]; this initial session is followed by a 12-week course of telephone-based support
to facilitate incremental goal setting and pacing of activities [78,79]. A 2002 RCT of the Angina
Plan (n=142), found that at 6 months follow-up, those assigned to the intervention group had
significant reductions in angina frequency, anxiety and depression, and SL nitrate usage, as
compared to controls who received standard education and counseling by a nurse [79]. Those
who received the Angina Plan also demonstrated significant improvements in physical
limitation scores, daily walking, and dietary habits [79]. A pragmatic RCT by Zetta et al. (n=
218) [82] found similar results for patients admitted to hospital for acute exacerbation of angina.
Angina Plan recipients reported significant improvements in knowledge and cardiac miscon‐
ceptions, social and leisure activities, perceived general health, and physical limitation.
Improvements in cardiac risk factors including body-mass index and exercise were also found
[82]. However, no significant improvements in anxiety and depression scores were found
based on intention-to-treat analyses; extracardiac depression was proposed as a potential
confounding factor diluting the treatment effect [82].
Recently, Furze et al. [83] evaluated (n= 142) a lay, peer-led adaptation of the Angina Plan in
response to healthcare resource constraints as well as increasing interest in lay-facilitated SMT
interventions. The Lay-facilitated Angina Management Program (LAMP) was delivered by
people who had experience with CAD either as patients or caregivers [83]; outcomes were
evaluated at 3 and 6 months post intervention. Compared to standard advice from a specialist
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nurse, the LAMP intervention did not significantly reduce the frequency of angina symptoms;
it was hypothesized that this may have been a function of effective medication regimens for
both groups [83]. Those in the intervention group did report significantly improved depression
(6 months), anxiety (3 and 6 months) and HRQL scores (3 and 6 months), compared to controls.
Significant improvements in hip-to-waist ratio were also found. The cost utility of the LAMP
was assessed in terms of quality-adjusted life years (QALY). A significant difference in average
QALY per patient of 0 045 (confidence interval [CI], 0 005-0 085) was found. Based on their
cost utility model, Furze et al. [83] estimated the average net benefit of the LAMP intervention
(over controls) at £354-360; there was some uncertainty around this estimate however due to
a lack of coefficient significance (from zero) [83]. While the LAMP was deemed cost-effective,
improvements in angina symptoms per se were not observed. Notably, this finding was in
contrast to evaluations of the nurse-facilitated version of the Angina Plan [79,82].
6. The chronic angina self-management program
The CASMP [17,81] is a disease-specific adaptation of the generic Stanford Chronic Disease
Self-Management Program (CDSMP). To develop the CASMP, McGillion et al. conducted a
qualitative evaluation of the self-management learning needs of individuals living with CSA;
perspectives from both patients and clinicians were solicited [19]. Based on this study,
adaptations of the CDSMP curriculum were made to address the following angina-specific
learning needs: safe exercise planning; relaxation and stress management; symptom monitor‐
ing, interpretation, and management techniques; CAD and related medication review;
decision making about seeking emergency medical assistance; diet; and, managing emotional
responses to angina [17,81]. The self-efficacy enhancing process elements of the original
CDSMP were retained [17,81].
The CASMP follows the CDSMP standardized 6-week, community small-group based format
(i.e. 2-hour sessions weekly, groups of 8-12 patients), but the program is delivered by nurse
facilitators rather than lay leaders. The program is delivered according to a facilitator manual
and participants receive a workbook to reinforce educational content. In a 2008 RCT (n=130),
the CASMP was found to significantly improve the frequency and stability of angina symp‐
toms compared to usual care at 3 months post-intervention. Significant improvements in self-
reported physical functioning, perceived self-efficacy, and general health status were also
found [81]. The CASMP did not reduce the financial burden of CSA on participants (estimated
from a societal perspective), perhaps due to the short time frame of the study [81].
Concomitant to the RCT [81], qualitative evaluation of the CASMP found positive shifts in the
perceived meaning of cardiac pain following self-management training [17]. CSA was initially
described by participants as a major negative life change characterized by fear, frustration,
limitations and anger [19]. Following the CASMP, chronic angina was interpreted more
constructively as a broad, ongoing health problem requiring continual self-management in
order to retain desired life goals and optimal levels of functioning [17]. Based on these positive
evaluations, plans to implement the CASMP at select cardiac centres in Canada are underway.
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7. Overall effectiveness of angina SMT programs: Results of meta-analyses
We first summarized the effectiveness of angina SMT interventions in a 2008 meta-analysis
[84]. The results of 7 trials, involving 949 CSA patients in total, were included. In each case,
the effects of a SMT intervention were compared to usual medical and/or nursing care as
described [74-77,79-81]. We found that those who underwent angina SMT experienced
significant reductions in the frequency of angina (nearly 3 less angina episodes per week) as
well as SL nitroglycerin use (approximately 4 times less per week) up to 6 months post-
intervention [84]. Significant, pooled effects were also found for angina-induced physical
limitation and HRQL-related disease perception, but we were uncertain of the stability of these
estimates due to broad confidence intervals [84]. At the time, we were unable to generate an
estimate of the effect of SMT on psychological well-being due to the heterogeneity of measures
used across trials to measure these HRQL dimensions. We signaled caution with respect to the
interpretation of our results due to the wide range (low to high) of methodological quality
across trials included in this review [84].
New, robust trial data contributed by Zetta et al. [82] and Furze et al. [83] allowed us to update
our meta-analysis in 2012 [85]; nine trials including 1282 CSA patients in total were included.
Outcome measures were more homogenous with the inclusion of these new data which
allowed us to examine the impact of angina SMT on psychological outcomes. Consistent with
our 2008 review [84], we found that angina SMT reduced the frequency of angina symptoms
and the use of SL nitrates. Self-management training also reduced physical limitation for CSA
patients. Our pooled estimates of effect for the impact on SMT for emotional well-being were
less certain. We did find a significant improvement in depression scores, but there was
considerable statistical heterogeneity for this outcome across trials [85]. Initially, we found no
impact on anxiety, but, sensitivity analysis—via removal of 1 trial [83] with the widest
confidence interval for this outcome—suggested that anxiety scores [85] are improved up to
six months following SMT.
Based on our systematic reviews [84,85], evidence is clear that SMT consistently improves
angina with respect to the frequency of symptoms and reduces the need for SL nitrates. The
positive effect of SMT on physical limitations imposed by angina also appears stable. What is
less certain is the potential for SMT to improve the psychological burden of CSA, particularly
anxiety. Noteworthy is the fact that the overall improvements we observed in depression
scores were yielded by the Angina Plan [78,79,82,83], suggesting that perhaps individualized
SMT programs my yield greater benefits in terms of emotional well-being.
Some key questions about the effectiveness of SMT for CSA management remain. A critical
element contributing to the effectiveness of intervention programs to date is the provision of
an array of self-management strategies that can be tailored to individual problems, needs and
preferences, in the context of living with chronic angina. This much is clear and entirely
consistent with the broader chronic disease-self-management literature [42-48], as well as
underlying principles of self-efficacy theory [52-54]. What is less clear is the ideal intervention
design—or particular elements thereof—that would yield maximum symptom benefits and
much needed improvements in HRQL for this heavily burdened population. For example,
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group-based SMT interventions are efficient and have been found to be equally effective as
individualized approaches for arresting chronic disease progression and managing symptoms
across populations; people with diabetes are one such example [86]. Yet, the available data
suggest that this may not be the case for CSA patients when it comes to psychological outcomes;
an individualized approach could be more effective.
There is also the question of whether angina SMT programs should be delivered by health
professionals or lay peers. Indeed, lay-led SMT models have been demonstrated widely to be
effective and cost-saving [42-48,82]. Such models are also idyllic in the sense that they embrace
the concept of patients as active self-managers and experts in terms of the chronic illness
experience [45]. However, in the case of CSA patients, Furze et al. [82] observed a high refusal
rate (46%) in the RCT of their lay-led SMT program.
Other key questions pertain to the overall cost-effectiveness of angina SMT implementation
as well as the ability of these programs to reduce the financial burden of CSA. The trial by
McGillion et al. [81] showed no impact on cost illness but the follow up period was brief. To
date, Furze et al.’s trial is the only study to [82] to examine comprehensively the cost utility of
angina SMT. While the cost results of this trial are certainly promising, they pertain to the
training and employ of lay leaders only.
8. Summary: Implications for research and practice
Without question, SMT interventions are gaining momentum in the arena of CSA manage‐
ment. Their positive impact on symptoms and aspects of HRQL is unequivocal. Relatively
speaking, as a class of interventions, SMT programs have not seen the widespread uptake in
cardiology as they have in other fields, such as rheumatology. Historically, this may be
explained by the overarching dominance of surgical and interventional strategies as mainstays
of effective treatment. But the culture is changing and the need to employ adjunctive secondary
prevention approaches, to help offset the burden of CAD, has been recognized worldwide [1,
87-91]. The recent incorporation of angina SMT into national clinical practice guidelines for
CAD management in both the UK [87] and Canada [88] speaks to this emerging cultural shift.
In order to more fully integrate angina SMT across health systems, funding support for
continued research, development and dissemination of these programs is crucial. Some
outstanding issues have major implications for the widespread uptake of angina SMT training.
As discussed, there are the critical questions which remain about optimal intervention design
(to yield maximal benefits) and cost effectiveness. These questions could perhaps be addressed
best via robust, multi-national trials with long-term follow up [85]. There must also be
however, a focused effort toward both integrated and end-of-study knowledge translation
strategies with the overall goal of mainstreaming angina SMT.
Typically, self-management interventions are developed and tested within academic centres
or research institutes, and formally (or informally) linked with a variety of hospital and
community-based settings [68]. Dissemination of these programs therefore depends on strong
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7. Overall effectiveness of angina SMT programs: Results of meta-analyses
We first summarized the effectiveness of angina SMT interventions in a 2008 meta-analysis
[84]. The results of 7 trials, involving 949 CSA patients in total, were included. In each case,
the effects of a SMT intervention were compared to usual medical and/or nursing care as
described [74-77,79-81]. We found that those who underwent angina SMT experienced
significant reductions in the frequency of angina (nearly 3 less angina episodes per week) as
well as SL nitroglycerin use (approximately 4 times less per week) up to 6 months post-
intervention [84]. Significant, pooled effects were also found for angina-induced physical
limitation and HRQL-related disease perception, but we were uncertain of the stability of these
estimates due to broad confidence intervals [84]. At the time, we were unable to generate an
estimate of the effect of SMT on psychological well-being due to the heterogeneity of measures
used across trials to measure these HRQL dimensions. We signaled caution with respect to the
interpretation of our results due to the wide range (low to high) of methodological quality
across trials included in this review [84].
New, robust trial data contributed by Zetta et al. [82] and Furze et al. [83] allowed us to update
our meta-analysis in 2012 [85]; nine trials including 1282 CSA patients in total were included.
Outcome measures were more homogenous with the inclusion of these new data which
allowed us to examine the impact of angina SMT on psychological outcomes. Consistent with
our 2008 review [84], we found that angina SMT reduced the frequency of angina symptoms
and the use of SL nitrates. Self-management training also reduced physical limitation for CSA
patients. Our pooled estimates of effect for the impact on SMT for emotional well-being were
less certain. We did find a significant improvement in depression scores, but there was
considerable statistical heterogeneity for this outcome across trials [85]. Initially, we found no
impact on anxiety, but, sensitivity analysis—via removal of 1 trial [83] with the widest
confidence interval for this outcome—suggested that anxiety scores [85] are improved up to
six months following SMT.
Based on our systematic reviews [84,85], evidence is clear that SMT consistently improves
angina with respect to the frequency of symptoms and reduces the need for SL nitrates. The
positive effect of SMT on physical limitations imposed by angina also appears stable. What is
less certain is the potential for SMT to improve the psychological burden of CSA, particularly
anxiety. Noteworthy is the fact that the overall improvements we observed in depression
scores were yielded by the Angina Plan [78,79,82,83], suggesting that perhaps individualized
SMT programs my yield greater benefits in terms of emotional well-being.
Some key questions about the effectiveness of SMT for CSA management remain. A critical
element contributing to the effectiveness of intervention programs to date is the provision of
an array of self-management strategies that can be tailored to individual problems, needs and
preferences, in the context of living with chronic angina. This much is clear and entirely
consistent with the broader chronic disease-self-management literature [42-48], as well as
underlying principles of self-efficacy theory [52-54]. What is less clear is the ideal intervention
design—or particular elements thereof—that would yield maximum symptom benefits and
much needed improvements in HRQL for this heavily burdened population. For example,
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group-based SMT interventions are efficient and have been found to be equally effective as
individualized approaches for arresting chronic disease progression and managing symptoms
across populations; people with diabetes are one such example [86]. Yet, the available data
suggest that this may not be the case for CSA patients when it comes to psychological outcomes;
an individualized approach could be more effective.
There is also the question of whether angina SMT programs should be delivered by health
professionals or lay peers. Indeed, lay-led SMT models have been demonstrated widely to be
effective and cost-saving [42-48,82]. Such models are also idyllic in the sense that they embrace
the concept of patients as active self-managers and experts in terms of the chronic illness
experience [45]. However, in the case of CSA patients, Furze et al. [82] observed a high refusal
rate (46%) in the RCT of their lay-led SMT program.
Other key questions pertain to the overall cost-effectiveness of angina SMT implementation
as well as the ability of these programs to reduce the financial burden of CSA. The trial by
McGillion et al. [81] showed no impact on cost illness but the follow up period was brief. To
date, Furze et al.’s trial is the only study to [82] to examine comprehensively the cost utility of
angina SMT. While the cost results of this trial are certainly promising, they pertain to the
training and employ of lay leaders only.
8. Summary: Implications for research and practice
Without question, SMT interventions are gaining momentum in the arena of CSA manage‐
ment. Their positive impact on symptoms and aspects of HRQL is unequivocal. Relatively
speaking, as a class of interventions, SMT programs have not seen the widespread uptake in
cardiology as they have in other fields, such as rheumatology. Historically, this may be
explained by the overarching dominance of surgical and interventional strategies as mainstays
of effective treatment. But the culture is changing and the need to employ adjunctive secondary
prevention approaches, to help offset the burden of CAD, has been recognized worldwide [1,
87-91]. The recent incorporation of angina SMT into national clinical practice guidelines for
CAD management in both the UK [87] and Canada [88] speaks to this emerging cultural shift.
In order to more fully integrate angina SMT across health systems, funding support for
continued research, development and dissemination of these programs is crucial. Some
outstanding issues have major implications for the widespread uptake of angina SMT training.
As discussed, there are the critical questions which remain about optimal intervention design
(to yield maximal benefits) and cost effectiveness. These questions could perhaps be addressed
best via robust, multi-national trials with long-term follow up [85]. There must also be
however, a focused effort toward both integrated and end-of-study knowledge translation
strategies with the overall goal of mainstreaming angina SMT.
Typically, self-management interventions are developed and tested within academic centres
or research institutes, and formally (or informally) linked with a variety of hospital and
community-based settings [68]. Dissemination of these programs therefore depends on strong
Self-Management Training for Chronic Stable Angina: Theory, Process, and Outcomes
http://dx.doi.org/10.5772/54635
227
partnerships between researchers and key stakeholder representatives, such as leaders in
regional health authorities. Ideally, these players should be involved at the onset of angina
SMT research programs and implementation to maximize the success of integrating these
programs into existing and diverse health system infrastructures [68]. The widespread success
of the Angina Plan in the UK [78,79,82,83] is an excellent example of the benefits of such an
integrated approach.
Policy makers and the general public also require timely notification of future developments
in angina SMT research, in accessible language. In the clinical arena, broader uptake of angina
SMT could be facilitated by the development of key competencies to adequately prepare health
care professionals to educate and consult with their CSA patients about the effectiveness of
SMT programs [88]. Akin to clinician preparation for patient counseling, there is also the
important question of patient readiness to engage in angina SMT. Patient preparedness for
self-management is an emerging field, not yet taken up by CSA researchers. Emerging
evidence suggests that one’s beliefs and perceptions about a) influential others contributing
to his or her overall state of health, and b) his or her own internal locus of control, may be key
factors in the pre-contemplation, or intention to engage in self-management practices [92].
Advancements in this area will be important to developing a better understanding of factors
that drive one’s readiness for angina self-management, and ultimately, who is likely to benefit
most from angina SMT training.
9. Conclusion
In summary, SMT interventions have much to offer in terms of offsetting the major, societal
impact of angina. As adjuncts to usual care, these relatively low cost-interventions are aligned
with current global emphasis on the need for treatment approaches which help CAD patients
better manage their long-term health. This chapter has provided an overview of self-manage‐
ment theory, key elements of intervention structure and process, as well as a comprehensive
review of the evidence pertaining to the effectiveness of angina SMT programs to date. Support
for continued research, knowledge translation and implementation work is critical to the
successful integration of angina self-management as an integral part of the routine care of
people living with CSA.
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impact of angina. As adjuncts to usual care, these relatively low cost-interventions are aligned
with current global emphasis on the need for treatment approaches which help CAD patients
better manage their long-term health. This chapter has provided an overview of self-manage‐
ment theory, key elements of intervention structure and process, as well as a comprehensive
review of the evidence pertaining to the effectiveness of angina SMT programs to date. Support
for continued research, knowledge translation and implementation work is critical to the
successful integration of angina self-management as an integral part of the routine care of
people living with CSA.
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1. Introduction
Atherogenesis constitutes a prominent mechanism in inducing stenosis of the vascular lu‐
men by multiple mechanisms within contextual reference of heterogeneity of pathways and
phenotype determinants. Reduction of low-density lipoprotein-C has well-established value
and constitutes a major guideline for cardiovascular disease prevention [38]. Redox state im‐
balance plays a role in preclinical atherosclerosis [7]. The realization of events constituting
the acute coronary syndromes is particularly critical in the evolution of lesions that further
compromise blood supply to target tissues. It is highly significant to consider the distribu‐
tion of individual lesions with reference to disturbed blood flow patterns within the vascu‐
lar arterial tree, as further evidenced by selectivity to vascular branch points. Disturbed flow
may hinder transport of nitric oxide particularly distal to a stenosis [17].
Evidential  parameters confirm a primarily quantitative series of  dimensional  effects  that
participates in the development of lesions and that ranges from constitutional progression
to environmental gene promotion particularly in the activation and dysfunction of endothe‐
lial cells.
High density lipoprotein has a wide range of functions including antiatherogenic, anti-in‐
flammatory and anti-oxidant action [30].
In such manner, also a highly heterogeneous series of conditioning influences participate in
inducing not only the creation of individual atherosclerotic plaques but also the evolution of
such plaques to unstable lesions inducing acute coronary events. Molecular mediators in‐
clude members of the chemokine family of leukocyte chemoattractants and their G protein-
coupled receptors [37].
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Distributional patterns of lesion infliction correlate also with procoagulant effects that system‐
ically compromise recoverability from injury to various components of the vascular wall.
2. Patterned autonomy
Patterned autonomy of lesion creation and of progression contrasts with a realization of pro‐
moted endothelial dysfunction in terms of quantitative dimensions. Lipids in atherosclerotic
lesions weaken cellular antioxidant action through generation of H2O and promote plaque
progression [33]. Lipoprotein plays a role in inducing endothelial dysfunction [32]. It is criti‐
cally significant to view the distribution of lesions that arise as hemodynamic forces of lami‐
nar flow on the one hand and as disturbed dynamics of flow at vascular branch points.
The further participation of pathways of identifiable injury arise from a realization of ongo‐
ing progression of individual lesions that conform to tunica intimal targeting in lipoprotein
deposition. Apolipoprotein E4 causes macrophage dysfunction and enhances apoptosis by
inducing ER stress; it is a major genetic risk factor in atherosclerosis and diabetes [2].
The various component remodellings within the vascular intima are paramount considera‐
tion in the realization of an injury that goes beyond the concept of a primary endothelial
form of injury. In such manner, the roles played by oxidized lipoproteins are central to a
wide distributional series of patterns that are distinguished primarily by their quantitative
attributes. Inflammation and metabolism are important drivers of atherogenesis in the con‐
text of HIV infection [18].
Primary disorders such as diabetes mellitus, hypertension, and abnormal homocysteine me‐
tabolism are examples of promoting pathways that contribute in the identification of sus‐
ceptibility patterns of non-resolution of emerging atherosclerotic lesions in various loci
within the arterial vascular tree. In such manner, compounding influences of highly hetero‐
geneous nature constitute a specific marker in the pathogenesis of atherosclerosis. Inflam‐
mation and immunity in the “infection hypothesis” may form a biologic substrate for
atherogenesis [28]. Fibroblast growth factor receptor 4 is implicated in vascular smooth mus‐
cle cell proliferation and atherosclerosis [5].
3. Agonists
Significant performance of injurious agonists allow for permissive emergence of dysfunc‐
tional endothelial cells in a mode of participation that includes a shift especially of pheno‐
typic determination of such vascular wall components as smooth muscle cells from the
tunica media. Within such a setting, the distributional attributes of a contractile versus se‐
cretory phenotype of smooth muscle cells allows for the expression of injurious agonists that
further compromise the recoverability from endothelial cell injury in particular. The func‐
tion of the ubiquitin-proteasome system deviates from the norm in atherogenesis and this
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may necessitate new UPS-based therapeutic modalities [29]. Indeed, the very identity of the
dysfunctional state of overlying endothelial cells may prove a derived parameter of conse‐
quence within systems of active remodelling of the intima as induced by such phenotypic
shifts in activity of smooth muscle cells in particular.
Aldose reductase in the polyol pathway promotes excessive accumulation of intracellular re‐
active oxygen species in various tissues of diabetic patients [34].
4. Injury
The systems of promotional realization of injury as induced by atherosclerotic plaques are a
significant compound system that incriminates adhesion of monocytes to dysfunctional or
activated endothelium.
The participation of injury to the arterial wall is complex and acts as a series of overlapping
influences that further contributes to injury as evidenced by the action of evolving hypoxic
influence and by procoagulant activity. Almost all coagulant proteins including tissue factor
are found in atherosclerotic plaques [19]. Low matrix metalloproteinase-2 levels correlate
with intra-cranial location of atherosclerosis [15].
The overlapping series of dynamic events in atherogenesis is permissive in promoting a
pathway realization that is central to hypoxia inducing further progression of the lesions.
High glycemic load glycemic index are related to significantly increased risk for atherogene‐
sis in women in particular [20].
5. Progression
In such manner, the promotional distributional significance of concurrent foci of injury is
paramount parameter in inducing the characterization of lesions that essentially progress.
Toll-like receptor signalling may link chronic inflammation with cardiovascular disease pro‐
gression and immune activation [31].
It is significant to view the parameters of quantitative nature in the development of individ‐
ual lesions that hemodynamically are closely related often to disturbed blood flow at vascu‐
lar branch points.
It is with referential background components of various identifiable elements of the vascular
wall that atherogenesis proves an integrative phenomenon of progression in its own right.
High density lipoprotein particle functionality is at least as important as HDL-C levels due
to effects on inflammation, hemostasis and apoptosis [22].
The individual participating roles played by such processes as monocyte rolling and subse‐
quent firm adhesion to endothelial cells helps characterize specific attributes of the activated
or dysfunctional endothelium. The decreased production of nitric oxide by dysfunctional
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endothelium is a prototype example of distributional nature in denoting a systemic partici‐
pation of further ongoing transformation in phenotype characterization of cellular compo‐
nents of the vascular wall as integrative phenomenon.
The realization of oxidized lipoproteins may well prove a central participant in the orches‐
tration of events inducing injury as a self-progressive culmination in atherogenesis and in
further progression of individual atherosclerotic plaques. Identification of pathway events
that distribute the lesions within systems of a primarily promotional nature indicates that
macrophages and foam cells promote atherogenesis as a primarily distributional series of
quantitative nature. Epigenetic modification of the genome may link environmental injury
to gene regulation [41]. Apoptosis and suppressed clearance of apoptotic macrophages ren‐
der plaques susceptible to rupture, promoting thrombosis [13].
6. Complicated plaque
The complicated atherosclerotic plaque is thus a series of overlying pathways of influence
that concurrently participate in identifying the different component systems in pathogene‐
sis. Regulating T cells and serum interleukin-10 may exert a protective role against plaque
rupture in patients with coronary atherosclerosis [11]. It is with contextual reference to oxi‐
dized lipoprotein deposits within the intima that phenomena of adherence to dysfunctional
endothelium induce leukocytes as systemic agonists in atherogenesis. The role of platelets in
atherothrombosis is well established [9].
The sharp distinction in identification of progression of an individual plaque from the rup‐
tured plaque permits the emergence of multiple profiles in developmental history of lesions
that individually evolve but that are systemically compounding and overlapping in profile
determination. NF-E2 related factor 2 pathway restores redox homeostasis and Nrf2 cross
talks with the proteasome [4].
The realization of injury to endothelial cells is therefore only an initial event in the once-real‐
ized reactivity to injury to multiple components of the vascular wall.
The dynamics of orchestration of various injurious agonists thus emerge as an essential
component system in atherogenesis in a manner that calls into operative participation multi‐
ple heterogeneous pathways ranging from procoagulant effect of disturbed blood flow, hy‐
poxia, dysfunctional reduction in nitric oxide production and action, and especially the
chemotactic influences as induced by oxidized lipoproteins deposited in the intima. Arachi‐
donic acid increases inflammation and enhances the ability of endothelial cells to bind mon‐
ocytes in vivo [12]. The further participation of remodelling of the intima as a result of
migration and proliferation of smooth muscle cells is evidence for a series of phenotypic
switches that allow permissive injury to multiple cell components and to matrix production
of proteoglycans.
It is within a systemically integrative series of active realizations that atherogenesis proves
an integrative expression of component pathways; this paradoxically determines a com‐
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pound pathobiologic profile that is individually determined by constituent components of
the vascular wall affected. Macrophages are exquisitely sensitive to their microenvironment,
influencing plaque rupture and thrombosis [40].
It is therefore in terms of quantitative realization that atherogenesis is both initiating and
progressive influence in the determination of profile progression of the individual athero‐
sclerotic plaque.
7. Foam cells
Foam cells are pivotal in inducing a series of chemotactic phenomena in atherogenesis in a
manner that contributes to the self-progressive nature of the disease process. In terms of dis‐
tributional injury, the paramount characterization of the processes in atherosclerosis is fo‐
cused clinically in the emergence of the complicated atherosclerotic plaque. In such a
setting, the contributions by procoagulation of the disturbed blood flow prove a central
player in the determination of stenosis as predisposition to plaque rupture.
Attributing significant paramount dynamics in atherogenesis to a series of events of accu‐
mulative effect of oxidized lipoprotein is a characterization in the establishment of self-pro‐
motional progression within any individual atherosclerotic lesion. It is the realization of
quantitative identification of such individual plaques that allows for the emergence of sys‐
temic effect within much of the vascular arterial tree.
Chronic inflammation is implicated in atherogenesis with cytokine involvement in all stages
of plaque development [3].
The distributional dynamics of promotional events are primarily permissive in a mode of
further contributing influence in atherogenesis. Hypoxia-inducible factor-1 initiates forma‐
tion of foam cells, endothelial cell dysfunction, apoptosis angiogenesis and progressive in‐
flammation [10].
It is only in terms of a systemic event that integrates as the individual atherosclerotic plaque
that one can realize a transformation of a primarily accumulative lesion to the complicated
atherosclerotic plaque.
8. Tunica intima
The multi-component history of injury would account for a concordance influence in deter‐
mining the realization of initiating injury to the endothelium and to the distributional contri‐
butions for further different forms of injury to other components of the vascular wall.
Parameters of progression are differential contributors to the essential nature of atherogene‐
sis that is both dysfunctional and activating to such cell components as the endothelium. Es‐
trogens have potent antioxidant activity and reverse endoplasmic reticulum stress in
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Parameters of progression are differential contributors to the essential nature of atherogene‐
sis that is both dysfunctional and activating to such cell components as the endothelium. Es‐
trogens have potent antioxidant activity and reverse endoplasmic reticulum stress in
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endothelial cells [14]. The proximity of the tunica intima to both overlying endothelium and
to tunica media promotes the interactivity of smooth muscle cells within paracrine and auto‐
crine systems of determining pathobiology. The significance attributed to such pathways as
deposition of proteoglycan matrix within the intima proves a heterogeneity of involvement
as significant characterization of multiple forms of progression of the individual atheroscler‐
otic plaque. In such manner, distributional dynamics within foci of involvement by athero‐
sclerosis allow for the emergence of parameters of progression that identifiably further
promote permissive conditions of a quantitative nature in accumulation and chemotaxis of
monocytes in particular.
9. Nonresolution
The complicated atherosclerotic plaque shows an essential neovascular component at its
base and this appears to be a primary source for the establishment of complications such as
intra-plaque hemorrhage and for rupture of the lipid core of the plaque into the vascular lu‐
men. It is in terms of ongoing proliferation of a phenotypically secretory smooth muscle cell
population that enlargement of the individual plaque proves self-progressive in dimensions
and also self-progressive in terms of transforming dynamics to the complicated or ruptured
plaque. In such manner, the overall contribution of injury to the overlying endothelium con‐
firms dimensions of non-resolution beyond the fatty streak stage. Inflammasomes regulate
proinflammatory caspases and interleukin-1 cytokines in response to various stimuli [24].
Integral participation of multiple foci of injury to a given point in vascular wall atherogene‐
sis hence proves an inbuilt progression that is quantitatively determined but that allows a
permissive microenvironment to promote transformability to the unstable plaque. It appears
significant to view the unstable plaque as a transforming event in its own right beyond the
dimensions of any individual atherosclerotic lesion. It is in such a setting that neovasculariza‐
tion of the plaque is a central agonist in the creation of acute coronary events as seen clinically.
The proinflammatory attributes of the atherosclerotic plaque accompany the dynamics of
the neovascularization phenomenon in promoting the emergence of a permissive micro-en‐
vironment within the vascular wall. Macrophages phagocytose apoptotic cells, clear necrotic
debris and repair tissues; these are challenged by local cell stressors that include hypoxia,
oxidative stress and protease activity [36].
The intimal remodelling is, in part, an expression of such pro-inflammatory activity. Im‐
mune responses to plaque antigens modulate inflammatory responses in the intima [39]. It is
in terms of ongoing participation of new agonists that the atherogenesis proves a promo‐
tional agonist in its own right in determining the dynamics of vascular stenosis and also of
instability as plaque rupture.
Thrombosis overlying the atherosclerotic plaque is a phenomenon as complicated plaque
emergence and is believed to be a direct contributor to the establishment of further compli‐
cations in clinically unstable angina. Venous and arterial thromboses are probably associat‐
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ed with overlapping risk factors [8]. The overall dimensions of plaque evolution are hence
highly complex, and such complexity is largely attributable to participants from the overly‐
ing luminally disturbed blood flow.
In spite of such considerations an essential role for hypoxia specifically affects the endotheli‐
um and other components of the vascular wall.
10. Neovascularization
The neovascularization at the base of the complicated atherosclerotic plaque may be an ex‐
pression of such overall effects of hypoxia that transforms accumulative phenomena of athe‐
rogenesis as complicated plaques that rupture into the lumen.
The pro-inflammatory nature of plaques appears also expressive parameter of such hypoxia
as a result of a neovascularity that further emerges as an over-riding phenomenon of per‐
missiveness in atherogenesis. In this regard Nuclear Factor-kappaB plays an orchestrating
role in formulating multiple heterogeneous elements in evolutionary permissiveness. As
HIV infected patients age, atherosclerosis has become an increasing cause of morbidity and
mortality, initiating immune and inflammatory responses [23].
The directional promotion in development of the unstable plaque is therefore an expression
of transformational dynamics that promotes the rupture of the overlying fibrous cap and the
extrusion of the lipid core. The biophysics of such fibrous cap appears instrumental particu‐
larly in the disruption of the junctional elements with the adjacent vascular wall.
The interplay of genetic factors with micro-environmental agonists is particularly significant
in terms of the dynamics of lipid accumulation within the plaque [16].
Such phenomenal increments play contributing roles of the overlying blood flow in redis‐
tributing lipoproteins and cholesterol within the vascular wall. The dimensions of the lipid
core are themselves determining agonists in plaque rupture, and a high content of such lipid
core to over 40% of the overall plaque is significant in this regard.
Redistribution of attributes within the individual atherosclerotic plaque appears a promo‐
tional feature as pro-inflammatory effects and as plaque neovasculature. The hypoxic envi‐
ronment would account for permissive emergence of multi-component parameters that
coordinate the characterization of the final complicated atherosclerotic plaque within di‐
mensions of accumulation of lipid and transformation to plaque rupture.
11. Integral atherogenesis
The complicated atherosclerotic plaque as integral atherogenesis is an overall principal par‐
ticipation in the progression of a lesion that is both pro-inflammatory and enlarging. Ad‐
vanced glycation end-products are implicated in the pathogenesis of diabetes-associated
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atherosclerosis by increasing smooth muscle cell susceptibility to insulin-like growth fac‐
tor-1 mitogenic effects [6].
The foam cells within the plaque are an expression of integrative participation within such
schemes of  complicating plaque formation as realized by such phenomena as lipid core
accumulation, chemotaxis, paracrine secretion of growth factors and cytokines and the expres‐
sive effects of oxidized lipoproteins in particular. The distributional nature of disturbed blood
flow is significant in the role of selective participation of injury to the overlying endothelial
cells that become permeable to the inflow of lipoproteins within the vascular wall. Low density
lipoproteins play a major role in initiating progressive atherosclerosis whereas high density
lipoproteins suppress inflammation and thrombosis [1].
Hence, an overall series of dimensional agonists conform to and further establish the emer‐
gence of hypoxic influence in the quantitative formulation of the individual atherosclerotic
plaque within a highly permissive micro-environment of vascular wall pathology. The sig‐
nificance of multi-component participation is symptomatic of the essential activation of en‐
dothelial cells that are at the interface with disturbed blood flow. Also, the accelerated or
aggressive forms of atherogenesis seen in many forms of dyslipoproteinemias illustrate such
phenomenon within parametric contexts of endothelial cell dysfunction.
12. Self-progression
Directional proportions in redistribution of injury to the vascular wall are conceptually a
mechanism of a quantitatively self-progressive establishment in atherogenesis.
The murine models of atherosclerosis, particularly the transgenic models of absent ApoE
gene and of absent low density lipoprotein receptor fed on a Western diet indicate the role
played by lipoproteins as initiators and promoters of an essentially permissive micro-envi‐
ronment that is instrumental in atherogenesis as micro-environmental conditioning and pre-
conditioning. In such manner, conditional remodelling of microenvironmental factors
involves the characterization of many of the contributing agonists in atherogenesis. Hypoxia
of the endothelium and intima is a central theme in such conditioning and allows for the
multiple agonists in atherogenesis to contribute to the essential individualization of the pla‐
que within systemizing schemes of vascular wall atherosclerosis. Pathological angiogenesis
enhances disease progression, increases macrophage infiltration and perpetuates necrosis
and hypoxia [25].
Cellular phenotype switches are a feature affecting particularly endothelial expression of ad‐
hesion molecules and the generation of secretory roles for smooth muscle cells. P-selectins
and to a lesser extent E-selectins are significant participants in adhesion of leukocytes to par‐
ticular sites in the endothelium and allow for contributions also by vascular adhesion mole‐
cules and intercellular adhesion molecules and integrins. The matrix proteoglycans
significantly accumulate as a result of such phenomena that promote chemotaxis of leuko‐
cytes from flowing blood and the drawing of smooth muscle cells into the intima.
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In such manner, distributional effects integrate as quantitative formulations of an atheroscler‐
otic plaque that re-characterizes dimensions of phenotype switching and formulates roles for
transforming cell types. Various nuclear receptors contribute to macrophage cholesterol me‐
tabolism, which in turn keeps the arteries in a chronically inflamed state [26].
13. Endothelial dysfunction
Incremental involvement of the intima corresponds to a progression that spatially conforms
to effects of a disturbed blood flow that interacts with the endothelium. Dysfunctionality of
endothelial cells arises within contexts of such interface phenomena in the realization of the
quantitative attributes of increasing hypoxic injury and as dictated by the an accumulation
of oxidized lipoprotein core.
Developmental parallels of involvement permit the destruction of the vascular intima that
however promotes dimensions of aggregation of monocytes and the transformation to foam
cells. In such manner, parameters of increasing involvement of the intima with atrophy of
the tunica media progressively increases the abnormal flow of blood and promotes distur‐
bed reactivity of endothelial cells. It is such cyclical disturbance that increases also the sus‐
ceptibility to progressive accumulation of lipoprotein within the vascular wall.
A conceptual realization of developmental events is suggestive of a series of parallel path‐
ways that coincidentally progress as overlapping systems of attempted reconstitution of
pathways of possible recovery in the face of incremental destruction of the vascular wall.
Monocyte recruitment into the vessel wall is a rate-limiting step in atherogenesis with a crit‐
ical role played by reactive oxygen species [35].
14. Permissiveness
In such events promotional permissiveness would prove a determining series of further pro‐
gression that calls into operative persistence the effects of hypoxia and of disturbed blood
flow that primarily target the endothelial cell bed.
Extension, both laterally and also deeply into the vascular wall, requires the activation of
response elements such as the shear stress response element that augments the distribution‐
al disturbance of interaction of tonicity of the vascular wall  with disturbed dynamics of
blood flow.
This phenomenon appears to augment further susceptibility to pro-inflammatory reactivity
in the wake of an enlarging plaque that increasingly constitutes the phenotypic switching of
such cell types as smooth muscle cells. Also, remodelling of the intima is both accumulative
of proteoglycans and also modulatory in adapting to new blood flow dynamics.
Substantial reconstitution of the vessel wall, hence, is attempted in the form of replacement
dynamics in the vascular wall in a manner that attempts the normalization, to some extent,
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and hypoxia [25].
Cellular phenotype switches are a feature affecting particularly endothelial expression of ad‐
hesion molecules and the generation of secretory roles for smooth muscle cells. P-selectins
and to a lesser extent E-selectins are significant participants in adhesion of leukocytes to par‐
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Monocyte recruitment into the vessel wall is a rate-limiting step in atherogenesis with a crit‐
ical role played by reactive oxygen species [35].
14. Permissiveness
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gression that calls into operative persistence the effects of hypoxia and of disturbed blood
flow that primarily target the endothelial cell bed.
Extension, both laterally and also deeply into the vascular wall, requires the activation of
response elements such as the shear stress response element that augments the distribution‐
al disturbance of interaction of tonicity of the vascular wall  with disturbed dynamics of
blood flow.
This phenomenon appears to augment further susceptibility to pro-inflammatory reactivity
in the wake of an enlarging plaque that increasingly constitutes the phenotypic switching of
such cell types as smooth muscle cells. Also, remodelling of the intima is both accumulative
of proteoglycans and also modulatory in adapting to new blood flow dynamics.
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of dynamics of blood flow. The adhesive molecules that are increasingly expressed on acti‐
vated and dysfunctional endothelial cells allow for the ingress of leukocytes such as mono‐
cytes and memory T lymphocytes in the face of destruction of the vascular wall. Such
parametric phenomena are paralleled by the procoagulant pathways that create and deposit
thrombus on the surface of the complicated or ulcerated atherosclerotic plaque.
In such manner of progression, primary systems of permissiveness implicate a plasticity that
is morphologically mirrored in dynamics of involvement of the plaque by the neovascula‐
ture invading the base of the plaque. It is in terms of ongoing incremental dynamics that the
essential morphological and dysfunctional attributes of a modelled plaque lesion come to re‐
constitute a focal lesion of dimensional origin within the vascular intima but that eventually
progresses as luminal stenosis and plaque rupture.
The multiplicity of plaque creation in the vascular intima denotes an ongoing cooperative
series of disturbances emanating from significant exposure of the endothelium to such le‐
sional promotional events as hypoxia and as further derived phenomena of a disturbed
blood flow pattern. In such manner, the incremental mirroring of patterned progression in
multiple plaques would correspond to representative further permissiveness in the face of
increasing destruction of the vascular wall. High density lipoprotein reverses cholesterol
transport and normalizes vascular function, in addition to antioxidative anti-inflammatory
and anti-apoptotic actions [21].
Developmental aggregation of events hence is formulated as eventually complicated pla‐
ques that formulate thrombogenesis and deposition on the ulcerative but enlarging or com‐
plicated plaque.
Simple realization of events in plaque rupture comes to constitute a patterned progression
that is transforming and which allows for the plasticity of reconstitutive pathways to
emerge as complications of the atherosclerotic plaque.
It is perhaps in terms of significant interplay of multiple attempts at removal of oxidized lip‐
oprotein that the dimensions of attempted reconstitution of the vascular wall come to opera‐
tively include a pro-inflammatory component in further promoting normalization of blood
flow dynamics.
15. Thrombosis
The thrombus that is deposited on the surface of plaques is also an attempt at streamlining
the luminal contours of the vessel wall in an attempt to accommodate new flow dynamics.
The response to injury hypothesis only partly accounts for the pathogenesis of an athero‐
sclerotic plaque that is centered on a core of involvement of the vascular intima. It is the ad‐
ditional formulation of a hypoxic micro-environment that further proves a driving initiative
in the development of serial plastic events that conformationally confirm the dimensions of
a plaque reconstitution at the interface of abnormal blood flow dynamics. Hence, the redis‐
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tributional series of phenomena come to model the individual lesion as hypoxic condition‐
ing of the micro-environment and of attempts at neovascularization at the base of the lesion.
Developmental dynamics hence are paramount considerations in the evaluation of a specific
plaque dimensionality. The overall conformations of lesions are centrally operative but dy‐
namically progressive in the face of both accumulative and transforming pathways of ago‐
nist action and response adaptations. Hyperinsulinemia appears to promote macrophage foam
cell formation and may thus promote atherogenesis in type-2 diabetics [27].
16. Hypoxia
Hypoxia is generated as a primary abnormality of the endothelium and as further propagat‐
ed via the vasa vasorum supplying the vascular wall.
The parameters of further development of the injury to the endothelium allow for interface
dynamics with abnormal blood flow that generate a secondary wave of proportional ampli‐
tude within the enlarging atherosclerotic plaque that evolves primarily as an end-stage com‐
plicated plaque lesion.
Distributional forces are driven by a series of hypoxic preconditions that promotes the char‐
acterization of individual lesions within context of further lesion infliction in other regions of
the endothelium. It is such premise that accounts for a multiplicity of events that create a
multifocal representation of atherosclerosis within the arterial vascular system, as denoted by
parameters of blood flow dynamics and as hypoxia-driven plastic effects on the endothelium.
It is in such manner that paramount representative pathways conform to a response to in‐
jury and also to primary agonistic action of a hypoxic conditioning of the microenvironment
of both endothelium and vascular intima.
Serial insult modulation of pathways include the re-establishment of multiple injuries to the
endothelium that are essentially hypoxic in origin and which conform to the development of
the plaque as primary emergent form of adaptation to endothelial involvement in particular.
17. Concluding remarks
The distributional  anatomy of  the individual  atheromatous plaque is  consistently repro‐
duced in multiple regions of the arterial vascular tree and in a manner of conformational
re-establishment of lesions as hypoxia of the endothelium and as dynamics of abnormal
blood flow. In such manner, the constituent representations of micro-environment pre-con‐
ditioning is paramount driving force in the creation of an essential plaque that conforma‐
tionally further propagates as multiple other plaques. The individuality of the plastic events
in  atherogenesis  relate  to  vascular  wall  injury  and to  destruction  within  the  contextual
further evolution of lipoprotein core formation and as a series of potential complications.
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It is in such manner that paramount representative pathways conform to a response to in‐
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in  atherogenesis  relate  to  vascular  wall  injury  and to  destruction  within  the  contextual
further evolution of lipoprotein core formation and as a series of potential complications.
Attributes of Hypoxic Preconditioning Determine the Complicating Atherogenesis of Plaques
http://dx.doi.org/10.5772/51127
247
The neovascularization events are responsive elements to a hypoxia generated within the
intima and affecting in particular the endothelial cells. Such endothelium is both activat‐
ed to express adhesion molecules and also dysfunctional with particular reduction in ni‐
tric oxide production.
The further amplification of vascular wall injury is indicative of parameters of parallel but
overlapping proportions in the creation of a highly plastic series of preconditioned micro-
environments. It is in terms not only of a response to injury but also of a series of reactivities
to hypoxia to the endothelium and intima that atherosclerosis proves a self-progressive lesion.
The dynamics of abnormal blood flow are constituent parameters to which the emergent
plaque conforms to in partial manner. The neovascularization of the lesion core adopts the
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The neovascularization events are responsive elements to a hypoxia generated within the
intima and affecting in particular the endothelial cells. Such endothelium is both activat‐
ed to express adhesion molecules and also dysfunctional with particular reduction in ni‐
tric oxide production.
The further amplification of vascular wall injury is indicative of parameters of parallel but
overlapping proportions in the creation of a highly plastic series of preconditioned micro-
environments. It is in terms not only of a response to injury but also of a series of reactivities
to hypoxia to the endothelium and intima that atherosclerosis proves a self-progressive lesion.
The dynamics of abnormal blood flow are constituent parameters to which the emergent
plaque conforms to in partial manner. The neovascularization of the lesion core adopts the
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